Introduction	O	O
of	O	O
a	O	O
methyl	B-IUPAC	O
group	B-MODIFIER	O
in	O	O
the	O	O
2	O	O
-	O	O
position	O	O
of	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
indole	O	O
resulted	O	O
in	O	O
further	O	O
increase	O	O
of	O	O
selectivity	O	O
for	O	O
the	O	O
5	O	O
-	O	O
HT2	O	O
receptor	O	O
.	O	O
Due	O	O
to	O	O
the	O	O
existence	O	O
of	O	O
several	O	O
chiral	O	O
centers	O	O
on	O	O
this	O	O
molecule	O	O
,	O	O
upon	O	O
the	O	O
formation	O	O
of	O	O
[	O	O
99mTc	O	O
]	O	O
TRODAT	O	O
-	O	O
1	O	O
complex	O	O
(	O	O
2	O	O
)	O	O
several	O	O
diastereomers	O	O
could	O	O
be	O	O
created	O	O
.	O	O
Thus	O	O
,	O	O
simple	O	O
replacement	O	O
of	O	O
the	O	O
terminal	O	O
propenyl	B-IUPAC	O
system	B-MODIFIER	O
[	O	O
C	O	O
(	O	O
16,17,18	O	O
)	O	O
]	O	O
in	O	O
7	O	O
with	O	O
a	O	O
cyclopropyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
produced	O	O
acid	O	O
8	O	O
[	O	O
(	B-IUPAC	B-IUPAC
2E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylthiochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
heptadienoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
with	O	O
markedly	O	O
reduced	O	O
activity	O	O
.	O	O
Thus	O	O
(	O	O
S	O	O
)	O	O
-	O	O
6b	O	O
has	O	O
a	O	O
lipophilicity	O	O
that	O	O
will	O	O
allow	O	O
a	O	O
relatively	O	O
higher	O	O
uptake	O	O
into	O	O
the	O	O
brain	O	O
compared	O	O
to	O	O
sulpiride	O	O
.	O	O
The	O	O
nigrostriatal	O	O
toxin	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyridine	I-IUPAC	I-IUPAC
(	O	O
MPTP	O	O
)	O	O
is	O	O
biotransformed	O	O
by	O	O
brain	O	O
monoamine	O	O
oxidase	O	O
(	O	O
MAO	O	O
)	O	O
to	O	O
an	O	O
unstable	O	O
dihydropyridinium	O	O
intermediate	O	O
that	O	O
reacts	O	O
with	O	O
cyanide	O	O
ion	O	O
to	O	O
form	O	O
an	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyridine	I-IUPAC	I-IUPAC
adduct	O	O
and	O	O
,	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
cyanide	O	O
ion	O	O
,	O	O
undergoes	O	O
disproportionation	O	O
to	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpyridinium	I-IUPAC	I-IUPAC
species	O	O
MPP+	O	O
and	O	O
MPTP	O	O
.	O	O
All	O	O
N	O	O
(	O	O
4	O	O
)	O	O
-	O	O
hydroxy	O	O
-	O	O
dCMP	O	O
(	O	O
6a	O	O
,	O	O
b	O	O
,	O	O
d	O	O
-	O	O
h	O	O
)	O	O
and	O	O
dUMP	O	O
analogues	O	O
studied	O	O
were	O	O
competitive	O	O
vs	O	O
dUMP	O	O
inhibitors	O	O
of	O	O
the	O	O
enzyme	O	O
.	O	O
We	O	O
have	O	O
prepared	O	O
fluoroalkyl	O	O
analogs	O	O
of	O	O
QNB	O	O
,	O	O
which	O	O
are	O	O
amenable	O	O
to	O	O
labeling	O	O
with	O	O
18F	O	O
,	O	O
for	O	O
potential	O	O
imaging	O	O
applications	O	O
with	O	O
positron	O	O
emission	O	O
tomography	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
within	O	O
this	O	O
series	O	O
of	O	O
compounds	O	O
are	O	O
discussed	O	O
.	O	O
In	O	O
the	O	O
cocaine	O	O
discrimination	O	O
test	O	O
,	O	O
all	O	O
analogues	O	O
showed	O	O
full	O	O
or	O	O
at	O	O
least	O	O
50%	O	O
generalization	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
3p	O	O
,	O	O
which	O	O
did	O	O
not	O	O
show	O	O
generalization	O	O
.	O	O
In	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
spacer	O	O
(	O	O
1	O	O
)	O	O
,	O	O
the	O	O
analogue	O	O
exhibited	O	O
dual	O	O
delta	O	O
-	O	O
agonism	O	O
(	O	O
pEC	O	O
(	O	O
50	O	O
)	O	O
,	O	O
7.28	O	O
)	O	O
and	O	O
delta	O	O
-	O	O
antagonism	O	O
(	O	O
pA	O	O
(	O	O
2	O	O
)	O	O
,	O	O
7.90	O	O
)	O	O
.	O	O
Requisite	O	O
heterocycles	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
7c	O	O
)	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
7d	O	O
)	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
7e	O	O
)	O	O
,	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
7f	O	O
)	O	O
were	O	O
synthesized	O	O
by	O	O
known	O	O
procedures	O	O
from	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
.	O	O
[	O	O
Cys	O	O
(	O	O
Acm	O	O
)	O	O
2	O	O
,	O	O
D	O	O
-	O	O
Trp	O	O
(	O	O
Boc	O	O
)	O	O
4	O	O
,	O	O
Lys	O	O
(	O	O
Boc	O	O
)	O	O
5	O	O
,	O	O
Thr	O	O
(	O	O
tBu	O	O
)	O	O
6	O	O
,	O	O
Cys	O	O
(	O	O
Acm	O	O
)	O	O
7	O	O
,	O	O
des	B-IUPAC	O
(	I-IUPAC	O
threoninol	I-IUPAC	O
)	I-IUPAC	O
]	I-IUPAC	O
-	I-IUPAC	O
octreotide	I-IUPAC	O
was	O	O
assembled	O	O
by	O	O
Fmoc	O	O
solid	O	O
-	O	O
phase	O	O
synthesis	O	O
and	O	O
the	O	O
intramolecular	O	O
disulfide	O	O
bond	O	O
formed	O	O
by	O	O
treatment	O	O
of	O	O
the	O	O
resin	O	O
-	O	O
bound	O	O
peptide	O	O
with	O	O
thallium	O	O
trifluoroacetate	O	O
[	O	O
Tl	O	O
(	O	O
Tfa	O	O
)	O	O
3	O	O
]	O	O
.	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
13	O	O
were	O	O
prepared	O	O
from	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
(	O	O
7	O	O
,	O	O
10	O	O
)	O	O
via	O	O
Curtius	O	O
rearrangement	O	O
.	O	O
Strips	O	O
of	O	O
rabbit	O	O
bladder	O	O
neck	O	O
were	O	O
employed	O	O
as	O	O
a	O	O
predictive	O	O
assay	O	O
for	O	O
antagonism	O	O
in	O	O
the	O	O
human	O	O
lower	O	O
tract	O	O
.	O	O
None	O	O
of	O	O
the	O	O
DNA	O	O
polymerases	O	O
examined	O	O
were	O	O
able	O	O
to	O	O
incorporate	O	O
this	O	O
compound	O	O
into	O	O
the	O	O
growing	O	O
DNA	O	O
chain	O	O
.	O	O
Four	O	O
polyamine	O	O
conjugates	O	O
are	O	O
synthesized	O	O
,	O	O
two	O	O
of	O	O
terephthalic	O	O
acid	O	O
[	O	B-IUPAC
N	B-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoylspermine	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
and	O	O
its	O	O
methyl	O	B-IUPAC
ester	O	I-IUPAC
(	O	O
6	O	O
)	O	O
]	O	O
and	O	O
two	O	O
of	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
[	O	I-IUPAC
(	O	I-IUPAC
S	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
4'	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
HO	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
DADFT	O	I-IUPAC
]	O	I-IUPAC
[	O	I-IUPAC
(	B-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diazadodecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
and	O	O
its	O	O
ethyl	O	B-IUPAC
ester	O	I-IUPAC
(	O	O
9	O	O
)	O	O
]	O	O
.	O	O
The	O	O
activity	O	O
of	O	O
the	O	O
title	O	O
compounds	O	O
was	O	O
determined	O	O
in	O	O
vitro	O	O
against	O	O
Gram	O	O
-	O	O
positive	O	O
and	O	O
Gram	O	O
-	O	O
negative	O	O
bacteria	O	O
,	O	O
and	O	O
the	O	O
in	O	O
vivo	O	O
efficacy	O	O
of	O	O
selected	O	O
derivatives	O	O
was	O	O
determined	O	O
using	O	O
a	O	O
mouse	O	O
infection	O	O
model	O	O
.	O	O
The	O	O
three	O	O
-	O	O
atom	O	O
-	O	O
bridged	O	O
analogue	O	O
4	O	O
was	O	O
somewhat	O	O
more	O	O
inhibitory	O	O
to	O	O
human	O	O
TS	O	O
than	O	O
methotrexate	O	O
(	O	O
MTX	O	O
)	O	O
.	O	O
The	O	O
new	O	O
compounds	O	O
,	O	O
bearing	O	O
a	O	O
branched	O	O
(	O	O
4	O	O
)	O	O
or	O	O
a	O	O
geometrically	O	O
constrained	O	O
benzyl	B-IUPAC	O
/	O	O
phenylethyl	B-IUPAC	B-IUPAC
amide	I-IUPAC	I-IUPAC
side	B-MODIFIER	B-MODIFIER
chain	I-MODIFIER	I-MODIFIER
(	O	O
5-8	O	O
)	O	O
,	O	O
represent	O	O
the	O	O
continuation	O	O
of	O	O
our	O	O
research	O	O
on	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzylindol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylglyoxylylamides	I-IUPAC	I-IUPAC
1	O	O
(	O	O
Da	O	O
Settimo	O	O
et	O	O
al.	O	O
,	O	O
1996	O	O
)	O	O
,	O	O
N'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylindol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylglyoxylohydrazides	I-IUPAC	I-IUPAC
2	O	O
(	O	O
Da	O	O
Settimo	O	O
et	O	O
al.	O	O
,	O	O
1998	O	O
)	O	O
,	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylglyoxylyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
3	O	O
(	O	O
Primofiore	O	O
et	O	O
al.	O	O
,	O	O
1989	O	O
)	O	O
.	O	O
Nine	O	O
compounds	O	O
with	O	O
BZ	O	O
receptor	O	O
IC50	O	O
binding	O	O
affinity	O	O
values	O	O
equal	O	O
or	O	O
superior	O	O
to	O	O
diazepam	O	O
were	O	O
evaluated	O	O
in	O	O
secondary	O	O
screening	O	O
.	O	O
Provided	O	O
these	O	O
types	O	O
of	O	O
purines	O	O
and	O	O
pyrimidines	O	O
do	O	O
not	O	O
exhibit	O	O
undesirable	O	O
toxicity	O	O
,	O	O
they	O	O
may	O	O
be	O	O
superior	O	O
to	O	O
O6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzylguanine	I-IUPAC	I-IUPAC
as	O	O
chemotherapeutic	O	O
adjuvants	O	O
for	O	O
enhancing	O	O
the	O	O
effectiveness	O	O
of	O	O
antitumor	O	O
drugs	O	O
for	O	O
which	O	O
the	O	O
mechanism	O	O
of	O	O
action	O	O
involves	O	O
modification	O	O
of	O	O
the	O	O
O6	O	O
-	O	O
position	O	O
of	O	O
DNA	O	O
guanine	O	O
residues	O	O
.	O	O
Substituted	O	O
indole	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamides	I-IUPAC	I-IUPAC
and	O	O
indole	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamides	I-IUPAC	I-IUPAC
have	O	O
been	O	O
found	O	O
to	O	O
be	O	O
potent	O	O
and	O	O
selective	O	O
antagonists	O	O
of	O	O
the	O	O
peptidoleukotrienes	O	O
.	O	O
The	O	O
initial	O	O
purpose	O	O
of	O	O
this	O	O
work	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
influence	O	O
of	O	O
different	O	O
groups	O	O
in	O	O
position	O	O
3	O	O
.	O	O
2	O	O
microM	O	O
)	O	O
was	O	O
shown	O	O
to	O	O
reside	O	O
exclusively	O	O
in	O	O
8	O	O
(	O	O
IC50	O	O
=	O	O
0.11	O	O
+	O	O
/	O	O
-	O	O
0.01	O	O
microM	O	O
;	O	O
EC50	O	O
=	O	O
0.71	O	O
+	O	O
/	O	O
-	O	O
0.11	O	O
microM	O	O
)	O	O
,	O	O
whereas	O	O
9	O	O
did	O	O
not	O	O
interact	O	O
significantly	O	O
with	O	O
AMPA	O	O
receptors	O	O
,	O	O
either	O	O
as	O	O
an	O	O
agonist	O	O
or	O	O
as	O	O
an	O	O
antagonist	O	O
.	O	O
The	O	O
data	O	O
indicated	O	O
that	O	O
a	O	O
considerable	O	O
degree	O	O
of	O	O
structural	O	O
variation	O	O
is	O	O
possible	O	O
while	O	O
still	O	O
retaining	O	O
nanomolar	O	O
affinity	O	O
at	O	O
sigma	O	O
receptors	O	O
.	O	O
All	O	O
radioactive	O	O
compounds	O	O
were	O	O
substrates	O	O
for	O	O
MGMT	O	O
,	O	O
as	O	O
demonstrated	O	O
using	O	O
a	O	O
competitive	O	O
repair	O	O
assay	O	O
.	O	O
Neither	O	O
the	O	O
chromophore	O	O
,	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbutyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ammonium	I-IUPAC	I-IUPAC
chloride	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
nor	O	O
the	O	O
side	O	O
-	O	O
chain	O	O
moiety	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxyhexanedioic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
,	O	O
as	O	O
separate	O	O
fragments	O	O
alone	O	O
showed	O	O
any	O	O
significant	O	O
activity	O	O
.	O	O
As	O	O
for	O	O
BTCP	O	O
,	O	O
all	O	O
of	O	O
the	O	O
compounds	O	O
tested	O	O
showed	O	O
Ki	O	O
values	O	O
&	O	O
gt	O	O
;	O	O
10,000	O	O
nM	O	O
for	O	O
displacement	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
TCP	O	O
from	O	O
rat	O	O
brain	O	O
homogenates	O	O
.	O	O
Radiochemical	O	O
yields	O	O
,	O	O
with	O	O
respect	O	O
to	O	O
initial	O	O
[	O	O
18F	O	O
]	O	O
fluoride	O	O
ion	O	O
radioactivity	O	O
,	O	O
were	O	O
68-72%	O	O
(	O	O
decay	O	O
-	O	O
corrected	O	O
)	O	O
and	O	O
49-52%	O	O
(	O	O
non	O	O
-	O	O
decay	O	O
-	O	O
corrected	O	O
)	O	O
,	O	O
and	O	O
the	O	O
specific	O	O
radioactivities	O	O
at	O	O
EOB	O	O
were	O	O
4-7	O	O
Ci	O	O
/	O	O
micromol	O	O
(	O	O
148-259	O	O
GBq	O	O
/	O	O
micromol	O	O
)	O	O
.	O	O
Screening	O	O
of	O	O
the	O	O
compounds	O	O
was	O	O
with	O	O
one	O	O
of	O	O
two	O	O
assays	O	O
.	O	O
(	I-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mandelate	I-IUPAC	I-IUPAC
.	O	O
The	O	O
ring	O	O
closure	O	O
of	O	O
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
5	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
cyclopentanecarboxamido	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzoylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminouracils	I-IUPAC	I-IUPAC
requires	O	O
drastic	O	O
reaction	O	O
conditions	O	O
.	O	O
O	O	O
(	O	O
6	O	O
)	O	O
-	O	O
Substituted	O	O
guanine	B-IUPAC	O
derivatives	B-MODIFIER	O
are	O	O
powerful	O	O
agents	O	O
used	O	O
for	O	O
tumor	O	O
cell	O	O
sensitization	O	O
by	O	O
inhibition	O	O
of	O	O
the	O	O
DNA	O	O
repair	O	O
enzyme	O	O
O	O	O
(	O	O
6	O	O
)	O	O
-	O	O
methylguanine	O	O
-	O	O
DNA	O	O
methyltransferase	O	O
(	O	O
MGMT	O	O
)	O	O
.	O	O
Biochemistry	O	O
1986	O	O
,	O	O
25	O	O
,	O	O
3021-3031	O	O
)	O	O
.	O	O
In	O	O
the	O	O
2,4	O	O
series	O	O
,	O	O
activity	O	O
against	O	O
aniline	O	O
hydroxylase	O	O
was	O	O
poor	O	O
or	O	O
absent	O	O
in	O	O
most	O	O
cases	O	O
.	O	O
The	O	O
key	O	O
compounds	O	O
11a	O	O
,	O	O
b	O	O
were	O	O
conveniently	O	O
obtained	O	O
by	O	O
Stille	O	O
coupling	O	O
between	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butylstannyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
and	O	O
the	O	O
corresponding	O	O
heteroaryl	O	O
halides	O	O
.	O	O
The	O	O
effect	O	O
of	O	O
the	O	O
compounds	O	O
was	O	O
time	O	O
-	O	O
,	O	O
pH	O	O
-	O	O
,	O	O
and	O	O
concentration	O	O
-	O	O
dependent	O	O
,	O	O
with	O	O
&	O	O
gt	O	O
;	O	O
50%	O	O
and	O	O
&	O	O
gt	O	O
;	O	O
80%	O	O
estrogen	O	O
-	O	O
binding	O	O
sites	O	O
inactivated	O	O
at	O	O
0	O	O
degrees	O	O
C	O	O
and	O	O
pH	O	O
8.5	O	O
,	O	O
for	O	O
the	O	O
less	O	O
active	O	O
and	O	O
more	O	O
active	O	O
compounds	O	O
,	O	O
respectively	O	O
;	O	O
the	O	O
corresponding	O	O
IC50	O	O
values	O	O
varied	O	O
from	O	O
approximately	O	O
20	O	O
nM	O	O
to	O	O
approximately	O	O
10	O	O
microM	O	O
.	O	O
C	O	O
-	O	O
terminal	O	O
modification	O	O
primarily	O	O
affected	O	O
mu	O	O
-	O	O
opioid	O	O
receptor	O	O
affinities	O	O
,	O	O
which	O	O
increased	O	O
maximally	O	O
1700	O	O
-	O	O
fold	O	O
relative	O	O
to	O	O
the	O	O
prototype	O	O
delta	O	O
-	O	O
antagonist	O	O
H	O	O
-	O	O
Dmt	O	O
-	O	O
Tic	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
and	O	O
differentially	O	O
modified	O	O
bioactivity	O	O
.	O	O
In	O	O
general	O	O
the	O	O
synthetic	O	O
route	O	O
involved	O	O
the	O	O
coupling	O	O
of	O	O
diethyl	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
prop	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ynylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
with	O	O
the	O	O
appropriate	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
quinazoline	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
deprotection	O	O
with	O	O
mild	O	O
alkali	O	O
.	O	O
Employing	O	O
a	O	O
recently	O	O
developed	O	O
q	O	O
-	O	O
jumping	O	O
molecular	O	O
dynamics	O	O
(	O	O
MD	O	O
)	O	O
simulation	O	O
method	O	O
,	O	O
which	O	O
allows	O	O
us	O	O
to	O	O
consider	O	O
the	O	O
flexibility	O	O
of	O	O
both	O	O
the	O	O
ligands	O	O
and	O	O
the	O	O
receptor	O	O
in	O	O
docking	O	O
studies	O	O
,	O	O
we	O	O
predicted	O	O
the	O	O
binding	O	O
models	O	O
of	O	O
phorbol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
13	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
,	O	O
phorbol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
12,13	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibutyrate	I-IUPAC	I-IUPAC
(	O	O
PDBu	O	O
)	O	O
,	O	O
indolactam	O	O
V	O	O
(	O	O
ILV	O	O
)	O	O
,	O	O
ingenol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
,	O	O
and	O	O
thymeleatoxin	O	O
to	O	O
PKC	O	O
.	O	O
Ring	O	O
substitution	O	O
(	O	O
e.g.	O	O
,	O	O
4	B-IUPAC	O
-	I-IUPAC	O
nitro	I-IUPAC	O
)	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylethylnyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
did	O	O
not	O	O
provide	O	O
enhanced	O	O
selectivity	O	O
,	O	O
as	O	O
it	O	O
did	O	O
for	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
styryl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	B-MODIFIER
dihydropyridines	B-IUPAC	B-IUPAC
.	O	O
Several	O	O
compounds	O	O
were	O	O
tested	O	O
as	O	O
spinal	O	O
anesthetics	O	O
.	O	O
Generally	O	O
,	O	O
the	O	O
(	O	O
R	O	O
)	O	O
-	O	O
enantiomers	O	O
displayed	O	O
higher	O	O
affinity	O	O
for	O	O
the	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
than	O	O
the	O	O
corresponding	O	O
(	O	O
S	O	O
)	O	O
-	O	O
enantiomers	O	O
.	O	O
Phosphates	O	O
of	O	O
the	O	O
aliphatic	O	O
alcohol	O	O
5e	O	O
could	O	O
be	O	O
obtained	O	O
by	O	O
both	O	O
methods	O	O
in	O	O
similar	O	O
yields	O	O
.	O	O
These	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
are	O	O
of	O	O
interest	O	O
as	O	O
novel	O	O
nAChR	O	O
probes	O	O
and	O	O
potential	O	O
metabolites	O	O
of	O	O
candidate	O	O
insecticides	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitroimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
picolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetamide	I-IUPAC	I-IUPAC
on	O	O
further	O	O
reaction	O	O
with	O	O
m	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloroperbenzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
produced	O	O
the	O	O
corresponding	O	O
N	O	B-IUPAC
-	O	I-IUPAC
oxide	O	I-IUPAC
.	O	O
The	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
were	O	O
not	O	O
as	O	O
active	O	O
.	O	O
Therefore	O	O
enantiomers	O	O
of	O	O
the	O	O
selected	O	O
hydroxamic	O	O
derivatives	O	O
of	O	O
cis	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexanedicarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
by	O	O
two	O	O
different	O	O
chiral	O	O
synthetic	O	O
routes	O	O
and	O	O
evaluated	O	O
in	O	O
vitro	O	O
for	O	O
their	O	O
ACE	O	O
inhibitor	O	O
potencies	O	O
.	O	O
Among	O	O
dihydroflavonol	O	O
analogues	O	O
,	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
styryl	I-IUPAC	I-IUPAC
instead	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
,	O	O
in	O	O
15	O	O
,	O	O
afforded	O	O
selectivity	O	O
for	O	O
human	O	O
A3	O	O
vs	O	O
rat	O	O
A1	O	O
or	O	O
A2A	O	O
receptors	O	O
.	O	O
In	O	O
an	O	O
in	O	O
vivo	O	O
mouse	O	O
model	O	O
for	O	O
T	O	O
.	O	O
Incubation	O	O
of	O	O
AdoHcy	O	O
hydrolase	O	O
with	O	O
7	O	O
or	O	O
15	O	O
resulted	O	O
in	O	O
irreversible	O	O
inactivation	O	O
and	O	O
release	O	O
of	O	O
bromide	O	O
ion	O	O
.	O	O
Reaction	O	O
of	O	O
2	O	O
with	O	O
diethanolamine	O	O
under	O	O
various	O	O
conditions	O	O
and	O	O
different	O	O
solvents	O	O
resulted	O	O
in	O	O
the	O	O
corresponding	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
precursors	O	I-IUPAC
,	O	O
which	O	O
were	O	O
subsequently	O	O
treated	O	O
with	O	O
SOCl2	O	O
to	O	O
yield	O	O
the	O	O
target	O	O
compounds	O	O
.	O	O
x	O	O
4	O	O
)	O	O
or	O	O
240	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
q	O	O
.	O	O
Potency	O	O
of	O	O
the	O	O
CAM	O	O
-	O	O
HOPO	O	O
ligands	O	O
for	O	O
in	O	O
vivo	O	O
chelation	O	O
of	O	O
Pu	O	O
(	O	O
IV	O	O
)	O	O
resembled	O	O
that	O	O
of	O	O
structurally	O	O
hexadentate	B-IUPAC	O
tris	I-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
hydroxypyridinonate	I-IUPAC	O
)	I-IUPAC	O
and	O	O
tris	B-IUPAC	O
(	I-IUPAC	O
sulfocatecholate	I-IUPAC	O
)	I-IUPAC	O
ligands	O	O
and	O	O
functionally	O	O
hexadentate	O	O
tetrakis	B-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
sulfocatecholate	I-IUPAC	O
)	I-IUPAC	O
and	O	O
tetrakis	B-IUPAC	O
(	I-IUPAC	O
carboxycatecholate	I-IUPAC	O
)	I-IUPAC	O
ligands	O	O
.	O	O
The	O	O
acetate	O	O
8	O	O
was	O	O
condensed	O	O
with	O	O
thymine	O	O
,	O	O
5	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	O
uracils	B-IUPAC	O
and	O	O
cytosines	B-IUPAC	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoropurine	I-IUPAC	I-IUPAC
to	O	O
give	O	O
pyrimidine	O	O
and	O	O
purine	O	O
nucleosides	O	O
.	O	O
However	O	O
,	O	O
it	O	O
increased	O	O
the	O	O
rotorod	O	O
deficit	O	O
produced	O	O
by	O	O
ethanol	O	O
at	O	O
anxiolytic	O	O
doses	O	O
,	O	O
an	O	O
indication	O	O
of	O	O
alcohol	O	O
interaction	O	O
.	O	O
By	O	O
a	O	O
slightly	O	O
different	O	O
procedure	O	O
,	O	O
5	O	O
was	O	O
converted	O	O
in	O	O
two	O	O
steps	O	O
to	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetamidopropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
hydrobromide	I-IUPAC	I-IUPAC
(	O	O
7d	O	O
)	O	O
.	O	O
The	O	O
yields	O	O
of	O	O
Thf	O	O
-	O	O
FU	O	O
and	O	O
more	O	O
especially	O	O
of	O	O
Thf2	O	O
-	O	O
FU	O	O
were	O	O
greatly	O	O
dependent	O	O
on	O	O
the	O	O
relative	O	O
amount	O	O
of	O	O
SnCl4	O	O
,	O	O
and	O	O
0.01-0.1	O	O
equiv	O	O
of	O	O
the	O	O
catalyst	O	O
with	O	O
respect	O	O
to	O	O
Me3Si	O	O
-	O	O
FU	O	O
gave	O	O
the	O	O
best	O	O
results	O	O
.	O	O
This	O	O
has	O	O
led	O	O
to	O	O
an	O	O
increased	O	O
interest	O	O
in	O	O
the	O	O
development	O	O
of	O	O
RGD	O	O
compounds	O	O
with	O	O
high	O	O
affinity	O	O
and	O	O
improved	O	O
selectivity	O	O
for	O	O
integrin	O	O
receptors	O	O
.	O	O
When	O	O
compared	O	O
to	O	O
1	O	O
,	O	O
compound	O	O
21	O	O
as	O	O
well	O	O
as	O	O
its	O	O
analogue	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenedioxyphthalazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
16	O	O
)	O	O
show	O	O
a	O	O
longer	O	O
lasting	O	O
anticonvulsant	O	O
activity	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thiohomofolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
has	O	O
been	O	O
accomplished	O	O
by	O	O
an	O	O
unambiguous	O	O
procedure	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
selected	O	O
compounds	O	O
showed	O	O
potential	O	O
antipsychotic	O	O
effects	O	O
.	O	O
No	O	O
5,6	O	O
-	O	O
olefinic	O	O
bond	O	O
regeneration	O	O
was	O	O
observed	O	O
for	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
analogs	B-MODIFIER	B-MODIFIER
.	O	O
The	O	O
most	O	O
active	O	O
heteroarotinoids	O	O
were	O	O
ester	O	O
10	O	O
[	O	O
methyl	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,2,4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetramethylthiochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
]	O	O
and	O	O
acid	O	O
11	O	O
[	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,2,4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetramethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzothiopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
]	O	O
.	O	O
The	O	O
affinities	O	O
of	O	O
the	O	O
compounds	O	O
for	O	O
[	O	O
3H	O	O
]	O	O
raclopride	O	O
-	O	O
labeled	O	O
cloned	O	O
human	O	O
dopamine	O	O
(	O	O
DA	O	O
)	O	O
D2	O	O
and	O	O
D3	O	O
receptors	O	O
as	O	O
well	O	O
as	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
8	O	O
-	O	O
OH	O	O
-	O	O
DPAT	O	O
-	O	O
labeled	O	O
rat	O	O
hippocampal	O	O
5	O	O
-	O	O
HT1A	O	O
receptors	O	O
were	O	O
determined	O	O
.	O	O
Most	O	O
of	O	O
the	O	O
compounds	O	O
were	O	O
less	O	O
potent	O	O
than	O	O
theophylline	O	O
and	O	O
none	O	O
were	O	O
remarkably	O	O
selective	O	O
for	O	O
A1	O	O
-	O	O
or	O	O
A2	O	O
-	O	O
adenosine	O	O
receptors	O	O
.	O	O
A	O	O
series	O	O
of	O	O
thymidylate	O	O
synthetase	O	O
inhibitors	O	O
was	O	O
synthesized	O	O
,	O	O
some	O	O
of	O	O
which	O	O
were	O	O
potential	O	O
irreversible	O	O
inhibitors	O	O
.	O	O
The	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butylbenzyl	I-IUPAC	I-IUPAC
-	O	O
quaternized	B-MODIFIER	O
analogue	I-MODIFIER	O
very	O	O
strongly	O	O
inhibited	O	O
(	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
&	O	O
lt	O	O
;	O	O
1	O	O
microM	O	O
)	O	O
growth	O	O
of	O	O
the	O	O
amastigote	O	O
stage	O	O
of	O	O
T	O	O
.	O	O
In	O	O
vivo	O	O
studies	O	O
in	O	O
mice	O	O
showed	O	O
that	O	O
the	O	O
pip	O	O
-	O	O
pip	O	O
complexes	O	O
are	O	O
significantly	O	O
less	O	O
toxic	O	O
than	O	O
cisplatin	O	O
.	O	O
A	O	O
quantitative	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
was	O	O
developed	O	O
between	O	O
these	O	O
two	O	O
series	O	O
that	O	O
correctly	O	O
predicted	O	O
the	O	O
potencies	O	O
of	O	O
six	O	O
additional	O	O
5	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	B-MODIFIER
pyrazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
that	O	O
were	O	O
synthesized	O	O
during	O	O
the	O	O
course	O	O
of	O	O
the	O	O
analysis	O	O
.	O	O
Evaluation	O	O
of	O	O
these	O	O
compounds	O	O
in	O	O
L1210	O	O
,	O	O
HFF	O	O
,	O	O
and	O	O
KB	O	O
cells	O	O
showed	O	O
that	O	O
the	O	O
sugar	O	O
-	O	O
modified	O	O
analogs	O	O
all	O	O
were	O	O
less	O	O
cytotoxic	O	O
than	O	O
their	O	O
corresponding	O	O
ribonucleoside	O	O
analogs	O	O
.	O	O
Preliminary	O	O
screening	O	O
indicated	O	O
methyl	B-IUPAC	B-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trichloroethenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
to	O	O
be	O	O
the	O	O
most	O	O
potent	O	O
derivative	O	O
in	O	O
the	O	O
series	O	O
.	O	O
(	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methanone	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
possessed	O	O
marked	O	O
central	O	O
depressant	O	O
activity	O	O
without	O	O
anticonvulsant	O	O
activity	O	O
and	O	O
without	O	O
impairment	O	O
of	O	O
motor	O	O
functioning	O	O
.	O	O
The	O	O
remaining	O	O
target	O	O
compounds	O	O
,	O	O
11-17	O	O
,	O	O
were	O	O
very	O	O
weak	O	O
or	O	O
inactive	O	O
as	O	O
inhibitors	O	O
of	O	O
both	O	O
uptake	O	O
systems	O	O
.	O	O
Optimization	O	O
of	O	O
ring	O	O
size	O	O
and	O	O
composition	O	O
led	O	O
to	O	O
the	O	O
discovery	O	O
of	O	O
cyclo	O	O
(	O	O
1-3	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DAsp	O	O
(	O	O
1	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DLys	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
DAla	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
5	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
0.82	O	O
nM	O	O
)	O	O
,	O	O
cyclo	O	O
(	O	O
1,1	O	O
'	O	O
-	O	O
3	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DAsp	O	O
(	O	O
1	O	O
)	O	O
(	O	O
Gly	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DOrn	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
DAla	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
13	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
0.34	O	O
nM	O	O
)	O	O
,	O	O
cyclo	O	O
(	O	O
1	O	O
,	O	O
1'	O	O
-	O	O
3	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DAsp	O	O
(	O	O
1	O	O
)	O	O
(	O	O
Gly	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DLys	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
DA	O	O
la	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
20	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
0.14	O	O
nM	O	O
)	O	O
,	O	O
and	O	O
cyclo	O	O
(	O	O
1,1	O	O
'	O	O
-	O	O
3	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DAsp	O	O
(	O	O
1	O	O
)	O	O
(	O	O
betaAla	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DOrn	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
DAla	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
21	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
0.17	O	O
nM	O	O
)	O	O
,	O	O
which	O	O
inhibited	O	O
ovulation	O	O
significantly	O	O
at	O	O
doses	O	O
equal	O	O
to	O	O
or	O	O
lower	O	O
than	O	O
25	O	O
microgram	O	O
/	O	O
rat	O	O
.	O	O
An	O	O
enzymatically	O	O
activated	O	O
liposome	O	O
-	O	O
based	O	O
drug	O	O
-	O	O
delivery	O	O
concept	O	O
involving	O	O
masked	O	O
antitumor	O	O
ether	O	O
lipids	O	O
(	O	O
AELs	O	O
)	O	O
has	O	O
been	O	O
investigated	O	O
.	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Nitrothien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
using	O	O
ceric	O	O
ammonium	O	O
nitrate	O	O
as	O	O
reagent	O	O
.	O	O
The	O	O
results	O	O
obtained	O	O
indicate	O	O
that	O	O
(	O	O
a	O	O
)	O	O
the	O	O
nature	O	O
of	O	O
the	O	O
substituent	O	O
in	O	O
position	O	O
1	O	O
has	O	O
an	O	O
important	O	O
influence	O	O
on	O	O
the	O	O
biological	O	O
activity	O	O
of	O	O
these	O	O
peptides	O	O
,	O	O
and	O	O
(	O	O
b	O	O
)	O	O
the	O	O
potency	O	O
of	O	O
antagonists	O	O
I	O	O
-	O	O
IV	O	O
(	O	O
all	O	O
less	O	O
potent	O	O
antagonists	O	O
than	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sarcosine	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threonine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
angiotensin	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
)	O	I-IUPAC
is	O	O
very	O	O
much	O	O
influenced	O	O
by	O	O
the	O	O
length	O	O
and	O	O
branching	O	O
of	O	O
the	O	O
side	O	O
chain	O	O
in	O	O
position	O	O
8	O	O
.	O	O
However	O	O
,	O	O
this	O	O
series	O	O
had	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
of	O	O
&	O	O
gt	O	O
;	O	O
100	O	O
microM	O	O
,	O	O
66.7	O	O
microM	O	O
,	O	O
and	O	O
15.5	O	O
microM	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
CHO	O	O
-	O	O
MG	O	O
cells	O	O
,	O	O
which	O	O
are	O	O
PAT	O	O
-	O	O
deficient	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
45	O	O
also	O	O
protected	O	O
gerbils	O	O
from	O	O
hippocampal	O	O
neuronal	O	O
degeneration	O	O
produced	O	O
by	O	O
either	O	O
hypoxia	O	O
or	O	O
intrastriatal	O	O
quinolinic	O	O
acid	O	O
injection	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanamido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
haloethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
of	O	O
arabinouridine	O	O
were	O	O
moderately	O	O
inhibitory	O	O
for	O	O
VZV	O	O
and	O	O
HSV	O	O
-	O	O
1	O	O
(	O	O
strain	O	O
KOS	O	O
)	O	O
,	O	O
whereas	O	O
compounds	O	O
10	O	O
and	O	O
11	O	O
were	O	O
inactive	O	O
against	O	O
herpes	O	O
viruses	O	O
.	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Phenylquinazolinones	I-IUPAC	I-IUPAC
were	O	O
marginally	O	O
less	O	O
potent	O	O
than	O	O
the	O	O
corresponding	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylquinazolinones	I-IUPAC	I-IUPAC
,	O	O
but	O	O
the	O	O
introduction	O	O
of	O	O
an	O	O
electron	O	O
-	O	O
withdrawing	O	O
or	O	O
electron	O	O
-	O	O
donating	O	O
4'	O	O
-	O	O
substituent	O	O
on	O	O
the	O	O
2	B-IUPAC	O
-	I-IUPAC	O
aryl	I-IUPAC	O
ring	B-MODIFIER	O
invariably	O	O
increased	O	O
potency	O	O
.	O	O
This	O	O
suggested	O	O
that	O	O
hybrid	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	O
-	I-IUPAC	O
thioether	I-IUPAC	O
ATP	I-IUPAC	O
derivatives	B-MODIFIER	O
might	O	O
be	O	O
potent	O	O
and	O	O
selective	O	O
for	O	O
certain	O	O
P2Y	O	O
-	O	O
receptors	O	O
,	O	O
as	O	O
was	O	O
shown	O	O
for	O	O
one	O	O
such	O	O
derivative	O	O
,	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ATP	I-IUPAC	I-IUPAC
.	O	O
Compound	O	O
10	O	O
was	O	O
also	O	O
effective	O	O
in	O	O
suppressing	O	O
seizures	O	O
induced	O	O
in	O	O
Swiss	O	O
mice	O	O
by	O	O
maximal	O	O
electroshock	O	O
(	O	O
MES	O	O
)	O	O
or	O	O
pentylenetetrazole	O	O
(	O	O
PTZ	O	O
)	O	O
.	O	O
Zone	O	O
assays	O	O
in	O	O
several	O	O
tumor	O	O
cell	O	O
lines	O	O
show	O	O
that	O	O
active	O	O
compounds	O	O
are	O	O
cytotoxic	O	O
agents	O	O
with	O	O
little	O	O
selectivity	O	O
for	O	O
tumor	O	O
cells	O	O
.	O	O
These	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
ligands	O	O
could	O	O
pass	O	O
across	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
and	O	O
enter	O	O
the	O	O
rat	O	O
brain	O	O
(	O	O
0.17-0.32%	O	O
of	O	O
injected	O	O
dose	O	O
per	O	O
gram	O	O
wet	O	O
tissue	O	O
)	O	O
.	O	O
About	O	O
2000X	O	O
less	O	O
2	O	O
than	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propanol	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
the	O	O
product	O	O
of	O	O
N	O	O
-	O	O
dealkylation	O	O
of	O	O
1	O	O
,	O	O
was	O	O
formed	O	O
.	O	O
Reduction	O	O
with	O	O
trimethyl	O	O
phosphite	O	O
of	O	O
the	O	O
furoxan	O	O
derivatives	O	O
afforded	O	O
the	O	O
corresponding	O	O
furazans	O	O
,	O	O
while	O	O
oxidation	O	O
with	O	O
an	O	O
equimolar	O	O
amount	O	O
of	O	O
30%	O	O
hydrogen	O	O
peroxide	O	O
in	O	O
acetic	O	O
acid	O	O
or	O	O
with	O	O
an	O	O
excess	O	O
of	O	O
81%	O	O
hydrogen	O	O
peroxide	O	O
in	O	O
trifluoroacetic	O	O
acid	O	O
afforded	O	O
the	O	O
corresponding	O	O
arylsulfinyl	B-IUPAC	O
and	O	O
arylsulfonyl	B-IUPAC	B-IUPAC
analogues	B-MODIFIER	B-MODIFIER
,	O	O
respectively	O	O
.	O	O
The	O	O
protecting	O	O
groups	O	O
were	O	O
removed	O	O
with	O	O
boron	O	O
trichloride	O	O
and	O	O
the	O	O
resulting	O	O
aglycone	O	O
glycosidated	O	O
with	O	O
optically	O	O
active	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoroacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
daunosamine	I-IUPAC	I-IUPAC
bromide	I-IUPAC	I-IUPAC
and	O	O
silver	O	O
trifluoromethanesulfonate	O	O
.	O	O
Of	O	O
the	O	O
compounds	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinoline	I-IUPAC	I-IUPAC
was	O	O
found	O	O
to	O	O
possess	O	O
the	O	O
highest	O	O
activity	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
type	O	O
5	O	O
compound	O	O
was	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
decyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diethylcarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
(	O	O
5a	O	O
)	O	O
.	O	O
Also	O	O
prepared	O	O
via	O	O
DEPC	O	O
coupling	O	O
was	O	O
a	O	O
mixture	O	O
of	O	O
the	O	O
four	O	O
possible	O	O
diastereomers	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpteroyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanoglutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
gamma	O	O
-	O	O
cyanoMTX	O	O
)	O	O
.	O	O
Allenic	O	O
isomerization	O	O
of	O	O
6b	O	O
gave	O	O
compound	O	O
5c	O	O
.	O	O
A	O	O
variety	O	O
of	O	O
1	O	O
-	O	O
O	O	O
-	O	O
acetylated	O	O
pentose	O	O
sugar	O	O
derivatives	O	O
were	O	O
condensed	O	O
with	O	O
silylated	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
,	O	O
followed	O	O
by	O	O
protection	O	O
,	O	O
to	O	O
afford	O	O
a	O	O
series	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
nucleosides	B-MODIFIER	B-MODIFIER
.	O	O
Indoles	O	O
substituted	B-MODIFIER	O
in	O	O
the	O	O
1	O	O
-	O	O
position	O	O
with	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
piperazinyl	I-IUPAC	I-IUPAC
had	O	O
generally	O	O
weaker	O	O
affinity	O	O
for	O	O
both	O	O
5	O	O
-	O	O
HT2	O	O
and	O	O
D2	O	O
receptors	O	O
compared	O	O
to	O	O
corresponding	O	O
4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
piperidinyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	O
and	O	O
1,2,3,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
indoles	B-IUPAC	O
.	O	O
In	O	O
contrast	O	O
,	O	O
II	O	O
bound	O	O
with	O	O
higher	O	O
affinity	O	O
to	O	O
muscarinic	O	O
receptors	O	O
in	O	O
brainstem	O	O
,	O	O
cerebellar	O	O
,	O	O
and	O	O
hypothalamic	O	O
nuclei	O	O
(	O	O
IC50	O	O
values	O	O
less	O	O
than	O	O
0.5	O	O
microM	O	O
)	O	O
than	O	O
to	O	O
receptors	O	O
in	O	O
thalamic	O	O
nuclei	O	O
(	O	O
IC50	O	O
values	O	O
between	O	O
0.5	O	O
and	O	O
2.0	O	O
microM	O	O
)	O	O
.	O	O
These	O	O
prodrugs	O	O
may	O	O
be	O	O
useful	O	O
for	O	O
prodrug	O	O
monotherapy	O	O
of	O	O
necrotic	O	O
tumors	O	O
that	O	O
liberate	O	O
beta	O	O
-	O	O
glucuronidase	O	O
or	O	O
for	O	O
antibody	O	O
-	O	O
directed	O	O
enzyme	O	O
prodrug	O	O
therapy	O	O
with	O	O
antibodies	O	O
that	O	O
can	O	O
deliver	O	O
beta	O	O
-	O	O
glucuronidase	O	O
to	O	O
target	O	O
tumor	O	O
cells	O	O
.	O	O
8,9	O	B-IUPAC
-	O	I-IUPAC
Dioxo	O	I-IUPAC
-	O	I-IUPAC
6	O	I-IUPAC
-	O	I-IUPAC
phenyl	O	I-IUPAC
-	O	I-IUPAC
1	O	I-IUPAC
-	O	I-IUPAC
aza	O	I-IUPAC
-	O	I-IUPAC
7	O	I-IUPAC
-	O	I-IUPAC
oxabicyclo	O	I-IUPAC
[	O	I-IUPAC
4.2.1	O	I-IUPAC
]	O	I-IUPAC
nonane	O	I-IUPAC
(	O	O
1	O	O
)	O	O
and	O	O
9,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dioxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxabicyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5.2.1	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
decane	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
examples	O	O
of	O	O
anti	O	O
-	O	O
Bredt	O	O
bicyclic	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxazolidinediones	I-IUPAC	I-IUPAC
,	O	O
were	O	O
investigated	O	O
as	O	O
anticonvulsants	O	O
in	O	O
mice	O	O
.	O	O
Two	O	O
complete	O	O
and	O	O
two	O	O
partial	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
scans	O	O
of	O	O
the	O	O
active	O	O
fragment	O	O
of	O	O
human	O	O
growth	O	O
hormone	O	O
-	O	O
releasing	O	O
hormone	O	O
,	O	O
[	O	O
Nle27	O	O
]	O	O
-	O	O
hGHRH	O	O
(	O	O
1-29	O	O
)	O	O
-	O	O
NH2	O	O
,	O	O
have	O	O
identified	O	O
potent	O	O
agonists	O	O
in	O	O
vitro	O	O
.	O	O
The	O	O
Ki	O	O
for	O	O
inhibition	O	O
of	O	O
human	O	O
DHFR	O	O
by	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
was	O	O
about	O	O
the	O	O
same	O	O
as	O	O
that	O	O
of	O	O
3	O	O
(	O	O
0.35	O	O
pM	O	O
)	O	O
,	O	O
11	O	O
-	O	O
fold	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
aminopterin	O	O
(	O	O
AMT	O	O
,	O	O
1	O	O
)	O	O
,	O	O
and	O	O
15	O	O
-	O	O
fold	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
methotrexate	O	O
(	O	O
MTX	O	O
,	O	O
2	O	O
)	O	O
.	O	O
Their	O	O
absolute	O	O
configurations	O	O
were	O	O
assigned	O	O
by	O	O
1H	O	O
NMR	O	O
analyses	O	O
.	O	O
This	O	O
paper	O	O
outlines	O	O
the	O	O
synthesis	O	O
of	O	O
selected	O	O
acid	O	O
mimics	O	O
of	O	O
the	O	O
non	O	O
-	O	O
peptide	O	O
CCK	O	O
-	O	O
B	O	O
selective	O	O
antagonist	O	O
CI	O	O
-	O	O
988	O	O
,	O	O
1	O	O
.	O	O
The	O	O
anticonvulsant	O	O
activity	O	O
of	O	O
all	O	O
compounds	O	O
was	O	O
assayed	O	O
against	O	O
audiogenic	O	O
seizures	O	O
induced	O	O
in	O	O
DBA	O	O
/	O	O
2	O	O
mice	O	O
.	O	O
No	O	O
compound	O	O
showed	O	O
death	O	O
when	O	O
dosed	O	O
at	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
however	O	O
,	O	O
most	O	O
compounds	O	O
did	O	O
show	O	O
signs	O	O
typical	O	O
of	O	O
dopamine	O	O
activity	O	O
.	O	O
A	O	O
variety	O	O
of	O	O
amine	O	O
complexes	O	O
with	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
boraadamatane	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
subsequently	O	O
evaluated	O	O
for	O	O
an	O	O
antiproliferative	O	O
effect	O	O
on	O	O
CD81	O	O
-	O	O
enriched	O	O
cell	O	O
lines	O	O
to	O	O
provide	O	O
evidence	O	O
for	O	O
binding	O	O
and	O	O
activation	O	O
of	O	O
CD81	O	O
.	O	O
A	O	O
series	O	O
of	O	O
dioxolane	O	O
analogues	B-MODIFIER	O
based	O	O
on	O	O
dexoxadrol	O	O
(	O	O
(	B-IUPAC	B-IUPAC
4S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxolane	I-IUPAC	I-IUPAC
)	O	O
and	O	O
etoxadrol	O	O
(	O	O
(	B-IUPAC	B-IUPAC
2S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxolane	I-IUPAC	I-IUPAC
)	O	I-IUPAC
were	O	O
prepared	O	O
and	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
displace	O	O
[	O	O
3H	O	O
]	O	O
TCP	O	O
(	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
)	O	O
from	O	O
PCP	O	O
(	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylcyclohexyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
)	O	O
binding	O	O
sites	O	O
in	O	O
rat	O	O
brain	O	O
tissue	O	O
homogenates	O	O
.	O	O
Although	O	O
it	O	O
was	O	O
hypothesized	O	O
that	O	O
these	O	O
new	O	O
agents	O	O
might	O	O
possess	O	O
high	O	O
affinity	O	O
for	O	O
the	O	O
serotonin	O	O
5	O	O
-	O	O
HT2A	O	O
/	O	O
2C	O	O
receptor	O	O
subtypes	O	O
,	O	O
unexpected	O	O
affinity	O	O
for	O	O
muscarinic	O	O
receptors	O	O
was	O	O
observed	O	O
.	O	O
In	O	O
the	O	O
2H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
category	O	O
the	O	O
parent	O	O
phenol	O	O
was	O	O
also	O	O
inactive	O	O
whereas	O	O
the	O	O
basic	O	O
ethers	O	O
16	O	O
and	O	O
26	O	O
were	O	O
modest	O	O
receptor	O	O
ligands	O	O
while	O	O
being	O	O
quite	O	O
active	O	O
as	O	O
antiestrogens	O	O
.	O	O
Prodrug	O	O
9b	O	O
was	O	O
found	O	O
to	O	O
be	O	O
stable	O	O
in	O	O
aqueous	O	O
solution	O	O
(	O	O
pH	O	O
7	O	O
)	O	O
but	O	O
readily	O	O
cleaved	O	O
by	O	O
phosphatases	O	O
to	O	O
liberate	O	O
5e	O	O
(	O	O
MSX	O	O
-	O	O
2	O	O
)	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
molecular	O	O
electrostatic	O	O
potentials	O	O
have	O	O
been	O	O
calculated	O	O
for	O	O
selected	O	O
conformations	O	O
and	O	O
the	O	O
absolute	O	O
configuration	O	O
of	O	O
the	O	O
potent	O	O
5	O	O
-	O	O
HT	O	O
-	O	O
receptor	O	O
agonist	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetralin	I-IUPAC	I-IUPAC
has	O	O
been	O	O
determined	O	O
,	O	O
by	O	O
X	O	O
-	O	O
ray	O	O
crystallography	O	O
of	O	O
the	O	O
synthetic	O	O
precursor	O	O
,	O	O
to	O	O
be	O	O
1S	O	O
,	O	O
2R	O	O
.	O	O
The	O	O
introduction	O	O
of	O	O
a	O	O
tetrahydropyrido	O	O
ring	O	O
with	O	O
bulky	O	O
hydrophobic	O	O
substituents	O	O
at	O	O
the	O	O
basic	O	O
nitrogen	O	O
provided	O	O
inhibitors	O	O
of	O	O
AChE	O	O
which	O	O
were	O	O
completely	O	O
inactive	O	O
toward	O	O
CEase	O	O
.	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thieno1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
\C5	I-IUPAC	I-IUPAC
\8F	I-IUPAC	I-IUPAC
xazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
act	O	O
as	O	O
acyl	O	O
-	O	O
enzyme	O	O
inhibitors	O	O
of	O	O
HLE	O	O
,	O	O
similar	O	O
to	O	O
the	O	O
inhibition	O	O
of	O	O
serine	O	O
proteases	O	O
by	O	O
4H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoxazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
.	O	O
Condensation	O	O
of	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
omega	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
AMP	O	O
with	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxysuccinimide	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
of	O	O
omega	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carbobenzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
gave	O	O
N6	O	O
-	O	O
(	O	O
CH2	O	O
)	O	O
nNHCO	O	O
(	O	O
CH2	O	O
)	O	O
mNH	O	O
-	O	O
Cbz	O	O
derivatives	O	O
of	O	O
AMP	O	O
which	O	O
,	O	O
upon	O	O
conversion	O	O
to	O	O
the	O	O
corresponding	O	O
derivatives	O	O
of	O	O
ATP	O	O
,	O	O
followed	O	O
by	O	O
removal	O	O
of	O	O
the	O	O
carbobenzyloxy	B-IUPAC	O
group	B-MODIFIER	O
and	O	O
iodoacetylation	O	O
,	O	O
as	O	O
described	O	O
above	O	O
,	O	O
gave	O	O
N6	O	O
-	O	O
(	O	O
CH2	O	O
)	O	O
nNHCO	O	O
(	O	O
CH2	O	O
)	O	O
mNHCOCH2I	O	O
-	O	O
ATP	O	O
derivatives	O	O
(	O	O
n	O	O
=	O	O
3	O	O
,	O	O
m	O	O
=	O	O
5	O	O
or	O	O
6	O	O
;	O	O
n	O	O
=	O	O
4	O	O
,	O	O
m	O	O
=	O	O
5	O	O
;	O	O
n	O	O
=	O	O
6	O	O
,	O	O
m	O	O
=	O	O
1	O	O
-	O	O
-	O	O
6	O	O
)	O	O
.	O	O
With	O	O
the	O	O
plasma	O	O
enzyme	O	O
,	O	O
the	O	O
ID50	O	O
values	O	O
were	O	O
II	O	O
,	O	O
1.6	O	O
X	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
M	O	O
;	O	O
III	O	O
,	O	O
5	O	O
X	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
M	O	O
;	O	O
V	O	O
,	O	O
1.2	O	O
X	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
M	O	O
;	O	O
VI	O	O
5	O	O
X	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
M	O	O
;	O	O
VII	O	O
5	O	O
X	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
M	O	O
;	O	O
VIII	O	O
,	O	O
5	O	O
X	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
M	O	O
.	O	O
Optimization	O	O
of	O	O
5	O	O
resulted	O	O
in	O	O
the	O	O
preparation	O	O
of	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
thien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenylprope	I-IUPAC	I-IUPAC
noic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
18	O	O
(	O	O
RPR111723	O	O
)	O	O
which	O	O
had	O	O
an	O	O
IC50	O	O
in	O	O
the	O	O
binding	O	O
assay	O	O
of	O	O
80	O	O
nM	O	O
on	O	O
the	O	O
ETA	O	O
receptor	O	O
and	O	O
a	O	O
pKB	O	O
of	O	O
6.5	O	O
in	O	O
the	O	O
functional	O	O
assay	O	O
,	O	O
measured	O	O
on	O	O
rat	O	O
aortic	O	O
strips	O	O
.	O	O
(	O	O
R	O	O
)	O	O
-	O	O
11b	O	O
was	O	O
not	O	O
an	O	O
inhibitor	O	O
of	O	O
murine	O	O
liver	O	O
AADC	O	O
.	O	O
A	O	O
diverse	O	O
set	O	O
of	O	O
compounds	O	O
was	O	O
synthesized	O	O
and	O	O
evaluated	O	O
to	O	O
probe	O	O
the	O	O
role	O	O
of	O	O
the	O	O
acidic	O	O
hydrogen	O	O
of	O	O
the	O	O
aminosulfonyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
1	O	O
in	O	O
imparting	O	O
this	O	O
selectivity	O	O
.	O	O
Two	O	O
of	O	O
the	O	O
compounds	O	O
possessed	O	O
Ki	O	O
values	O	O
of	O	O
about	O	O
2x	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
M	O	O
with	O	O
guanine	O	O
aminohydrolase	O	O
,	O	O
but	O	O
no	O	O
inhibition	O	O
of	O	O
xanthine	O	O
oxidase	O	O
was	O	O
observed	O	O
by	O	O
any	O	O
at	O	O
5	O	O
x	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
M	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
potent	O	O
inhibitors	O	O
of	O	O
growth	O	O
in	O	O
folate	O	O
-	O	O
dependent	O	O
bacteria	O	O
,	O	O
Streptococcus	O	O
faecium	O	O
and	O	O
Lactobacillus	O	O
casei	O	O
.	O	O
Furthermore	O	O
,	O	O
it	O	O
antagonizes	O	O
in	O	O
vivo	O	O
seizures	O	O
induced	O	O
by	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
)	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
ATPA	O	O
)	O	O
,	O	O
and	O	O
kainate	O	O
(	O	O
KA	O	O
)	O	O
,	O	O
and	O	O
its	O	O
anticonvulsant	O	O
activity	O	O
is	O	O
reversed	O	O
by	O	O
pretreatment	O	O
with	O	O
aniracetam	O	O
.	O	O
An	O	O
alternate	O	O
synthesis	O	O
utilizing	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiophenoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butanone	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triaminopyrimidine	I-IUPAC	I-IUPAC
has	O	O
also	O	O
been	O	O
carried	O	O
out	O	O
.	O	O
The	O	O
(	O	O
malonato	O	O
)	O	O
platinum	O	O
(	O	O
II	O	O
)	O	O
complex	O	O
1m	O	O
and	O	O
the	O	O
(	O	B-IUPAC
glycolato	O	I-IUPAC
)	O	I-IUPAC
platinum	O	I-IUPAC
(	O	I-IUPAC
II	O	I-IUPAC
)	O	I-IUPAC
complexes	O	B-MODIFIER
3d	O	O
-	O	O
g	O	O
were	O	O
selected	O	O
for	O	O
further	O	O
studies	O	O
based	O	O
on	O	O
the	O	O
greater	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
antitumor	O	O
activity	O	O
and	O	O
desirable	O	O
physical	O	O
properties	O	O
.	O	O
The	O	O
corresponding	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
of	O	O
this	O	O
new	O	O
heterocyclic	O	O
ring	O	O
system	O	O
was	O	O
similarly	O	O
prepared	O	O
from	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonitrile	I-IUPAC	I-IUPAC
.	O	O
The	O	O
5	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
were	O	O
prepared	O	O
from	O	O
methyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phthalimidopentanoate	I-IUPAC	I-IUPAC
and	O	O
4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
amino	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
deoxy	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
N10	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
formyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
deaza	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
and	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
deazapteroic	I-PARTIUPAC	I-IUPAC
acid	I-PARTIUPAC	I-IUPAC
,	O	O
respectively	O	O
.	O	O
Although	O	O
generally	O	O
less	O	O
active	O	O
,	O	O
the	O	O
4,5,7	O	O
-	O	O
unsubstituted	O	O
,	O	O
4	O	B-MODIFIER
-	O	I-MODIFIER
mono	O	I-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
,	O	O
cis	O	O
-	O	O
and	O	O
trans	O	O
-	O	O
5,7	O	O
-	O	O
di	O	O
-	O	O
Me	O	O
-	O	O
substituted	O	O
,	O	O
and	O	O
cis	O	B-PARTIUPAC
-	O	I-PARTIUPAC
4,5	O	I-PARTIUPAC
-	O	I-PARTIUPAC
di	O	O
-	O	O
Me	O	O
-	O	O
substituted	O	O
analogues	O	O
of	O	O
1	O	O
also	O	O
exhibited	O	O
some	O	O
significant	O	O
desired	O	O
activity	O	O
.	O	O
We	O	O
conclude	O	O
that	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azacyclic	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
chromans	I-IUPAC	I-IUPAC
appear	O	O
to	O	O
be	O	O
a	O	O
promising	O	O
new	O	O
class	O	O
of	O	O
nicotine	O	O
agonists	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideaza	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
of	O	O
3	O	O
was	O	O
the	O	O
most	O	O
active	O	O
member	O	O
of	O	O
the	O	O
series	O	O
,	O	O
with	O	O
an	O	O
IC50	O	O
=	O	O
0.33	O	O
nM	O	O
versus	O	O
1.8	O	O
nM	O	O
for	O	O
3	O	O
and	O	O
15	O	O
nM	O	O
for	O	O
MTX	O	O
.	O	O
59	O	O
nM	O	O
at	O	O
human	O	O
A3	O	O
receptors	O	O
and	O	O
was	O	O
moderately	O	O
selective	O	O
for	O	O
that	O	O
subtype	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
compound	O	O
was	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
with	O	O
an	O	O
IC50	O	O
of	O	O
6.4	O	O
x	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
M	O	O
.	O	O
(	O	O
N	O	O
)	O	O
-	O	O
Methanocarba	O	O
-	O	O
T	O	O
(	O	O
2	O	O
)	O	O
was	O	O
further	O	O
evaluated	O	O
as	O	O
a	O	O
component	O	O
of	O	O
a	O	O
short	O	O
oligodeoxynucleotide	O	O
(	O	O
ODN	O	O
)	O	O
phosphorothioate	O	O
(	O	O
5'	O	O
-	O	O
CTTCATTTTTTCTTC	O	O
-	O	O
3'	O	O
)	O	O
where	O	O
all	O	O
thymidines	O	O
were	O	O
replaced	O	O
by	O	O
2	O	O
.	O	O
Several	O	O
benzoxazole	B-IUPAC	O
-	O	O
and	O	O
1,2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxadiazole	I-IUPAC	I-IUPAC
-	O	O
derived	O	O
analogues	B-MODIFIER	O
were	O	O
found	O	O
to	O	O
be	O	O
potent	O	O
inhibitors	O	O
of	O	O
aldose	O	O
reductase	O	O
from	O	O
human	O	O
placenta	O	O
and	O	O
were	O	O
orally	O	O
active	O	O
in	O	O
preventing	O	O
sorbitol	O	O
accumulation	O	O
in	O	O
rat	O	O
sciatic	O	O
nerve	O	O
,	O	O
in	O	O
an	O	O
acute	O	O
test	O	O
of	O	O
diabetic	O	O
complications	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acylethynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracils	I-IUPAC	I-IUPAC
have	O	O
also	O	O
shown	O	O
in	O	O
vitro	O	O
activity	O	O
against	O	O
CCRF	O	O
-	O	O
CEM	O	O
and	O	O
L1210/0	O	O
tumor	O	O
cell	O	O
lines	O	O
.	O	O
)	O	O
and	O	O
P	O	O
.	O	O
Several	O	O
novel	O	O
substituted	B-MODIFIER	O
tetrahydro	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
hexahydro	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzisothiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxides	I-IUPAC	I-IUPAC
and	O	O
thiadiazinones	B-IUPAC	O
were	O	O
prepared	O	O
and	O	O
examined	O	O
in	O	O
a	O	O
series	O	O
of	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
tests	O	O
to	O	O
determine	O	O
their	O	O
pharmacological	O	O
profile	O	O
.	O	O
A	O	O
series	B-MODIFIER	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
furoxans	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
by	O	O
oxidation	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylglyoxymes	I-IUPAC	I-IUPAC
with	O	O
dinitrogen	O	O
tetroxide	O	O
.	O	O
The	O	O
configuration	O	O
of	O	O
the	O	O
cyclopentane	O	O
unit	O	O
determined	O	O
the	O	O
affinity	O	O
profile	O	O
:	O	O
a	O	O
1R	O	O
configuration	O	O
,	O	O
as	O	O
in	O	O
(	O	O
+	O	O
)	O	O
-	O	O
3	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
4	O	O
,	O	O
conferred	O	O
higher	O	O
affinity	O	O
at	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
-	O	O
adrenoreceptors	O	O
,	O	O
whereas	O	O
a	O	O
1S	O	O
configuration	O	O
,	O	O
as	O	O
in	O	O
(	O	O
-	O	O
)	O	O
-	O	O
3	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
4	O	O
,	O	O
produced	O	O
higher	O	O
affinity	O	O
for	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
receptors	O	O
.	O	O
All	O	O
compounds	O	O
were	O	O
tested	O	O
for	O	O
activity	O	O
against	O	O
HCMV	O	O
and	O	O
HSV	O	O
-	O	O
1	O	O
.	O	O
A	O	O
cyclic	O	O
3	O	O
-	O	O
keto	O	O
derivative	O	O
was	O	O
5	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
at	O	O
A3	O	O
receptors	O	O
than	O	O
a	O	O
related	O	O
open	O	O
-	O	O
ring	O	O
analogue	O	O
.	O	O
Substituted	B-MODIFIER	O
9H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indoles	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
carbolines	O	O
)	O	O
,	O	O
identified	O	O
in	O	O
our	O	O
laboratory	O	O
as	O	O
potential	O	O
pharmacophores	O	O
for	O	O
designing	O	O
macrofilaricidal	O	O
agents	O	O
,	O	O
have	O	O
been	O	O
explored	O	O
further	O	O
for	O	O
identifying	O	O
the	O	O
pharmacophore	O	O
responsible	O	O
for	O	O
the	O	O
high	O	O
order	O	O
of	O	O
adulticidal	O	O
activity	O	O
.	O	O
From	O	O
salicyclic	O	O
acid	O	O
,	O	O
the	O	O
two	O	O
enantiomers	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzamide	I-IUPAC	I-IUPAC
(	O	O
6b	O	O
)	O	O
were	O	O
prepared	O	O
in	O	O
a	O	O
five	O	O
-	O	O
step	O	O
synthesis	O	O
.	O	O
A	O	O
series	O	O
of	O	O
new	O	O
enantiomerically	O	O
pure	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyrans	I-IUPAC	I-IUPAC
(	O	O
3	B-IUPAC	O
-	I-IUPAC	O
aminochromans	I-IUPAC	O
)	O	O
has	O	O
been	O	O
synthesized	O	O
from	O	O
(	B-PARTIUPAC	B-PARTIUPAC
R	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
.	O	O
The	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzoate	I-IUPAC	I-IUPAC
23	O	O
was	O	O
nearly	O	O
twice	O	O
as	O	O
active	O	O
as	O	O
codeine	O	O
in	O	O
the	O	O
mouse	O	O
hot	O	O
-	O	O
plate	O	O
assay	O	O
.	O	O
Interestingly	O	O
,	O	O
another	O	O
analogue	O	O
of	O	O
this	O	O
series	O	O
,	O	O
[	O	O
Dmt1	O	O
,	O	O
d	O	O
-	O	O
1	O	O
-	O	O
Nal4	O	O
]	O	O
endomorphin	O	O
-	O	O
1	O	O
,	O	O
turned	O	O
out	O	O
to	O	O
be	O	O
a	O	O
moderately	O	O
potent	O	O
mixed	O	O
mu	O	O
-	O	O
agonist	O	O
/	O	O
delta	O	O
-	O	O
antagonist	O	O
.	O	O
Therefore	O	O
,	O	O
(	O	O
i	O	O
)	O	O
to	O	O
develop	O	O
affinity	O	O
labels	O	O
of	O	O
the	O	O
receptor	O	O
not	O	O
susceptible	O	O
to	O	O
hydrolysis	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
to	O	O
specify	O	O
the	O	O
structural	O	O
requirements	O	O
for	O	O
17	O	O
alpha	O	O
-	O	O
electrophilic	O	O
estradiol	O	O
derivatives	O	O
to	O	O
be	O	O
potent	O	O
affinity	O	O
labels	O	O
of	O	O
the	O	O
receptor	O	O
,	O	O
we	O	O
prepared	O	O
four	O	O
17	B-IUPAC	B-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
haloacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
estradiols	I-IUPAC	I-IUPAC
.	O	O
All	O	O
of	O	O
these	O	O
compounds	O	O
were	O	O
cytotoxic	O	O
to	O	O
H	O	O
.	O	O
The	O	O
3	O	O
-	O	O
and	O	O
4	O	B-MODIFIER
-	O	I-MODIFIER
monosubstituted	O	I-MODIFIER
and	O	O
the	O	O
3,4	O	O
-	O	O
disubstituted	O	O
benzoate	O	O
esters	O	O
were	O	O
examined	O	O
for	O	O
qualitative	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
with	O	O
respect	O	O
to	O	O
parameters	O	O
Esc	O	O
and	O	O
pi	O	O
.	O	O
(	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methanone	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
also	O	O
has	O	O
a	O	O
favorable	O	O
anticonvulsant	O	O
depression	O	O
ratio	O	O
.	O	O
These	O	O
tetraamines	O	O
include	O	O
a	O	O
simple	O	O
linear	O	O
analogue	O	O
of	O	O
DESPM	O	O
,	O	O
N1	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
spermine	I-IUPAC	I-IUPAC
(	O	O
FDESPM	O	O
)	O	O
,	O	O
the	O	O
cyclic	O	O
analogues	O	O
of	O	O
DESPM	O	O
,	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminobutane	I-IUPAC	I-IUPAC
[	O	O
PIP	O	O
(	O	O
4,4,4	O	O
)	O	O
]	O	O
and	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminobutane	I-IUPAC	I-IUPAC
[	O	O
PIP	O	O
(	O	O
5,4,5	O	O
)	O	O
]	O	O
,	O	O
and	O	O
their	O	O
aromatic	O	O
counterparts	O	O
,	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminobutane	I-IUPAC	I-IUPAC
[	O	O
PYR	O	O
(	O	O
4,4,4	O	O
)	O	O
]	O	O
and	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminobutane	I-IUPAC	I-IUPAC
[	O	O
PYR	O	O
(	O	O
5,4,5	O	O
)	O	O
]	O	O
.	O	O
The	O	O
ability	O	O
of	O	O
selected	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyridinones	I-IUPAC	I-IUPAC
to	O	O
facilitate	O	O
the	O	O
excretion	O	O
of	O	O
iron	O	O
in	O	O
bile	O	O
was	O	O
investigated	O	O
in	O	O
non	O	O
-	O	O
iron	O	O
-	O	O
overloaded	O	O
,	O	O
bile	O	O
duct	O	O
-	O	O
cannulated	O	O
rats	O	O
and	O	O
in	O	O
a	O	O
[	O	O
59Fe	O	O
]	O	O
ferritin	O	O
-	O	O
loaded	O	O
rat	O	O
model	O	O
.	O	O
An	O	O
antagonism	O	O
toward	O	O
the	O	O
negative	O	O
influence	O	O
exerted	O	O
by	O	O
endogenous	O	O
adenosine	O	O
on	O	O
the	O	O
heart	O	O
seems	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
contractile	O	O
activity	O	O
of	O	O
compound	O	O
28	O	O
.	O	O
Fifteen	O	O
of	O	O
these	O	O
analogues	O	O
(	O	O
all	O	O
but	O	O
6	O	O
)	O	O
appear	O	O
as	O	O
potent	O	O
or	O	O
more	O	O
potent	O	O
in	O	O
vivo	O	O
oxytocin	O	O
antagonists	O	O
than	O	O
C	O	O
(	O	O
pA2	O	O
=	O	O
7.37	O	O
+	O	O
/	O	O
-	O	O
0.17	O	O
)	O	O
.	O	O
Additional	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
encompassing	O	O
a	O	O
variety	O	O
of	O	O
heterocyclic	O	O
side	O	O
chains	O	O
are	O	O
discussed	O	O
.	O	O
Its	O	O
p	O	B-IUPAC
-	O	I-IUPAC
methoxy	O	I-IUPAC
analogue	O	B-MODIFIER
5c	O	O
is	O	O
a	O	O
mixed	O	O
inhibitor	O	O
of	O	O
norepinephrine	O	O
and	O	O
serotonin	O	O
reuptake	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
187	O	O
nM	O	O
at	O	O
the	O	O
NET	O	O
and	O	O
56	O	O
nM	O	O
at	O	O
the	O	O
SERT	O	O
)	O	O
.	O	O
The	O	O
macrofilaricidal	O	O
activity	O	O
was	O	O
initially	O	O
evaluated	O	O
in	O	O
vivo	O	O
against	O	O
Acanthoeilonema	O	O
viteae	O	O
.	O	O
6	O	B-IUPAC
-	O	I-IUPAC
[	O	I-IUPAC
5	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
Amidinophenyl	O	I-IUPAC
)	O	I-IUPAC
furan	O	I-IUPAC
-	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
yl	O	I-IUPAC
]	O	I-IUPAC
nicotinamidine	O	I-IUPAC
(	O	O
8a	O	O
)	O	O
was	O	O
synthesized	O	O
from	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
nicotinonitrile	I-IUPAC	I-IUPAC
(	O	O
4a	O	O
)	O	O
,	O	O
through	O	O
the	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyamidoxime	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
hydrogenation	O	O
.	O	O
Twenty	O	O
-	O	O
six	O	O
compounds	O	O
derived	O	O
from	O	O
the	O	O
5	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
deaza	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
5,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dideazaaminopterin	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
of	O	O
aminopterin	O	O
analogues	O	O
were	O	O
evaluated	O	O
for	O	O
antiarthritic	O	O
activity	O	O
in	O	O
the	O	O
mouse	O	O
type	O	O
II	O	O
collagen	O	O
model	O	O
.	O	O
Against	O	O
Ma	O	O
DHFR	O	O
,	O	O
28	O	O
had	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
and	O	O
SI	O	O
values	O	O
of	O	O
1.5	O	O
nM	O	O
and	O	O
430	O	O
,	O	O
respectively	O	O
,	O	O
compared	O	O
with	O	O
300	O	O
nM	O	O
and	O	O
610	O	O
for	O	O
TMP	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
the	O	O
most	O	O
potent	O	O
Pgp	O	O
inhibitors	O	O
were	O	O
found	O	O
among	O	O
AbA	O	O
analogues	O	O
with	O	O
[	O	O
betaHO	O	O
-	O	O
MeVal	O	O
(	O	O
9	O	O
)	O	O
]	O	O
residue	O	O
alterations	O	O
,	O	O
with	O	O
some	O	O
data	O	O
suggesting	O	O
a	O	O
negative	O	O
impact	O	O
of	O	O
the	O	O
[	O	O
L	O	O
-	O	O
Leu	O	O
(	O	O
8	O	O
)	O	O
-	O	O
L	O	O
-	O	O
betaHOMeVal	O	O
(	O	O
9	O	O
)	O	O
-	O	O
D	O	O
-	O	O
Hmp	O	O
(	O	O
1	O	O
)	O	O
]	O	O
gamma	O	O
-	O	O
turn	O	O
secondary	O	O
structure	O	O
on	O	O
Pgp	O	O
inhibitory	O	O
potential	O	O
.	O	O
Moreover	O	O
,	O	O
in	O	O
vivo	O	O
binding	O	O
of	O	O
the	O	O
methyl	O	O
homologue	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
8	O	O
in	O	O
the	O	O
monkey	O	O
brain	O	O
could	O	O
be	O	O
inhibited	O	O
by	O	O
PBR	O	O
-	O	O
selective	O	O
2	O	O
or	O	O
1	O	O
,	O	O
indicating	O	O
that	O	O
some	O	O
of	O	O
the	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
8	O	O
binding	O	O
was	O	O
due	O	O
to	O	O
PBR	O	O
.	O	O
Analogues	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
4-6	O	O
exhibit	O	O
no	O	O
detectable	O	O
antidiuretic	O	O
agonistic	O	O
activity	O	O
.	O	O
The	O	O
identification	O	O
of	O	O
triazolinone	O	O
-	O	O
based	O	O
sulfonamide	O	O
derivatives	O	O
combining	O	O
high	O	O
AT1	O	O
affinity	O	O
,	O	O
considerably	O	O
enhanced	O	O
AT2	O	O
potency	O	O
,	O	O
and	O	O
favorable	O	O
in	O	O
vivo	O	O
properties	O	O
provides	O	O
insights	O	O
relevant	O	O
to	O	O
the	O	O
design	O	O
of	O	O
dual	O	O
AT1	O	O
/	O	O
AT2	O	O
receptor	O	O
antagonists	O	O
.	O	O
The	O	O
C3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
is	O	O
10	O	O
-	O	O
fold	O	O
less	O	O
active	O	O
than	O	O
H1	O	O
,	O	O
and	O	O
SQS	O	O
inhibitory	O	O
activity	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
the	O	O
methyl	O	O
ester	O	O
was	O	O
retained	O	O
only	O	O
in	O	O
those	O	O
C3	O	O
-	O	O
heterocycle	O	O
-	O	O
substituted	O	O
H1	O	O
analogues	O	O
for	O	O
which	O	O
electrostatic	O	O
potential	O	O
maps	O	O
of	O	O
the	O	O
C3	O	O
-	O	O
substituent	O	O
were	O	O
closely	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
a	O	O
methyl	O	O
ester	O	O
.	O	O
Agonist	O	O
effects	O	O
were	O	O
sensitive	O	O
to	O	O
blockade	O	O
by	O	O
the	O	O
selective	O	O
H	O	O
(	O	O
1	O	O
)	O	O
-	O	O
receptor	O	O
antagonist	O	O
mepyramine	O	O
(	O	O
pA	O	O
(	O	O
2	O	O
)	O	O
approximately	O	O
9	O	O
(	O	O
guinea	O	O
-	O	O
pig	O	O
)	O	O
and	O	O
pA	O	O
(	O	O
2	O	O
)	O	O
approximately	O	O
8	O	O
(	O	O
rat	O	O
aorta	O	O
)	O	O
)	O	O
.	O	O
Analogues	O	O
of	O	O
degarelix	O	O
were	O	O
synthesized	O	O
,	O	O
characterized	O	O
,	O	O
and	O	O
screened	O	O
for	O	O
the	O	O
antagonism	O	O
of	O	O
GnRH	O	O
-	O	O
induced	O	O
response	O	O
in	O	O
a	O	O
reporter	O	O
gene	O	O
assay	O	O
in	O	O
HEK	O	O
-	O	O
293	O	O
cells	O	O
expressing	O	O
the	O	O
human	O	O
GnRH	O	O
receptor	O	O
.	O	O
Reaction	O	O
of	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dibromopropene	I-IUPAC	I-IUPAC
(	O	O
19	O	O
)	O	O
with	O	O
adenine	O	O
(	O	O
18	O	O
)	O	O
led	O	O
to	O	O
bromoalkene	O	O
20	O	O
,	O	O
which	O	O
was	O	O
benzoylated	O	O
to	O	O
give	O	O
N6	B-IUPAC	O
,	I-IUPAC	O
N6	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dibenzoyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
23	O	O
.	O	O
3	O	B-IUPAC
-	O	I-IUPAC
Deoxy	O	I-IUPAC
-	O	I-IUPAC
2,5	O	I-IUPAC
-	O	I-IUPAC
di	O	I-IUPAC
-	O	I-IUPAC
O	O	I-IUPAC
-	O	I-IUPAC
p	O	I-IUPAC
-	O	I-IUPAC
nitrobenzoyl	O	I-IUPAC
-	O	I-IUPAC
alpha	O	I-IUPAC
-	O	I-IUPAC
D	O	I-IUPAC
-	O	I-IUPAC
threo	O	I-IUPAC
-	O	I-IUPAC
entofuranosyl	O	I-IUPAC
bromide	O	I-IUPAC
(	O	O
1	O	O
)	O	O
reacted	O	O
with	O	O
mercuric	O	O
cyanide	O	O
to	O	O
give	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
anhydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
lyxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexononitrile	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
which	O	O
upon	O	O
acid	O	O
hydrolysis	O	O
of	O	O
the	O	O
CN	O	O
group	O	O
gave	O	O
acid	O	O
3	O	O
.	O	O
2	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
Chloro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
2	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
bromo	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fucose	I-IUPAC	I-IUPAC
(	O	O
9a	O	O
,	O	O
9b	O	O
,	O	O
and	O	O
13	O	O
,	O	O
respectively	O	O
)	O	O
have	O	O
been	O	O
prepared	O	O
by	O	O
addition	O	O
of	O	O
the	O	O
appropriate	O	O
halogen	O	O
to	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fucal	I-IUPAC	I-IUPAC
,	O	O
followed	O	O
by	O	O
hydrolysis	O	O
of	O	O
the	O	O
anomeric	O	O
halogen	O	O
and	O	O
the	O	O
acetyl	O	O
groups	O	O
.	O	O
The	O	O
relative	O	O
activities	O	O
for	O	O
mRNA	O	O
induction	O	O
of	O	O
the	O	O
pS2	O	O
gene	O	O
in	O	O
MCF	O	O
-	O	O
7	O	O
cell	O	O
cultures	O	O
by	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
estrogens	I-IUPAC	I-IUPAC
closely	O	O
parallel	O	O
the	O	O
relative	O	O
binding	O	O
affinities	O	O
.	O	O
These	O	O
results	O	O
suggested	O	O
that	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
tripeptide	O	O
was	O	O
likely	O	O
to	O	O
assume	O	O
a	O	O
folded	O	O
conformation	O	O
favoring	O	O
the	O	O
close	O	O
proximity	O	O
of	O	O
the	O	O
side	O	O
chains	O	O
of	O	O
residues	O	O
1	O	O
and	O	O
3	O	O
.	O	O
All	O	O
of	O	O
the	O	O
test	O	O
compounds	O	O
were	O	O
potent	O	O
inhibitors	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
5	O	O
-	O	O
HT	O	O
uptake	O	O
into	O	O
synaptosomes	O	O
in	O	O
vitro	O	O
,	O	O
with	O	O
the	O	O
S	O	O
enantiomer	O	O
of	O	O
6	O	O
being	O	O
most	O	O
active	O	O
.	O	O
This	O	O
compound	O	O
is	O	O
noncompetitive	O	O
with	O	O
the	O	O
ubiquinone	O	O
substrate	O	O
and	O	O
interacts	O	O
with	O	O
a	O	O
site	O	O
which	O	O
is	O	O
mutually	O	O
exclusive	O	O
with	O	O
that	O	O
of	O	O
rotenone	O	O
but	O	O
nonexclusive	O	O
with	O	O
that	O	O
of	O	O
piericidin	O	O
and	O	O
several	O	O
other	O	O
inhibitors	O	O
of	O	O
NADH	O	O
dehydrogenase	O	O
.	O	O
This	O	O
study	O	O
emphasizes	O	O
the	O	O
importance	O	O
of	O	O
the	O	O
metabolic	O	O
conversion	O	O
of	O	O
the	O	O
enantiomers	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylpiperidine	I-IUPAC	I-IUPAC
(	O	O
3	O	O
-	O	O
PPP	O	O
)	O	O
into	O	O
their	O	O
catechol	O	O
analogues	O	O
,	O	O
the	O	O
enantiomers	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylpiperidine	I-IUPAC	I-IUPAC
.	O	O
Selective	O	O
methylation	O	O
of	O	O
the	O	O
phenolic	B-MODIFIER	O
hydroxyl	B-IUPAC	O
group	B-MODIFIER	O
of	O	O
to	O	O
give	O	O
1	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbutyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ammoniohexanoate	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
,	O	O
resulted	O	O
in	O	O
a	O	O
small	O	O
decrease	O	O
in	O	O
activity	O	O
.	O	O
These	O	O
data	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
mifentidine	O	O
,	O	O
like	O	O
cimetidine	O	O
,	O	O
acts	O	O
through	O	O
the	O	O
neutral	O	O
species	O	O
.	O	O
Good	O	O
penetration	O	O
into	O	O
the	O	O
CNS	O	O
was	O	O
documented	O	O
both	O	O
after	O	O
subcutaneous	O	O
and	O	O
peroral	O	O
administration	O	O
of	O	O
Lu	O	O
28-179	O	O
by	O	O
ex	O	O
vivo	O	O
binding	O	O
studies	O	O
.	O	O
A	O	O
similar	O	O
sequence	O	O
starting	O	O
from	O	O
methyl	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
delta	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyloxycarbonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ornithine	I-IUPAC	I-IUPAC
led	O	O
to	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoindolyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopentanoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
and	O	O
the	O	O
(	B-IUPAC	B-IUPAC
6R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
4	O	O
.	O	O
The	O	O
diamines	O	B-IUPAC
N	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoaceto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
xylidide	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
aceto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
xylidide	I-IUPAC	I-IUPAC
(	O	O
29	O	O
)	O	O
are	O	O
especially	O	O
promising	O	O
in	O	O
this	O	O
respect	O	O
.	O	O
Since	O	O
the	O	O
binding	O	O
conformation	O	O
of	O	O
residue	O	O
1	O	O
must	O	O
be	O	O
included	O	O
in	O	O
this	O	O
limited	O	O
conformational	O	O
intersection	O	O
,	O	O
its	O	O
elucidation	O	O
is	O	O
facilitated	O	O
.	O	O
Substitution	O	O
at	O	O
the	O	O
ortho	O	O
or	O	O
meta	O	O
positions	O	O
of	O	O
the	O	O
phenyl	O	B-IUPAC
rings	O	B-MODIFIER
,	O	O
replacement	O	O
by	O	O
thiopheneyl	O	O
or	O	O
cyclohexyl	O	O
moieties	O	O
,	O	O
or	O	O
constraining	O	O
in	O	O
a	O	O
planar	O	O
phenanthrene	O	O
system	O	O
resulted	O	O
in	O	O
compounds	O	O
that	O	O
were	O	O
less	O	O
effective	O	O
inhibitors	O	O
of	O	O
ADP	O	O
-	O	O
induced	O	O
platelet	O	O
aggregation	O	O
.	O	O
Most	O	O
notably	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
fluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperazine	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
and	O	O
hexahydro	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diazepine	I-IUPAC	I-IUPAC
(	O	O
16	O	O
,	O	O
fluorohomopiperazine	O	O
)	O	O
at	O	O
the	O	O
quinolone	O	O
C	O	O
-	O	O
7	O	O
position	O	O
produced	O	O
products	O	O
with	O	O
similar	O	O
in	O	O
vitro	O	O
antibacterial	O	O
activity	O	O
as	O	O
the	O	O
ciprofloxacin	O	O
reference	O	O
.	O	O
As	O	O
deduced	O	O
by	O	O
the	O	O
rotarod	O	O
test	O	O
,	O	O
all	O	O
the	O	O
compounds	O	O
exhibit	O	O
a	O	O
toxicity	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
1	O	O
.	O	O
X	O	O
-	O	O
ray	O	O
analyses	O	O
of	O	O
1	O	O
and	O	O
2	O	O
are	O	O
reported	O	O
,	O	O
and	O	O
compound	O	O
1	O	O
is	O	O
the	O	O
first	O	O
example	O	O
in	O	O
which	O	O
the	O	O
cbdca	O	O
ligand	O	O
is	O	O
coordinated	O	O
to	O	O
a	O	O
ruthenium	O	O
center	O	O
.	O	O
This	O	O
publication	O	O
describes	O	O
the	O	O
synthesis	O	O
and	O	O
optimization	O	O
of	O	O
a	O	O
novel	O	O
series	O	O
of	O	O
stilbene	O	O
endothelin	O	O
antagonists	O	O
.	O	O
Three	O	O
analogs	O	O
,	O	O
5	O	O
(	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylmorphinan	I-IUPAC	I-IUPAC
)	O	O
,	O	O
14	O	O
(	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylmorphinan	I-IUPAC	I-IUPAC
)	O	O
,	O	O
and	O	O
15	O	O
(	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylmorphinan	I-IUPAC	I-IUPAC
)	O	O
were	O	O
found	O	O
to	O	O
possess	O	O
potent	O	O
anticonvulsant	O	O
activity	O	O
with	O	O
full	O	O
efficacy	O	O
(	O	O
ED50	O	O
25	O	O
,	O	O
5.6	O	O
,	O	O
and	O	O
3.9	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
sc	O	O
,	O	O
respectively	O	O
)	O	O
in	O	O
the	O	O
rat	O	O
supramaximal	O	O
electroshock	O	O
(	O	O
MES	O	O
)	O	O
test	O	O
.	O	O
Each	O	O
compound	O	O
was	O	O
characterized	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
following	O	O
:	O	O
structure	O	O
,	O	O
(	B-IUPAC	B-IUPAC
hydroxyimino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
dissociation	O	O
constant	O	O
,	O	O
nucleophilicity	O	O
toward	O	O
trigonal	O	O
carbon	O	O
and	O	O
tetrahedral	O	O
phosphorus	O	O
,	O	O
octanol	O	O
-	O	O
buffer	O	O
partition	O	O
coefficient	O	O
,	O	O
reversible	O	O
inhibition	O	O
of	O	O
eel	O	O
acetylcholinesterase	O	O
(	O	O
AChE	O	O
)	O	O
,	O	O
and	O	O
in	O	O
vitro	O	O
reactivation	O	O
of	O	O
AChE	O	O
inhibited	O	O
by	O	O
ethyl	O	B-IUPAC
p	O	I-IUPAC
-	O	I-IUPAC
nitrophenyl	O	I-IUPAC
methylphosphonate	O	I-IUPAC
.	O	O
This	O	O
compound	O	O
does	O	O
not	O	O
bind	O	O
in	O	O
vivo	O	O
to	O	O
alpha7	O	O
nicotinic	O	O
or	O	O
5HT3	O	O
receptors	O	O
.	O	O
The	O	O
1	O	O
:	O	O
1	O	O
diastereomeric	O	O
mixtures	O	O
thus	O	O
obtained	O	O
were	O	O
separated	O	O
by	O	O
chromatography	O	O
,	O	O
using	O	O
poly	O	O
(	O	O
D	O	O
-	O	O
phenylglycine	O	O
)	O	O
as	O	O
the	O	O
chiral	O	O
stationary	O	O
phase	O	O
.	O	O
gondii	O	O
DHFR	O	O
.	O	O
A	O	O
family	O	O
of	O	O
analogues	O	O
of	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
/	O	O
D2Nal	O	O
(	O	O
8	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
that	O	O
contain	O	O
a	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminomethylphenylalanine	I-IUPAC	I-IUPAC
(	O	O
IAmp	O	O
)	O	O
at	O	O
position	O	O
9	O	O
was	O	O
identified	O	O
that	O	O
has	O	O
high	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
human	O	O
somatostatin	O	O
receptor	O	O
subtype	O	O
1	O	O
(	O	O
sst1	O	O
)	O	O
.	O	O
Incubation	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxytryptamine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
with	O	O
L	O	B-IUPAC
-	O	I-IUPAC
cysteine	O	I-IUPAC
and	O	O
pig	O	O
or	O	O
bovine	O	O
brain	O	O
microsomes	O	O
and	O	O
an	O	O
NADPH	O	O
-	O	O
generating	O	O
system	O	O
or	O	O
with	O	O
synaptosomes	O	O
results	O	O
in	O	O
the	O	O
rapid	O	O
formation	O	O
of	O	O
the	O	O
(	B-MODIFIER	O
2R	I-MODIFIER	O
,	I-MODIFIER	O
4R	I-MODIFIER	O
)	I-MODIFIER	O
-	I-MODIFIER	O
and	O	O
(	B-MODIFIER	O
2S	I-MODIFIER	O
,	I-MODIFIER	O
4R	I-MODIFIER	O
)	I-MODIFIER	O
-	I-MODIFIER	O
epimers	I-MODIFIER	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazolidine	I-IUPAC	I-IUPAC
.	O	O
Although	O	O
this	O	O
substituent	O	O
may	O	O
play	O	O
a	O	O
minor	O	O
role	O	O
in	O	O
orienting	O	O
the	O	O
conformation	O	O
of	O	O
the	O	O
5	O	B-IUPAC
-	O	I-IUPAC
methoxy	O	I-IUPAC
group	O	B-MODIFIER
in	O	O
derivatives	O	O
such	O	O
as	O	O
4	O	O
and	O	O
5	O	O
,	O	O
there	O	O
appears	O	O
to	O	O
be	O	O
some	O	O
other	O	O
,	O	O
as	O	O
yet	O	O
unknown	O	O
,	O	O
critical	O	O
receptor	O	O
interaction	O	O
.	O	O
The	O	O
affinity	O	O
of	O	O
(	O	O
S	O	O
)	O	O
-	O	O
FIPCT	O	O
and	O	O
(	O	O
R	O	O
)	O	O
-	O	O
FIPCT	O	O
for	O	O
SERT	O	O
was	O	O
127	O	O
-	O	O
and	O	O
20	O	O
-	O	O
fold	O	O
lower	O	O
,	O	O
respectively	O	O
,	O	O
than	O	O
for	O	O
DAT	O	O
.	O	O
A	O	O
comparison	O	O
of	O	O
the	O	O
conformations	O	O
of	O	O
these	O	O
analogues	O	O
with	O	O
those	O	O
displayed	O	O
by	O	O
Leu5	O	O
-	O	O
enkephalin	O	O
has	O	O
also	O	O
been	O	O
made	O	O
,	O	O
and	O	O
unexpected	O	O
similarities	O	O
have	O	O
been	O	O
revealed	O	O
.	O	O
The	O	O
presence	O	O
of	O	O
an	O	O
additional	O	O
methyl	O	O
group	O	O
at	O	O
the	O	O
C	O	O
-	O	O
2	O	O
position	O	O
(	O	O
R3	O	O
in	O	O
3	O	O
)	O	O
of	O	O
the	O	O
cis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
analog	B-MODIFIER	O
resulted	O	O
in	O	O
enhancement	O	O
of	O	O
in	O	O
vitro	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
binding	O	O
affinity	O	O
,	O	O
with	O	O
the	O	O
(	O	O
2	O	O
beta	O	O
,	O	O
3a	O	O
alpha	O	O
,	O	O
9a	O	O
alpha	O	O
)	O	O
-	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
isomer	O	O
displaying	O	O
potency	O	O
35	O	O
times	O	O
greater	O	O
than	O	O
the	O	O
(	O	O
2	O	O
alpha	O	O
,	O	O
3a	O	O
alpha	O	O
,	O	O
9a	O	O
alpha	O	O
)	O	O
-	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
isomer	O	O
.	O	O
Although	O	O
there	O	O
existed	O	O
extensive	O	O
metabolizers	O	O
and	O	O
poor	O	O
metabolizers	O	O
in	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
administrated	O	O
6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxyquinazoline	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
1b	O	O
and	O	O
1c	O	O
)	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyquinazoline	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
16k	O	O
showed	O	O
no	O	O
metabolic	O	O
polymorphism	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
high	O	O
potency	O	O
of	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dialkylxanthines	I-IUPAC	I-IUPAC
,	O	O
the	O	O
parent	O	O
compounds	O	O
were	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carboxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
theophylline	O	O
and	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dipropylxanthine	I-IUPAC	I-IUPAC
.	O	O
The	O	O
ampicillin	O	O
derivative	O	O
7b	O	O
(	O	O
HKI	O	O
9924154	O	O
)	O	O
and	O	O
the	O	O
corresponding	O	O
amoxicillin	O	O
derivative	O	O
8	O	O
(	O	O
HKI	O	O
9924155	O	O
)	O	O
represent	O	O
the	O	O
most	O	O
active	O	O
compounds	O	O
.	O	O
Removal	O	O
of	O	O
the	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyl	I-IUPAC	I-IUPAC
and	O	O
allyl	B-IUPAC	B-IUPAC
groups	B-MODIFIER	B-MODIFIER
gave	O	O
2,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
which	O	O
was	O	O
phosphitylated	O	O
with	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diisopropylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phosphine	I-IUPAC	I-IUPAC
to	O	O
give	O	O
the	O	O
fully	O	O
protected	O	O
trisphosphite	O	O
triester	O	O
.	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulfanylpyrimidine	I-IUPAC	I-IUPAC
gave	O	O
,	O	O
on	O	O
treatment	O	O
with	O	O
diisopropyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloroethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methylphosphonate	I-IUPAC	I-IUPAC
in	O	O
the	O	O
presence	O	O
of	O	O
NaH	O	O
and	O	O
subsequent	O	O
deprotection	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonomethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
sulfanyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
.	O	O
The	O	O
most	O	O
active	O	O
member	O	O
of	O	O
the	O	O
series	O	O
is	O	O
the	O	O
dihydrodiol	B-IUPAC	B-IUPAC
derivative	B-MODIFIER	B-MODIFIER
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylcholanthrene	I-IUPAC	I-IUPAC
,	O	O
which	O	O
contains	O	O
a	O	O
bay	O	O
region	O	O
methyl	B-IUPAC	O
group	B-MODIFIER	O
.	O	O
In	O	O
the	O	O
delayed	O	O
-	O	O
type	O	O
hypersensitivity	O	O
(	O	O
DTH	O	O
)	O	O
mouse	O	O
model	O	O
,	O	O
a	O	O
model	O	O
of	O	O
skin	O	O
inflammation	O	O
,	O	O
a	O	O
5%	O	O
solution	O	O
of	O	O
7d	O	O
reduced	O	O
edema	O	O
by	O	O
69%	O	O
compared	O	O
to	O	O
control	O	O
animals	O	O
.	O	O
The	O	O
latter	O	O
is	O	O
presumably	O	O
formed	O	O
by	O	O
dephosphorylation	O	O
of	O	O
FdUMP	O	O
by	O	O
plasma	O	O
5'	O	O
-	O	O
nucleotidases	O	O
or	O	O
phosphatases	O	O
.	O	O
Confirmed	O	O
in	O	O
vitro	O	O
cytotoxic	O	O
activity	O	O
that	O	O
parallels	O	O
antimicrobial	O	O
activity	O	O
was	O	O
found	O	O
for	O	O
juncusol	O	O
(	O	O
1a	O	O
)	O	O
,	O	O
desvinyljuncusol	O	O
(	O	O
2h	O	O
)	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenanthrene	I-IUPAC	I-IUPAC
(	O	O
3h	O	O
)	O	O
,	O	O
and	O	O
the	O	O
quaternary	B-MODIFIER	O
dimethyl	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ammonium	I-IUPAC	I-IUPAC
salts	B-MODIFIER	I-IUPAC
2d	O	O
and	O	O
3d	O	O
in	O	O
a	O	O
human	O	O
lymphoblastic	O	O
leukemia	O	O
cell	O	O
culture	O	O
(	O	O
CCRF	O	O
-	O	O
CEM	O	O
,	O	O
IC50	O	O
=	O	O
nt	O	O
,	O	O
9.3	O	O
,	O	O
nt	O	O
,	O	O
0.9	O	O
and	O	O
1.4	O	O
microgram	O	O
/	O	O
mL	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
B	O	O
-	O	O
16	O	O
mouse	O	O
melanoma	O	O
cell	O	O
culture	O	O
(	O	O
IC50	O	O
=	O	O
12.5	O	O
,	O	O
17.5	O	O
,	O	O
27.7	O	O
,	O	O
0.3	O	O
,	O	O
and	O	O
0.5	O	O
microgram	O	O
/	O	O
mL	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
and	O	O
L	O	O
-	O	O
1210	O	O
mouse	O	O
lymphocytic	O	O
leukemia	O	O
cell	O	O
culture	O	O
(	O	O
IC50	O	O
=	O	O
13.8	O	O
,	O	O
10.2	O	O
,	O	O
24.5	O	O
,	O	O
1.3	O	O
,	O	O
and	O	O
3.7	O	O
micrograms	O	O
/	O	O
mL	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
The	O	O
3	B-IUPAC	O
-	I-IUPAC	O
halogenated	I-IUPAC	O
2	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylhistamines	I-IUPAC	I-IUPAC
(	O	O
halogen	O	O
=	O	O
Br	O	O
(	O	O
35	O	O
)	O	O
and	O	O
I	O	O
(	O	O
36	O	O
)	O	O
)	O	O
were	O	O
equipotent	O	O
with	O	O
histamine	O	O
,	O	O
while	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
histamine	I-IUPAC	I-IUPAC
(	O	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethanamine	I-IUPAC	I-IUPAC
(	O	O
39	O	O
)	O	O
)	O	O
was	O	O
significantly	O	O
more	O	O
potent	O	O
than	O	O
histamine	O	O
(	O	O
39	O	O
:	O	O
pD2	O	O
=	O	O
6.81	O	O
,	O	O
relative	O	O
activity	O	O
=	O	O
128%	O	O
)	O	O
.	O	O
A	O	O
bulky	O	O
N5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diphenylacetyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
,	O	O
13	O	O
,	O	O
displayed	O	O
a	O	O
Ki	O	O
value	O	O
of	O	O
0	O	O
.	O	O
The	O	O
first	O	O
two	O	O
templates	O	O
studied	O	O
in	O	O
previous	O	O
investigations	O	O
corresponded	O	O
to	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxyribonolactone	I-IUPAC	I-IUPAC
(	O	O
template	O	O
I	O	O
)	O	O
and	O	O
4,4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
gamma	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyrolactone	I-IUPAC	I-IUPAC
(	O	O
template	O	O
II	O	O
)	O	O
,	O	O
with	O	O
the	O	O
latter	O	O
producing	O	O
potent	O	O
protein	O	O
kinase	O	O
C	O	O
(	O	O
PK	O	O
-	O	O
C	O	O
)	O	O
ligands	O	O
with	O	O
low	O	O
nanomolar	O	O
binding	O	O
affinities	O	O
.	O	O
High	O	O
activity	O	O
(	O	O
greater	O	O
than	O	O
100%	O	O
ILS	O	O
)	O	O
was	O	O
likewise	O	O
shown	O	O
by	O	O
the	O	O
bis	B-PARTIUPAC	B-IUPAC
(	I-PARTIUPAC	I-IUPAC
2,5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dimethylbenzyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
,	O	I-IUPAC
bis	B-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2,6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dichlorobenzyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
,	O	O
and	O	O
di	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
picolyl	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
of	O	O
MTX	O	O
and	O	O
by	O	O
the	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbutyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
of	O	O
DCM	O	O
.	O	O
Compound	O	O
5	O	O
was	O	O
the	O	O
more	O	O
potent	O	O
with	O	O
activity	O	O
against	O	O
human	O	O
cytomegalovirus	O	O
and	O	O
herpes	O	O
simplex	O	O
virus	O	O
type	O	O
1	O	O
.	O	O
However	O	O
,	O	O
the	O	O
pKa	O	O
of	O	O
the	O	O
nitrogens	O	O
in	O	O
the	O	O
groups	O	O
differ	O	O
;	O	O
thus	O	O
,	O	O
the	O	O
extent	O	O
of	O	O
protonation	O	O
and	O	O
the	O	O
charge	O	O
characteristics	O	O
among	O	O
the	O	O
members	O	O
of	O	O
the	O	O
groups	O	O
differ	O	O
.	O	O
Receptor	O	O
-	O	O
binding	O	O
studies	O	O
suggest	O	O
that	O	O
this	O	O
activity	O	O
was	O	O
not	O	O
a	O	O
consequence	O	O
of	O	O
activity	O	O
at	O	O
either	O	O
benzodiazepine	O	O
or	O	O
NMDA	O	O
-	O	O
type	O	O
glutamate	O	O
receptors	O	O
.	O	O
Reaction	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoquinone	I-IUPAC	I-IUPAC
imine	I-IUPAC	I-IUPAC
with	O	O
hydrochloric	O	O
acid	O	O
gave	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyacetanilide	I-IUPAC	I-IUPAC
,	O	O
whereas	O	O
ethanethiol	O	O
,	O	O
aniline	O	O
,	O	O
and	O	O
ethanol	O	O
gave	O	O
tetrahedral	O	O
adducts	O	O
resulting	O	O
from	O	O
addition	O	O
to	O	O
the	O	O
imine	O	O
carbon	O	O
.	O	O
In	O	O
regard	O	O
to	O	O
6,7	B-IUPAC	O
-	I-IUPAC	O
dimethoxy	I-IUPAC	O
groups	B-MODIFIER	O
,	O	O
ethoxy	O	O
analogues	O	O
showed	O	O
potent	O	O
activity	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
16b	O	O
is	O	O
0.04	O	O
microM	O	O
;	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
17a	O	O
is	O	O
0.01	O	O
microM	O	O
)	O	O
and	O	O
further	O	O
extension	O	O
of	O	O
the	O	O
alkyl	O	O
group	O	O
reduced	O	O
activity	O	O
.	O	O
1c	O	O
was	O	O
moderately	O	O
stable	O	O
in	O	O
aqueous	O	O
buffers	O	O
over	O	O
the	O	O
pH	O	O
range	O	O
1-7.4	O	O
(	O	O
T1/2	O	O
&	O	O
gt	O	O
;	O	O
30	O	O
h	O	O
)	O	O
.	O	O
Compound	O	O
13	O	O
does	O	O
not	O	O
affect	O	O
[	O	O
3H	O	O
]	O	O
glycine	O	O
binding	O	O
at	O	O
the	O	O
strychnine	O	O
-	O	O
insensitive	O	O
glycine	O	O
binding	O	O
site	O	O
,	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
MK801	O	O
binding	O	O
studies	O	O
showed	O	O
that	O	O
the	O	O
(	B-IUPAC	B-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazole	I-IUPAC	I-IUPAC
,	O	O
even	O	O
if	O	O
is	O	O
formed	O	O
,	O	O
would	O	O
probably	O	O
have	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
activity	O	O
of	O	O
tetrazol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylglycine	I-IUPAC	I-IUPAC
at	O	O
the	O	O
NMDA	O	O
receptor	O	O
.	O	O
The	O	O
5,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanone	I-IUPAC	I-IUPAC
proved	O	O
to	O	O
be	O	O
the	O	O
better	O	O
template	O	O
for	O	O
the	O	O
construction	O	O
of	O	O
DAG	O	O
surrogates	O	O
that	O	O
were	O	O
demonstrated	O	O
to	O	O
have	O	O
high	O	O
binding	O	O
affinities	O	O
for	O	O
the	O	O
biological	O	O
target	O	O
,	O	O
protein	O	O
kinase	O	O
C	O	O
(	O	O
PK	O	O
-	O	O
C	O	O
)	O	O
.	O	O
We	O	O
also	O	O
report	O	O
a	O	O
revision	O	O
of	O	O
our	O	O
previous	O	O
comparative	O	O
molecular	O	O
field	O	O
analysis	O	O
(	O	O
CoMFA	O	O
)	O	O
study	O	O
of	O	O
the	O	O
PAT	O	O
ligands	O	O
that	O	O
yields	O	O
a	O	O
highly	O	O
predictive	O	O
model	O	O
for	O	O
66	O	O
compounds	O	O
with	O	O
a	O	O
cross	O	O
-	O	O
validated	O	O
R	O	O
(	O	O
2	O	O
)	O	O
(	O	O
q	O	O
(	O	O
2	O	O
)	O	O
)	O	O
value	O	O
of	O	O
0.67	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
formamides	O	O
32	O	O
(	O	O
N	B-IUPAC	O
-	I-IUPAC	O
heptyl	I-IUPAC	O
)	O	O
and	O	O
33	O	O
(	O	O
N	B-IUPAC	O
-	I-IUPAC	O
octyl	I-IUPAC	O
)	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
inhibiting	O	O
the	O	O
type	O	O
I	O	O
enzyme	O	O
(	O	O
IC50s	O	O
=	O	O
9.57	O	O
and	O	O
16.9	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
showed	O	O
also	O	O
strong	O	O
inhibitory	O	O
activity	O	O
(	O	O
IC50s	O	O
=	O	O
14.0	O	O
and	O	O
18.4	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
for	O	O
human	O	O
type	O	O
II	O	O
5	O	O
alpha	O	O
-	O	O
reductase	O	O
,	O	O
in	O	O
comparison	O	O
to	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
1'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
androst	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
MK	O	O
-	O	O
906	O	O
;	O	O
IC50	O	O
=	O	O
4.53	O	O
nM	O	O
)	O	O
.	O	O
Also	O	O
,	O	O
the	O	O
active	O	O
imidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
3	O	O
was	O	O
shown	O	O
to	O	O
cause	O	O
the	O	O
accumulation	O	O
of	O	O
cells	O	O
at	O	O
mitosis	O	O
.	O	O
The	O	O
present	O	O
survey	O	O
indicates	O	O
that	O	O
in	O	O
many	O	O
cases	O	O
such	O	O
reagents	O	O
may	O	O
be	O	O
difficult	O	O
of	O	O
access	O	O
when	O	O
data	O	O
are	O	O
not	O	O
available	O	O
regarding	O	O
structural	O	O
or	O	O
physicochemical	O	O
features	O	O
of	O	O
the	O	O
target	O	O
enzyme	O	O
adjacent	O	O
to	O	O
its	O	O
catalytic	O	O
site	O	O
.	O	O
Cathepsin	O	O
B	O	O
was	O	O
weakly	O	O
inhibited	O	O
by	O	O
most	O	O
compounds	O	O
in	O	O
this	O	O
study	O	O
.	O	O
It	O	O
displayed	O	O
a	O	O
potency	O	O
5	O	O
-	O	O
fold	O	O
higher	O	O
than	O	O
that	O	O
shown	O	O
by	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenedioxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzodiazepine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
,	O	O
GYKI	O	O
52466	O	O
)	O	O
,	O	O
a	O	O
well	O	O
-	O	O
known	O	O
noncompetitive	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
)	O	O
receptor	O	O
antagonist	O	O
.	O	O
This	O	O
was	O	O
demonstrated	O	O
by	O	O
assays	O	O
with	O	O
mutants	O	O
deficient	O	O
in	O	O
components	O	O
of	O	O
the	O	O
iron	O	O
transport	O	O
systems	O	O
.	O	O
HBr	O	O
)	O	O
was	O	O
found	O	O
to	O	O
be	O	O
more	O	O
potent	O	O
as	O	O
an	O	O
inhibitor	O	O
of	O	O
the	O	O
NADH	O	O
:	O	O
UBQ	O	O
activity	O	O
(	O	O
IC50	O	O
=	O	O
15-17	O	O
microM	O	O
)	O	O
than	O	O
the	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thienylimidazoles	I-IUPAC	I-IUPAC
such	O	O
as	O	O
10	O	O
.	O	O
The	O	O
new	O	O
leads	O	O
with	O	O
potent	O	O
H3	O	O
receptor	O	O
antagonist	O	O
activity	O	O
belong	O	O
to	O	O
a	O	O
series	O	O
of	O	O
derivatives	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propanol	I-IUPAC	I-IUPAC
with	O	O
carbamate	O	O
(	O	O
4-7	O	O
)	O	O
,	O	O
ester	O	O
(	O	O
8-16	O	O
)	O	O
,	O	O
and	O	O
ether	O	O
(	O	O
17-22	O	O
)	O	O
as	O	O
functional	O	O
groups	O	O
.	O	O
The	O	O
diamidines	O	O
8a	O	O
,	O	O
8c	O	O
,	O	O
and	O	O
14b	O	O
gave	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
versus	O	O
T	O	O
.	O	O
Correlations	O	O
between	O	O
antibacterial	O	O
potency	O	O
of	O	O
all	O	O
the	O	O
synthesized	O	O
7	B-IUPAC	O
-	I-IUPAC	O
azetidinylquinolones	I-IUPAC	O
and	O	O
naphthyridines	O	O
and	O	O
their	O	O
calculated	O	O
electronic	O	O
properties	O	O
and	O	O
experimental	O	O
capacity	O	O
factors	O	O
were	O	O
established	O	O
.	O	O
Thus	O	O
,	O	O
hydroxylation	O	O
of	O	O
norspermine	O	O
analogues	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
way	O	O
to	O	O
maintain	O	O
the	O	O
compounds	O	O
'	O	O
antiproliferative	O	O
activity	O	O
while	O	O
reducing	O	O
their	O	O
toxicity	O	O
.	O	O
All	O	O
members	O	O
of	O	O
the	O	O
series	O	O
were	O	O
designed	O	O
to	O	O
have	O	O
a	O	O
1,3	O	B-IUPAC
-	O	I-IUPAC
dioxolane	O	I-IUPAC
ring	O	B-MODIFIER
moiety	O	I-MODIFIER
in	O	O
their	O	O
carrier	O	O
ligands	O	O
to	O	O
increase	O	O
water	O	O
solubility	O	O
.	O	O
The	O	O
high	O	O
antiradiation	O	O
activity	O	O
and	O	O
low	O	O
toxicity	O	O
of	O	O
sodium	B-IUPAC	O
3	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypropyl	I-IUPAC	I-IUPAC
hydrogen	I-IUPAC	I-IUPAC
phosphorothioate	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
suggested	O	O
the	O	O
introduction	O	O
of	O	O
hydroxyl	B-IUPAC	O
groups	B-MODIFIER	O
into	O	O
other	O	O
types	O	O
of	O	O
radioprotective	O	O
phosphorothioates	O	O
.	O	O
PET	O	O
study	O	O
determined	O	O
that	O	O
the	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
ligands	O	O
preferably	O	O
accumulate	O	O
in	O	O
the	O	O
occipital	O	O
cortex	O	O
of	O	O
the	O	O
monkey	O	O
brain	O	O
,	O	O
a	O	O
region	O	O
with	O	O
a	O	O
high	O	O
density	O	O
of	O	O
PBR	O	O
in	O	O
the	O	O
primate	O	O
brain	O	O
.	O	O
Molecular	O	O
mechanical	O	O
calculations	O	O
on	O	O
AMPA	O	O
,	O	O
ATPA	O	O
,	O	O
and	O	O
ABPA	O	O
using	O	O
the	O	O
program	O	O
MM2	O	O
showed	O	O
that	O	O
conformations	O	O
of	O	O
AMPA	O	O
,	O	O
ABPA	O	O
,	O	O
and	O	O
especially	O	O
ATPA	O	O
by	O	O
rotation	O	O
of	O	O
the	O	O
amino	O	O
acid	O	O
side	O	O
chain	O	O
have	O	O
energy	O	O
barriers	O	O
.	O	O
Assuming	O	O
that	O	O
the	O	O
interaction	O	O
between	O	O
these	O	O
racemic	O	O
compounds	O	O
and	O	O
PK	O	O
-	O	O
C	O	O
is	O	O
stereospecific	O	O
,	O	O
the	O	O
potency	O	O
of	O	O
the	O	O
active	O	O
enantiomer	O	O
is	O	O
anticipated	O	O
to	O	O
double	O	O
.	O	O
Individual	O	O
substitution	O	O
of	O	O
the	O	O
nine	O	O
most	O	O
potent	O	O
peptides	O	O
identified	O	O
from	O	O
the	O	O
Ala	O	O
series	O	O
with	O	O
the	O	O
helix	O	O
promoter	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoisobutyric	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
Aib	O	O
)	O	O
produced	O	O
similar	O	O
results	O	O
,	O	O
except	O	O
for	O	O
[	O	O
Aib8	O	O
]	O	O
(	O	O
doubling	O	O
vs	O	O
[	O	O
Ala8	O	O
]	O	O
)	O	O
,	O	O
[	O	O
Aib9	O	O
]	O	O
(	O	O
having	O	O
vs	O	O
[	O	O
Ala9	O	O
]	O	O
)	O	O
,	O	O
and	O	O
[	O	O
Aib15	O	O
]	O	O
(	O	O
10	O	O
-	O	O
fold	O	O
decrease	O	O
vs	O	O
[	O	O
Ala15	O	O
]	O	O
)	O	O
.	O	O
The	O	O
antitumor	O	O
activity	O	O
of	O	O
various	O	O
platinum	O	O
(	O	O
II	O	O
)	O	O
complexes	O	O
of	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexanediamine	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexylamine	I-IUPAC	I-IUPAC
isomers	O	B-MODIFIER
against	O	O
leukemia	O	O
P388	O	O
was	O	O
evaluated	O	O
by	O	O
means	O	O
of	O	O
the	O	O
platinum	O	O
analogue	O	O
study	O	O
protocol	O	O
recommended	O	O
by	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
.	O	O
This	O	O
study	O	O
identified	O	O
these	O	O
structural	O	O
classes	O	O
as	O	O
novel	O	O
DNA	O	O
-	O	O
PK	O	O
inhibitors	O	O
and	O	O
delineated	O	O
initial	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
against	O	O
DNA	O	O
-	O	O
PK	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
our	O	O
recent	O	O
findings	O	O
that	O	O
[	B-IUPAC	B-IUPAC
188Re	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
tricarbonyl	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cyclopentadienylcarbonate	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
rhenium	I-IUPAC	I-IUPAC
(	O	O
[	O	O
188Re	O	O
]	O	O
CpTR	O	O
-	O	O
COOH	O	O
)	O	O
was	O	O
recognized	O	O
as	O	O
an	O	O
aromatic	O	O
compound	O	O
and	O	O
was	O	O
metabolized	O	O
as	O	O
such	O	O
in	O	O
the	O	O
body	O	O
,	O	O
[	O	O
99mTc	O	O
]	O	O
cyclopentadienyltricarbonyltechnetium	O	O
(	O	O
[	O	O
99mTc	O	O
]	O	O
CpTT	O	O
)	O	O
was	O	O
conjugated	O	O
at	O	O
the	O	O
omega	O	O
-	O	O
position	O	O
of	O	O
pentadecanoic	O	O
acid	O	O
to	O	O
prepare	O	O
[	O	O
99mTc	O	O
]	O	O
CpTT	O	O
-	O	O
PA	O	O
.	O	O
The	O	O
first	O	O
stage	O	O
of	O	O
acid	O	O
hydrolysis	O	O
of	O	O
these	O	O
four	O	O
oxazaphosphorines	O	O
is	O	O
a	O	O
P	O	O
-	O	O
N	O	O
bond	O	O
cleavage	O	O
of	O	O
the	O	O
six	O	O
-	O	O
membered	O	O
ring	O	O
leading	O	O
to	O	O
the	O	O
phosphoramidic	O	O
acid	O	O
monoesters	O	O
(	O	O
2a	O	O
-	O	O
d	O	O
)	O	O
of	O	O
type	O	O
R'	O	O
HN	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
3	O	O
)	O	O
OP	O	O
(	O	O
O	O	O
)	O	O
(	O	O
OH	O	O
)	O	O
NHR	O	O
,	O	O
with	O	O
R	O	O
and	O	O
/	O	O
or	O	O
R'	O	O
=	O	O
H	O	O
or	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
2	O	O
)	O	O
Cl	O	O
.	O	O
The	O	O
conformational	O	O
characteristics	O	O
of	O	O
two	O	O
series	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxytryptamine	I-IUPAC	I-IUPAC
(	O	O
5	O	O
-	O	O
HT	O	O
)	O	O
receptor	O	O
agonists	O	O
,	O	O
monophenolic	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dialkylated	B-MODIFIER	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminotetralins	I-IUPAC	I-IUPAC
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylcyclopropylamines	I-IUPAC	I-IUPAC
,	O	O
have	O	O
been	O	O
studied	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
experimental	O	O
(	O	O
NMR	O	O
spectroscopy	O	O
)	O	O
and	O	O
theoretical	O	O
(	O	O
molecular	O	O
mechanics	O	O
and	O	O
MNDO	O	O
calculations	O	O
)	O	O
methods	O	O
.	O	O
The	O	O
syntheses	O	O
and	O	O
anthelmintic	O	O
activities	O	O
of	O	O
31	O	O
3	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
isothiocyanatophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxadiazoles	I-IUPAC	I-IUPAC
are	O	O
reported	O	O
.	O	O
The	O	O
data	O	O
showed	O	O
that	O	O
endocytosis	O	O
of	O	O
the	O	O
octameric	O	O
RGD	O	O
derivative	O	O
was	O	O
significantly	O	O
higher	O	O
by	O	O
comparison	O	O
to	O	O
other	O	O
compounds	O	O
in	O	O
this	O	O
study	O	O
.	O	O
Attempts	O	O
to	O	O
synthesize	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
homoibotenic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4f	O	O
)	O	O
,	O	O
a	O	O
potential	O	O
receptor	O	O
alkylating	O	O
agent	O	O
,	O	O
were	O	O
unsuccessful	O	O
.	O	O
Condensation	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trimethylsilyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyethyl	I-IUPAC	I-IUPAC
acetoxymethyl	I-IUPAC	I-IUPAC
ether	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
SnCl4	O	O
afforded	O	O
the	O	O
acetate	O	O
ester	O	O
7	O	O
,	O	O
which	O	O
on	O	O
deprotection	O	O
with	O	O
NaOMe	O	O
gave	O	O
3	O	O
in	O	O
50-60%	O	O
overall	O	O
yield	O	O
.	O	O
Med.	O	O
Chem.	O	O
,	O	O
preceding	O	O
papers	O	O
in	O	O
this	O	O
issue	O	O
)	O	O
,	O	O
we	O	O
found	O	O
H	O	O
-	O	O
c	O	O
[	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
Phe	O	O
-	O	O
Trp	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
]	O	O
-	O	O
OH	O	O
(	O	O
OLT	O	O
-	O	O
8	O	O
,	O	O
2	O	O
)	O	O
,	O	O
H	O	O
-	O	O
c	O	O
[	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
Phe	O	O
-	O	O
L	O	O
-	O	O
threo	O	O
-	O	O
beta	O	O
-	O	O
MeTrp	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
]	O	O
-	O	O
OH	O	O
(	O	O
4	O	O
)	O	O
and	O	O
H	O	O
-	O	O
c	O	O
[	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
Phe	O	O
-	O	O
D	O	O
-	O	O
threo	O	O
-	O	O
beta	O	O
-	O	O
MeTrp	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
]	O	O
-	O	O
OH	O	O
(	O	O
5	O	O
)	O	O
to	O	O
have	O	O
very	O	O
high	O	O
affinity	O	O
for	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.7	O	O
,	O	O
1.8	O	O
,	O	O
and	O	O
4.0	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
5	O	O
-	O	O
to	O	O
10	O	O
-	O	O
fold	O	O
selectivity	O	O
versus	O	O
the	O	O
other	O	O
sst	O	O
's	O	O
.	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
aralkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
with	O	O
3,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxy	I-IUPAC	I-IUPAC
or	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
substitution	B-MODIFIER	B-MODIFIER
in	O	O
the	O	O
aryl	O	O
/	O	O
aralkyl	O	B-IUPAC
moiety	O	B-MODIFIER
and	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
aralkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
with	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
substitution	B-MODIFIER	B-MODIFIER
in	O	O
the	O	O
aryl	O	O
/	O	O
aralkyl	O	B-IUPAC
moiety	O	B-MODIFIER
were	O	O
obtained	O	O
by	O	O
reaction	O	O
of	O	O
the	O	O
corresponding	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanothiophenes	I-IUPAC	I-IUPAC
with	O	I-IUPAC
chloroformamidine	O	I-IUPAC
hydrochloride	O	I-IUPAC
.	O	O
The	O	O
effect	O	O
of	O	O
substitution	O	O
in	O	O
the	O	O
acyclic	O	O
structure	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
(	O	O
HEPT	O	O
)	O	O
on	O	O
anti	O	O
-	O	O
HIV	O	O
-	O	O
1	O	O
activity	O	O
was	O	O
investigated	O	O
by	O	O
synthesizing	O	O
a	O	O
series	O	O
of	O	O
deoxy	B-IUPAC	O
analogs	B-MODIFIER	O
and	O	O
related	O	O
compounds	O	O
.	O	O
The	O	O
SAR	O	O
between	O	O
compound	O	O
1	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethylamine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
suggested	O	O
that	O	O
the	O	O
alkyl	O	O
group	O	O
on	O	O
the	O	O
1	O	O
-	O	O
position	O	O
carbon	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethylamine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
played	O	O
the	O	O
role	O	O
of	O	O
one	O	O
of	O	O
the	O	O
propyl	O	O
groups	O	O
on	O	O
the	O	O
aminic	O	O
nitrogen	O	O
of	O	O
compound	O	O
1	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
overall	O	O
superior	O	O
affinity	O	O
,	O	O
high	O	O
selectivity	O	O
for	O	O
the	O	O
ETA	O	O
receptor	O	O
(	O	O
Ki	O	O
,	O	O
0.46	O	O
nM	O	O
for	O	O
ETA	O	O
and	O	O
13000	O	O
nM	O	O
for	O	O
ETB	O	O
)	O	O
,	O	O
and	O	O
good	O	O
oral	O	O
bioavailability	O	O
(	O	O
48%	O	O
in	O	O
rats	O	O
)	O	O
,	O	O
A	O	O
-	O	O
216546	O	O
(	O	O
10a	O	O
)	O	O
was	O	O
selected	O	O
as	O	O
a	O	O
potential	O	O
clinical	O	O
backup	O	O
for	O	O
1	O	O
.	O	O
Compounds	O	O
7a	O	O
,	O	O
b	O	O
,	O	O
analogues	O	O
of	O	O
AMPA	O	O
bearing	O	O
a	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazolyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
as	O	O
the	O	O
distal	O	O
carboxylic	O	O
functionality	O	O
,	O	O
showed	O	O
only	O	O
moderate	O	O
affinity	O	O
for	O	O
[	O	O
3H	O	O
]	O	O
AMPA	O	O
receptor	O	O
binding	O	O
sites	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
2.7	O	O
+	O	O
/	O	O
-	O	O
0.4	O	O
microM	O	O
and	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
2.6	O	O
+	O	O
/	O	O
-	O	O
0.6	O	O
microM	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
correlating	O	O
with	O	O
electrophysiological	O	O
data	O	O
from	O	O
the	O	O
rat	O	O
cortical	O	O
wedge	O	O
model	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
280	O	O
+	O	O
/	O	O
-	O	O
48	O	O
microM	O	O
and	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
586	O	O
+	O	O
/	O	O
-	O	O
41	O	O
microM	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
The	O	O
compounds	O	O
8	O	O
,	O	O
15a	O	O
,	O	O
and	O	O
15b	O	O
have	O	O
no	O	O
effect	O	O
as	O	O
inhibitors	O	O
of	O	O
AMPA	O	O
binding	O	O
,	O	O
in	O	O
agreement	O	O
with	O	O
in	O	O
vivo	O	O
studies	O	O
that	O	O
have	O	O
shown	O	O
that	O	O
8	O	O
does	O	O
not	O	O
affect	O	O
the	O	O
firing	O	O
of	O	O
central	O	O
neurons	O	O
whereas	O	O
15a	O	O
and	O	O
15b	O	O
are	O	O
antagonists	O	O
at	O	O
NMDA	O	O
receptors	O	O
,	O	O
a	O	O
subpopulation	O	O
of	O	O
excitatory	O	O
receptors	O	O
not	O	O
affected	O	O
by	O	O
AMPA	O	O
.	O	O
The	O	O
representative	O	O
compound	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
26b	O	O
,	O	O
CV	O	O
-	O	O
11974	O	O
)	O	O
,	O	O
inhibited	O	O
the	O	O
specific	O	O
binding	O	O
of	O	O
[	O	O
125I	O	O
]	O	O
AII	O	O
to	O	O
bovine	O	O
adrenal	O	O
cortical	O	O
membrane	O	O
with	O	O
an	O	O
IC50	O	O
value	O	O
of	O	O
1.1	O	O
x	O	O
10	O	O
(	O	O
-	O	O
7	O	O
)	O	O
M	O	O
.	O	O
Evaluation	O	O
of	O	O
these	O	O
analogues	O	O
for	O	O
binding	O	O
to	O	O
muscarinic	O	O
and	O	O
dopamine	O	O
binding	O	O
sites	O	O
in	O	O
comparison	O	O
with	O	O
clozapine	O	O
and	O	O
other	O	O
5H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dibenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazepine	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
of	O	O
clozapine	O	O
shows	O	O
that	O	O
the	O	O
dopamine	O	O
D	O	O
-	O	O
1	O	O
and	O	O
D	O	O
-	O	O
2	O	O
receptor	O	O
affinities	O	O
of	O	O
both	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylidene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dicarbo	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
and	O	O
its	O	O
corresponding	O	O
distal	O	B-IUPAC
-	O	I-IUPAC
chloro	O	I-IUPAC
derivative	O	B-MODIFIER
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylidene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpiperazino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
cycloheptene	I-IUPAC	I-IUPAC
,	O	O
are	O	O
retained	O	O
.	O	O
All	O	O
indolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinolines	I-IUPAC	I-IUPAC
belonging	O	O
to	O	O
the	O	O
5H	O	O
series	O	O
,	O	O
i.e.	O	O
,	O	O
bearing	O	O
a	O	O
methyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
pyridine	O	O
nitrogen	O	O
,	O	O
showed	O	O
significant	O	O
activity	O	O
against	O	O
procaryotic	O	O
and	O	O
eucaryotic	O	O
organisms	O	O
.	O	O
Treatment	O	O
of	O	O
3	O	O
with	O	O
sodium	O	O
methoxide	O	O
in	O	O
methanol	O	O
provided	O	O
a	O	O
good	O	O
yield	O	O
of	O	O
methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formimidate	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
.	O	O
It	O	O
is	O	O
nearly	O	O
inactive	O	O
at	O	O
the	O	O
time	O	O
of	O	O
administration	O	O
,	O	O
and	O	O
therefore	O	O
can	O	O
be	O	O
administered	O	O
,	O	O
at	O	O
high	O	O
dose	O	O
,	O	O
with	O	O
no	O	O
concern	O	O
for	O	O
hypoglycemia	O	O
.	O	O
Syntheses	O	O
of	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,3,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
TFPe	O	O
-	O	O
dUrd	O	O
)	O	O
(	O	O
1	O	O
)	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,3,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,3,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
,	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,3,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
from	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloromercuri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
are	O	O
described	O	O
.	O	O
In	O	O
the	O	O
present	O	O
investigation	O	O
,	O	O
the	O	O
last	O	O
two	O	O
possible	O	O
modes	O	O
of	O	O
generating	O	O
conformationally	O	O
semirigid	O	O
diacylglycerol	O	O
(	O	O
DAG	O	O
)	O	O
analogues	O	O
embedded	O	O
into	O	O
five	O	O
-	O	O
membered	O	O
ring	O	O
lactones	O	O
as	O	O
templates	O	O
III	O	O
and	O	O
IV	O	O
are	O	O
investigated	O	O
.	O	O
H	O	O
.	O	O
The	O	O
sedative	O	O
effect	O	O
of	O	O
20	O	O
,	O	O
evaluated	O	O
in	O	O
the	O	O
open	O	O
field	O	O
test	O	O
in	O	O
rats	O	O
,	O	O
appeared	O	O
at	O	O
doses	O	O
twice	O	O
as	O	O
high	O	O
as	O	O
those	O	O
inducing	O	O
a	O	O
minimal	O	O
anxiolytic	O	O
-	O	O
like	O	O
effect	O	O
and	O	O
was	O	O
similar	O	O
to	O	O
the	O	O
effects	O	O
of	O	O
diazepam	O	O
.	O	O
In	O	O
contrast	O	O
to	O	O
other	O	O
inhibitors	O	O
of	O	O
PNMT	O	O
,	O	O
it	O	O
is	O	O
also	O	O
highly	O	O
selective	O	O
toward	O	O
PNMT	O	O
in	O	O
comparison	O	O
with	O	O
its	O	O
affinity	O	O
toward	O	O
the	O	O
alpha	O	O
2	O	O
-	O	O
adrenoceptor	O	O
(	O	O
PNMT	O	O
Ki	O	O
=	O	O
0.55	O	O
microM	O	O
,	O	O
alpha	O	O
2	O	O
Ki	O	O
=	O	O
100	O	O
microM	O	O
,	O	O
selectivity	O	O
[	O	O
alpha	O	O
2	O	O
Ki	O	O
/	O	O
PNMT	O	O
Ki	O	O
]	O	O
=	O	O
180	O	O
)	O	O
.	O	O
2	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
Aminomethyl	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
aminobutyric	O	I-IUPAC
acid	O	I-IUPAC
(	O	O
isoornithine	O	O
)	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylisoornithine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylisoornithine	I-IUPAC	I-IUPAC
were	O	O
not	O	O
decarboxylated	O	O
by	O	O
liver	O	O
ornithine	O	O
decarboxylase	O	O
(	O	O
ODC	O	O
,	O	O
EC	O	O
4.1.1.17	O	O
)	O	O
of	O	O
thioacetamide	O	O
-	O	O
treated	O	O
rats	O	O
but	O	O
were	O	O
good	O	O
competitive	O	O
inhibitors	O	O
of	O	O
the	O	O
enzyme	O	O
(	O	O
Ki	O	O
ranged	O	O
from	O	O
0.72	O	O
to	O	O
1.79	O	O
mM	O	O
)	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
selective	O	O
incorporation	O	O
of	O	O
deuterium	O	O
into	O	O
these	O	O
products	O	O
,	O	O
we	O	O
provide	O	O
rational	O	O
mechanistic	O	O
interpretations	O	O
of	O	O
the	O	O
disproportionation	O	O
reaction	O	O
and	O	O
the	O	O
rearrangement	O	O
of	O	O
the	O	O
cyano	O	O
adducts	O	O
.	O	O
A	O	O
series	O	O
of	O	O
8	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
trifluoromethyl	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
substituted	O	B-MODIFIER
quinolones	O	B-IUPAC
has	O	O
been	O	O
prepared	O	O
and	O	O
evaluated	O	O
for	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
antibacterial	O	O
activity	O	O
,	O	O
and	O	O
phototolerance	O	O
in	O	O
a	O	O
mouse	O	O
phototolerance	O	O
assay	O	O
.	O	O
(	O	B-IUPAC
E	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
[	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
Methylthio	O	I-IUPAC
)	O	I-IUPAC
phenyl	O	I-IUPAC
]	O	I-IUPAC
-	O	I-IUPAC
1	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
piperidinyl	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
3	O	I-IUPAC
-	O	I-IUPAC
buten	O	I-IUPAC
-	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
one	O	I-IUPAC
hydrochloride	O	I-IUPAC
(	O	O
44	O	O
,	O	O
RMI	O	O
14	O	O
133A	O	O
)	O	O
was	O	O
found	O	O
to	O	O
inhibit	O	O
ADP	O	O
-	O	O
induced	O	O
aggregation	O	O
of	O	O
blood	O	O
platelets	O	O
.	O	O
The	O	O
high	O	O
binding	O	O
affinity	O	O
of	O	O
the	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diazabicyclo	I-IUPAC	I-IUPAC
[	O	I-IUPAC
4.3.0	O	I-IUPAC
]	O	I-IUPAC
nonanes	B-IUPAC	I-IUPAC
12	O	O
suggests	O	O
that	O	O
these	O	O
may	O	O
approximate	O	O
the	O	O
methyl	O	O
and	O	O
pyrrolidine	O	O
ring	O	O
conformations	O	O
found	O	O
in	O	O
1	O	O
when	O	O
it	O	O
is	O	O
bound	O	O
to	O	O
the	O	O
sigma	O	O
receptor	O	O
.	O	O
Whereas	O	O
mixtures	O	O
of	O	O
regioisomeric	O	O
5	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzothiazoles	I-IUPAC	I-IUPAC
were	O	O
formed	O	O
from	O	O
the	O	O
established	O	O
Jacobsen	O	O
cyclization	O	O
of	O	O
precursor	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiobenzanilides	I-IUPAC	I-IUPAC
,	O	O
two	O	O
modifications	O	O
to	O	O
this	O	O
general	O	O
process	O	O
have	O	O
allowed	O	O
the	O	O
synthesis	O	O
of	O	O
pure	O	O
samples	O	O
of	O	O
these	O	O
target	O	O
compounds	O	O
.	O	O
The	O	O
prodrugs	O	O
were	O	O
found	O	O
to	O	O
be	O	O
quite	O	O
stable	O	O
at	O	O
physiological	O	O
pH	O	O
and	O	O
were	O	O
more	O	O
than	O	O
200	O	O
-	O	O
fold	O	O
less	O	O
active	O	O
as	O	O
inactivators	O	O
of	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkylguanine	I-IUPAC	I-IUPAC
-	O	O
DNA	O	O
alkyltransferase	O	O
(	O	O
alkyltransferase	O	O
)	O	O
than	O	O
either	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylguanine	I-IUPAC	I-IUPAC
or	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyguanosine	I-IUPAC	I-IUPAC
.	O	O
Compound	O	O
14	O	O
interacts	O	O
selectively	O	O
with	O	O
the	O	O
GABA	O	O
receptors	O	O
but	O	O
less	O	O
effectively	O	O
than	O	O
isonipecotic	O	O
acid	O	O
and	O	O
the	O	O
cis	O	O
-	O	O
isomer	O	O
22	O	O
.	O	O
The	O	O
replacement	O	O
of	O	O
the	O	O
phenyl	O	O
ring	O	O
in	O	O
etoxadrol	O	O
by	O	O
either	O	O
a	O	O
2	O	O
-	O	O
or	O	O
3	O	O
-	O	O
thienyl	O	O
ring	O	O
led	O	O
to	O	O
compounds	O	O
with	O	O
affinity	O	O
comparable	O	O
to	O	O
etoxadrol	O	O
,	O	O
and	O	O
the	O	O
replacement	O	O
of	O	O
the	O	O
ethyl	O	B-IUPAC
moiety	O	B-MODIFIER
on	O	O
etoxadrol	O	O
's	O	O
dioxolane	O	O
ring	O	O
with	O	O
propyl	O	O
(	O	O
7	O	O
)	O	O
or	O	O
isopropyl	O	O
(	O	O
8	O	O
)	O	O
led	O	O
to	O	O
compounds	O	O
which	O	O
were	O	O
more	O	O
potent	O	O
than	O	O
etoxadrol	O	O
or	O	O
PCP	O	O
.	O	O
These	O	O
findings	O	O
encouraged	O	O
us	O	O
to	O	O
determine	O	O
the	O	O
structural	O	O
differences	O	O
between	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexanediamine	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexylamine	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
.	O	O
Antibacterial	O	O
efficacy	O	O
and	O	O
pharmacokinetic	O	O
and	O	O
physicochemical	O	O
properties	O	O
of	O	O
selected	O	O
derivatives	O	O
were	O	O
compared	O	O
to	O	O
the	O	O
relevant	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azetidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	O
and	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azetidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
(	O	O
for	O	O
Part	O	O
1	O	O
,	O	O
see	O	O
:	O	O
J	O	O
.	O	O
The	O	O
MIC50	O	O
value	O	O
for	O	O
the	O	O
most	O	O
potent	O	O
agents	O	O
in	O	O
this	O	O
study	O	O
against	O	O
S	O	O
.	O	O
A	O	O
single	O	O
scalar	O	O
11-11	O	O
a	O	O
1H	O	O
NMR	O	O
coupling	O	O
in	O	O
the	O	O
2D	O	O
-	O	O
COSY	O	O
spectrum	O	O
is	O	O
indicative	O	O
of	O	O
an	O	O
adduct	O	O
species	O	O
that	O	O
has	O	O
an	O	O
S	O	O
configuration	O	O
at	O	O
the	O	O
C	O	O
-	O	O
11	O	O
position	O	O
.	O	O
A	O	O
similar	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
4	O	O
)	O	O
was	O	O
obtained	O	O
from	O	O
3'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thymidine	I-IUPAC	I-IUPAC
by	O	O
the	O	O
use	O	O
of	O	O
phosphoryl	O	O
chloride	O	O
as	O	O
the	O	O
condensing	O	O
agent	O	O
.	O	O
Contrary	O	O
to	O	O
what	O	O
has	O	O
been	O	O
found	O	O
with	O	O
simple	O	O
primary	O	O
dialkyl	O	O
esters	O	O
,	O	O
ortho	O	B-IUPAC
-	O	O
substituted	O	B-MODIFIER
dibenzyl	O	B-IUPAC
esters	O	I-IUPAC
of	O	O
MTX	O	O
produce	O	O
longer	O	O
survival	O	O
on	O	O
a	O	O
q3dX3	O	O
schedule	O	O
than	O	O
does	O	O
MTX	O	O
itself	O	O
and	O	O
show	O	O
a	O	O
dose	O	O
-	O	O
sparing	O	O
effect	O	O
comparable	O	O
to	O	O
that	O	O
of	O	O
MTX	O	O
at	O	O
shorter	O	O
treatment	O	O
intervals	O	O
.	O	O
When	O	O
evaluated	O	O
for	O	O
inhibition	O	O
of	O	O
the	O	O
AII	O	O
pressor	O	O
response	O	O
,	O	O
the	O	O
benchmark	O	O
benzoylsulfonamide	O	O
9	O	O
(	O	O
L	O	O
-	O	O
159,913	O	O
)	O	O
was	O	O
efficacious	O	O
in	O	O
several	O	O
species	O	O
and	O	O
was	O	O
superior	O	O
to	O	O
losartan	O	O
(	O	O
1a	O	O
)	O	O
in	O	O
conscious	O	O
rhesus	O	O
monkeys	O	O
.	O	O
Furthermore	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxazolidinediones	I-IUPAC	I-IUPAC
and	O	O
hydantoins	O	O
must	O	O
either	O	O
orient	O	O
differently	O	O
in	O	O
the	O	O
same	O	O
binding	O	O
site	O	O
or	O	O
interact	O	O
with	O	O
different	O	O
sites	O	O
on	O	O
the	O	O
neuronal	O	O
voltage	O	O
-	O	O
dependent	O	O
sodium	O	O
channel	O	O
.	O	O
The	O	O
stereochemistry	O	O
of	O	O
a	O	O
hydroxy	O	O
group	O	O
at	O	O
C	O	O
-	O	O
4	O	O
of	O	O
compound	O	O
25	O	O
and	O	O
that	O	O
at	O	O
C	O	O
-	O	O
6	O	O
of	O	O
compounds	O	O
36	O	O
and	O	O
37	O	O
were	O	O
determined	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
(	O	O
1	O	O
)	O	O
H	O	O
NMR	O	O
spectroscopy	O	O
in	O	O
each	O	O
case	O	O
.	O	O
The	O	O
catalytic	O	O
reduction	O	O
product	O	O
of	O	O
2	O	O
,	O	O
consisting	O	O
of	O	O
a	O	O
mixture	O	O
of	O	O
diastereomers	O	O
,	O	O
exhibited	O	O
powerful	O	O
antifolate	O	O
activity	O	O
against	O	O
both	O	O
these	O	O
organisms	O	O
.	O	O
Inhibitors	O	O
of	O	O
PARP	O	O
have	O	O
clinical	O	O
potential	O	O
as	O	O
resistance	O	O
-	O	O
modifying	O	O
agents	O	O
capable	O	O
of	O	O
potentiating	O	O
radiotherapy	O	O
and	O	O
the	O	O
cytotoxicity	O	O
of	O	O
some	O	O
forms	O	O
of	O	O
cancer	O	O
chemotherapy	O	O
.	O	O
The	O	O
oxidative	O	O
hydrolysis	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thiouracil	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
gave	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
46-57	O	O
)	O	O
.	O	O
Furthermore	O	O
,	O	O
alkyl	O	O
substitution	O	O
also	O	O
appears	O	O
to	O	O
be	O	O
important	O	O
since	O	O
the	O	O
stripped	O	O
down	O	O
polyamines	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethylenediamine	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
and	O	O
N1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diethylenetriamine	I-IUPAC	I-IUPAC
(	O	O
16	O	O
)	O	O
exhibited	O	O
relatively	O	O
low	O	O
binding	O	O
affinity	O	O
.	O	O
Larger	O	O
N	O	O
-	O	O
substituents	O	O
in	O	O
both	O	O
phenylpiperidines	O	O
and	O	O
OHBQs	O	O
increase	O	O
both	O	O
pre	O	O
-	O	O
and	O	O
postsynaptic	O	O
dopaminergic	O	O
activity	O	O
.	O	O
3D	O	O
QSAR	O	O
models	O	O
developed	O	O
may	O	O
be	O	O
used	O	O
in	O	O
designing	O	O
and	O	O
predicting	O	O
the	O	O
uPA	O	O
inhibitory	O	O
activity	O	O
of	O	O
novel	O	O
molecules	O	O
.	O	O
5	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
.	O	O
Based	O	O
upon	O	O
the	O	O
observed	O	O
results	O	O
,	O	O
it	O	O
is	O	O
concluded	O	O
that	O	O
differential	O	O
effects	O	O
of	O	O
alpha	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthoflavone	I-IUPAC	I-IUPAC
on	O	O
aryl	O	O
hydrocarbon	O	O
skin	O	O
tumorigenesis	O	O
may	O	O
be	O	O
the	O	O
result	O	O
of	O	O
differential	O	O
enzyme	O	O
induction	O	O
rather	O	O
than	O	O
the	O	O
result	O	O
of	O	O
differential	O	O
enzyme	O	O
inhibition	O	O
.	O	O
Two	O	O
chemical	O	O
series	O	O
derived	O	O
from	O	O
the	O	O
general	O	O
structures	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tertioalkylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
series	O	O
I	O	O
)	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tertioalkylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
series	O	O
II	O	O
)	O	O
were	O	O
developed	O	O
.	O	O
omega	O	O
-	O	O
Hydroxylation	O	O
was	O	O
a	O	O
minor	O	O
metabolic	O	O
pathway	O	O
in	O	O
the	O	O
microsomal	O	O
incubation	O	O
.	O	O
Nearly	O	O
complete	O	O
loss	O	O
of	O	O
potency	O	O
was	O	O
seen	O	O
for	O	O
[	O	O
Ala1	O	O
]	O	O
,	O	O
[	O	O
Ala3	O	O
]	O	O
,	O	O
[	O	O
Ala5	O	O
]	O	O
,	O	O
[	O	O
Ala6	O	O
]	O	O
,	O	O
[	O	O
Ala10	O	O
]	O	O
,	O	O
[	O	O
Ala11	O	O
]	O	O
,	O	O
[	O	O
Ala13	O	O
]	O	O
,	O	O
[	O	O
Ala14	O	O
]	O	O
,	O	O
and	O	O
[	O	O
Ala23	O	O
]	O	O
,	O	O
whereas	O	O
[	O	O
Ala16	O	O
]	O	O
,	O	O
[	O	O
Ala18	O	O
]	O	O
,	O	O
[	O	O
Ala24	O	O
]	O	O
,	O	O
[	O	O
Ala25	O	O
]	O	O
,	O	O
[	O	O
Ala26	O	O
]	O	O
,	O	O
and	O	O
[	O	O
Ala29	O	O
]	O	O
yielded	O	O
equipotent	O	O
analogues	O	O
and	O	O
[	O	O
Ala7	O	O
]	O	O
,	O	O
[	O	O
Ala12	O	O
]	O	O
,	O	O
[	O	O
Ala17	O	O
]	O	O
,	O	O
[	O	O
Ala20	O	O
]	O	O
,	O	O
[	O	O
Ala21	O	O
]	O	O
,	O	O
and	O	O
[	O	O
Ala27	O	O
]	O	O
gave	O	O
weak	O	O
agonists	O	O
with	O	O
potencies	O	O
15-40%	O	O
that	O	O
of	O	O
the	O	O
standard	O	O
.	O	O
[	O	O
(	O	O
123	O	O
)	O	O
I	O	O
]	O	O
ZIENT	O	O
uptake	O	O
in	O	O
the	O	O
diencephalon	O	O
achieved	O	O
transient	O	O
equilibrium	O	O
at	O	O
157	O	O
min	O	O
.	O	O
The	O	O
three	O	O
most	O	O
potent	O	O
compounds	O	O
in	O	O
both	O	O
tests	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
indan	I-IUPAC	I-IUPAC
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylindan	I-IUPAC	I-IUPAC
,	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetramethylindan	I-IUPAC	I-IUPAC
were	O	O
selected	O	O
for	O	O
further	O	O
investigations	O	O
.	O	O
The	O	O
sodium	O	O
salt	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
was	O	O
condensed	O	O
with	O	O
(	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
bromide	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
to	O	O
provide	O	O
the	O	O
corresponding	O	O
protected	O	O
acyclic	O	O
nucleoside	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimid	I-IUPAC	I-IUPAC
ine	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
.	O	O
Although	O	O
all	O	O
the	O	O
ligands	O	O
have	O	O
high	O	O
affinity	O	O
for	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
PKCdelta	O	O
C1b	O	O
,	O	O
our	O	O
site	O	O
-	O	O
directed	O	O
mutagenic	O	O
results	O	O
showed	O	O
that	O	O
ILV	O	O
is	O	O
the	O	O
ligand	O	O
most	O	O
sensitive	O	O
to	O	O
structural	O	O
perturbations	O	O
of	O	O
the	O	O
binding	O	O
site	O	O
while	O	O
ingenol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
is	O	O
the	O	O
least	O	O
sensitive	O	O
among	O	O
the	O	O
four	O	O
classes	O	O
of	O	O
ligands	O	O
examined	O	O
here	O	O
.	O	O
Acylated	O	O
derivatives	O	O
of	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
and	O	O
other	O	O
modifications	O	O
were	O	O
prepared	O	O
in	O	O
an	O	O
effort	O	O
to	O	O
provide	O	O
A3	O	O
subtype	O	O
selectivity	O	O
.	O	O
Survival	O	O
was	O	O
prolonged	O	O
to	O	O
the	O	O
same	O	O
degree	O	O
as	O	O
with	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
clindamycin	O	O
,	O	O
another	O	O
widely	O	O
used	O	O
drug	O	O
against	O	O
toxoplasmosis	O	O
.	O	O
We	O	O
tried	O	O
to	O	O
strengthen	O	O
these	O	O
properties	O	O
by	O	O
introducing	O	O
the	O	O
structurally	O	O
modified	O	O
tyrosine	O	O
residue	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethyltyrosine	I-IUPAC	I-IUPAC
(	O	O
Dmt	O	O
)	O	O
in	O	O
place	O	O
of	O	O
Tyr1	O	O
.	O	O
Consequently	O	O
,	O	O
the	O	O
insertion	O	O
of	O	O
appropriate	O	O
substituents	O	O
in	O	O
the	O	O
phenyl	O	O
ring	O	O
of	O	O
8	O	O
may	O	O
represent	O	O
the	O	O
basis	O	O
of	O	O
designing	O	O
new	O	O
selective	O	O
ligands	O	O
for	O	O
alpha1	O	O
-	O	O
adrenoreceptor	O	O
subtypes	O	O
.	O	O
Certain	O	O
derivatives	O	O
containing	O	O
the	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrazine	I-IUPAC	I-IUPAC
(	O	I-IUPAC
1	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydropteridine	I-IUPAC	I-IUPAC
)	O	I-IUPAC
ring	B-MODIFIER	B-MODIFIER
system	I-MODIFIER	I-MODIFIER
are	O	O
active	O	O
against	O	O
experimental	O	O
neoplasms	O	O
in	O	O
mice	O	O
.	O	O
Concentrations	O	O
for	O	O
50%	O	O
KB	O	O
/	O	O
HeLa	O	O
cells	O	O
arrested	O	O
in	O	O
G2	O	O
/	O	O
M	O	O
after	O	O
treatment	O	O
with	O	O
9h	O	O
and	O	O
9l	O	O
were	O	O
determined	O	O
and	O	O
found	O	O
to	O	O
be	O	O
in	O	O
the	O	O
range	O	O
of	O	O
0.2	O	O
microM	O	O
.	O	O
Compound	O	O
4	O	O
was	O	O
a	O	O
dual	O	O
DHFR	O	O
-	O	O
TS	O	O
inhibitor	O	O
against	O	O
the	O	O
bifunctional	O	O
enzyme	O	O
derived	O	O
from	O	O
Toxoplasma	O	O
gondii	O	O
(	O	O
tg	O	O
)	O	O
.	O	O
In	O	O
an	O	O
imaging	O	O
experiment	O	O
with	O	O
[	O	O
(	O	O
18	O	O
)	O	O
F	O	O
]	O	O
(	O	O
S	O	O
)	O	O
-	O	O
FIPCT	O	O
in	O	O
a	O	O
rhesus	O	O
monkey	O	O
with	O	O
its	O	O
left	O	O
hemisphere	O	O
lesioned	O	O
with	O	O
MPTP	O	O
,	O	O
radioactivity	O	O
was	O	O
reduced	O	O
to	O	O
background	O	O
in	O	O
the	O	O
caudate	O	O
and	O	O
putamen	O	O
of	O	O
the	O	O
lesioned	O	O
hemisphere	O	O
.	O	O
17	B-IUPAC	B-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Alkyl	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
arylamides	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
45	O	O
,	O	O
46	O	O
,	O	O
48	O	O
,	O	O
and	O	O
51	O	O
exhibited	O	O
highly	O	O
potent	O	O
inhibitory	O	O
activity	O	O
for	O	O
human	O	O
type	O	O
I	O	O
5	O	O
alpha	O	O
-	O	O
reductase	O	O
with	O	O
IC50s	O	O
of	O	O
1.77	O	O
,	O	O
2.42	O	O
,	O	O
2.93	O	O
,	O	O
and	O	O
5.44	O	O
nM	O	O
,	O	O
respectively	O	O
,	O	O
while	O	O
moderate	O	O
to	O	O
no	O	O
effect	O	O
was	O	O
observed	O	O
on	O	O
the	O	O
type	O	O
II	O	O
enzyme	O	O
(	O	O
100	O	O
&	O	O
lt	O	O
;	O	O
IC50s	O	O
&	O	O
lt	O	O
;	O	O
1000	O	O
nM	O	O
)	O	O
,	O	O
except	O	O
for	O	O
compound	O	O
48	O	O
(	O	O
IC50	O	O
=	O	O
3.75	O	O
nM	O	O
)	O	O
.	O	O
Compounds	O	O
19b	O	O
,	O	O
20b	O	O
,	O	O
and	O	O
the	O	O
3'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cyclic	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phosphate	I-IUPAC	I-IUPAC
21b	O	O
are	O	O
less	O	O
active	O	O
than	O	O
1	O	O
.	O	O
While	O	O
17	O	O
(	O	O
IC50	O	O
=	O	O
0.016	O	O
microM	O	O
)	O	O
was	O	O
somewhat	O	O
less	O	O
potent	O	O
than	O	O
10	O	O
,	O	O
its	O	O
selectivity	O	O
,	O	O
as	O	O
defined	O	O
by	O	O
the	O	O
ratio	O	O
IC50	O	O
(	O	O
rat	O	O
liver	O	O
)	O	O
/	O	O
IC50	O	O
(	O	O
T	O	O
.	O	O
Our	O	O
aim	O	O
was	O	O
to	O	O
develop	O	O
an	O	O
(	O	O
18	O	O
)	O	O
F	O	O
-	O	O
labeled	O	O
acetylcholine	O	O
analogue	O	O
useful	O	O
for	O	O
brain	O	O
AChE	O	O
mapping	O	O
with	O	O
PET	O	O
,	O	O
since	O	O
(	O	O
18	O	O
)	O	O
F	O	O
,	O	O
with	O	O
a	O	O
longer	O	O
half	O	O
-	O	O
life	O	O
,	O	O
has	O	O
advantages	O	O
over	O	O
(	O	O
11	O	O
)	O	O
C	O	O
.	O	O
The	O	O
A	O	O
ring	O	O
nitrogen	O	O
analogues	O	O
(	O	O
7	B-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
8	B-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
and	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenanthridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
)	O	O
were	O	O
an	O	O
order	O	O
of	O	O
magnitude	O	O
less	O	O
potent	O	O
than	O	O
C	O	O
ring	O	O
nitrogen	O	O
analogues	O	O
(	O	O
1	B-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
2	B-PARTIUPAC	B-MODIFIER
-	I-PARTIUPAC	I-MODIFIER
,	O	O
3	B-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenanthridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
)	O	O
.	O	O
Single	O	O
doses	O	O
(	O	O
200-400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
of	O	O
8a	O	O
and	O	O
8b	O	O
produced	O	O
significant	O	O
increase	O	O
in	O	O
life	O	O
span	O	O
(	O	O
257-371%	O	O
)	O	O
in	O	O
mice	O	O
bearing	O	O
ip	O	O
implanted	O	O
L1210/0	O	O
leukemia	O	O
.	O	O
Both	O	O
compounds	O	O
are	O	O
biologically	O	O
active	O	O
as	O	O
inhibitors	O	O
of	O	O
the	O	O
growth	O	O
of	O	O
cultured	O	O
mouse	O	O
fibroblasts	O	O
and	O	O
are	O	O
able	O	O
to	O	O
compete	O	O
for	O	O
the	O	O
specific	O	O
binding	O	O
of	O	O
radiolabeled	O	O
triamcinolone	O	O
acetonide	O	O
to	O	O
the	O	O
L929	O	O
cell	O	O
receptor	O	O
.	O	O
The	O	O
conjugates	O	O
can	O	O
use	O	O
bacterial	O	O
iron	O	O
siderophore	O	O
uptake	O	O
routes	O	O
to	O	O
penetrate	O	O
the	O	O
Gram	O	O
-	O	O
negative	O	O
outer	O	O
membrane	O	O
permeability	O	O
barrier	O	O
.	O	O
With	O	O
use	O	O
of	O	O
Heindel	O	O
's	O	O
triazene	O	O
method	O	O
for	O	O
introduction	O	O
of	O	O
the	O	O
radionuclide	O	O
,	O	O
the	O	O
iodine	O	O
-	O	O
125	O	O
-	O	O
labeled	O	O
substituted	O	O
benzamide	O	O
was	O	O
obtained	O	O
with	O	O
a	O	O
calculated	O	O
specific	O	O
activity	O	O
of	O	O
136	O	O
Ci	O	O
/	O	O
mmol	O	O
and	O	O
14%	O	O
radiochemical	O	O
yield	O	O
.	O	O
A	O	O
series	O	O
of	O	O
aporphine	O	O
nitrogen	O	O
mustards	O	O
and	O	O
their	O	O
congeners	O	O
(	O	O
1b	O	O
-	O	O
g	O	O
)	O	O
has	O	O
been	O	O
prepared	O	O
.	O	O
These	O	O
various	O	O
thiazolidine	O	O
derivatives	O	O
are	O	O
formed	O	O
by	O	O
nucleophilic	O	O
addition	O	O
of	O	O
the	O	O
thiol	O	O
residues	O	O
of	O	O
cysteine	O	O
or	O	O
glutathione	O	O
to	O	O
the	O	O
aldehyde	B-IUPAC	O
group	B-MODIFIER	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyindole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetaldehyde	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
the	O	O
primary	O	O
product	O	O
of	O	O
the	O	O
monoamine	O	O
oxidase	O	O
-	O	O
mediated	O	O
oxidative	O	O
deamination	O	O
of	O	O
1	O	O
.	O	O
We	O	O
have	O	O
expanded	O	O
our	O	O
structure	O	O
-	O	O
activity	O	O
studies	O	O
in	O	O
this	O	O
series	O	O
,	O	O
in	O	O
an	O	O
attempt	O	O
to	O	O
further	O	O
increase	O	O
the	O	O
ETA	O	O
selectivity	O	O
.	O	O
The	O	O
conformationally	O	O
restricted	O	O
linear	O	O
tricyclic	O	O
analogs	O	O
of	O	O
5	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetralins	I-IUPAC	I-IUPAC
were	O	O
investigated	O	O
for	O	O
their	O	O
serotonergic	O	O
and	O	O
dopaminergic	O	O
properties	O	O
.	O	O
It	O	O
is	O	O
suggested	O	O
that	O	O
van	O	O
der	O	O
Waals	O	O
forces	O	O
and	O	O
pi	O	O
interactions	O	O
may	O	O
govern	O	O
the	O	O
inhibitor	O	O
-	O	O
platelet	O	O
interaction	O	O
.	O	O
In	O	O
view	O	O
of	O	O
the	O	O
fact	O	O
that	O	O
3	O	O
and	O	O
its	O	O
B	O	O
-	O	O
ring	O	O
analogues	O	O
cannot	O	O
form	O	O
polyglutamates	O	O
,	O	O
their	O	O
high	O	O
cytotoxicity	O	O
relative	O	O
to	O	O
the	O	O
corresponding	O	O
B	O	O
-	O	O
ring	O	O
analogues	O	O
of	O	O
AMT	O	O
is	O	O
noteworthy	O	O
.	O	O
The	O	O
best	O	O
analogue	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthalenylsulfonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolidinedione	I-IUPAC	I-IUPAC
(	O	O
AY	O	O
-	O	O
31,637	O	O
)	O	O
was	O	O
equipotent	O	O
to	O	O
ciglitazone	O	O
in	O	O
two	O	O
animal	O	O
models	O	O
of	O	O
NIDDM	O	O
.	O	O
The	O	O
in	O	O
vivo	O	O
antagonistic	O	O
activity	O	O
of	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sarcosine	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylthreonine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
angiotensin	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
is	O	O
reduced	O	O
considerably	O	O
by	O	O
shortening	O	O
the	O	O
chain	O	O
length	O	O
by	O	O
one	O	O
carbon	O	O
atom	O	O
as	O	O
is	O	O
in	O	O
V	O	O
.	O	O
(	O	O
S	O	O
)	O	O
-	O	O
11a	O	O
was	O	O
evaluated	O	O
as	O	O
a	O	O
substrate	O	O
for	O	O
P815	O	O
tryptophan	O	O
hydroxylase	O	O
and	O	O
determined	O	O
to	O	O
have	O	O
an	O	O
apparent	O	O
Km	O	O
of	O	O
4.31	O	O
+	O	O
/	O	O
-	O	O
1.07	O	O
mM	O	O
,	O	O
essentially	O	O
half	O	O
the	O	O
value	O	O
previously	O	O
reported	O	O
for	O	O
the	O	O
racemic	O	O
mixture	O	O
of	O	O
11a	O	O
with	O	O
rat	O	O
brain	O	O
stem	O	O
tryptophan	O	O
hydroxylase	O	O
.	O	O
Metabolic	O	O
studies	O	O
of	O	O
the	O	O
polyamine	O	O
-	O	O
vectored	O	O
(	O	O
S	O	O
)	O	O
-	O	O
4'	O	O
-	O	O
(	O	O
HO	O	O
)	O	O
-	O	O
DADFTs	O	O
in	O	O
rodents	O	O
indicated	O	O
that	O	O
not	O	O
only	O	O
did	O	O
the	O	O
expected	O	O
deaminopropylation	O	O
step	O	O
occur	O	O
,	O	O
but	O	O
also	O	O
a	O	O
surprisingly	O	O
high	O	O
level	O	O
of	O	O
oxidative	O	O
deamination	O	O
at	O	O
the	O	O
terminal	O	O
primary	O	O
nitrogens	O	O
took	O	O
place	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
because	O	O
positive	O	O
chronotropic	O	O
actions	O	O
of	O	O
substituents	B-MODIFIER	O
with	O	O
allyl	B-IUPAC	O
,	O	O
aminoalkyl	B-IUPAC	O
,	O	O
alkoxyalkyl	B-IUPAC	O
,	O	O
and	O	O
normal	O	O
alkyl	B-IUPAC	O
groups	B-MODIFIER	O
were	O	O
much	O	O
less	O	O
than	O	O
tracheal	O	O
muscle	O	O
became	O	O
very	O	O
high	O	O
with	O	O
substitutions	B-MODIFIER	O
of	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butenyl	I-IUPAC	I-IUPAC
,	O	O
(	B-IUPAC	B-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
,	O	I-IUPAC
2'	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxyethyl	I-IUPAC	I-IUPAC
,	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxypropyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
at	O	O
the	O	O
1	O	O
-	O	O
position	O	O
and	O	O
of	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxyethyl	I-IUPAC	I-IUPAC
,	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxopropyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
at	O	O
the	O	O
7	O	O
-	O	O
position	O	O
,	O	O
compared	O	O
with	O	O
theophylline	O	O
and	O	O
the	O	O
corresponding	O	O
unsubstituted	O	O
xanthines	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propylxanthine	I-IUPAC	I-IUPAC
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylxanthine	I-IUPAC	I-IUPAC
.	O	O
Compounds	O	O
3	O	O
and	O	O
4	O	O
were	O	O
powerful	O	O
inhibitors	O	O
of	O	O
recombinant	O	O
human	O	O
FPGS	O	O
,	O	O
whereas	O	O
1	O	O
and	O	O
2	O	O
were	O	O
exceptionally	O	O
efficient	O	O
FPGS	O	O
substrates	O	O
,	O	O
with	O	O
the	O	O
reduced	O	O
compound	O	O
2	O	O
giving	O	O
a	O	O
K	O	O
(	O	O
m	O	O
)	O	O
(	O	O
0.018	O	O
microM	O	O
)	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
any	O	O
other	O	O
substrate	O	O
identified	O	O
to	O	O
date	O	O
.	O	O
Increasing	O	O
fluorine	O	O
substitution	O	O
was	O	O
found	O	O
to	O	O
decrease	O	O
basicity	O	O
of	O	O
the	O	O
formamidino	O	O
group	O	O
substantially	O	O
(	O	O
3a	O	O
,	O	O
pKa	O	O
=	O	O
8.65	O	O
;	O	O
3b	O	O
,	O	O
pKa	O	O
=	O	O
8.12	O	O
;	O	O
3c	O	O
,	O	O
pKa	O	O
=	O	O
6.60	O	O
;	O	O
3d	O	O
,	O	O
pKa	O	O
=	O	O
6.14	O	O
)	O	O
,	O	O
while	O	O
having	O	O
a	O	O
modest	O	O
effect	O	O
on	O	O
the	O	O
imidazole	O	O
portion	O	O
.	O	O
At	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
po	O	O
in	O	O
rats	O	O
,	O	O
18	O	O
and	O	O
92	O	O
(	O	O
L	O	O
-	O	O
162,234	O	O
)	O	O
produced	O	O
85-87%	O	O
peak	O	O
inhibition	O	O
of	O	O
the	O	O
AII	O	O
pressor	O	O
response	O	O
with	O	O
duration	O	O
exceeding	O	O
6	O	O
h	O	O
.	O	O
When	O	O
the	O	O
methylputrescines	O	O
formally	O	O
derived	O	O
from	O	O
the	O	O
decarboxylation	O	O
of	O	O
several	O	O
isoornithines	O	O
were	O	O
assayed	O	O
on	O	O
rat	O	O
liver	O	O
ODC	O	O
,	O	O
it	O	O
was	O	O
found	O	O
that	O	O
only	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylputrescine	I-IUPAC	I-IUPAC
decreased	O	O
the	O	O
enzymatic	O	O
activity	O	O
.	O	O
However	O	O
the	O	O
effect	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
substitution	B-MODIFIER	B-MODIFIER
was	O	O
less	O	O
pronounced	O	O
in	O	O
the	O	O
5,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dideaza	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
than	O	O
in	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
.	O	O
Together	O	O
with	O	O
the	O	O
X	O	O
-	O	O
ray	O	O
structure	O	O
of	O	O
phorbol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
13	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
in	O	O
complex	O	O
with	O	O
PKCdelta	O	O
C1b	O	O
,	O	O
the	O	O
predicted	O	O
binding	O	O
models	O	O
of	O	O
PDBu	O	O
,	O	O
ILV	O	O
,	O	O
ingenol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
,	O	O
and	O	O
thymeleatoxin	O	O
in	O	O
complex	O	O
with	O	O
PKC	O	O
showed	O	O
that	O	O
the	O	O
binding	O	O
of	O	O
these	O	O
ligands	O	O
to	O	O
PKC	O	O
is	O	O
governed	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
several	O	O
highly	O	O
specific	O	O
and	O	O
optimal	O	O
hydrogen	O	O
bonds	O	O
and	O	O
hydrophobic	O	O
contacts	O	O
.	O	O
Identification	O	O
of	O	O
the	O	O
structural	O	O
features	O	O
that	O	O
are	O	O
necessary	O	O
for	O	O
activity	O	O
was	O	O
accomplished	O	O
by	O	O
evaluation	O	O
of	O	O
modified	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deazapteridines	I-IUPAC	I-IUPAC
and	O	O
ring	O	O
and	O	O
ring	O	O
-	O	O
opened	O	O
analogues	O	O
.	O	O
1,3,5	B-MODIFIER	O
-	I-MODIFIER	O
Substituted	I-MODIFIER	O
indoles	O	O
and	O	O
indazoles	O	O
have	O	O
been	O	O
studied	O	O
as	O	O
receptor	O	O
antagonists	O	O
of	O	O
the	O	O
peptidoleukotrienes	O	O
.	O	O
casei	O	O
dihydrofolate	O	O
reductase	O	O
.	O	O
Competition	O	O
binding	O	O
in	O	O
cells	O	O
stably	O	O
expressing	O	O
the	O	O
transfected	O	O
human	O	O
DAT	O	O
and	O	O
serotonin	O	O
transporter	O	O
(	O	O
SERT	O	O
)	O	O
labeled	O	O
by	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
WIN	O	O
35428	O	O
and	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
citalopram	O	O
,	O	O
respectively	O	O
,	O	O
demonstrated	O	O
the	O	O
following	O	O
order	O	O
of	O	O
DAT	O	O
affinity	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
in	O	O
nM	O	O
)	O	O
:	O	O
GBR	O	O
12909	O	O
(	O	O
0.36	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
CIT	O	O
(	O	O
0.48	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
(	O	O
S	O	O
)	O	O
-	O	O
FIPCT	O	O
(	O	O
0.67	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
&	O	O
gt	O	O
;	O	O
(	O	O
R	O	O
)	O	O
-	O	O
FIPCT	O	O
(	O	O
3.2	O	O
)	O	O
.	O	O
In	O	O
cultured	O	O
L1210	O	O
leukemia	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrobenzylaminopurine	I-IUPAC	I-IUPAC
and	O	O
the	O	O
corresponding	O	O
ribonucleoside	O	O
were	O	O
better	O	O
growth	O	O
inhibitors	O	O
than	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyladenosine	I-IUPAC	I-IUPAC
,	O	O
while	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrobenzyladenosine	I-IUPAC	I-IUPAC
,	O	O
its	O	O
2'	O	B-IUPAC
-	O	I-IUPAC
deoxy	O	I-IUPAC
analog	O	B-MODIFIER
,	O	O
and	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorobenzyladenosine	I-IUPAC	I-IUPAC
were	O	O
as	O	O
active	O	O
as	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyladenosine	I-IUPAC	I-IUPAC
.	O	O
Various	O	O
substituted	O	B-MODIFIER
isoquinoline	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxaldehyde	I-IUPAC	I-IUPAC
thiosemicarbazones	I-IUPAC	I-IUPAC
(	O	O
12	O	O
compounds	O	O
)	O	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
antineoplastic	O	O
activity	O	O
in	O	O
mice	O	O
bearing	O	O
the	O	O
L1210	O	O
leukemia	O	O
.	O	O
The	O	O
absolute	O	O
configuration	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
10	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
10	O	O
was	O	O
determined	O	O
by	O	O
single	O	O
-	O	O
crystal	O	O
X	O	O
-	O	O
ray	O	O
diffractometry	O	O
of	O	O
the	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mandelate	I-IUPAC	I-IUPAC
salt	B-MODIFIER	I-IUPAC
.	O	O
The	O	O
receptor	O	O
binding	O	O
potencies	O	O
IC50	O	O
values	O	O
are	O	O
48	O	O
(	O	O
1	O	O
)	O	O
,	O	O
126	O	O
(	O	O
2	O	O
)	O	O
,	O	O
40	O	O
(	O	O
3	O	O
)	O	O
,	O	O
19	O	O
(	O	O
4	O	O
)	O	O
,	O	O
100	O	O
(	O	O
5	O	O
)	O	O
,	O	O
48	O	O
(	O	O
6	O	O
)	O	O
,	O	O
2000	O	O
(	O	O
7	O	O
)	O	O
,	O	O
52	O	O
(	O	O
8	O	O
)	O	O
,	O	O
113	O	O
(	O	O
9	O	O
)	O	O
,	O	O
512	O	O
(	O	O
10	O	O
)	O	O
,	O	O
128	O	O
(	O	O
11	O	O
)	O	O
,	O	O
1000	O	O
(	O	O
12	O	O
)	O	O
,	O	O
2000	O	O
(	O	O
13	O	O
)	O	O
,	O	O
500	O	O
(	O	O
14	O	O
)	O	O
,	O	O
and	O	O
200	O	O
nM	O	O
(	O	O
15	O	O
)	O	O
.	O	O
6	B-IUPAC	O
-	I-IUPAC	O
Hydroxypyrimidines	I-IUPAC	O
substituted	B-MODIFIER	O
at	O	O
positions	O	O
2	O	O
and	O	O
4	O	O
by	O	O
hydrogen	O	O
,	O	O
methyl	O	B-IUPAC
,	O	O
amino	O	O
,	O	O
cyclopropylamino	O	O
,	O	O
dimethylamino	O	B-IUPAC
,	O	O
methylsulfanyl	O	O
,	O	O
or	O	O
hydroxyl	O	B-IUPAC
group	O	B-MODIFIER
afford	O	O
by	O	O
the	O	O
reaction	O	O
with	O	O
diisopropyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloroethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methylphosphonate	I-IUPAC	I-IUPAC
in	O	O
the	O	O
presence	O	O
of	O	O
NaH	O	O
,	O	O
Cs	O	O
(	O	O
2	O	O
)	O	O
CO	O	O
(	O	O
3	O	O
)	O	O
,	O	O
or	O	O
DBU	O	O
a	O	O
mixture	O	O
of	O	O
N	B-PARTIUPAC	B-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
1	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diisopropylphosphorylmethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isomers	B-MODIFIER	B-MODIFIER
which	O	O
were	O	O
converted	O	O
to	O	O
the	O	O
free	O	O
phosphonic	O	O
acids	O	O
by	O	O
treatment	O	O
with	O	O
bromotrimethylsilane	O	O
followed	O	O
by	O	O
hydrolysis	O	O
.	O	O
More	O	O
detailed	O	O
biological	O	O
studies	O	O
conducted	O	O
with	O	O
the	O	O
most	O	O
potent	O	O
inhibitor	O	O
NU7163	O	O
(	O	O
48	O	O
;	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.19	O	O
microM	O	O
)	O	O
demonstrated	O	O
ATP	O	O
-	O	O
competitive	O	O
DNA	O	O
-	O	O
PK	O	O
inhibition	O	O
,	O	O
with	O	O
a	O	O
K	O	O
(	O	O
i	O	O
)	O	O
value	O	O
of	O	O
24	O	O
nM	O	O
,	O	O
and	O	O
48	O	O
exhibited	O	O
selectivity	O	O
for	O	O
DNA	O	O
-	O	O
PK	O	O
compared	O	O
with	O	O
the	O	O
related	O	O
enzymes	O	O
ATM	O	O
,	O	O
ATR	O	O
,	O	O
mTOR	O	O
,	O	O
and	O	O
PI	O	O
3	O	O
-	O	O
K	O	O
(	O	O
p110alpha	O	O
)	O	O
.	O	O
gondii	O	O
DHFR	O	O
,	O	O
with	O	O
an	O	O
IC50	O	O
of	O	O
0.0064	O	O
microM	O	O
corresponding	O	O
again	O	O
to	O	O
a	O	O
minor	O	O
increase	O	O
in	O	O
activity	O	O
over	O	O
TMQ	O	O
and	O	O
PTX	O	O
.	O	O
It	O	O
is	O	O
apparent	O	O
that	O	O
the	O	O
intrinsic	O	O
activity	O	O
of	O	O
a	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminotetralin	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
may	O	O
be	O	O
modified	O	O
by	O	O
varying	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
substituents	B-MODIFIER	B-MODIFIER
.	O	O
In	O	O
vivo	O	O
characterization	O	O
of	O	O
[	O	O
18F	O	O
]	O	O
F	O	O
-	O	O
A	O	O
-	O	O
85380	O	O
showed	O	O
promising	O	O
properties	O	O
for	O	O
PET	O	O
imaging	O	O
of	O	O
central	O	O
nAChRs	O	O
.	O	O
Treatment	O	O
of	O	O
the	O	O
tetraacetyl	B-IUPAC	B-IUPAC
derivative	B-MODIFIER	B-MODIFIER
of	O	O
4	O	O
with	O	O
Lawesson	O	O
's	O	O
reagent	O	O
and	O	O
subsequent	O	O
deacetylation	O	O
furnished	O	O
a	O	O
mixture	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosylpyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiocarboxamide	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
and	O	O
the	O	O
corresponding	O	O
nitrile	B-IUPAC	O
derivative	B-MODIFIER	O
(	O	O
16	O	O
)	O	O
.	O	O
This	O	O
was	O	O
confirmed	O	O
by	O	O
an	O	O
X	O	O
-	O	O
ray	O	O
crystallographic	O	O
analysis	O	O
of	O	O
9	O	O
.	O	O
The	O	O
new	O	O
analogues	O	O
were	O	O
all	O	O
obtained	O	O
from	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
via	O	O
a	O	O
Sonogashira	O	O
reaction	O	O
,	O	O
followed	O	O
,	O	O
where	O	O
appropriate	O	O
,	O	O
by	O	O
catalytic	O	O
hydrogenation	O	O
.	O	O
(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O
A	O	O
series	O	O
of	O	O
22	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxycholesterol	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
with	O	O
a	O	O
modified	O	O
side	O	O
chain	O	O
terminus	O	O
was	O	O
prepared	O	O
.	O	O
In	O	O
studies	O	O
with	O	O
L1210	O	O
cells	O	O
in	O	O
vitro	O	O
,	O	O
a	O	O
concentration	O	O
of	O	O
200	O	O
microM	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylquinazolinone	I-IUPAC	I-IUPAC
(	O	O
6	O	O
,	O	O
NU1025	O	O
)	O	O
(	O	O
IC50	O	O
value	O	O
0.40	O	O
microM	O	O
)	O	O
potentiated	O	O
the	O	O
cytotoxicity	O	O
of	O	O
the	O	O
monomethylating	O	O
agent	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyltriazen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
and	O	O
gamma	O	O
-	O	O
radiation	O	O
3.5	O	O
-	O	O
and	O	O
1.4	O	O
-	O	O
fold	O	O
,	O	O
respectively	O	O
,	O	O
at	O	O
the	O	O
10%	O	O
survival	O	O
level	O	O
.	O	O
Both	O	O
of	O	O
these	O	O
polyamine	O	O
analogues	O	O
are	O	O
shown	O	O
to	O	O
be	O	O
more	O	O
active	O	O
against	O	O
L1210	O	O
murine	O	O
leukemia	O	O
cell	O	O
growth	O	O
than	O	O
either	O	O
N	B-IUPAC	O
(	I-IUPAC	O
1	I-IUPAC	O
)	I-IUPAC	O
,	I-IUPAC	O
N	I-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diethylnorspermine	I-IUPAC	I-IUPAC
(	O	O
DENSPM	O	O
)	O	O
or	O	O
(	B-IUPAC	B-IUPAC
2R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
10R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxynorspermine	I-IUPAC	I-IUPAC
[	O	O
(	O	O
2R	O	O
,	O	O
10R	O	O
)	O	O
-	O	O
(	O	O
HO	O	O
)	O	O
(	O	O
2	O	O
)	O	O
DENSPM	O	O
]	O	O
after	O	O
96	O	O
h	O	O
of	O	O
treatment	O	O
;	O	O
the	O	O
activity	O	O
was	O	O
comparable	O	O
to	O	O
that	O	O
of	O	O
(	B-IUPAC	B-IUPAC
2S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
10S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxynorspermine	I-IUPAC	I-IUPAC
[	O	O
(	O	O
2S	O	O
,	O	O
10S	O	O
)	O	O
-	O	O
(	O	O
HO	O	O
)	O	O
(	O	O
2	O	O
)	O	O
DENSPM	O	O
]	O	O
at	O	O
96	O	O
h	O	O
.	O	O
The	O	O
monocylic	O	O
analogue	O	O
[	O	O
dPen1	O	O
,	O	O
(	O	O
Glu4	O	O
,	O	O
Lys8	O	O
)	O	O
]	O	O
oxytocin	O	O
was	O	O
a	O	O
weak	O	O
oxytocin	O	O
antagonist	O	O
with	O	O
a	O	O
pA2	O	O
value	O	O
of	O	O
5.8	O	O
in	O	O
the	O	O
uterotonic	O	O
assay	O	O
.	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Fluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	O
-	I-IUPAC	O
QNB	I-IUPAC	O
,	O	O
and	O	O
(	O	O
R	O	O
,	O	O
R	O	O
)	O	O
-	O	O
IQNB	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
fluoroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	O
QNB	I-IUPAC	O
exhibit	O	O
selectivity	O	O
for	O	O
the	O	O
M1	O	O
subtype	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
fluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	O
-	I-IUPAC	O
QNB	I-IUPAC	O
exhibits	O	O
selectivity	O	O
for	O	O
the	O	O
M2	O	O
subtype	O	O
.	O	O
In	O	O
an	O	O
attempt	O	O
to	O	O
increase	O	O
the	O	O
combined	O	O
toxicity	O	O
of	O	O
the	O	O
metabolic	O	O
end	O	O
-	O	O
products	O	O
[	O	O
acrolein	O	O
(	O	O
4	O	O
)	O	O
and	O	O
phosphoramide	O	O
mustard	O	O
(	O	O
3	O	O
)	O	O
]	O	O
from	O	O
cyclophosphamide	O	O
(	O	O
1	O	O
)	O	O
,	O	O
the	O	O
analog	B-MODIFIER	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxazaphosphorine	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
(	O	O
2	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trifluoromethylcyclophosphamide	I-IUPAC	I-IUPAC
)	O	O
was	O	O
synthesized	O	O
and	O	O
its	O	O
metabolism	O	O
and	O	O
antitumor	O	O
activity	O	O
studied	O	O
.	O	O
Most	O	O
of	O	O
the	O	O
target	O	O
compounds	O	O
were	O	O
more	O	O
potent	O	O
than	O	O
the	O	O
corresponding	O	O
secondary	O	O
amides	O	O
and	O	O
had	O	O
improved	O	O
therapeutic	O	O
margins	O	O
toward	O	O
CNS	O	O
toxicity	O	O
.	O	O
However	O	O
,	O	O
the	O	O
21	O	O
-	O	O
hydroxylated	O	O
erythromycin	O	O
A	O	O
analogue	O	O
was	O	O
weaker	O	O
in	O	O
potency	O	O
than	O	O
the	O	O
corresponding	O	O
erythromycin	O	O
B	O	O
congener	O	O
and	O	O
much	O	O
weaker	O	O
than	O	O
the	O	O
epoxy	O	O
derivative	O	O
.	O	O
A	O	O
series	O	O
of	O	O
N2	B-PARTIUPAC	O
(	O	O
and	O	O
N4	B-PARTIUPAC	O
)	O	O
-	B-PARTIUPAC	O
aryl	B-PARTIUPAC	O
-	B-PARTIUPAC	O
N4	B-PARTIUPAC	O
(	O	O
and	O	O
N2	B-PARTIUPAC	B-IUPAC
)	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
dialkylamino	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
alkyl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2,4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
quinazolinediamines	I-PARTIUPAC	I-IUPAC
has	O	O
been	O	O
synthesized	O	O
for	O	O
antimalarial	O	O
evaluation	O	O
.	O	O
Combination	O	O
of	O	O
the	O	O
best	O	O
substituent	O	O
in	O	O
each	O	O
of	O	O
these	O	O
positions	O	O
enhanced	O	O
the	O	O
overall	O	O
activity	O	O
.	O	O
However	O	O
13	O	O
was	O	O
no	O	O
more	O	O
potent	O	O
than	O	O
PTX	O	O
against	O	O
M	O	O
.	O	O
The	O	O
protected	O	O
intermediates	O	O
required	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
all	O	O
of	O	O
these	O	O
peptides	O	O
were	O	O
prepared	O	O
by	O	O
the	O	O
solid	O	O
-	O	O
phase	O	O
method	O	O
and	O	O
cleaved	O	O
from	O	O
the	O	O
resin	O	O
by	O	O
ammonolysis	O	O
.	O	O
The	O	O
4H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
,	O	O
the	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
,	O	O
the	O	O
4H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
,	O	O
and	O	O
the	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
found	O	O
to	O	O
be	O	O
inactive	O	O
or	O	O
only	O	O
marginally	O	O
activate	O	O
as	O	O
receptor	O	O
ligands	O	O
or	O	O
estrogen	O	O
agonists	O	O
-	O	O
antagonists	O	O
.	O	O
Biological	O	O
tests	O	O
indicate	O	O
hexahydro	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indeno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridines	I-IUPAC	I-IUPAC
to	O	O
be	O	O
potential	O	O
human	O	O
antidepressants	O	O
with	O	O
additional	O	O
stimulating	O	O
properties	O	O
.	O	O
Further	O	O
,	O	O
the	O	O
octanol	O	O
-	O	O
water	O	O
partition	O	O
coefficient	O	O
of	O	O
(	O	O
S	O	O
)	O	O
-	O	O
6b	O	O
as	O	O
determined	O	O
by	O	O
reverse	O	O
-	O	O
phase	O	O
high	O	O
-	O	O
performance	O	O
liquid	O	O
chromatography	O	O
was	O	O
found	O	O
to	O	O
be	O	O
40	O	O
times	O	O
greater	O	O
than	O	O
that	O	O
for	O	O
sulpiride	O	O
.	O	O
These	O	O
compounds	O	O
exhibit	O	O
different	O	O
affinities	O	O
for	O	O
the	O	O
muscarinic	O	O
receptor	O	O
tissue	O	O
subtypes	O	O
in	O	O
vitro	O	O
.	O	O
Dimethylamine	O	O
removed	O	O
the	O	O
ester	O	O
groups	O	O
and	O	O
opened	O	O
the	O	O
epoxide	O	O
to	O	O
give	O	O
the	O	O
amino	O	O
alcohol	O	O
24	O	O
.	O	O
The	O	O
corresponding	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
5'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylcarboxamidoadenosine	I-IUPAC	I-IUPAC
(	O	O
NECA	O	O
)	O	O
and	O	O
Ado	O	O
are	O	O
used	O	O
as	O	O
reference	O	O
compounds	O	O
.	O	O
This	O	O
compound	O	O
had	O	O
the	O	O
following	O	O
binding	O	O
affinities	O	O
:	O	O
IC50	O	O
(	O	O
sigma	O	O
1	O	O
)	O	O
=	O	O
1200	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
sigma	O	O
2	O	O
)	O	O
=	O	O
2.5	O	O
nM	O	O
.	O	O
(	B-PARTIUPAC	O
Trifluoromethyl	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
nitro	B-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
and	O	O
other	O	O
benzyl	O	O
esters	O	O
substituted	O	O
with	O	O
electron	O	O
-	O	O
withdrawing	O	O
groups	O	O
were	O	O
specific	O	O
for	O	O
A3	O	O
receptors	O	O
with	O	O
nanomolar	O	O
Ki	O	O
values	O	O
and	O	O
selectivity	O	O
as	O	O
high	O	O
as	O	O
37000	O	O
-	O	O
fold	O	O
.	O	O
Criteria	O	O
required	O	O
for	O	O
good	O	O
oral	O	O
activity	O	O
in	O	O
the	O	O
latter	O	O
model	O	O
include	O	O
an	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentadienamide	I-IUPAC	I-IUPAC
,	O	O
a	O	O
second	O	O
phenyl	B-PARTIUPAC	O
or	O	O
a	O	O
four	O	O
-	O	O
or	O	O
five	O	O
-	O	O
carbon	O	O
alkyl	B-PARTIUPAC	O
moiety	B-MODIFIER	O
in	O	O
the	O	O
5	O	O
-	O	O
position	O	O
of	O	O
the	O	O
diene	O	O
,	O	O
and	O	O
an	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
carboxamide	O	O
nitrogen	O	O
atom	O	O
.	O	O
Conversion	O	O
of	O	O
the	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenolic	I-IUPAC	I-IUPAC
1,2,3,4,5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzazocines	I-IUPAC	I-IUPAC
to	O	O
the	O	O
corresponding	O	O
8	B-IUPAC	O
-	I-IUPAC	O
thiophenolic	I-IUPAC	O
analogues	B-MODIFIER	O
was	O	O
achieved	O	O
by	O	O
three	O	O
different	O	O
routes	O	O
.	O	O
Also	O	O
7	B-IUPAC	O
-	I-IUPAC	O
aza	I-IUPAC	O
and	O	O
8	B-IUPAC	O
-	I-IUPAC	O
aza	I-IUPAC	O
substitution	B-MODIFIER	O
on	O	O
the	O	O
parent	O	O
quinazoline	O	O
ring	O	O
has	O	O
a	O	O
detrimental	O	O
effect	O	O
on	O	O
the	O	O
interaction	O	O
with	O	O
beta	O	O
-	O	O
PDGFR	O	O
.	O	O
Overall	O	O
,	O	O
there	O	O
was	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
correlation	O	O
of	O	O
the	O	O
activities	O	O
against	O	O
the	O	O
different	O	O
kinases	O	O
,	O	O
with	O	O
c	O	O
-	O	O
Src	O	O
being	O	O
generally	O	O
the	O	O
most	O	O
sensitive	O	O
to	O	O
structural	O	O
changes	O	O
.	O	O
None	O	O
of	O	O
the	O	O
bis	O	O
(	O	O
carbamates	O	O
)	O	O
prepared	O	O
was	O	O
active	O	O
against	O	O
murine	O	O
P388	O	O
lymphocytic	O	O
leukemia	O	O
.	O	O
Interestingly	O	O
,	O	O
the	O	O
same	O	O
substitutions	O	O
at	O	O
positions	O	O
2	O	O
and	O	O
7	O	O
,	O	O
with	O	O
l	O	O
-	O	O
threo	O	O
-	O	O
beta	O	O
-	O	O
MeTrp	O	O
at	O	O
position	O	O
8	O	O
,	O	O
yielded	O	O
a	O	O
much	O	O
less	O	O
selective	O	O
analogue	O	O
(	O	O
20	O	O
)	O	O
.	O	O
Apparent	O	O
affinity	O	O
of	O	O
the	O	O
compounds	O	O
for	O	O
P2Y	O	O
-	O	O
purinoceptors	O	O
was	O	O
established	O	O
by	O	O
measurement	O	O
of	O	O
P2Y	O	O
-	O	O
purinoceptor	O	O
-	O	O
promoted	O	O
phospholipase	O	O
C	O	O
activity	O	O
in	O	O
turkey	O	O
erythrocyte	O	O
membranes	O	O
and	O	O
relaxation	O	O
of	O	O
carbachol	O	O
-	O	O
contracted	O	O
smooth	O	O
muscle	O	O
in	O	O
three	O	O
different	O	O
preparations	O	O
(	O	O
guinea	O	O
pig	O	O
taenia	O	O
coli	O	O
,	O	O
rabbit	O	O
aorta	O	O
,	O	O
and	O	O
rabbit	O	O
mesenteric	O	O
artery	O	O
)	O	O
.	O	O
The	O	O
position	O	O
of	O	O
radiolabeling	O	O
in	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
was	O	O
confirmed	O	O
by	O	O
[	O	O
(	O	O
11/13	O	O
)	O	O
C	O	O
]	O	O
colabeling	O	O
and	O	O
subsequent	O	O
carbon	O	O
-	O	O
13	O	O
NMR	O	O
spectroscopy	O	O
.	O	O
This	O	O
new	O	O
ligand	O	O
offers	O	O
several	O	O
unique	O	O
advantages	O	O
,	O	O
including	O	O
high	O	O
specific	O	O
activity	O	O
,	O	O
high	O	O
binding	O	O
affinity	O	O
,	O	O
and	O	O
low	O	O
nonspecific	O	O
binding	O	O
,	O	O
all	O	O
of	O	O
which	O	O
make	O	O
it	O	O
an	O	O
excellent	O	O
probe	O	O
for	O	O
the	O	O
investigation	O	O
and	O	O
characterization	O	O
of	O	O
5	O	O
-	O	O
HT1A	O	O
receptors	O	O
.	O	O
Compound	O	O
27	O	O
also	O	O
was	O	O
converted	O	O
to	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodoacetamidomethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
by	O	O
treatment	O	O
with	O	O
ammonia	O	O
,	O	O
chloroacetyl	O	O
chloride	O	O
,	O	O
base	O	O
saponification	O	O
,	O	O
and	O	O
finally	O	O
sodium	O	O
iodide	O	O
.	O	O
Benzoate	O	O
substitutions	O	O
in	O	O
the	O	O
ortho	O	O
position	O	O
relative	O	O
to	O	O
the	O	O
terminal	O	O
carboxylate	O	O
(	O	O
9d	O	O
,	O	O
k	O	O
,	O	O
r	O	O
)	O	O
are	O	O
well	O	O
-	O	O
tolerated	O	O
;	O	O
however	O	O
,	O	O
a	O	O
methoxy	O	O
substituent	O	O
meta	O	O
relative	O	O
to	O	O
the	O	O
terminal	O	O
carboxylate	O	O
gives	O	O
rise	O	O
to	O	O
only	O	O
weakly	O	O
active	O	O
analogues	O	O
(	O	O
9x	O	O
)	O	O
.	O	O
Also	O	O
effective	O	O
are	O	O
bis	O	O
(	O	O
alkoxymethyl	O	O
)	O	O
and	O	O
mixed	O	O
alkylalkoxymethyl	O	O
derivatives	O	O
of	O	O
5,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diphenylhydantoin	I-IUPAC	I-IUPAC
.	O	O
The	O	O
isosteric	O	O
benzene	O	O
-	O	O
thiophene	O	O
replacement	O	O
accounts	O	O
for	O	O
an	O	O
enhanced	O	O
stability	O	O
of	O	O
the	O	O
acyl	O	O
-	O	O
enzyme	O	O
intermediates	O	O
.	O	O
These	O	O
results	O	O
suggest	O	O
(	O	O
a	O	O
)	O	O
an	O	O
alternate	O	O
pathway	O	O
for	O	O
the	O	O
formation	O	O
of	O	O
heptapeptide	O	O
III	O	O
,	O	O
viz	O	O
.	O	O
It	O	O
was	O	O
found	O	O
that	O	O
polar	O	O
functional	O	O
groups	O	O
suitable	O	O
for	O	O
the	O	O
attachment	O	O
of	O	O
a	O	O
prodrug	O	O
moiety	O	O
were	O	O
tolerated	O	O
on	O	O
the	O	O
styryl	O	O
ring	O	O
and	O	O
even	O	O
better	O	O
on	O	O
the	O	O
3	O	O
-	O	O
substituent	O	O
.	O	O
These	O	O
effects	O	O
of	O	O
8	O	O
and	O	O
9	O	O
proved	O	O
to	O	O
be	O	O
enantioselective	O	O
,	O	O
(	O	O
R	O	O
)	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
8	O	O
and	O	O
(	O	O
R	O	O
)	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
9	O	O
being	O	O
the	O	O
active	O	O
inhibitors	O	O
of	O	O
both	O	O
uptake	O	O
systems	O	O
.	O	O
The	O	O
one	O	O
exception	O	O
is	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
THIQ	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
,	O	O
which	O	O
was	O	O
found	O	O
to	O	O
display	O	O
the	O	O
opposite	O	O
stereoselectivity	O	O
at	O	O
the	O	O
alpha	O	O
(	O	O
2	O	O
)	O	O
-	O	O
adrenoceptor	O	O
.	O	O
For	O	O
the	O	O
former	O	O
complexes	O	O
,	O	O
trans	O	O
isomers	O	O
are	O	O
more	O	O
efficacious	O	O
than	O	O
the	O	O
corresponding	O	O
cis	O	O
isomers	O	O
.	O	O
These	O	O
compounds	O	O
represent	O	O
conformationally	O	O
constrained	O	O
direct	O	O
analogues	O	O
of	O	O
the	O	O
corresponding	O	O
potent	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentadienecarboxamides	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
.	O	O
Elaboration	O	O
of	O	O
the	O	O
required	O	O
oligo	B-IUPAC	O
(	I-IUPAC	O
gamma	I-IUPAC	O
-	I-IUPAC	O
L	I-IUPAC	O
-	I-IUPAC	O
glutamate	I-IUPAC	O
)	I-IUPAC	O
chain	O	O
was	O	O
achieved	O	O
one	O	O
unit	O	O
at	O	O
a	O	O
time	O	O
,	O	O
beginning	O	O
with	O	O
the	O	O
coupling	O	O
of	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
dibenzyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
with	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
followed	O	O
by	O	O
selective	O	O
removal	O	O
of	O	O
the	O	O
tert	O	B-IUPAC
-	O	I-IUPAC
butyloxycarbonyl	O	I-IUPAC
grouping	O	B-MODIFIER
and	O	O
another	O	O
coupling	O	O
step	O	O
with	O	O
5	O	O
or	O	O
7	O	O
as	O	O
required	O	O
.	O	O
The	O	O
distribution	O	O
coefficient	O	O
values	O	O
of	O	O
a	O	O
range	O	O
of	O	O
48	O	O
hydroxypyridinones	O	O
and	O	O
their	O	O
corresponding	O	O
iron	O	O
(	O	O
III	O	O
)	O	O
complexes	O	O
between	O	O
1	O	B-IUPAC
-	O	I-IUPAC
octanol	O	I-IUPAC
and	O	O
MOPS	O	O
buffer	O	O
(	O	O
pH	O	O
7.4	O	O
)	O	O
are	O	O
reported	O	O
.	O	O
Western	O	O
blotting	O	O
analysis	O	O
demonstrated	O	O
that	O	O
9h	O	O
caused	O	O
a	O	O
shift	O	O
in	O	O
tubulin	O	O
concentration	O	O
from	O	O
the	O	O
polymerized	O	O
state	O	O
found	O	O
in	O	O
the	O	O
cell	O	O
pellet	O	O
to	O	O
the	O	O
unpolymerized	O	O
state	O	O
found	O	O
in	O	O
the	O	O
cell	O	O
supernatant	O	O
.	O	O
avium	O	O
DHFR	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.47	O	O
nM	O	O
,	O	O
SI	O	O
=	O	O
1300	O	O
)	O	O
but	O	O
was	O	O
not	O	O
potent	O	O
or	O	O
selective	O	O
against	O	O
either	O	O
P	O	O
.	O	O
Analysis	O	O
of	O	O
DNA	O	O
and	O	O
Annexin	O	O
-	O	O
V	O	O
-	O	O
FLUOS	O	O
staining	O	O
indicated	O	O
that	O	O
compound	O	O
4	O	O
causes	O	O
cell	O	O
death	O	O
by	O	O
apoptosis	O	O
.	O	O
This	O	O
compound	O	O
is	O	O
a	O	O
homofolate	O	O
analogue	O	O
of	O	O
5,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methenyltetrahydrofolate	I-IUPAC	I-IUPAC
which	O	O
serves	O	O
as	O	O
one	O	O
precursor	O	O
to	O	O
the	O	O
10	O	O
-	O	O
formyl	O	O
one	O	O
-	O	O
carbon	O	O
donor	O	O
for	O	O
the	O	O
first	O	O
transformylation	O	O
in	O	O
de	O	O
novo	O	O
purine	O	O
biosynthesis	O	O
,	O	O
namely	O	O
,	O	O
the	O	O
conversion	O	O
of	O	O
glycinamide	O	O
ribonucleotide	O	O
(	O	O
GAR	O	O
)	O	O
to	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
formylglycinamide	I-IUPAC	I-IUPAC
ribonucleotide	I-IUPAC	I-IUPAC
(	O	O
FGAR	O	O
)	O	O
,	O	O
catalyzed	O	O
by	O	O
the	O	O
enzyme	O	O
glycinamide	O	O
ribonucleotide	O	O
transformylase	O	O
(	O	O
EC	O	O
2.1.2.2	O	O
)	O	O
.	O	O
Prazosin	O	O
-	O	O
related	O	O
quinazolines	O	O
4-20	O	O
were	O	O
synthesized	O	O
,	O	O
and	O	O
their	O	O
biological	O	O
profiles	O	O
at	O	O
alpha1	O	O
-	O	O
adrenoreceptor	O	O
subtypes	O	O
were	O	O
assessed	O	O
by	O	O
functional	O	O
experiments	O	O
in	O	O
isolated	O	O
rat	O	O
vas	O	O
deferens	O	O
(	O	O
alpha1A	O	O
)	O	O
,	O	O
spleen	O	O
(	O	O
alpha1B	O	O
)	O	O
,	O	O
and	O	O
aorta	O	O
(	O	O
alpha1D	O	O
)	O	O
and	O	O
by	O	O
binding	O	O
assays	O	O
in	O	O
CHO	O	O
cells	O	O
expressing	O	O
human	O	O
cloned	O	O
alpha1	O	O
-	O	O
adrenoreceptor	O	O
subtypes	O	O
.	O	O
Thus	O	O
we	O	O
searched	O	O
for	O	O
a	O	O
benzyl	O	O
ester	O	O
surrogate	O	O
that	O	O
would	O	O
be	O	O
more	O	O
resistant	O	O
to	O	O
hydrolytic	O	O
enzymes	O	O
.	O	O
More	O	O
interestingly	O	O
,	O	O
the	O	O
intermediate	O	O
compound	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyloxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propenoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
5	O	O
was	O	O
equiactive	O	O
with	O	O
3	O	O
.	O	O
The	O	O
N9	O	O
-	O	O
CH3	O	O
analogues	O	O
were	O	O
synthesized	O	O
via	O	O
a	O	O
regiospecific	O	O
reductive	O	O
methylation	O	O
of	O	O
the	O	O
corresponding	O	O
N9	O	O
-	O	O
H	O	O
precursors	O	O
.	O	O
However	O	O
the	O	O
Ki	O	O
of	O	O
the	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
was	O	O
27	O	O
-	O	O
fold	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
1	O	O
,	O	O
and	O	O
that	O	O
of	O	O
the	O	O
5,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dideaza	I-IUPAC	I-IUPAC
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideaza	I-IUPAC	I-IUPAC
,	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideaza	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
was	O	O
approximately	O	O
50	O	O
-	O	O
fold	O	O
lower	O	O
.	O	O
Optimization	O	O
of	O	O
the	O	O
structural	O	O
parameters	O	O
for	O	O
this	O	O
activity	O	O
yiedled	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluorobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
41	O	O
)	O	O
and	O	O
its	O	O
sulfoxide	O	O
,	O	O
42	O	O
.	O	O
To	O	O
examine	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
conformation	O	O
of	O	O
the	O	O
pharmacophore	O	O
and	O	O
the	O	O
level	O	O
of	O	O
agonistic	O	O
activity	O	O
of	O	O
this	O	O
type	O	O
of	O	O
ligand	O	O
,	O	O
we	O	O
synthesized	O	O
a	O	O
series	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
{	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
or	I-IUPAC	I-IUPAC
CH3	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
}	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
methanone	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
and	O	O
found	O	O
that	O	O
the	O	O
combination	O	O
of	O	O
a	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
and	O	O
a	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
pyridine	O	O
ring	O	O
synergistically	O	O
affected	O	O
their	O	O
5	O	O
-	O	O
HT1A	O	O
agonist	O	O
properties	O	O
.	O	O
Principal	O	O
efforts	O	O
focused	O	O
on	O	O
triazoles	O	O
bearing	O	O
an	O	O
n	O	O
-	O	O
alkyl	O	O
substitutent	O	O
at	O	O
C3	O	O
and	O	O
a	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxybenzoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
,	I-IUPAC	O
(	I-IUPAC	B-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxybiphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
,	O	O
or	O	O
[	B-IUPAC	B-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
side	B-MODIFIER	B-MODIFIER
chain	I-MODIFIER	I-MODIFIER
at	O	O
N4	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
39	O	O
was	O	O
also	O	O
found	O	O
to	O	O
be	O	O
active	O	O
against	O	O
hookworms	O	O
in	O	O
dogs	O	O
at	O	O
a	O	O
single	O	O
,	O	O
oral	O	O
dose	O	O
of	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
Compounds	O	O
with	O	O
potent	O	O
receptor	O	O
binding	O	O
also	O	O
potently	O	O
inhibited	O	O
the	O	O
quipazine	O	O
-	O	O
induced	O	O
head	O	O
twitch	O	O
syndrome	O	O
in	O	O
rats	O	O
.	O	O
The	O	O
C2	O	O
'	O	O
-	O	O
endo	O	O
-	O	O
C1	O	O
'	O	O
-	O	O
exo	O	O
conformation	O	O
,	O	O
the	O	O
anti	O	O
conformation	O	O
of	O	O
thymine	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
glycosidic	O	O
bond	O	O
,	O	O
and	O	O
the	O	O
gauche+	O	O
conformation	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
C4	O	O
'	O	O
-	O	O
C5	O	O
'	O	O
bond	O	O
are	O	O
characteristic	O	O
for	O	O
the	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxythymidine	I-IUPAC	I-IUPAC
structure	O	O
in	O	O
the	O	O
crystals	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
of	O	O
3	O	O
was	O	O
also	O	O
tested	O	O
at	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
against	O	O
a	O	O
panel	O	O
of	O	O
50	O	O
human	O	O
tumor	O	O
cell	O	O
lines	O	O
in	O	O
culture	O	O
and	O	O
was	O	O
consistently	O	O
more	O	O
potent	O	O
than	O	O
3	O	O
,	O	O
with	O	O
IC50	O	O
values	O	O
in	O	O
the	O	O
low	O	O
-	O	O
nanomolar	O	O
to	O	O
subnanomolar	O	O
range	O	O
against	O	O
most	O	O
of	O	O
the	O	O
tumors	O	O
.	O	O
The	O	O
introduction	O	O
of	O	O
hydroxyl	B-IUPAC	O
groups	B-MODIFIER	O
significantly	O	O
enhanced	O	O
the	O	O
radioprotective	O	O
properties	O	O
of	O	O
nonhydroxylated	O	O
parent	O	O
compounds	O	O
,	O	O
however	O	O
,	O	O
only	O	O
in	O	O
the	O	O
case	O	O
of	O	O
intraperitoneally	O	O
administered	O	O
.	O	O
Compounds	O	O
10	O	O
and	O	O
21	O	O
were	O	O
also	O	O
able	O	O
to	O	O
reduce	O	O
neuronal	O	O
cell	O	O
death	O	O
induced	O	O
by	O	O
the	O	O
application	O	O
of	O	O
KA	O	O
(	O	O
100	O	O
microM	O	O
)	O	O
.	O	O
avium	O	O
DHFR	O	O
,	O	O
and	O	O
its	O	O
SI	O	O
was	O	O
no	O	O
better	O	O
than	O	O
that	O	O
of	O	O
TMP	O	O
.	O	O
The	O	O
site	O	O
of	O	O
glycosylation	O	O
and	O	O
the	O	O
anomeric	O	O
configuration	O	O
of	O	O
these	O	O
nucleosides	O	O
have	O	O
been	O	O
assigned	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
1'	O	O
NMR	O	O
and	O	O
UV	O	O
spectral	O	O
characteristics	O	O
and	O	O
by	O	O
single	O	O
-	O	O
crystal	O	O
X	O	O
-	O	O
ray	O	O
analysis	O	O
for	O	O
27-29	O	O
.	O	O
By	O	O
contrast	O	O
,	O	O
compound	O	O
8b	O	O
showed	O	O
no	O	O
appreciable	O	O
affinity	O	O
for	O	O
Glu	O	O
uptake	O	O
sites	O	O
,	O	O
neither	O	O
synaptosomal	O	O
nor	O	O
cloned	O	O
.	O	O
Substitutions	O	O
at	O	O
positions	O	O
3	O	O
(	O	O
[	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Dap	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
degarelix	I-IUPAC	I-IUPAC
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
2.71	O	O
nM	O	O
)	O	O
(	O	O
5	O	O
)	O	O
,	O	O
7	O	O
(	O	O
[	B-IUPAC	O
Pra	I-IUPAC	O
(	I-IUPAC	O
7	I-IUPAC	O
)	I-IUPAC	O
]	I-IUPAC	O
degarelix	I-IUPAC	O
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
2.11	O	O
nM	O	O
)	O	O
(	O	O
16	O	O
)	O	O
,	O	O
and	O	O
8	O	O
(	O	O
[	B-IUPAC	O
N	I-IUPAC	O
(	I-IUPAC	O
delta	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
IGly	I-IUPAC	O
)	I-IUPAC	O
Orn	I-IUPAC	O
(	I-IUPAC	O
8	I-IUPAC	O
)	I-IUPAC	O
]	I-IUPAC	O
degarelix	I-IUPAC	O
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.38	O	O
nM	O	O
)	O	O
(	O	O
20	O	O
)	O	O
and	O	O
N	O	O
-	O	O
methylation	O	O
(	O	O
[	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Leu	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
degarelix	I-IUPAC	I-IUPAC
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.47	O	O
nM	O	O
)	O	O
(	O	O
32	O	O
)	O	O
yielded	O	O
analogues	O	O
that	O	O
were	O	O
equipotent	O	O
to	O	O
degarelix	O	O
(	O	O
2	O	O
)	O	O
in	O	O
vitro	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.64	O	O
nM	O	O
)	O	O
but	O	O
shorter	O	O
acting	O	O
in	O	O
vivo	O	O
.	O	O
Pyrazofurin	O	O
derivatives	O	O
modified	O	O
at	O	O
the	O	O
1	O	O
-	O	O
,	O	O
4	O	O
-	O	O
,	O	O
or	O	O
5	O	O
-	O	O
position	O	O
showed	O	O
neither	O	O
antiviral	O	O
nor	O	O
cytostatic	O	O
activity	O	O
in	O	O
cell	O	O
culture	O	O
.	O	O
Thus	O	O
,	O	O
nine	O	O
new	O	O
bis	O	B-IUPAC
-	O	I-IUPAC
carbamates	O	I-IUPAC
:	O	I-IUPAC
methoxycarbonyl	B-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
2,2,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trichloroethoxycarbonyl	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
ethylthiocarbonyl	B-IUPAC	B-IUPAC
(	O	O
4	O	O
)	O	O
,	O	O
benzyloxycarbonyl	B-IUPAC	B-IUPAC
(	O	O
5	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
en	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methoxycarbonyl	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
,	O	O
phenoxycarbonyl	B-IUPAC	B-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenoxycarbonyl	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenoxycarbonyl	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
and	O	O
a	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbonate	I-IUPAC	I-IUPAC
ethoxycarbonyloxy	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
of	O	O
the	O	O
bis	O	B-IUPAC
-	O	I-IUPAC
amidine	O	I-IUPAC
1	O	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
.	O	O
Acetylacetone	O	O
was	O	O
condensed	O	O
with	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylidene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribose	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
:	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzylidene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribose	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
,	O	O
2,3,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetraacetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribose	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
and	O	O
2,3,4,5,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pentaacetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glucose	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
to	O	O
yield	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ylidene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentanedione	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
2	O	O
,	O	O
11	O	O
,	O	O
12	O	O
,	O	O
and	O	O
13	O	O
,	O	O
respectively	O	O
.	O	O
Its	O	O
selectivity	O	O
is	O	O
about	O	O
400	O	O
-	O	O
fold	O	O
over	O	O
the	O	O
NET	O	O
and	O	O
about	O	O
1000	O	O
-	O	O
fold	O	O
over	O	O
the	O	O
DAT	O	O
.	O	O
The	O	O
inactivation	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
stereospecific	O	O
since	O	O
a	O	O
D	O	O
derivative	O	O
led	O	O
to	O	O
no	O	O
irreversible	O	O
inactivation	O	O
.	O	O
The	O	O
product	O	O
(	O	O
3a	O	O
)	O	O
,	O	O
of	O	O
the	O	O
condensation	O	O
reaction	O	O
between	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nicotinonitrile	I-IUPAC	I-IUPAC
and	O	O
2	O	O
,	O	O
undergoes	O	O
Suzuki	O	O
coupling	O	O
with	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyanophenylboronic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
to	O	O
furnish	O	O
4a	O	O
in	O	O
good	O	O
yield	O	O
.	O	O
aureus	O	O
,	O	O
clearly	O	O
indicating	O	O
that	O	O
the	O	O
2,6	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
dimethylpyridinyl	I-PARTIUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
is	O	O
optimal	O	O
.	O	O
Introduction	O	O
of	O	O
substituents	O	O
at	O	O
the	O	O
5	O	O
-	O	O
,	O	O
7	O	O
-	O	O
,	O	O
and	O	O
5,7	O	O
-	O	O
positions	O	O
resulted	O	O
in	O	O
analogues	O	O
having	O	O
selective	O	O
NMDA	O	O
antagonist	O	O
action	O	O
,	O	O
as	O	O
a	O	O
result	O	O
of	O	O
blockade	O	O
of	O	O
the	O	O
glycine	O	O
modulatory	O	O
(	O	O
or	O	O
coagonist	O	O
)	O	O
site	O	O
on	O	O
the	O	O
NMDA	O	O
receptor	O	O
.	O	O
A	O	O
series	O	O
of	O	O
C11	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aporphines	I-IUPAC	I-IUPAC
and	O	O
C11	B-MODIFIER	O
-	I-MODIFIER	O
oxygenated	I-MODIFIER	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
noraporphines	I-IUPAC	I-IUPAC
has	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
central	O	O
serotonergic	O	O
and	O	O
dopaminergic	O	O
effects	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O
Thus	O	O
,	O	O
the	O	O
synthesis	O	O
of	O	O
some	O	O
3	O	B-MODIFIER
-	O	I-MODIFIER
NH	O	I-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
derivatives	O	B-MODIFIER
(	O	O
2a	O	O
,	O	O
3a	O	O
,	O	O
4a	O	O
)	O	O
starting	O	O
from	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinoxalinecarbonitrile	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
(	O	O
1a	O	O
)	O	O
is	O	O
described	O	O
.	O	O
This	O	O
inactivation	O	O
was	O	O
very	O	O
rapid	O	O
but	O	O
reversible	O	O
,	O	O
with	O	O
regeneration	O	O
of	O	O
enzyme	O	O
activity	O	O
being	O	O
spontaneous	O	O
and	O	O
hydrazine	O	O
-	O	O
accelerated	O	O
,	O	O
suggestive	O	O
of	O	O
the	O	O
intermediacy	O	O
of	O	O
a	O	O
stable	O	O
acyl	O	O
enzyme	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
replacement	O	O
of	O	O
the	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylallyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,9	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzomorphan	I-IUPAC	I-IUPAC
[	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1b	O	O
,	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentazocine	I-IUPAC	I-IUPAC
]	O	I-IUPAC
with	O	O
a	O	O
2'	O	O
-	O	O
H	O	O
or	O	O
2'	O	O
-	O	O
F	O	O
group	O	O
resulted	O	O
in	O	O
a	O	O
2	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
potency	O	O
.	O	O
Some	O	O
of	O	O
the	O	O
reported	O	O
analogues	O	O
,	O	O
namely	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercapto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcyclohexaneacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercapto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcyclohexaneacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyltryosine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercaptocyclohexaneacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyltyrosine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercapto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylcyclohexaneacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercapto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylcyclohexaneacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyltyrosine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
,	O	O
are	O	O
among	O	O
the	O	O
most	O	O
potent	O	O
and	O	O
selective	O	O
antagonists	O	O
of	O	O
the	O	O
vasopressor	O	O
response	O	O
to	O	O
arginine	O	O
-	O	O
vasopressin	O	O
reported	O	O
to	O	O
date	O	O
.	O	O
carinii	O	O
at	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
x	O	O
5	O	O
days	O	O
(	O	O
ip	O	O
)	O	O
and	O	O
against	O	O
B	O	O
.	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Bromostyryl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propargylxanthine	I-IUPAC	I-IUPAC
(	O	O
BS	O	O
-	O	O
DMPX	O	O
,	O	O
11	O	O
)	O	O
and	O	O
the	O	O
analogous	B-MODIFIER	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxystyryl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
xanthine	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
MS	O	O
-	O	O
DMPX	O	O
,	O	O
5b	O	O
)	O	O
were	O	O
used	O	O
as	O	O
starting	O	O
points	O	O
.	O	O
Two	O	O
series	O	O
of	O	O
peptide	O	O
analogues	O	O
,	O	O
(	O	O
a	O	O
)	O	O
p	O	O
-	O	O
substituted	O	O
analogues	O	O
,	O	O
[	O	O
p	O	O
-	O	O
X	O	O
-	O	O
Phe	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
,	O	O
where	O	O
X	O	O
=	O	O
F	O	O
,	O	O
Cl	O	O
,	O	O
Br	O	O
,	O	O
I	O	O
,	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
,	O	O
NO	O	O
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
(	O	O
b	O	O
)	O	O
[	O	O
D	O	O
-	O	O
Phe	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
,	O	O
[	O	O
Trp	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
,	O	O
and	O	O
[	O	O
Chex	O	O
-	O	O
Ala	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
,	O	O
were	O	O
synthesized	O	O
,	O	O
and	O	O
their	O	O
biological	O	O
activity	O	O
was	O	O
examined	O	O
.	O	O
Three	O	O
series	O	O
of	O	O
benzamides	O	O
of	O	O
N	B-MODIFIER	B-IUPAC
,	I-MODIFIER	I-IUPAC
N	I-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
disubstituted	I-MODIFIER	I-IUPAC
ethylenediamines	B-IUPAC	I-IUPAC
(	O	O
linear	B-MODIFIER	O
alkane	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamines	I-IUPAC	I-IUPAC
)	O	I-IUPAC
,	O	O
1	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrrolidines	I-IUPAC	I-IUPAC
,	O	O
and	O	O
1	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrrolidines	I-IUPAC	I-IUPAC
(	O	I-IUPAC
cyclic	B-MODIFIER	I-IUPAC
alkane	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamines	I-IUPAC	I-IUPAC
)	O	I-IUPAC
were	O	O
designed	O	O
and	O	O
synthesized	O	O
as	O	O
potential	O	O
neuroleptics	O	O
.	O	O
Binding	O	O
studies	O	O
were	O	O
performed	O	O
using	O	O
[	O	O
3H	O	O
]	O	O
isradipine	O	O
as	O	O
a	O	O
reference	O	O
ligand	O	O
.	O	O
No	O	O
.	O	O
These	O	O
data	O	O
further	O	O
support	O	O
a	O	O
pharmacophore	O	O
model	O	O
in	O	O
which	O	O
the	O	O
region	O	O
occupied	O	O
by	O	O
the	O	O
aryl	O	O
ring	O	O
is	O	O
a	O	O
lipophilic	O	O
pocket	O	O
with	O	O
electropositive	O	O
character	O	O
.	O	O
Increasing	O	O
the	O	O
chain	O	O
length	O	O
and	O	O
the	O	O
lipophilicity	O	O
of	O	O
the	O	O
N	O	O
-	O	O
substituent	O	O
result	O	O
in	O	O
compounds	O	O
in	O	O
which	O	O
high	O	O
affinity	O	O
for	O	O
sigma	O	O
2	O	O
binding	O	O
sites	O	O
is	O	O
retained	O	O
and	O	O
with	O	O
selectivity	O	O
for	O	O
sigma	O	O
2	O	O
vs	O	O
sigma	O	O
1	O	O
binding	O	O
sites	O	O
(	O	O
e.g.	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
:	O	O
IC50	O	O
-	O	O
(	O	O
sigma	O	O
1	O	O
)	O	O
=	O	O
1.5	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
sigma	O	O
2	O	O
)	O	O
=	O	O
0.07	O	O
nM	O	O
)	O	O
.	O	O
Similarly	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthraquinone	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
afforded	O	O
a	O	O
mixture	O	O
of	O	O
cis	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracenes	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
which	O	O
yielded	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracene	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
on	O	O
treatment	O	O
with	O	O
HCl	O	O
.	O	O
The	O	O
technique	O	O
for	O	O
the	O	O
separation	O	O
of	O	O
3	O	O
from	O	O
4	O	O
is	O	O
described	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
investigated	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
of	O	O
the	O	O
6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxyquinazolinyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
.	O	O
Combined	O	O
in	O	O
situ	O	O
with	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propanediamine	I-IUPAC	I-IUPAC
,	O	O
benzylamine	O	O
,	O	O
spermine	O	O
,	O	O
spermidine	O	O
,	O	O
1,3,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tris	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzene	I-IUPAC	I-IUPAC
,	O	O
or	O	O
desferrioxamine	O	O
B	O	O
and	O	O
excess	O	O
triethylamine	O	O
,	O	O
the	O	O
latter	O	O
intermediate	O	O
gave	O	O
the	O	O
corresponding	O	O
amides	O	O
in	O	O
isolated	O	O
yields	O	O
ranging	O	O
from	O	O
16%	O	O
to	O	O
60%	O	O
.	O	O
A	O	O
detailed	O	O
conformational	O	O
analysis	O	O
of	O	O
(	O	O
N	O	O
)	O	O
-	O	O
methanocarba	O	O
-	O	O
T	O	O
(	O	O
2	O	O
)	O	O
and	O	O
(	O	O
S	O	O
)	O	O
-	O	O
methanocarba	O	O
-	O	O
T	O	O
(	O	O
12	O	O
)	O	O
,	O	O
as	O	O
representative	O	O
examples	O	O
of	O	O
conformationally	O	O
rigid	O	O
pseudorotational	O	O
antipodes	O	O
,	O	O
revealed	O	O
that	O	O
in	O	O
addition	O	O
to	O	O
their	O	O
different	O	O
forms	O	O
of	O	O
ring	O	O
pucker	O	O
,	O	O
(	O	O
S	O	O
)	O	O
-	O	O
methanocarba	O	O
-	O	O
T	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
rather	O	O
stiff	O	O
molecule	O	O
with	O	O
fewer	O	O
low	O	O
-	O	O
energy	O	O
conformational	O	O
states	O	O
available	O	O
compared	O	O
to	O	O
(	O	O
N	O	O
)	O	O
-	O	O
methanocarba	O	O
-	O	O
T	O	O
.	O	O
Further	O	O
biological	O	O
studies	O	O
with	O	O
these	O	O
compounds	O	O
are	O	O
described	O	O
.	O	O
All	O	O
derivatives	O	O
of	O	O
propargylfolate	O	O
were	O	O
active	O	O
against	O	O
the	O	O
growth	O	O
of	O	O
Streptococcus	O	O
faecium	O	O
,	O	O
but	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
7,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropropargylfolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
all	O	O
were	O	O
inactive	O	O
against	O	O
L	O	O
.	O	O
NaH	O	O
-	O	O
mediated	O	O
alkylation	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
with	O	O
certain	O	O
alkyl	O	O
bromides	O	O
gave	O	O
N7	O	O
-	O	O
and	O	O
N9	O	O
-	O	O
alkylated	O	O
derivatives	O	O
(	O	O
7a	O	O
-	O	O
d	O	O
and	O	O
6a	O	O
-	O	O
d	O	O
)	O	O
,	O	O
the	O	O
N9	O	O
-	O	O
isomer	O	O
being	O	O
the	O	O
major	O	O
product	O	O
.	O	O
In	O	O
vitro	O	O
,	O	O
the	O	O
fluoro	O	B-IUPAC
derivative	O	B-MODIFIER
of	O	O
A	O	O
-	O	O
85380	O	O
(	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azetidinylmethoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
or	O	O
F	O	O
-	O	O
A	O	O
-	O	O
85380	O	O
)	O	O
competitively	O	O
displaced	O	O
[	O	O
3H	O	O
]	O	O
cytisine	O	O
or	O	O
[	O	B-IUPAC
3H	O	I-IUPAC
]	O	I-IUPAC
epibatidine	O	I-IUPAC
with	O	O
Ki	O	O
values	O	O
of	O	O
48	O	O
and	O	O
46	O	O
pM	O	O
,	O	O
respectively	O	O
.	O	O
Thus	O	O
,	O	O
none	O	O
of	O	O
the	O	O
compounds	O	O
showed	O	O
an	O	O
advantage	O	O
over	O	O
CGS	O	O
9896	O	O
(	O	O
Yokoyama	O	O
et	O	O
al.	O	O
J	O	O
.	O	O
The	O	O
most	O	O
active	O	O
and	O	O
selective	O	O
compound	O	O
we	O	O
found	O	O
in	O	O
the	O	O
present	O	O
series	O	O
is	O	O
compound	O	O
8b	O	O
[	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acetoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenylmethylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azatricyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4.3.1.0	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
decane	I-IUPAC	I-IUPAC
]	O	O
.	O	O
The	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indenes	I-IUPAC	I-IUPAC
(	O	O
+	O	O
)	O	O
-	O	O
14b	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
15b	O	O
represent	O	O
selective	O	O
D1	O	O
agonists	O	O
lacking	O	O
a	O	O
catechol	O	O
group	O	O
,	O	O
which	O	O
should	O	O
meet	O	O
the	O	O
prerequisites	O	O
for	O	O
a	O	O
central	O	O
nervous	O	O
system	O	O
penetration	O	O
.	O	O
)	O	O
.	O	O
Formylation	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pteridinediamine	I-IUPAC	I-IUPAC
gave	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pteridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
formamide	I-IUPAC	I-IUPAC
.	O	O
Using	O	O
the	O	O
chemically	O	O
reactive	O	O
functional	O	O
groups	O	O
on	O	O
tyrosine	O	O
and	O	O
p	O	B-IUPAC
-	O	I-IUPAC
aminophenylalanine	O	I-IUPAC
in	O	O
position	O	O
9	O	O
,	O	O
we	O	O
prepared	O	O
iodinated	O	O
,	O	O
photoreactive	O	O
,	O	O
and	O	O
affinity	O	O
ligands	O	O
,	O	O
i.e.	O	O
,	O	O
[	O	B-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylalanine	I-IUPAC	I-IUPAC
,	I-IUPAC	O
9	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
iodotyrosine	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	O	O
AVT	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
desamino	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azidophenylalanine	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	O
AVT	O	O
,	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
desamino	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
biotinylphenylalanine	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	O
AVT	O	O
,	O	O
respectively	O	O
.	O	O
sigma	O	O
-	O	O
Receptor	O	O
Ki	O	O
's	O	O
ranged	O	O
from	O	O
0.55	O	O
nM	O	O
for	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butylpiperazine	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
to	O	O
654	O	O
nM	O	O
for	O	O
16	O	O
.	O	O
The	O	O
syntheses	O	O
of	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7,8,9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
10H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amine	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
,	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8,9,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amine	I-IUPAC	I-IUPAC
(	O	O
9a	O	O
)	O	O
,	O	O
and	O	O
the	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trimethyl	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
(	O	O
9b	O	O
)	O	O
are	O	O
described	O	O
.	O	O
The	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propargyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
and	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propargyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
hypoxanthine	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
analogues	B-MODIFIER	B-MODIFIER
were	O	O
converted	O	O
to	O	O
the	O	O
corresponding	O	O
5'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tributylstannyl	I-IUPAC	I-IUPAC
intermediates	B-MODIFIER	B-MODIFIER
(	O	O
9	O	O
and	O	O
13	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
which	O	O
gave	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
and	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
hypoxanthine	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
after	O	O
iododestannylation	O	O
.	O	O
The	O	O
ribofuranosyl	B-IUPAC	O
derivative	B-MODIFIER	O
12	O	O
showed	O	O
a	O	O
significant	O	O
activity	O	O
against	O	O
type	O	O
1	O	O
herpes	O	O
simplex	O	O
virus	O	O
.	O	O
In	O	O
the	O	O
8	O	O
-	O	O
substituted	O	O
series	O	O
(	O	O
R1	O	O
in	O	O
3	O	O
)	O	O
,	O	O
only	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
allyl	I-IUPAC	I-IUPAC
analogs	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
.	O	O
X	O	O
-	O	O
ray	O	O
analysis	O	O
carried	O	O
out	O	O
on	O	O
17	O	O
and	O	O
28	O	O
and	O	O
molecular	O	O
modeling	O	O
investigations	O	O
extended	O	O
also	O	O
to	O	O
related	O	O
derivatives	O	O
allowed	O	O
a	O	O
possible	O	O
rationalization	O	O
between	O	O
structure	O	O
and	O	O
inotropic	O	O
activity	O	O
for	O	O
this	O	O
series	O	O
of	O	O
compounds	O	O
.	O	O
A	O	O
series	O	O
of	O	O
substituted	O	O
racemic	O	O
naphthofurans	O	O
were	O	O
synthesized	O	O
as	O	O
"	O	O
hybrid	O	O
"	O	O
molecules	O	O
of	O	O
the	O	O
two	O	O
major	O	O
prototypical	O	O
hallucinogenic	O	O
drug	O	O
classes	O	O
,	O	O
the	O	O
phenethylamines	O	O
and	O	O
the	O	O
tryptamines	O	O
/	O	O
ergolines	O	O
.	O	O
Based	O	O
on	O	O
the	O	O
toxicological	O	O
findings	O	O
,	O	O
it	O	O
was	O	O
decided	O	O
not	O	O
to	O	O
pursue	O	O
compound	O	O
65	O	O
clinically	O	O
.	O	O
A	O	O
number	O	O
of	O	O
nucleoside	O	O
analogues	O	O
have	O	O
been	O	O
either	O	O
used	O	O
clinically	O	O
as	O	O
anticancer	O	O
drugs	O	O
or	O	O
evaluated	O	O
in	O	O
clinical	O	O
studies	O	O
,	O	O
while	O	O
new	O	O
nucleoside	O	O
analogues	O	O
continue	O	O
to	O	O
show	O	O
promise	O	O
.	O	O
Treatment	O	O
of	O	O
ethyl	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabinofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrrole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
with	O	O
hydrazine	O	O
afforded	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabinofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
.	O	O
A	O	O
new	O	O
metabolic	O	O
pathway	O	O
of	O	O
terminal	O	O
hydroxylation	O	O
(	O	O
omega	O	O
-	O	O
hydroxylation	O	O
)	O	O
of	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
propranolol	O	O
(	O	O
1	O	O
)	O	O
was	O	O
established	O	O
.	O	O
Specific	O	O
binding	O	O
ratios	O	O
[	O	O
region	O	O
of	O	O
interest	O	O
(	O	O
ROI	O	O
)	O	O
/	O	O
cerebellum	O	O
-	O	O
1	O	O
]	O	O
in	O	O
control	O	O
studies	O	O
for	O	O
cortex	O	O
(	O	O
Ctx	O	O
)	O	O
and	O	O
hippocampus	O	O
(	O	O
H	O	O
)	O	O
were	O	O
higher	O	O
for	O	O
[	O	O
carbonyl	O	O
-	O	O
11C	O	O
]	O	O
4a	O	O
and	O	O
[	O	O
18F	O	O
]	O	O
4d	O	O
compared	O	O
to	O	O
[	O	O
18F	O	O
]	O	O
4b	O	O
and	O	O
[	O	O
18F	O	O
]	O	O
4c	O	O
.	O	O
There	O	O
is	O	O
reported	O	O
the	O	O
first	O	O
four	O	O
members	O	O
of	O	O
heteroarotinoids	O	O
,	O	O
the	O	O
names	O	O
of	O	O
which	O	O
are	O	O
ethyl	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylthiochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
(	O	O
1b	O	O
)	O	O
,	O	O
ethyl	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylchroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
(	O	O
1c	O	O
)	O	O
,	O	O
ethyl	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxothiochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
(	O	O
1d	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylchroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
1e	O	O
)	O	O
.	O	O
Condensation	O	O
of	O	O
19	O	O
with	O	O
morpholine	O	O
followed	O	O
by	O	O
catalytic	O	O
reduction	O	O
of	O	O
the	O	O
nitro	O	O
group	O	O
and	O	O
treatment	O	O
with	O	O
thiosemicarbazide	O	O
afforded	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
morpholinoisoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxaldehyde	I-IUPAC	I-IUPAC
thiosemicarbazone	I-IUPAC	I-IUPAC
(	O	O
22	O	O
)	O	O
.	O	O
Among	O	O
the	O	O
more	O	O
active	O	O
compounds	O	O
synthesized	O	O
are	O	O
tricyclo	B-IUPAC	O
[	I-IUPAC	O
3.3.1.1	I-IUPAC	O
(	I-IUPAC	O
3,7	I-IUPAC	O
)	I-IUPAC	O
]	I-IUPAC	O
dec	I-IUPAC	B-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
2	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
yl	I-IUPAC	I-PARTIUPAC
[	I-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoethyl+	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
,	O	O
tricyclo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3.3.1.1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
dec	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulfopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
,	O	O
monosodium	O	O
salt	O	O
(	O	O
27	O	O
)	O	O
,	O	O
and	O	O
tricyclo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3.3.1.1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
dec	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylsulfinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
mino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
34	O	O
)	O	O
which	O	O
have	O	O
CCK	O	O
-	O	O
B	O	O
binding	O	O
affinities	O	O
of	O	O
IC50	O	O
=	O	O
2.6	O	O
,	O	O
1.3	O	O
,	O	O
and	O	O
1.7	O	O
nM	O	O
,	O	O
CCK	O	O
-	O	O
A	O	O
/	O	O
-	O	O
B	O	O
ratios	O	O
of	O	O
650	O	O
,	O	O
780	O	O
,	O	O
and	O	O
550	O	O
and	O	O
pK	O	O
(	O	O
a	O	O
)	O	O
values	O	O
of	O	O
6.5	O	O
,	O	O
less	O	O
than	O	O
1	O	O
,	O	O
and	O	O
7.0	O	O
,	O	O
respectively	O	O
.	O	O
This	O	O
investigation	O	O
was	O	O
conducted	O	O
to	O	O
study	O	O
the	O	O
role	O	O
of	O	O
phenylalanine	O	O
at	O	O
position	O	O
6	O	O
on	O	O
the	O	O
glucagon	O	O
mechanism	O	O
of	O	O
action	O	O
.	O	O
The	O	O
duration	O	O
of	O	O
action	O	O
was	O	O
also	O	O
determined	O	O
in	O	O
the	O	O
castrated	O	O
male	O	O
rat	O	O
assay	O	O
to	O	O
measure	O	O
the	O	O
extent	O	O
(	O	O
efficacy	O	O
and	O	O
duration	O	O
of	O	O
action	O	O
)	O	O
of	O	O
inhibition	O	O
of	O	O
luteinizing	O	O
hormone	O	O
(	O	O
LH	O	O
)	O	O
release	O	O
.	O	O
Also	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
hydroxyl	B-IUPAC	O
or	O	O
OBz	O	O
group	O	O
configuration	O	O
at	O	O
C3	O	O
on	O	O
the	O	O
condensation	O	O
stereoselectivity	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyfuranosides	I-IUPAC	I-IUPAC
with	O	O
silylated	O	O
thymine	O	O
has	O	O
been	O	O
studied	O	O
.	O	O
The	O	O
insertion	O	O
of	O	O
substituents	O	O
on	O	O
the	O	O
benzene	O	O
ring	O	O
of	O	O
8	O	O
affected	O	O
,	O	O
according	O	O
to	O	O
the	O	O
type	O	O
and	O	O
the	O	O
position	O	O
of	O	O
the	O	O
substituent	O	O
,	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
alpha1	O	O
-	O	O
adrenoreceptors	O	O
.	O	O
Thus	O	O
,	O	O
4b	O	O
,	O	O
d	O	O
,	O	O
e	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
affinity	O	O
at	O	O
muscarinic	O	O
M1	O	O
-	O	O
M5	O	O
receptors	O	O
and	O	O
also	O	O
assessed	O	O
for	O	O
their	O	O
functional	O	O
characteristics	O	O
at	O	O
the	O	O
M1	O	O
and	O	O
M2	O	O
isoforms	O	O
.	O	O
By	O	O
contrast	O	O
,	O	O
1H	O	O
NMR	O	O
and	O	O
IR	O	O
spectra	O	O
of	O	O
bromo	O	O
ester	O	O
21	O	O
are	O	O
indicative	O	O
of	O	O
syn	O	O
-	O	O
conformation	O	O
of	O	O
adenine	O	O
.	O	O
Some	O	O
compounds	O	O
acted	O	O
as	O	O
specific	O	O
calpain	O	O
inhibitors	O	O
,	O	O
with	O	O
comparable	O	O
activity	O	O
on	O	O
both	O	O
calpains	O	O
I	O	O
and	O	O
II	O	O
and	O	O
a	O	O
lack	O	O
of	O	O
activity	O	O
on	O	O
cathepsin	O	O
B	O	O
(	O	O
e.g.	O	O
,	O	O
40	O	O
,	O	O
42	O	O
,	O	O
48	O	O
,	O	O
70	O	O
)	O	O
.	O	O
Since	O	O
neither	O	O
11	O	O
nor	O	O
12	O	O
is	O	O
appreciably	O	O
carcinogenic	O	O
,	O	O
the	O	O
carcinogenic	O	O
metabolism	O	O
of	O	O
7,12	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracene	I-IUPAC	I-IUPAC
(	O	O
DMBA	O	O
)	O	O
probably	O	O
does	O	O
not	O	O
involve	O	O
attack	O	O
at	O	O
the	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
.	O	O
Neither	O	O
the	O	O
conformation	O	O
with	O	O
lowest	O	O
potential	O	O
energy	O	O
nor	O	O
any	O	O
other	O	O
electron	O	O
-	O	O
derived	O	O
parameter	O	O
correlate	O	O
with	O	O
these	O	O
data	O	O
.	O	O
This	O	O
compound	O	O
produces	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
cGMP	O	O
which	O	O
is	O	O
likely	O	O
to	O	O
cause	O	O
inhibition	O	O
at	O	O
an	O	O
early	O	O
stage	O	O
of	O	O
the	O	O
platelet	O	O
activation	O	O
pathway	O	O
.	O	O
(	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methanone	I-IUPAC	I-IUPAC
(	O	O
21	O	O
)	O	O
was	O	O
the	O	O
most	O	O
active	O	O
compound	O	O
against	O	O
pentylenetetrazole	O	O
-	O	O
induced	O	O
convulsions	O	O
.	O	O
Derivatives	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
23	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
15	O	O
nM	O	O
)	O	O
,	O	O
in	O	O
which	O	O
the	O	O
phenyl	O	O
ring	O	O
contains	O	O
substituents	O	O
,	O	O
have	O	O
been	O	O
synthesized	O	O
.	O	O
3D	O	O
contour	O	O
maps	O	O
generated	O	O
from	O	O
these	O	O
models	O	O
were	O	O
analyzed	O	O
individually	O	O
,	O	O
which	O	O
provides	O	O
the	O	O
regions	O	O
in	O	O
space	O	O
where	O	O
interactive	O	O
fields	O	O
may	O	O
influence	O	O
the	O	O
activity	O	O
.	O	O
mol	O	O
(	O	O
-	O	O
1	O	O
)	O	O
by	O	O
comparison	O	O
with	O	O
the	O	O
analogue	O	O
with	O	O
the	O	O
cationic	O	O
nitrogen	O	O
atom	O	O
of	O	O
the	O	O
quaternary	O	O
replaced	O	O
by	O	O
an	O	O
ether	O	O
oxygen	O	O
atom	O	O
.	O	O
Pirenzepine	O	O
displayed	O	O
three	O	O
energy	O	O
minima	O	O
,	O	O
differing	O	O
in	O	O
the	O	O
relative	O	O
position	O	O
of	O	O
the	O	O
piperazine	O	O
ring	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
tricyclic	O	O
system	O	O
.	O	O
The	O	O
glutathione	O	O
conjugates	O	O
,	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
glutathione	I-IUPAC	I-IUPAC
,	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
glutathione	I-IUPAC	I-IUPAC
,	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzylglutathione	I-IUPAC	I-IUPAC
,	O	O
and	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylglutathione	I-IUPAC	I-IUPAC
were	O	O
studied	O	O
as	O	O
inhibitors	O	O
of	O	O
the	O	O
transferase	O	O
A	O	O
catalyzed	O	O
conjugation	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dinitrobenzene	I-IUPAC	I-IUPAC
.	O	O
The	O	O
rank	O	O
order	O	O
of	O	O
potency	O	O
was	O	O
(	O	O
R	O	O
,	O	O
S	O	O
)	O	O
-	O	O
trans	O	O
-	O	O
8	O	O
-	O	O
OH	O	O
-	O	O
PIPAT	O	O
&	O	O
gt	O	O
;	O	O
(	O	O
R	O	O
,	O	O
S	O	O
)	O	O
-	O	O
8	O	O
-	O	O
OH	O	O
-	O	O
DPAT	O	O
&	O	O
gt	O	O
;	O	O
WB4101	O	O
&	O	O
gt	O	O
;	O	O
5	O	O
-	O	O
HT	O	O
&	O	O
gt	O	O
;	O	O
(	O	B-IUPAC
R	O	I-IUPAC
,	O	I-IUPAC
S	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
trans	O	I-IUPAC
-	O	I-IUPAC
7	O	I-IUPAC
-	O	O
OH	O	O
-	O	O
PIPAT	O	O
&	O	O
gt	O	O
;	O	O
(	O	O
R	O	O
,	O	O
S	O	O
)	O	O
-	O	O
7	O	O
-	O	O
OH	O	O
-	O	O
DPAT	O	O
&	O	O
gt	O	O
;	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propranolol	I-IUPAC	I-IUPAC
&	O	O
gt	O	O
;	O	O
spiperone	O	O
&	O	O
gt	O	O
;	O	O
&	O	O
gt	O	O
;	O	O
ketanserin	O	O
&	O	O
gt	O	O
;	O	O
&	O	O
gt	O	O
;	O	O
dopamine	O	O
&	O	O
gt	O	O
;	O	O
atropine	O	O
.	O	O
In	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
another	O	O
necessary	O	O
factor	O	O
to	O	O
elicit	O	O
the	O	O
potent	O	O
ACAT	O	O
inhibitory	O	O
activity	O	O
was	O	O
lipophilicity	O	O
of	O	O
the	O	O
molecules	O	O
.	O	O
Several	O	O
N	O	O
(	O	O
1	O	O
)	O	O
-	O	O
substituted	O	O
polyamines	O	O
containing	O	O
various	O	O
spacer	O	O
units	O	O
between	O	O
nitrogen	O	O
centers	O	O
were	O	O
synthesized	O	O
as	O	O
their	O	O
respective	O	O
HCl	O	O
salts	O	O
.	O	O
Syntheses	O	O
and	O	O
biological	O	O
activities	O	O
of	O	O
26	O	O
N4	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	B-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
as	O	O
analogs	O	O
of	O	O
naturally	O	O
occurring	O	O
modified	O	O
nucleic	O	O
acid	O	O
bases	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
purin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylcarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threonine	I-IUPAC	I-IUPAC
and	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
delta2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopentenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
,	O	O
are	O	O
described	O	O
.	O	O
Taken	O	O
together	O	O
,	O	O
these	O	O
results	O	O
strongly	O	O
suggest	O	O
that	O	O
the	O	O
two	O	O
forms	O	O
of	O	O
tomaymycin	O	O
bound	O	O
to	O	O
d	O	O
(	O	O
ATGCAT	O	O
)	O	O
2	O	O
are	O	O
the	O	O
11S	O	O
,	O	O
11aS	O	O
and	O	O
11R	O	O
,	O	O
11aS	O	O
species	O	O
,	O	O
oriented	O	O
with	O	O
their	O	O
aromatic	O	O
rings	O	O
to	O	O
the	O	O
3'	O	O
and	O	O
5'	O	O
sides	O	O
,	O	O
respectively	O	O
,	O	O
of	O	O
the	O	O
covalently	O	O
modified	O	O
guanines	O	O
.	O	O
Numerous	O	O
3	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	B-MODIFIER
-	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylanilino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracils	I-IUPAC	I-IUPAC
(	O	O
EMAU	O	O
)	O	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
screened	O	O
for	O	O
their	O	O
capacity	O	O
to	O	O
inhibit	O	O
the	O	O
replication	O	O
-	O	O
specific	O	O
bacterial	O	O
DNA	O	O
polymerase	O	O
IIIC	O	O
(	O	O
pol	O	O
IIIC	O	O
)	O	O
and	O	O
the	O	O
growth	O	O
of	O	O
Gram+	O	O
bacteria	O	O
in	O	O
culture	O	O
.	O	O
The	O	O
results	O	O
indicated	O	O
that	O	O
,	O	O
after	O	O
a	O	O
single	O	O
oral	O	O
administration	O	O
,	O	O
these	O	O
compounds	O	O
inhibited	O	O
immobility	O	O
in	O	O
the	O	O
FST	O	O
more	O	O
potently	O	O
and	O	O
more	O	O
extensively	O	O
than	O	O
the	O	O
clinically	O	O
used	O	O
antidepressant	O	O
imipramine	O	O
.	O	O
Because	O	O
of	O	O
strong	O	O
cytotoxic	O	O
effect	O	O
of	O	O
compound	O	O
4	O	O
on	O	O
melanoma	O	O
cells	O	O
(	O	O
HBL	O	O
,	O	O
ME	O	O
67.3	O	O
,	O	O
and	O	O
ME	O	O
67.1	O	O
)	O	O
,	O	O
a	O	O
potential	O	O
mechanism	O	O
of	O	O
action	O	O
was	O	O
examined	O	O
.	O	O
The	O	O
11	B-IUPAC	O
-	I-IUPAC	O
O	I-IUPAC	O
-	I-IUPAC	O
mesylate	I-IUPAC	O
of	O	O
5	O	O
on	O	O
LiAlH4	O	O
reduction	O	O
followed	O	O
by	O	O
mild	O	O
acid	O	O
treatment	O	O
and	O	O
demethylation	O	O
under	O	O
alkaline	O	O
conditions	O	O
gave	O	O
9	O	O
.	O	O
None	O	O
of	O	O
the	O	O
compounds	O	O
improved	O	O
upon	O	O
1a	O	O
in	O	O
inhibiting	O	O
the	O	O
growth	O	O
of	O	O
L1210	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O
Treatment	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dicyanopyrrole	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
with	O	O
triethyl	O	O
orthoformate	O	O
followed	O	O
by	O	O
alkylation	O	O
via	O	O
the	O	O
sodium	O	O
salt	O	O
method	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
alkylating	O	O
agents	O	O
furnished	O	O
the	O	O
corresponding	O	O
1	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
pyrroles	O	B-IUPAC
2a	O	O
-	O	O
k	O	O
.	O	O
Virtually	O	O
all	O	O
tumors	O	O
which	O	O
are	O	O
present	O	O
as	O	O
solid	O	O
masses	O	O
contain	O	O
hypoxic	O	O
cells	O	O
,	O	O
while	O	O
normal	O	O
cells	O	O
generally	O	O
have	O	O
an	O	O
adequate	O	O
supply	O	O
of	O	O
oxygen	O	O
.	O	O
While	O	O
exo	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
amino	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
5	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
exo	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxybenzonorbornene	I-IUPAC	I-IUPAC
(	O	O
7	O	O
and	O	O
10	O	O
,	O	O
respectively	O	O
)	O	O
were	O	O
prepared	O	O
from	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzonorbornadiene	I-IUPAC	I-IUPAC
by	O	O
azidomercuration	O	O
/	O	O
demercuration	O	O
and	O	O
reduction	O	O
,	O	O
it	O	O
was	O	O
necessary	O	O
to	O	O
employ	O	O
both	O	O
normal	O	O
(	O	O
inversion	O	O
of	O	O
configuration	O	O
)	O	O
and	O	O
abnormal	O	O
(	O	O
retention	O	O
of	O	O
configuration	O	O
)	O	O
Mitsunobu	O	O
reactions	O	O
to	O	O
prepare	O	O
,	O	O
stereoselectively	O	O
,	O	O
exo	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
amino	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
6	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
exo	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxybenzonorbornene	I-IUPAC	I-IUPAC
(	O	O
8	O	O
and	O	O
9	O	O
,	O	O
respectively	O	O
)	O	O
from	O	O
6	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzonorbornen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
.	O	O
The	O	O
conclusion	O	O
was	O	O
reached	O	O
that	O	O
certain	O	O
conformations	O	O
,	O	O
which	O	O
do	O	O
not	O	O
resemble	O	O
those	O	O
of	O	O
lowest	O	O
potential	O	O
energy	O	O
,	O	O
cannot	O	O
be	O	O
adopted	O	O
by	O	O
the	O	O
inactive	O	O
compounds	O	O
.	O	O
Optimized	O	O
structures	O	O
of	O	O
all	O	O
the	O	O
synthesized	O	O
ligands	O	O
were	O	O
fitted	O	O
to	O	O
the	O	O
known	O	O
crystal	O	O
structure	O	O
of	O	O
an	O	O
AMPA	O	O
-	O	O
GluR2	O	O
construct	O	O
.	O	O
A	O	O
reevaluation	O	O
of	O	O
binding	O	O
orientation	O	O
for	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxymethyloxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
was	O	O
therefore	O	O
undertaken	O	O
,	O	O
which	O	O
indicated	O	O
a	O	O
180	O	O
degrees	O	O
reversal	O	O
of	O	O
the	O	O
binding	O	O
orientation	O	O
within	O	O
the	O	O
PTP1B	O	O
catalytic	O	O
site	O	O
.	O	O
The	O	O
above	O	O
esters	O	O
were	O	O
hydrolyzed	O	O
to	O	O
the	O	O
relative	O	O
carboxylic	O	O
acids	O	O
21-30	O	O
,	O	O
which	O	O
were	O	O
decarboxylated	O	O
to	O	O
the	O	O
corresponding	O	O
2,4	B-MODIFIER	O
-	I-MODIFIER	O
disubstituted	I-MODIFIER	O
pyrimidines	B-IUPAC	O
31-40	O	O
.	O	O
The	O	O
presence	O	O
of	O	O
an	O	O
appropriately	O	O
situated	O	O
N	O	O
-	O	O
3	O	O
atom	O	O
,	O	O
however	O	O
,	O	O
as	O	O
in	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazole	I-IUPAC	I-IUPAC
,	O	O
significantly	O	O
decreases	O	O
both	O	O
the	O	O
Ki	O	O
and	O	O
alphaKi	O	O
of	O	O
these	O	O
mixed	O	O
type	O	O
inhibitors	O	O
.	O	O
The	O	O
preclinical	O	O
development	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamides	I-IUPAC	I-IUPAC
as	O	O
resistance	O	O
-	O	O
modifying	O	O
agents	O	O
in	O	O
cancer	O	O
chemotherapy	O	O
is	O	O
described	O	O
.	O	O
AlDH	O	O
activity	O	O
was	O	O
only	O	O
partially	O	O
restored	O	O
on	O	O
incubation	O	O
with	O	O
mercaptoethanol	O	O
(	O	O
20	O	O
mM	O	O
)	O	O
for	O	O
1	O	O
h	O	O
.	O	O
All	O	O
of	O	O
these	O	O
compounds	O	O
were	O	O
tested	O	O
in	O	O
Vero	O	O
cell	O	O
cultures	O	O
against	O	O
a	O	O
spectrum	O	O
of	O	O
viruses	O	O
.	O	O
The	O	O
values	O	O
of	O	O
delta	O	O
Tm	O	O
reached	O	O
19	O	O
degrees	O	O
C	O	O
and	O	O
1.6	O	O
degrees	O	O
C	O	O
for	O	O
the	O	O
most	O	O
substituted	O	O
compounds	O	O
of	O	O
both	O	O
series	O	O
.	O	O
From	O	O
this	O	O
series	O	O
of	O	O
compounds	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropyluracil	I-IUPAC	I-IUPAC
(	O	O
33	O	O
)	O	O
was	O	O
selected	O	O
for	O	O
clinical	O	O
evaluation	O	O
.	O	O
The	O	O
use	O	O
of	O	O
beta	O	O
-	O	O
MePhe	O	O
as	O	O
a	O	O
replacement	O	O
for	O	O
Phe3	O	O
was	O	O
based	O	O
upon	O	O
the	O	O
desire	O	O
to	O	O
reduce	O	O
the	O	O
conformational	O	O
flexibility	O	O
of	O	O
the	O	O
Phe3	O	O
side	O	O
chain	O	O
by	O	O
imposing	O	O
a	O	O
steric	O	O
rotational	O	O
constraint	O	O
in	O	O
the	O	O
form	O	O
of	O	O
the	O	O
beta	O	B-IUPAC
-	O	I-IUPAC
methyl	O	I-IUPAC
substituent	O	B-MODIFIER
and	O	O
to	O	O
thus	O	O
deduce	O	O
the	O	O
residue	O	O
3	O	O
side	O	O
chain	O	O
orientation	O	O
in	O	O
the	O	O
delta	O	O
receptor	O	O
-	O	O
bound	O	O
conformation	O	O
from	O	O
the	O	O
correlation	O	O
between	O	O
delta	O	O
receptor	O	O
binding	O	O
affinities	O	O
and	O	O
conformational	O	O
preferences	O	O
.	O	O
5,10	B-IUPAC	O
-	I-IUPAC	O
Dideazaaminopterins	I-IUPAC	O
were	O	O
synthesized	O	O
by	O	O
similar	O	O
alkylation	O	O
of	O	O
the	O	O
carbanions	O	O
of	O	O
appropriate	O	O
4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
carboxyphenylacetic	I-PARTIUPAC	I-IUPAC
,	O	O
(	B-PARTIUPAC	B-IUPAC
5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
carboxy	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
thienyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
acetic	I-PARTIUPAC	I-IUPAC
,	O	O
or	O	O
(	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
.	O	O
The	O	O
order	O	O
of	O	O
anti	O	O
-	O	O
HIV	O	O
potency	O	O
of	O	O
pyrimidine	O	O
analogues	O	O
was	O	O
as	O	O
follows	O	O
:	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
cytosine	O	O
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodocytosine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
cytosine	O	O
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromocytosine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
thymine	O	O
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylcytosine	I-IUPAC	I-IUPAC
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodocytosine	I-IUPAC	I-IUPAC
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chlorocytosine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
tested	O	O
as	O	O
specific	O	O
inhibitors	O	O
of	O	O
the	O	O
NADH	O	O
:	O	O
ubiquinone	O	O
(	O	O
UBQ	O	O
)	O	O
reductase	O	O
activity	O	O
of	O	O
NADH	O	O
dehydrogenase	O	O
in	O	O
mitochondrial	O	O
membranes	O	O
.	O	O
Previous	O	O
findings	O	O
suggesting	O	O
that	O	O
5,10	B-IUPAC	O
-	I-IUPAC	O
dialkyl	I-IUPAC	O
-	O	O
substituted	B-MODIFIER	O
derivatives	I-MODIFIER	O
of	O	O
5,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dideazaaminopterin	I-IUPAC	I-IUPAC
warranted	O	O
study	O	O
as	O	O
potential	O	O
antifolates	O	O
prompted	O	O
synthesis	O	O
of	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazaaminopterin	I-IUPAC	I-IUPAC
(	O	O
12a	O	O
)	O	O
.	O	O
The	O	O
resulting	O	O
1	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
dialkylamino	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
alkyl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
amino	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
4	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
methyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
5H	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
pyrido	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
4,3	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
b	I-PARTIUPAC	I-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
benzo	I-PARTIUPAC	I-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
e	I-PARTIUPAC	I-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
-	B-PARTIUPAC	B-PARTIUPAC
benzo	I-PARTIUPAC	I-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
g	I-PARTIUPAC	I-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
indoles	I-PARTIUPAC	I-PARTIUPAC
,	O	O
as	O	O
well	O	O
as	O	O
hydroxy	O	O
derivatives	O	O
obtained	O	O
by	O	O
demethylation	O	O
of	O	O
methoxylated	O	O
compounds	O	O
with	O	O
hydrobromic	O	O
acid	O	O
,	O	O
were	O	O
tested	O	O
for	O	O
antitumor	O	O
activity	O	O
in	O	O
vitro	O	O
(	O	O
leukemic	O	O
and	O	O
solid	O	O
tumor	O	O
cells	O	O
)	O	O
and	O	O
in	O	O
vivo	O	O
on	O	O
various	O	O
experimental	O	O
tumor	O	O
models	O	O
using	O	O
the	O	O
standard	O	O
NCI	O	O
protocols	O	O
.	O	O
These	O	O
compounds	O	O
are	O	O
antagonists	O	O
at	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aspartate	I-IUPAC	I-IUPAC
(	O	O
NMDA	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propanoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
)	O	O
subclasses	O	O
of	O	O
ligand	O	O
gated	O	O
ion	O	O
channel	O	O
(	O	O
ionotropic	O	O
)	O	O
EAA	O	O
receptors	O	O
.	O	O
A	O	O
number	O	O
of	O	O
7	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonitrile	I-IUPAC	I-IUPAC
,	O	I-IUPAC
-	B-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
,	O	O
and	O	O
-	B-IUPAC	O
5	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thiocarboxamide	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
related	O	O
to	O	O
the	O	O
nucleoside	O	O
antibiotics	O	O
toyocamycin	O	O
and	O	O
sangivamycin	O	O
were	O	O
prepared	O	O
and	O	O
tested	O	O
for	O	O
their	O	O
activity	O	O
against	O	O
human	O	O
cytomegalovirus	O	O
(	O	O
HCMV	O	O
)	O	O
and	O	O
herpes	O	O
simplex	O	O
virus	O	O
type	O	O
-	O	O
1	O	O
(	O	O
HSV	O	O
-	O	O
1	O	O
)	O	O
.	O	O
While	O	O
FdUMP	O	O
and	O	O
6a	O	O
showed	O	O
a	O	O
higher	O	O
affinity	O	O
and	O	O
greater	O	O
inactivation	O	O
power	O	O
with	O	O
the	O	O
parental	O	O
cell	O	O
than	O	O
FdUrd	O	O
-	O	O
resistant	O	O
cell	O	O
enzyme	O	O
,	O	O
an	O	O
opposite	O	O
relationship	O	O
could	O	O
be	O	O
seen	O	O
with	O	O
5	O	B-IUPAC
-	O	I-IUPAC
hydroxymethyl	O	I-IUPAC
-	O	O
dUMP	O	O
.	O	O
5	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
Acylethynyl	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
2,4	O	I-IUPAC
-	O	I-IUPAC
dimethoxypyrimidines	O	I-IUPAC
(	O	O
3-6	O	O
)	O	O
were	O	O
synthesized	O	O
in	O	O
excellent	O	O
yields	O	O
from	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trimethylsilyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethynyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
by	O	O
treatment	O	O
with	O	O
acid	O	O
chlorides	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
anhydrous	O	O
aluminum	O	O
chloride	O	O
.	O	O
Among	O	O
them	O	O
,	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cyclohexyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimida	I-IUPAC	I-IUPAC
zole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
(	O	O
10s	O	O
,	O	O
TCV	O	O
-	O	O
116	O	O
)	O	O
was	O	O
selected	O	O
as	O	O
a	O	O
candidate	O	O
for	O	O
clinical	O	O
evaluation	O	O
.	O	O
This	O	O
suggests	O	O
that	O	O
both	O	O
the	O	O
action	O	O
on	O	O
A1	O	O
receptors	O	O
or	O	O
interaction	O	O
with	O	O
adenosine	O	O
and	O	O
the	O	O
cyclic	O	O
AMP	O	O
-	O	O
PDE	O	O
inhibitory	O	O
activity	O	O
contribute	O	O
to	O	O
the	O	O
bronchodilator	O	O
action	O	O
of	O	O
1	O	O
-	O	O
and	O	O
7	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
xanthines	O	B-IUPAC
.	O	O
The	O	O
newly	O	O
prepared	O	O
[	O	O
125I	O	O
]	O	O
iodoproxyfan	O	O
(	O	O
23	O	O
)	O	O
possesses	O	O
advantageous	O	O
pharmacological	O	O
properties	O	O
and	O	O
fulfills	O	O
all	O	O
criteria	O	O
of	O	O
a	O	O
useful	O	O
radioligand	O	O
.	O	O
Using	O	O
the	O	O
combined	O	O
protection	O	O
of	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxymethyl	I-IUPAC	I-IUPAC
and	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trimethylsilyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
,	O	O
a	O	O
free	O	O
carboxylic	O	O
acid	O	O
was	O	O
formed	O	O
at	O	O
the	O	O
5	O	O
-	O	O
position	O	O
allowing	O	O
various	O	O
substitutions	O	O
.	O	O
This	O	O
analogue	O	O
(	O	O
46	O	O
)	O	O
was	O	O
17	O	O
times	O	O
more	O	O
potent	O	O
than	O	O
the	O	O
standard	O	O
.	O	O
Most	O	O
of	O	O
these	O	O
derivatives	O	O
are	O	O
more	O	O
active	O	O
than	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenedioxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzodiazepine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
,	O	O
GYKI	O	O
52466	O	O
)	O	O
,	O	O
a	O	O
well	O	O
-	O	O
known	O	O
noncompetitive	O	O
AMPA	O	O
receptor	O	O
antagonist	O	O
.	O	O
The	O	O
nonapeptide	O	O
[	O	O
des	O	O
-	O	O
Asp1	O	O
]	O	O
angiotensin	O	O
I	O	O
(	O	O
IV	O	O
)	O	O
,	O	O
synthesized	O	O
by	O	O
Merrifield	O	O
's	O	O
solid	O	O
-	O	O
phase	O	O
procedure	O	O
,	O	O
was	O	O
tested	O	O
as	O	O
a	O	O
possible	O	O
substrate	O	O
for	O	O
the	O	O
converting	O	O
enzymes	O	O
from	O	O
porcine	O	O
lung	O	O
and	O	O
plasma	O	O
.	O	O
The	O	O
replacement	O	O
of	O	O
the	O	O
[	O	O
Phe	O	O
(	O	O
3	O	O
)	O	O
-	O	O
MePhe	O	O
(	O	O
4	O	O
)	O	O
-	O	O
Pro	O	O
(	O	O
5	O	O
)	O	O
]	O	O
tripeptide	O	O
by	O	O
an	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminocaprylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
or	O	O
the	O	O
N	O	O
(	O	O
7	O	O
)	O	O
(	O	O
)	O	O
-	O	O
desmethylation	O	O
of	O	O
MeVal	O	O
(	O	O
7	O	O
)	O	O
led	O	O
to	O	O
only	O	O
a	O	O
3.3	O	O
-	O	O
fold	O	O
decreased	O	O
capacity	O	O
to	O	O
inhibit	O	O
Pgp	O	O
function	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
Pgp	O	O
inhibitory	O	O
potential	O	O
of	O	O
aureobasidins	O	O
,	O	O
though	O	O
favored	O	O
by	O	O
the	O	O
establishment	O	O
of	O	O
an	O	O
antiparallel	O	O
beta	O	O
-	O	O
sheet	O	O
between	O	O
the	O	O
[	O	O
D	O	O
-	O	O
Hmp	O	O
(	O	O
1	O	O
)	O	O
-	O	O
L	O	O
-	O	O
MeVal	O	O
(	O	O
2	O	O
)	O	O
-	O	O
L	O	O
-	O	O
Phe	O	O
(	O	O
3	O	O
)	O	O
]	O	O
and	O	O
[	O	O
L	O	O
-	O	O
aIle	O	O
(	O	O
6	O	O
)	O	O
-	O	O
L	O	O
-	O	O
MeVal	O	O
(	O	O
7	O	O
)	O	O
-	O	O
L	O	O
-	O	O
Leu	O	O
(	O	O
8	O	O
)	O	O
-	O	O
]	O	O
tripeptides	O	O
,	O	O
does	O	O
not	O	O
critically	O	O
depend	O	O
on	O	O
the	O	O
occurrence	O	O
of	O	O
the	O	O
[	O	O
L	O	O
-	O	O
Phe	O	O
(	O	O
3	O	O
)	O	O
-	O	O
L	O	O
-	O	O
MePhe	O	O
(	O	O
4	O	O
)	O	O
-	O	O
L	O	O
-	O	O
Pro	O	O
(	O	O
5	O	O
)	O	O
-	O	O
L	O	O
-	O	O
aIle	O	O
(	O	O
6	O	O
)	O	O
]	O	O
type	O	O
II	O	O
'	O	O
beta	O	O
-	O	O
turn	O	O
secondary	O	O
structure	O	O
.	O	O
A	O	O
novel	O	O
synthesis	O	O
of	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoadipic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
suitable	O	O
for	O	O
large	O	O
-	O	O
scale	O	O
preparation	O	O
is	O	O
also	O	O
described	O	O
.	O	O
-	O	O
2	O	O
cells	O	O
,	O	O
but	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromoacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
hypoxanthine	I-IUPAC	I-IUPAC
displayed	O	O
in	O	O
vivo	O	O
activity	O	O
against	O	O
Trypanosoma	O	O
rhodesiense	O	O
.	O	O
The	O	O
new	O	O
analogues	O	O
were	O	O
tested	O	O
as	O	O
inhibitors	O	O
of	O	O
DHFR	O	O
from	O	O
Pneumocystis	O	O
carinii	O	O
(	O	O
Pc	O	O
)	O	O
,	O	O
Toxoplasma	O	O
gondii	O	O
(	O	O
Tg	O	O
)	O	O
,	O	O
and	O	O
Mycobacterium	O	O
avium	O	O
(	O	O
Ma	O	O
)	O	O
,	O	O
three	O	O
life	O	O
-	O	O
threatening	O	O
pathogens	O	O
often	O	O
found	O	O
in	O	O
AIDS	O	O
patients	O	O
and	O	O
individuals	O	O
whose	O	O
immune	O	O
system	O	O
is	O	O
impaired	O	O
as	O	O
a	O	O
result	O	O
of	O	O
treatment	O	O
with	O	O
immunosuppressive	O	O
chemotherapy	O	O
or	O	O
radiation	O	O
.	O	O
A	O	O
number	O	O
of	O	O
compounds	O	O
bioisosterically	O	O
derived	O	O
from	O	O
10	O	O
,	O	O
including	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
isothiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
isoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,3,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyrid	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
isoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
,	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,3,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyrid	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
isothiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
,	O	O
were	O	O
synthesized	O	O
and	O	O
tested	O	O
as	O	O
GABAA	O	O
receptor	O	O
ligands	O	O
.	O	O
Compound	O	O
32	O	O
behaved	O	O
as	O	O
a	O	O
competitive	O	O
CCK	O	O
(	O	O
2	O	O
)	O	O
receptor	O	O
antagonist	O	O
in	O	O
vitro	O	O
as	O	O
judged	O	O
by	O	O
its	O	O
inhibition	O	O
of	O	O
pentagastrin	O	O
-	O	O
stimulated	O	O
acid	O	O
secretion	O	O
in	O	O
an	O	O
isolated	O	O
,	O	O
lumen	O	O
-	O	O
perfused	O	O
,	O	O
immature	O	O
rat	O	O
stomach	O	O
assay	O	O
(	O	O
pK	O	O
(	O	O
B	O	O
)	O	O
=	O	O
6.74	O	O
+	O	O
/	O	O
-	O	O
0.27	O	O
)	O	O
and	O	O
by	O	O
its	O	O
displacement	O	O
of	O	O
[	O	O
(	O	O
125	O	O
)	O	O
I	O	O
]	O	O
CCK	O	O
-	O	O
8S	O	O
from	O	O
CCK	O	O
(	O	O
2	O	O
)	O	O
sites	O	O
in	O	O
mouse	O	O
cortical	O	O
homogenates	O	O
(	O	O
pK	O	O
(	O	O
i	O	O
)	O	O
=	O	O
6.99	O	O
+	O	O
/	O	O
-	O	O
0.05	O	O
)	O	O
.	O	O
Each	O	O
configurational	O	O
isomer	O	O
of	O	O
1	O	O
was	O	O
evaluated	O	O
for	O	O
its	O	O
ability	O	O
to	O	O
inhibit	O	O
the	O	O
binding	O	O
of	O	O
retinoic	O	O
acid	O	O
to	O	O
CRABP	O	O
(	O	O
chick	O	O
skin	O	O
)	O	O
and	O	O
to	O	O
inhibit	O	O
the	O	O
chemical	O	O
induction	O	O
of	O	O
ornithine	O	O
decarboxylase	O	O
in	O	O
mouse	O	O
skin	O	O
.	O	O
Optimization	O	O
of	O	O
the	O	O
4	O	O
-	O	O
substituent	O	O
has	O	O
provided	O	O
antagonists	O	O
having	O	O
nanomolar	O	O
affinity	O	O
,	O	O
including	O	O
the	O	O
urea	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroquinoline	I-IUPAC	I-IUPAC
(	O	O
35	O	O
;	O	O
IC50	O	O
=	O	O
7.4	O	O
nM	O	O
vs	O	O
[	O	O
3H	O	O
]	O	O
glycine	O	O
binding	O	O
;	O	O
Kb	O	O
=	O	O
130	O	O
nM	O	O
for	O	O
block	O	O
of	O	O
NMDA	O	O
responses	O	O
in	O	O
the	O	O
rat	O	O
cortical	O	O
slice	O	O
)	O	O
,	O	O
which	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
potent	O	O
NMDA	O	O
antagonists	O	O
yet	O	O
found	O	O
.	O	O
In	O	O
agreement	O	O
with	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
of	O	O
other	O	O
chxn	O	O
-	O	O
containing	O	O
platinum	O	O
(	O	O
II	O	O
)	O	O
complexes	O	O
both	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
kappaN	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetato	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
kappaO	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamine	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
platinum	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
show	O	O
superior	O	O
potency	O	O
than	O	O
the	O	O
corresponding	O	O
cis	O	O
-	O	O
congener	O	O
whereas	O	O
the	O	O
trans	O	O
-	O	O
R	O	O
,	O	O
R	O	O
isomer	O	O
displays	O	O
the	O	O
highest	O	O
activity	O	O
.	O	O
Under	O	O
similar	O	O
treatment	O	O
conditions	O	O
(	O	O
drug	O	O
dose	O	O
:	O	O
5.0	O	O
micromol	O	O
/	O	O
kg	O	O
;	O	O
light	O	O
dose	O	O
:	O	O
135	O	O
J	O	O
/	O	O
cm	O	O
(	O	O
2	O	O
)	O	O
,	O	O
tumors	O	O
were	O	O
exposed	O	O
to	O	O
light	O	O
for	O	O
30	O	O
min	O	O
at	O	O
24	O	O
h	O	O
postinjection	O	O
)	O	O
,	O	O
the	O	O
benzobacteriochlorins	O	O
containing	O	O
N	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
-	O	O
imide	O	O
ring	O	O
system	O	O
produced	O	O
enhanced	O	O
photosensitizing	O	O
efficacy	O	O
with	O	O
limited	O	O
skin	O	O
phototoxicity	O	O
.	O	O
In	O	O
receptor	O	O
binding	O	O
(	O	O
IC50	O	O
values	O	O
)	O	O
and	O	O
rat	O	O
cortical	O	O
wedge	O	O
electrophysiological	O	O
(	O	O
EC50	O	O
values	O	O
)	O	O
studies	O	O
,	O	O
7c	O	O
(	O	O
IC50	O	O
=	O	O
5.5	O	O
+	O	O
/	O	O
-	O	O
0.6	O	O
microM	O	O
;	O	O
EC50	O	O
=	O	O
96	O	O
+	O	O
/	O	O
-	O	O
5	O	O
microM	O	O
)	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
markedly	O	O
weaker	O	O
than	O	O
7a	O	O
(	O	O
IC50	O	O
=	O	O
0.57	O	O
+	O	O
/	O	O
-	O	O
0.16	O	O
microM	O	O
;	O	O
EC50	O	O
=	O	O
7.4	O	O
+	O	O
/	O	O
-	O	O
0.2	O	O
microM	O	O
)	O	O
as	O	O
an	O	O
AMPA	O	O
agonist	O	O
,	O	O
whereas	O	O
7b	O	O
,	O	O
d	O	O
,	O	O
e	O	O
were	O	O
inactive	O	O
.	O	O
In	O	O
rat	O	O
brain	O	O
membranes	O	O
,	O	O
all	O	O
12	O	O
compounds	O	O
displayed	O	O
poor	O	O
affinity	O	O
for	O	O
[	O	O
(	O	O
125	O	O
)	O	O
I	O	O
]	O	O
-	O	O
alpha	O	O
-	O	O
bunagarotoxin	O	O
binding	O	O
sites	O	O
.	O	O
The	O	O
chloromethyl	O	O
compounds	O	O
,	O	O
5	O	O
and	O	O
10	O	O
,	O	O
yielded	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxymethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracene	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
and	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxymethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracene	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
on	O	O
treatment	O	O
with	O	O
acetate	O	O
ion	O	O
.	O	O
The	O	O
syntheses	O	O
and	O	O
physical	O	O
properties	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodothiophene	I-IUPAC	I-IUPAC
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodothiophene	I-IUPAC	I-IUPAC
are	O	O
described	O	O
.	O	O
Preparation	O	O
of	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
(	O	O
26-31	O	O
)	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiouracil	I-IUPAC	I-IUPAC
(	O	O
32-45	O	O
)	O	O
derivatives	B-MODIFIER	B-MODIFIER
was	O	O
carried	O	O
out	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
LDA	O	O
lithiation	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
(	O	O
9-14	O	O
)	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiouracil	I-IUPAC	I-IUPAC
(	O	O
15-25	O	O
)	O	O
followed	O	O
by	O	O
reaction	O	O
with	O	O
diaryl	O	O
disulfides	O	O
.	O	O
Cytallene	O	O
(	O	O
5b	O	O
)	O	O
and	O	O
6'	B-IUPAC	O
beta	I-IUPAC	O
-	I-IUPAC	O
hydroxyaristeromycin	I-IUPAC	O
(	O	O
10	O	O
)	O	O
exhibited	O	O
significant	O	O
activity	O	O
against	O	O
Friend	O	O
and	O	O
Rauscher	O	O
murine	O	O
leukemia	O	O
viruses	O	O
.	O	O
To	O	O
synthesize	O	O
potent	O	O
antagonists	O	O
of	O	O
the	O	O
mu	O	O
-	O	O
opioid	O	O
receptor	O	O
,	O	O
we	O	O
prepared	O	O
a	O	O
series	O	O
of	O	O
endomorphin	O	O
-	O	O
1	O	O
and	O	O
endomorphin	O	O
-	O	O
2	O	O
analogues	O	O
with	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
(	O	O
d	O	O
-	O	O
1	O	O
-	O	O
Nal	O	O
)	O	O
or	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
(	O	O
d	O	O
-	O	O
2	O	O
-	O	O
Nal	O	O
)	O	O
in	O	O
position	O	O
4	O	O
.	O	O
A	O	O
series	O	O
of	O	O
N	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pyridinyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
butyl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5,5	I-PARTIUPAC	I-IUPAC
-	O	I-IUPAC
disubstituted	B-MODIFIER	I-IUPAC
-	O	I-IUPAC
pentadienamides	B-PARTIUPAC	I-IUPAC
was	O	O
prepared	O	O
and	O	O
evaluated	O	O
for	O	O
PAF	O	O
-	O	O
antagonist	O	O
activity	O	O
.	O	O
Propargylfolic	O	O
acid	O	O
and	O	O
its	O	O
reduced	O	O
derivatives	O	O
were	O	O
weak	O	O
inhibitors	O	O
of	O	O
L	O	O
.	O	O
Deoxygenation	O	O
gave	O	O
the	O	O
corresponding	O	O
pyrazines	O	O
VII	O	O
.	O	O
The	O	O
corresponding	O	O
beta	O	O
-	O	O
aryl	O	O
-	O	O
substituted	O	O
lactones	O	O
,	O	O
by	O	O
contrast	O	O
,	O	O
are	O	O
potent	O	O
acylating	O	O
agents	O	O
that	O	O
lead	O	O
to	O	O
acyl	O	O
enzymes	O	O
of	O	O
high	O	O
stability	O	O
.	O	O
A	O	O
water	O	O
soluble	O	O
derivative	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
morpholinylbutyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
EMAU	I-IUPAC	I-IUPAC
hydrochloride	I-IUPAC	I-IUPAC
,	O	O
given	O	O
subcutaneously	O	O
,	O	O
prolonged	O	O
the	O	O
life	O	O
of	O	O
infected	O	O
mice	O	O
in	O	O
a	O	O
dose	O	O
dependent	O	O
manner	O	O
.	O	O
Compound	O	O
3	O	O
is	O	O
the	O	O
first	O	O
example	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
of	O	O
a	O	O
2,4	O	B-IUPAC
-	O	I-IUPAC
diamino	O	I-IUPAC
classical	O	O
antifolate	O	O
that	O	O
has	O	O
potent	O	O
inhibitory	O	O
activity	O	O
against	O	O
both	O	O
human	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
and	O	O
human	O	O
thymidylate	O	O
synthase	O	O
(	O	O
TS	O	O
)	O	O
.	O	O
The	O	O
guanine	O	O
derivatives	O	O
(	O	O
8	O	O
,	O	O
21	O	O
)	O	O
showed	O	O
potent	O	O
and	O	O
selective	O	O
activity	O	O
against	O	O
herpes	O	O
simplex	O	O
virus	O	O
types	O	O
1	O	O
and	O	O
2	O	O
and	O	O
varicella	O	O
zoster	O	O
virus	O	O
in	O	O
cell	O	O
cultures	O	O
and	O	O
8	O	O
is	O	O
more	O	O
active	O	O
than	O	O
acyclovir	O	O
.	O	O
Both	O	O
6	O	O
and	O	O
11	O	O
were	O	O
found	O	O
to	O	O
substitute	O	O
with	O	O
high	O	O
potency	O	O
in	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylenedioxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methamphetamine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
and	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzodioxol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butane	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
trained	O	O
rats	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
prevent	O	O
phosphorylation	O	O
of	O	O
a	O	O
model	O	O
substrate	O	O
by	O	O
c	O	O
-	O	O
Src	O	O
,	O	O
FGF	O	O
-	O	O
1	O	O
receptor	O	O
,	O	O
and	O	O
PDGF	O	O
-	O	O
beta	O	O
receptor	O	O
enzymes	O	O
.	O	O
Three	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminopteridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
omega	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
dibenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
azepines	I-IUPAC	I-IUPAC
(	O	O
19-21	O	O
)	O	O
were	O	O
also	O	O
synthesized	O	O
and	O	O
tested	O	O
.	O	O
This	O	O
suggests	O	O
that	O	O
while	O	O
substitution	O	O
of	O	O
a	O	O
polar	O	O
functionality	O	O
at	O	O
C	O	O
-	O	O
21	O	O
does	O	O
not	O	O
abolish	O	O
antibacterial	O	O
activity	O	O
,	O	O
introduction	O	O
of	O	O
vicinal	O	O
polar	O	O
groups	O	O
at	O	O
both	O	O
C	O	O
-	O	O
12	O	O
and	O	O
C	O	O
-	O	O
21	O	O
may	O	O
lead	O	O
to	O	O
reduction	O	O
in	O	O
potency	O	O
.	O	O
Parallel	O	O
treatment	O	O
with	O	O
a	O	O
"	O	O
dibromomethylene	O	O
Wittig	O	O
reagent	O	O
"	O	O
and	O	O
deprotection	O	O
gave	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hex	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
which	O	O
also	O	O
was	O	O
prepared	O	O
by	O	O
successive	O	O
bromination	O	O
and	O	O
dehydrobromination	O	O
of	O	O
the	O	O
6'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromohomovinyl	I-IUPAC	I-IUPAC
nucleoside	I-IUPAC	I-IUPAC
8	O	O
.	O	O
Adenine	O	O
analogue	O	O
14	O	O
was	O	O
active	O	O
against	O	O
HBV	O	O
(	O	O
IC50	O	O
2	O	O
microM	O	O
)	O	O
,	O	O
VZV	O	O
(	O	O
IC50	O	O
2.5	O	O
microM	O	O
)	O	O
,	O	O
and	O	O
HHV	O	O
-	O	O
6	O	O
(	O	O
IC50	O	O
14	O	O
microM	O	O
)	O	O
.	O	O
Among	O	O
numerous	O	O
variations	O	O
at	O	O
C5	O	O
,	O	O
benzylthio	O	O
groups	O	O
gave	O	O
the	O	O
best	O	O
potency	O	O
.	O	O
Acylated	O	O
derivatives	O	O
and	O	O
one	O	O
alkyl	O	O
derivative	O	O
of	O	O
the	O	O
5	O	B-IUPAC
-	O	I-IUPAC
amino	O	I-IUPAC
group	O	B-MODIFIER
and	O	O
other	O	O
modifications	O	O
were	O	O
prepared	O	O
in	O	O
an	O	O
effort	O	O
to	O	O
enhance	O	O
A2B	O	O
or	O	O
A3	O	O
subtype	O	O
potency	O	O
.	O	O
This	O	O
would	O	O
give	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrazole	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
,	O	O
the	O	O
tetrazole	O	O
acid	O	O
analog	O	O
of	O	O
glycine	O	O
;	O	O
and	O	O
glycine	O	O
is	O	O
involved	O	O
in	O	O
NMDA	O	O
receptor	O	O
activation	O	O
.	O	O
Compounds	O	O
3a	O	O
,	O	O
b	O	O
are	O	O
transient	O	O
intermediates	O	O
,	O	O
which	O	O
in	O	O
strongly	O	O
acidic	O	O
medium	O	O
are	O	O
not	O	O
observed	O	O
with	O	O
(	O	O
31	O	O
)	O	O
P	O	O
NMR	O	O
.	O	O
This	O	O
observation	O	O
eliminates	O	O
the	O	O
last	O	O
remaining	O	O
uncertainty	O	O
regarding	O	O
conformational	O	O
features	O	O
of	O	O
the	O	O
pharmacophore	O	O
elements	O	O
in	O	O
the	O	O
delta	O	O
receptor	O	O
-	O	O
bound	O	O
state	O	O
,	O	O
allowing	O	O
the	O	O
proposal	O	O
of	O	O
a	O	O
complete	O	O
model	O	O
.	O	O
An	O	O
N5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
was	O	O
highly	O	O
selective	O	O
for	O	O
A2A	O	O
receptors	O	O
.	O	O
At	O	O
P2X	O	O
-	O	O
receptors	O	O
,	O	O
no	O	O
activity	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
rabbit	O	O
saphenous	O	O
artery	O	O
,	O	O
but	O	O
variable	O	O
degrees	O	O
of	O	O
activity	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
guinea	O	O
pig	O	O
vas	O	O
deferens	O	O
and	O	O
bladder	O	O
depending	O	O
on	O	O
distal	O	O
substituents	O	O
of	O	O
the	O	O
thioether	O	O
moiety	O	O
.	O	O
(	O	O
all	O	O
-	O	O
E	O	O
)	O	O
-	O	O
1	O	O
was	O	O
further	O	O
evaluated	O	O
for	O	O
its	O	O
ability	O	O
to	O	O
prevent	O	O
the	O	O
induction	O	O
of	O	O
mouse	O	O
skin	O	O
papillomas	O	O
and	O	O
to	O	O
induce	O	O
signs	O	O
of	O	O
vitamin	O	O
A	O	O
toxicity	O	O
in	O	O
mice	O	O
.	O	O
The	O	O
palladium	O	O
-	O	O
catalyzed	O	O
cross	O	O
-	O	O
coupling	O	O
reaction	O	O
between	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
and	O	O
stannylated	O	O
heteroaromatics	O	O
was	O	O
optimized	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
.	O	O
The	O	O
ID50	O	O
of	O	O
3	O	O
against	O	O
L1210	O	O
mouse	O	O
leukemia	O	O
cells	O	O
in	O	O
culture	O	O
was	O	O
1.7	O	O
x	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
M	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
1	O	O
x	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
M	O	O
for	O	O
FU	O	O
.	O	O
From	O	O
the	O	O
findings	O	O
of	O	O
this	O	O
study	O	O
,	O	O
it	O	O
appears	O	O
that	O	O
norepinephrine	O	O
has	O	O
a	O	O
different	O	O
active	O	O
site	O	O
binding	O	O
orientation	O	O
than	O	O
most	O	O
known	O	O
substrates	O	O
and	O	O
competitive	O	O
inhibitors	O	O
of	O	O
PNMT	O	O
.	O	O
The	O	O
esterase	O	O
activity	O	O
of	O	O
the	O	O
enzyme	O	O
was	O	O
commensurably	O	O
inhibited	O	O
.	O	O
The	O	O
pyrimidine	O	O
nucleosides	O	O
(	O	O
9a	O	O
-	O	O
c	O	O
,	O	O
10b	O	O
,	O	O
c	O	O
)	O	O
exhibited	O	O
no	O	O
cytotoxic	O	O
activity	O	O
against	O	O
a	O	O
panel	O	O
of	O	O
60	O	O
human	O	O
cancer	O	O
cell	O	O
lines	O	O
.	O	O
The	O	O
enantiomeric	O	O
purity	O	O
of	O	O
the	O	O
stereoisomers	O	O
was	O	O
determined	O	O
by	O	O
a	O	O
high	O	O
-	O	O
performance	O	O
liquid	O	O
chromatography	O	O
-	O	O
chiral	O	O
stationary	O	O
phase	O	O
technique	O	O
(	O	O
HPLC	O	O
-	O	O
CSP	O	O
)	O	O
.	O	O
For	O	O
this	O	O
,	O	O
the	O	O
uPAR	O	O
antagonist	O	O
cyclo	O	O
[	O	O
19,31	O	O
]	O	O
[	O	O
D	O	O
-	O	O
Cys	O	O
(	O	O
19	O	O
)	O	O
]	O	O
-	O	O
uPA	O	O
(	O	O
19	O	O
)	O	O
(	O	O
-	O	O
)	O	O
(	O	O
31	O	O
)	O	O
was	O	O
optimized	O	O
to	O	O
efficiently	O	O
interrupt	O	O
binding	O	O
of	O	O
uPA	O	O
to	O	O
cellular	O	O
uPAR	O	O
.	O	O
Conventional	O	O
functional	O	O
group	O	O
transformations	O	O
involving	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
4	O	O
furnished	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
5a	O	O
-	O	O
1	O	O
and	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
analogs	B-MODIFIER	B-MODIFIER
6a	O	O
-	O	O
l	O	O
.	O	O
Compound	O	O
7	O	O
bound	O	O
strongly	O	O
to	O	O
5	O	O
-	O	O
HT1A	O	O
receptors	O	O
and	O	O
would	O	O
be	O	O
expected	O	O
to	O	O
be	O	O
a	O	O
novel	O	O
anxiolytic	O	O
.	O	O
Under	O	O
similar	O	O
conditions	O	O
analogues	O	O
(	O	O
[	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
gamma	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
IGly	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
Dab	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
degarelix	I-IUPAC	I-IUPAC
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.56	O	O
nM	O	O
)	O	O
(	O	O
21	O	O
)	O	O
and	O	O
(	O	O
[	O	O
IOrn	O	O
(	O	O
8	O	O
)	O	O
]	O	O
degarelix	O	O
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.72	O	O
nM	O	O
)	O	O
(	O	O
18	O	O
)	O	O
had	O	O
a	O	O
longer	O	O
duration	O	O
of	O	O
action	O	O
{	O	O
inhibited	O	O
LH	O	O
(	O	O
&	O	O
gt	O	O
;	O	O
96	O	O
h	O	O
)	O	O
release	O	O
}	O	O
than	O	O
azaline	O	O
B	O	O
;	O	O
however	O	O
they	O	O
were	O	O
shorter	O	O
acting	O	O
than	O	O
degarelix	O	O
.	O	O
Two	O	O
adenosine	O	O
diphosphate	O	O
analogues	O	O
were	O	O
equipotent	O	O
to	O	O
the	O	O
corresponding	O	O
ATP	O	O
analogues	O	O
.	O	O
Changing	O	O
the	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1f	O	O
to	O	O
an	O	O
H	O	O
,	O	O
F	O	O
,	O	O
Cl	O	O
,	O	O
Br	O	O
,	O	O
I	O	O
,	O	O
NHAc	O	O
,	O	O
or	O	O
NHSO2CH3	O	O
resulted	O	O
in	O	O
a	O	O
5	O	O
-	O	O
fold	O	O
or	O	O
greater	O	O
loss	O	O
in	O	O
potency	O	O
.	O	O
However	O	O
,	O	O
exo	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxybenzonorbornene	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
and	O	O
anti	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxybenzonorbornene	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
displayed	O	O
significant	O	O
activity	O	O
as	O	O
inhibitors	O	O
toward	O	O
PNMT	O	O
.	O	O
trans	O	O
-	O	O
Catechol	O	O
analogs	O	O
had	O	O
low	O	O
affinity	O	O
for	O	O
[	O	O
3H	O	O
]	O	O
4	O	O
sites	O	O
,	O	O
and	O	O
although	O	O
they	O	O
inhibited	O	O
TH	O	O
activity	O	O
,	O	O
this	O	O
effect	O	O
was	O	O
not	O	O
blocked	O	O
by	O	O
known	O	O
sigma	O	O
or	O	O
dopamine	O	O
antagonists	O	O
.	O	O
These	O	O
observations	O	O
suggest	O	O
that	O	O
the	O	O
introduction	O	O
of	O	O
an	O	O
ethyl	O	O
group	O	O
in	O	O
the	O	O
N	O	O
(	O	O
6	O	O
)	O	O
-	O	O
position	O	O
and	O	O
an	O	O
ethylcarboxamido	O	O
substituent	O	O
in	O	O
the	O	O
4'	O	O
-	O	O
position	O	O
of	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylhydroxypropynyladenosine	I-IUPAC	I-IUPAC
could	O	O
lead	O	O
to	O	O
a	O	O
compound	O	O
endowed	O	O
with	O	O
high	O	O
potency	O	O
at	O	O
the	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
receptor	O	O
.	O	O
Compound	O	O
45	O	O
[	B-IUPAC	O
N	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cyclopentyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylindol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenzenesulfonamide	I-IUPAC	I-IUPAC
,	O	O
ICI	O	O
204,219	O	O
;	O	O
pKB	O	O
=	O	O
9.67	O	O
+	O	O
/	O	O
-	O	O
0.13	O	O
,	O	O
Ki	O	O
=	O	O
0.3	O	O
+	O	O
/	O	O
-	O	O
0.03	O	O
nM	O	O
,	O	O
po	O	O
ED50	O	O
=	O	O
0.3	O	O
mg	O	O
/	O	O
kg	O	O
]	O	O
is	O	O
currently	O	O
under	O	O
clinical	O	O
investigation	O	O
for	O	O
asthma	O	O
.	O	O
A	O	O
phosphorylation	O	O
method	O	O
,	O	O
employing	O	O
methyl	O	B-IUPAC
dichlorophosphate	O	I-IUPAC
,	O	O
was	O	O
developed	O	O
and	O	O
applied	O	O
in	O	O
the	O	O
synthesis	O	O
of	O	O
two	O	O
analogues	O	O
of	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexadecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
palmitoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sn	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glycero	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphoethanolamine	I-IUPAC	I-IUPAC
poly	I-IUPAC	I-IUPAC
(	I-IUPAC	O
ethylene	I-IUPAC	O
glycol	I-IUPAC	O
)	I-IUPAC	O
.	O	O
Substitution	O	O
of	O	O
an	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylidene	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
onto	O	O
the	O	O
7	B-MODIFIER	O
-	I-MODIFIER	O
keto	I-MODIFIER	O
precursor	I-MODIFIER	O
of	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
morphan	I-IUPAC	I-IUPAC
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1	O	O
,	O	O
produces	O	O
compounds	O	O
(	O	O
+	O	O
)	O	O
-	O	O
2	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
9	O	O
(	O	O
6.4-52.6	O	O
nM	O	O
,	O	O
sigma	O	O
2	O	O
)	O	O
,	O	O
which	O	O
have	O	O
at	O	O
least	O	O
a	O	O
475-3906	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
affinity	O	O
for	O	O
the	O	O
sigma	O	O
2	O	O
receptor	O	O
subtype	O	O
relative	O	O
to	O	O
the	O	O
keto	O	O
precursor	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1	O	O
(	O	O
Ki	O	O
=	O	O
25	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
nM	O	O
)	O	O
.	O	O
The	O	O
presence	O	O
of	O	O
a	O	O
methyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
on	O	O
N	O	O
(	O	O
6	O	O
)	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkynyladenosines	I-IUPAC	I-IUPAC
,	O	O
inducing	O	O
an	O	O
increase	O	O
in	O	O
affinity	O	O
at	O	O
the	O	O
human	O	O
A	O	O
(	O	O
3	O	O
)	O	O
receptor	O	O
and	O	O
a	O	O
decrease	O	O
at	O	O
the	O	O
other	O	O
subtypes	O	O
,	O	O
resulted	O	O
in	O	O
an	O	O
increase	O	O
in	O	O
A	O	O
(	O	O
3	O	O
)	O	O
selectivity	O	O
.	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
nitrogen	O	O
substitution	O	O
enhances	O	O
the	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
the	O	O
D	O	O
-	O	O
2	O	O
receptor	O	O
.	O	O
It	O	O
is	O	O
suggested	O	O
that	O	O
nipecotamides	O	O
interact	O	O
with	O	O
anionic	O	O
platelet	O	O
sites	O	O
located	O	O
7	O	O
A	O	O
from	O	O
each	O	O
other	O	O
and	O	O
connected	O	O
by	O	O
a	O	O
hydrophobic	O	O
well	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
general	O	O
structure	O	O
-	O	O
-	O	O
activity	O	O
relationship	O	O
trends	O	O
found	O	O
for	O	O
the	O	O
acyl	B-IUPAC	O
substituent	B-MODIFIER	O
in	O	O
our	O	O
earlier	O	O
series	O	O
,	O	O
five	O	O
groups	O	O
of	O	O
compounds	O	O
were	O	O
tested	O	O
,	O	O
diaryl	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
or	O	O
alkylarylpropanoyl	B-IUPAC	B-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
their	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
analogues	I-MODIFIER	O
,	O	O
and	O	O
urea	O	O
,	O	O
carbamate	O	O
and	O	O
amino	O	O
acid	O	O
derivatives	O	O
.	O	O
We	O	O
have	O	O
prepared	O	O
the	O	O
radiolabeled	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
,	O	O
(	O	O
125	O	O
)	O	O
ITyr	O	O
(	O	O
11	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
(	O	O
125	O	O
)	O	O
I	O	O
-	O	O
25	O	O
)	O	O
and	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
,	O	O
(	O	O
125	O	O
)	O	O
ITyr	O	O
(	O	O
11	O	O
)	O	O
]	O	O
-	O	O
Cbm	O	O
-	O	O
SRIF	O	O
(	O	O
(	O	O
125	O	O
)	O	O
I	O	O
-	O	O
27	O	O
)	O	O
,	O	O
used	O	O
them	O	O
as	O	O
in	O	O
vitro	O	O
tracers	O	O
,	O	O
and	O	O
found	O	O
them	O	O
to	O	O
be	O	O
superior	O	O
to	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,5	O	O
)	O	O
-	O	O
[	O	O
(	O	O
125	O	O
)	O	O
ITyr	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
(	O	O
125	O	O
)	O	O
I	O	O
-	O	O
16	O	O
)	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
sst1	O	O
tumors	O	O
in	O	O
receptor	O	O
autoradiography	O	O
studies	O	O
.	O	O
Analogue	O	O
13	O	O
inhibited	O	O
the	O	O
growth	O	O
of	O	O
L1210	O	O
murine	O	O
leukemic	O	O
cells	O	O
with	O	O
an	O	O
IC50	O	O
of	O	O
6	O	O
x	O	O
10	O	O
(	O	O
5	O	O
)	O	O
M	O	O
in	O	O
culture	O	O
.	O	O
Two	O	O
lower	O	O
homologues	O	O
of	O	O
10	O	O
were	O	O
weak	O	O
partial	O	O
H	O	O
(	O	O
1	O	O
)	O	O
-	O	O
receptor	O	O
agonists	O	O
while	O	O
two	O	O
higher	O	O
homologues	O	O
of	O	O
10	O	O
were	O	O
silent	O	O
antagonists	O	O
endowed	O	O
with	O	O
micromolar	O	O
affinity	O	O
for	O	O
rat	O	O
and	O	O
guinea	O	O
-	O	O
pig	O	O
H	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
.	O	O
The	O	O
open	O	O
-	O	O
chain	O	O
compounds	O	O
(	O	O
1b	O	O
)	O	O
were	O	O
less	O	O
active	O	O
than	O	O
the	O	O
corresponding	O	O
aziridine	O	O
ring	O	O
compounds	O	O
(	O	O
1a	O	O
)	O	O
.	O	O
The	O	O
NOEs	O	O
observed	O	O
between	O	O
tomaymycin	O	O
protons	O	O
and	O	O
adenine	O	O
H2	O	O
protons	O	O
are	O	O
in	O	O
accord	O	O
with	O	O
molecular	O	O
modeling	O	O
studies	O	O
.	O	O
In	O	O
fact	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
boraadamantane	I-IUPAC	I-IUPAC
.	I-IUPAC	O
The	O	O
capacity	O	O
of	O	O
ligand	O	O
1	O	O
and	O	O
its	O	O
Ga	O	O
(	O	O
III	O	O
)	O	O
and	O	O
Fe	O	O
(	O	O
III	O	O
)	O	O
complexes	O	O
to	O	O
destroy	O	O
the	O	O
tyrosyl	O	O
radical	O	O
of	O	O
the	O	O
presumed	O	O
target	O	O
ribonucleotide	O	O
reductase	O	O
is	O	O
reported	O	O
.	O	O
Although	O	O
compounds	O	O
9b	O	O
and	O	O
9c	O	O
at	O	O
44	O	O
mg	O	O
and	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
x	O	O
1	O	O
showed	O	O
a	O	O
T	O	O
/	O	O
C	O	O
of	O	O
147	O	O
and	O	O
149	O	O
,	O	O
respectively	O	O
,	O	O
this	O	O
group	O	O
of	O	O
compounds	O	O
was	O	O
found	O	O
to	O	O
be	O	O
less	O	O
effective	O	O
than	O	O
some	O	O
of	O	O
the	O	O
sulfur	O	O
-	O	O
containing	O	O
drugs	O	O
that	O	O
we	O	O
previously	O	O
described	O	O
(	O	O
e.g.	O	O
sulfenosine	O	O
and	O	O
sulfinosine	O	O
)	O	O
.	O	O
They	O	O
caused	O	O
an	O	O
initial	O	O
rise	O	O
in	O	O
blood	O	O
pressure	O	O
(	O	O
30	O	O
min	O	O
of	O	O
infusion	O	O
,	O	O
250	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
in	O	O
vagotomized	O	O
,	O	O
ganglion	O	O
-	O	O
blocked	O	O
rats	O	O
)	O	O
of	O	O
16.57	O	O
,	O	O
9.80	O	O
,	O	O
22.80	O	O
,	O	O
32.00	O	O
,	O	O
7.00	O	O
,	O	O
15.06	O	O
,	O	O
32.50	O	O
,	O	O
and	O	O
11.42	O	O
mmHg	O	O
and	O	O
showed	O	O
secretory	O	O
activity	O	O
(	O	O
isolated	O	O
cat	O	O
adrenal	O	O
medulla	O	O
)	O	O
of	O	O
1.0	O	O
,	O	O
0.1	O	O
,	O	O
0.01	O	O
,	O	O
0.1	O	O
,	O	O
less	O	O
than	O	O
0.01	O	O
,	O	O
0.1	O	O
,	O	O
less	O	O
than	O	O
0.01	O	O
,	O	O
and	O	O
0.05%	O	O
of	O	O
angiotensin	O	O
II	O	O
.	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Choroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
norapocodeine	I-IUPAC	I-IUPAC
(	O	O
1e	O	O
)	O	O
was	O	O
obtained	O	O
from	O	O
the	O	O
chlorination	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
norapocodeine	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
with	O	O
SOCl2	O	O
.	O	O
Reaction	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diazoimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
with	O	O
the	O	O
novel	O	O
labeling	O	O
agent	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
isocyanate	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
gave	O	O
[	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
temozolomide	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
in	O	O
14-20%	O	O
radiochemical	O	O
yield	O	O
from	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
isocyanate	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
(	O	O
decay	O	O
corrected	O	O
)	O	O
.	O	O
Ethyl	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyloxybenzoate	I-IUPAC	I-IUPAC
,	O	O
ethyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyloxybenzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
ethyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromobenzyloxybenzoates	I-IUPAC	I-IUPAC
,	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
o	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyloxyphenyl	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
exhibited	O	O
the	O	O
most	O	O
favorable	O	O
spectrum	O	O
of	O	O
activity	O	O
.	O	O
1-4	O	O
are	O	O
analogues	O	O
of	O	O
A	O	O
,	O	O
5-10	O	O
are	O	O
analogues	O	O
of	O	O
B	O	O
,	O	O
and	O	O
11-16	O	O
are	O	O
analogues	O	O
of	O	O
C	O	O
.	O	O
Additionally	O	O
,	O	O
we	O	O
introduced	O	O
CalphaMe	O	O
-	O	O
leucine	O	O
residues	O	O
in	O	O
lieu	O	O
of	O	O
leucine	O	O
at	O	O
positions	O	O
14	O	O
,	O	O
15	O	O
,	O	O
19	O	O
,	O	O
27	O	O
,	O	O
and	O	O
37	O	O
in	O	O
[	O	O
DHis32	O	O
]	O	O
astressin	O	O
.	O	O
As	O	O
part	O	O
of	O	O
a	O	O
program	O	O
in	O	O
which	O	O
we	O	O
are	O	O
attempting	O	O
(	O	O
a	O	O
)	O	O
to	O	O
delineate	O	O
the	O	O
structural	O	O
features	O	O
at	O	O
positions	O	O
1-9	O	O
in	O	O
our	O	O
previously	O	O
reported	O	O
antidiuretic	O	O
antagonists	O	O
required	O	O
for	O	O
antidiuretic	O	O
antagonism	O	O
and	O	O
(	O	O
b	O	O
)	O	O
to	O	O
obtain	O	O
analogues	O	O
with	O	O
enhanced	O	O
antiantidiuretic	O	O
potency	O	O
and	O	O
/	O	O
or	O	O
selectivity	O	O
,	O	O
we	O	O
have	O	O
synthesized	O	O
14	O	O
new	O	O
analogues	O	O
of	O	O
the	O	O
antidiuretic	O	O
antagonist	O	O
[	B-IUPAC	O
1	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercapto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclopentamethylenepropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	O
,	I-IUPAC	O
2	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylalanine	I-IUPAC	I-IUPAC
,	I-IUPAC	O
4	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
valine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
[	O	O
d	O	O
-	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2VAVP	O	O
)	O	O
,	O	O
in	O	O
which	O	O
the	O	O
valine	O	O
residue	O	O
at	O	O
position	O	O
4	O	O
was	O	O
replaced	O	O
by	O	O
the	O	O
following	O	O
L	B-IUPAC	O
-	I-IUPAC	O
amino	I-IUPAC	O
acids	I-IUPAC	O
and	O	O
glycine	B-PARTIUPAC	O
:	O	O
Ile	O	O
,	O	O
Abu	O	O
,	O	O
Thr	O	O
,	O	O
Ala	O	O
,	O	O
Gln	O	O
,	O	O
Lys	O	O
,	O	O
Cha	O	O
,	O	O
Nle	O	O
,	O	O
Nva	O	O
,	O	O
Phe	O	O
,	O	O
Leu	O	O
,	O	O
Gly	O	O
,	O	O
Tyr	O	O
,	O	O
and	O	O
Pro	O	O
.	O	O
When	O	O
the	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboalkoxy	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
was	O	O
replaced	O	O
with	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethenyl	I-IUPAC	I-IUPAC
,	O	O
the	O	O
resulting	O	O
analogue	O	O
11	O	O
demonstrated	O	O
the	O	O
highest	O	O
DAT	O	O
binding	O	O
affinity	O	O
in	O	O
the	O	O
series	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
1.81	O	O
nM	O	O
)	O	O
with	O	O
DAT	O	O
selectivity	O	O
over	O	O
serotonin	O	O
transporters	O	O
(	O	O
SERT	O	O
;	O	O
989	O	O
-	O	O
fold	O	O
)	O	O
,	O	O
norepinephrine	O	O
transporters	O	O
(	O	O
NET	O	O
;	O	O
261	O	O
-	O	O
fold	O	O
)	O	O
and	O	O
muscarinic	O	O
receptors	O	O
(	O	O
90	O	O
-	O	O
fold	O	O
)	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
13	O	O
heteroarotinoids	O	O
were	O	O
synthesized	O	O
.	O	O
These	O	O
reaction	O	O
sequences	O	O
involved	O	O
different	O	O
reductive	O	O
processes	O	O
.	O	O
Structure	O	O
-	O	O
-	O	O
activity	O	O
relationships	O	O
are	O	O
discussed	O	O
in	O	O
terms	O	O
of	O	O
cholesterol	O	O
-	O	O
lowering	O	O
activity	O	O
together	O	O
with	O	O
effects	O	O
on	O	O
weight	O	O
gain	O	O
and	O	O
liver	O	O
lipids	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Ureidopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
(	O	O
6-26	O	O
)	O	O
were	O	O
prepared	O	O
by	O	O
displacement	O	O
of	O	O
the	O	O
ethoxy	O	O
group	O	O
of	O	O
the	O	O
carbamate	O	O
2	O	O
by	O	O
amino	O	O
acids	O	O
and	O	O
a	O	O
variety	O	O
of	O	O
amines	O	O
and	O	O
by	O	O
a	O	O
reaction	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
with	O	O
isocyanates	O	O
.	O	O
Series	O	O
of	O	O
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
9,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4,6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
6,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diones	I-IUPAC	I-IUPAC
and	O	O
2	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
9,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
6,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoquinolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
blood	O	O
pressure	O	O
lowering	O	O
properties	O	O
in	O	O
anesthetized	O	O
normotensive	O	O
cats	O	O
and	O	O
conscious	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
.	O	O
Examination	O	O
of	O	O
the	O	O
PTP1B	O	O
inhibitory	O	O
potency	O	O
of	O	O
an	O	O
extensive	O	O
series	O	O
of	O	O
phosphotyrosyl	B-IUPAC	O
(	O	O
pTyr	O	O
)	O	O
mimetics	B-MODIFIER	O
(	O	O
Xxx	O	O
)	O	O
expressed	O	O
in	O	O
the	O	O
EGFr	O	O
-	O	O
derived	O	O
hexapeptide	O	O
platform	O	O
Ac	O	O
-	O	O
Asp	O	O
-	O	O
Ala	O	O
-	O	O
Asp	O	O
-	O	O
Xxx	O	O
-	O	O
Leu	O	O
-	O	O
amide	O	O
previously	O	O
led	O	O
to	O	O
the	O	O
finding	O	O
of	O	O
high	O	O
inhibitory	O	O
potency	O	O
when	O	O
Xxx	O	O
=	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonodifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenylalanyl	I-IUPAC	I-IUPAC
(	O	O
F2Pmp	O	O
)	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
0.2	O	O
microM	O	O
)	O	O
and	O	O
when	O	O
Xxx	O	O
=	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxymethyloxyphenylalanyl	I-IUPAC	I-IUPAC
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
3.6	O	O
microM	O	O
)	O	O
.	O	O
At	O	O
the	O	O
3	O	O
-	O	O
position	O	O
of	O	O
the	O	O
dihydropyridine	O	O
ring	O	O
,	O	O
esters	O	O
were	O	O
much	O	O
more	O	O
selective	O	O
for	O	O
A3	O	O
receptors	O	O
than	O	O
closely	O	O
related	O	O
thioester	O	O
,	O	O
amide	O	O
,	O	O
and	O	O
ketone	O	O
derivatives	O	O
.	O	O
We	O	O
were	O	O
unable	O	O
to	O	O
reproduce	O	O
the	O	O
dedifferentiation	O	O
effect	O	O
of	O	O
reversine	O	O
,	O	O
previously	O	O
reported	O	O
,	O	O
or	O	O
to	O	O
demonstrate	O	O
any	O	O
connection	O	O
between	O	O
A	O	O
(	O	O
3	O	O
)	O	O
AR	O	O
antagonist	O	O
effects	O	O
and	O	O
dedifferentiation	O	O
.	O	O
The	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
of	O	O
these	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amides	I-IUPAC	I-IUPAC
and	O	O
related	O	O
compounds	O	O
are	O	O
discussed	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
these	O	O
two	O	O
assays	O	O
.	O	O
5,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanone	I-IUPAC	I-IUPAC
and	O	O
its	O	O
isomer	O	O
4,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanone	I-IUPAC	I-IUPAC
were	O	O
investigated	O	O
as	O	O
possible	O	O
templates	O	O
for	O	O
the	O	O
construction	O	O
of	O	O
conformationally	O	O
constrained	O	O
analogues	O	O
of	O	O
the	O	O
biologically	O	O
important	O	O
second	O	O
messenger	O	O
,	O	O
diacylglycerol	O	O
(	O	O
DAG	O	O
)	O	O
.	O	O
In	O	O
vivo	O	O
antiallergic	O	O
activity	O	O
evaluation	O	O
confirmed	O	O
efficiency	O	O
of	O	O
45	O	O
in	O	O
sensitized	O	O
guinea	O	O
pig	O	O
late	O	O
phase	O	O
eosinophilia	O	O
inhibition	O	O
,	O	O
after	O	O
parenteral	O	O
and	O	O
oral	O	O
administration	O	O
at	O	O
5	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
respectively	O	O
.	O	O
A	O	O
Langendorff	O	O
guinea	O	O
pig	O	O
heart	O	O
preparation	O	O
served	O	O
for	O	O
the	O	O
assay	O	O
of	O	O
agonist	O	O
potency	O	O
of	O	O
a	O	O
series	O	O
of	O	O
26	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aralkoxyadenosines	I-IUPAC	I-IUPAC
at	O	O
the	O	O
A1	O	O
and	O	O
A2	O	O
receptors	O	O
of	O	O
,	O	O
respectively	O	O
,	O	O
the	O	O
atrioventricular	O	O
node	O	O
(	O	O
conduction	O	O
block	O	O
)	O	O
and	O	O
coronary	O	O
arteries	O	O
(	O	O
vasodilation	O	O
)	O	O
.	O	O
A	O	O
number	O	O
of	O	O
4,7	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
benzopyran	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
crude	O	O
rat	O	O
lens	O	O
aldose	O	O
reductase	O	O
inhibitory	O	O
activity	O	O
.	O	O
(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O
A	O	O
series	O	O
of	O	O
2,6	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxyphenyl	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
ketones	I-IUPAC	I-IUPAC
has	O	O
been	O	O
investigated	O	O
as	O	O
inhibitors	O	O
of	O	O
hepatic	O	O
microsomal	O	O
aniline	O	O
hydroxylase	O	O
and	O	O
aminopyrine	O	O
demethylase	O	O
activities	O	O
.	O	O
Two	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydrobenzofuran	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
of	O	O
hallucinogenic	O	O
amphetamines	O	O
were	O	O
prepared	O	O
and	O	O
evaluated	O	O
for	O	O
activity	O	O
in	O	O
the	O	O
two	O	O
-	O	O
lever	O	O
drug	O	O
-	O	O
discrimination	O	O
paradigm	O	O
in	O	O
rats	O	O
trained	O	O
to	O	O
discriminate	O	O
saline	O	O
from	O	O
LSD	O	O
tartrate	O	O
(	O	O
0.08	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
for	O	O
the	O	O
ability	O	O
to	O	O
displace	O	O
[	O	O
125I	O	O
]	O	O
-	O	O
(	O	O
R	O	O
)	O	O
-	O	O
DOI	O	O
[	B-IUPAC	O
(	I-IUPAC	B-IUPAC
125I	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropane	I-IUPAC	I-IUPAC
)	I-IUPAC	O
from	O	O
rat	O	O
cortical	O	O
homogenate	O	O
5	O	O
-	O	O
HT2	O	O
receptors	O	O
.	O	O
Condensation	O	O
of	O	O
appropriately	O	O
substituted	O	B-MODIFIER
(	O	B-IUPAC
arylmethyl	O	I-IUPAC
)	O	I-IUPAC
triphenylphosphoranes	O	I-IUPAC
with	O	O
4	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylenedioxycyclohexanone	I-IUPAC	I-IUPAC
,	O	O
followed	O	O
by	O	O
hydrogenation	O	O
(	O	O
H2	O	O
/	O	O
Pd	O	O
-	O	O
C	O	O
)	O	O
and	O	O
acidolysis	O	O
,	O	O
yielded	O	O
the	O	O
corresponding	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexanones	I-IUPAC	I-IUPAC
,	O	O
which	O	O
were	O	O
then	O	O
condensed	O	O
with	O	O
cyanoguanidine	O	O
to	O	O
form	O	O
the	O	O
tetrahydroquinazolines	O	O
.	O	O
Tumor	O	O
cell	O	O
migration	O	O
and	O	O
metastasis	O	O
in	O	O
cancer	O	O
are	O	O
facilitated	O	O
by	O	O
interaction	O	O
of	O	O
the	O	O
serine	O	O
protease	O	O
urokinase	O	O
type	O	O
plasminogen	O	O
activator	O	O
(	O	O
uPA	O	O
)	O	O
with	O	O
its	O	O
receptor	O	O
uPAR	O	O
(	O	O
CD	O	O
87	O	O
)	O	O
.	O	O
Their	O	O
anti	O	O
-	O	O
VZV	O	O
activity	O	O
was	O	O
similar	O	O
or	O	O
higher	O	O
to	O	O
that	O	O
of	O	O
EDU	O	O
and	O	O
approximately	O	O
5-12	O	O
-	O	O
fold	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
acyclovir	O	O
.	O	O
Overall	O	O
comparison	O	O
of	O	O
the	O	O
results	O	O
indicate	O	O
that	O	O
1	O	O
is	O	O
subject	O	O
to	O	O
considerable	O	O
conformational	O	O
freedom	O	O
and	O	O
suggests	O	O
that	O	O
the	O	O
sigma	O	O
receptor	O	O
is	O	O
not	O	O
subject	O	O
to	O	O
rigid	O	O
stereochemical	O	O
restraints	O	O
with	O	O
1	O	O
.	O	O
Compound	O	O
4	O	O
was	O	O
essentially	O	O
inactive	O	O
(	O	O
IC50	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
M	O	O
,	O	O
CCRF	O	O
-	O	O
CEM	O	O
)	O	O
.	O	O
v	O	O
.	O	O
The	O	O
synthesized	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
anthraquinone	B-IUPAC	O
derivatives	B-MODIFIER	O
have	O	O
first	O	O
half	O	O
-	O	O
wave	O	O
reduction	O	O
potentials	O	O
of	O	O
-	O	O
0.52	O	O
to	O	O
-	O	O
0.56	O	O
V	O	O
at	O	O
pH	O	O
7.0	O	O
,	O	O
which	O	O
are	O	O
the	O	O
lowest	O	O
oxidation	O	O
-	O	O
reduction	O	O
potentials	O	O
of	O	O
quinone	O	O
bioreductive	O	O
alkylating	O	O
agents	O	O
synthesized	O	O
by	O	O
this	O	O
laboratory	O	O
to	O	O
date	O	O
.	O	O
Hydrolysis	O	O
with	O	O
sodium	O	O
hydroxide	O	O
solution	O	O
gave	O	O
the	O	O
corresponding	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
dioxamic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
.	O	O
The	O	O
following	O	O
substitutions	O	O
and	O	O
deletions	O	O
,	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
,	O	O
were	O	O
employed	O	O
in	O	O
A	O	O
,	O	O
B	O	O
,	O	O
and	O	O
C	O	O
:	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaminopenicillamine	I-IUPAC	I-IUPAC
(	O	O
dP	O	O
)	O	O
;	O	O
D	O	O
-	O	O
Tyr	O	O
(	O	O
Alk	O	O
)	O	O
2	O	O
(	O	O
where	O	O
Alk	O	O
=	O	O
Me	O	O
or	O	O
Et	O	O
)	O	O
,	O	O
D	O	O
-	O	O
Phe2	O	O
;	O	O
Val4	O	O
,	O	O
Thr4	O	O
;	O	O
delta	O	O
3	O	O
-	O	O
Pro7	O	O
;	O	O
Lys8	O	O
,	O	O
Cit8	O	O
;	O	O
desGly9	O	O
,	O	O
desGly	O	O
-	O	O
NH2	O	O
(	O	O
9	O	O
)	O	O
,	O	O
Ala	O	O
-	O	O
NH2	O	O
(	O	O
9	O	O
)	O	O
;	O	O
Leu	O	O
-	O	O
NH2	O	O
(	O	O
9	O	O
)	O	O
;	O	O
Arg	O	O
-	O	O
NH2	O	O
(	O	O
9	O	O
)	O	O
.	O	O
The	O	O
anti	O	O
-	O	O
orthopoxvirus	O	O
activity	O	O
of	O	O
pyrimidine	O	O
may	O	O
be	O	O
favored	O	O
by	O	O
the	O	O
introduction	O	O
of	O	O
hydrophilic	O	O
moieties	O	O
to	O	O
the	O	O
5	O	O
-	O	O
position	O	O
side	O	O
chain	O	O
.	O	O
Tissue	O	O
distribution	O	O
studies	O	O
in	O	O
rats	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
125I	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
iodothiophene	I-IUPAC	I-IUPAC
showed	O	O
high	O	O
brain	O	O
uptake	O	O
(	O	O
5	O	O
min	O	O
,	O	O
2.77%	O	O
dose	O	O
/	O	O
g	O	O
;	O	O
30	O	O
min	O	O
,	O	O
2.51%	O	O
dose	O	O
/	O	O
g	O	O
)	O	O
and	O	O
good	O	O
brain	O	O
/	O	O
blood	O	O
(	O	O
B	O	O
/	O	O
B	O	O
)	O	O
ratios	O	O
(	O	O
5	O	O
min	O	O
,	O	O
6/1	O	O
;	O	O
30	O	O
min	O	O
3.8/1	O	O
.	O	O
The	O	O
title	O	O
compounds	O	O
displayed	O	O
partial	O	O
agonism	O	O
on	O	O
contractile	O	O
H	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
of	O	O
the	O	O
guinea	O	O
-	O	O
pig	O	O
ileum	O	O
and	O	O
endothelium	O	O
-	O	O
denuded	O	O
aorta	O	O
,	O	O
respectively	O	O
,	O	O
except	O	O
10	O	O
(	O	O
histaprodifen	O	O
;	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diphenylpropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethanamine	I-IUPAC	I-IUPAC
)	O	O
which	O	O
was	O	O
a	O	O
full	O	O
agonist	O	O
in	O	O
the	O	O
ileum	O	O
assay	O	O
.	O	O
Compounds	O	O
4	O	O
,	O	O
7	O	O
,	O	O
and	O	O
15	O	O
were	O	O
not	O	O
inhibitory	O	O
to	O	O
a	O	O
variety	O	O
of	O	O
viruses	O	O
in	O	O
cell	O	O
culture	O	O
,	O	O
and	O	O
weak	O	O
cytotoxicity	O	O
was	O	O
observed	O	O
only	O	O
for	O	O
CEM	O	O
cells	O	O
.	O	O
Fluorinated	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzothiazoles	I-IUPAC	I-IUPAC
were	O	O
potently	O	O
cytotoxic	O	O
(	O	O
GI	O	O
(	O	O
50	O	O
)	O	O
&	O	O
lt	O	O
;	O	O
1	O	O
nM	O	O
)	O	O
in	O	O
vitro	O	O
in	O	O
sensitive	O	O
human	O	O
breast	O	O
MCF	O	O
-	O	O
7	O	O
(	O	O
ER+	O	O
)	O	O
and	O	O
MDA	O	O
468	O	O
(	O	O
ER	O	O
-	O	O
)	O	O
cell	O	O
lines	O	O
but	O	O
inactive	O	O
(	O	O
GI	O	O
(	O	O
50	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
10	O	O
microM	O	O
)	O	O
against	O	O
PC	O	O
3	O	O
prostate	O	O
,	O	O
nonmalignant	O	O
HBL	O	O
100	O	O
breast	O	O
,	O	O
and	O	O
HCT	O	O
116	O	O
colon	O	O
cells	O	O
.	O	O
Urokinase	O	O
-	O	O
type	O	O
plasminogen	O	O
activator	O	O
(	O	O
uPA	O	O
)	O	O
,	O	O
a	O	O
trypsin	O	O
-	O	O
like	O	O
serine	O	O
protease	O	O
,	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
large	O	O
number	O	O
of	O	O
malignancies	O	O
,	O	O
tumor	O	O
cell	O	O
invasion	O	O
,	O	O
angiogenesis	O	O
and	O	O
metastasis	O	O
;	O	O
hence	O	O
,	O	O
the	O	O
potent	O	O
and	O	O
selective	O	O
inhibitors	O	O
of	O	O
uPA	O	O
may	O	O
therefore	O	O
be	O	O
therapeutically	O	O
useful	O	O
drugs	O	O
for	O	O
treatment	O	O
of	O	O
various	O	O
forms	O	O
of	O	O
cancer	O	O
.	O	O
Among	O	O
tricyclic	O	O
quinazoline	O	O
derivatives	O	O
,	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxoimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinazoline	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
21a	O	O
showed	O	O
potent	O	O
activity	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.10	O	O
microM	O	O
)	O	O
.	O	O
A	O	O
group	O	O
of	O	O
racemic	B-MODIFIER	O
alkyl	B-IUPAC	O
and	O	O
2	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
phenethyl	I-PARTIUPAC	I-IUPAC
1,4	I-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
dihydro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
2,6	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
dimethyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
3	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
nitro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
4	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
3	B-MODIFIER	I-PARTIUPAC
-	I-MODIFIER	I-PARTIUPAC
or	O	O
6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
2	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
pyridyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pyridinecarboxylates	I-PARTIUPAC	I-IUPAC
(	O	O
13a	O	O
-	O	O
q	O	O
)	O	O
was	O	O
prepared	O	O
using	O	O
a	O	O
modified	O	O
Hantzsch	O	O
reaction	O	O
that	O	O
involved	O	O
the	O	O
condensation	O	O
of	O	O
a	O	O
3	B-MODIFIER	O
-	I-MODIFIER	O
or	O	O
6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxaldehyde	I-IUPAC	I-IUPAC
(	O	O
7a	O	O
-	O	O
j	O	O
)	O	O
with	O	O
an	O	O
alkyl	B-IUPAC	O
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenethyl	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminocrotonate	I-IUPAC	I-IUPAC
(	O	O
11a	O	O
-	O	O
d	O	O
)	O	O
and	O	O
nitroacetone	O	O
(	O	O
12	O	O
)	O	O
.	O	O
With	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoquinone	I-IUPAC	I-IUPAC
imine	I-IUPAC	I-IUPAC
,	O	O
water	O	O
and	O	O
aniline	O	O
gave	O	O
substitution	O	O
on	O	O
the	O	O
imine	O	O
carbon	O	O
,	O	O
yielding	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoquinone	I-IUPAC	I-IUPAC
and	O	O
3,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoquinone	I-IUPAC	I-IUPAC
imine	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
.	O	O
DAP	O	O
was	O	O
selectively	O	O
blocked	O	O
by	O	O
the	O	O
carbobenzoxy	O	O
(	O	O
Cbz	O	O
)	O	O
group	O	O
to	O	O
give	O	O
3	O	O
-	O	O
N	O	O
-	O	O
Cbz	O	O
-	O	O
DAP	O	O
(	O	O
2a	O	O
)	O	O
.	O	O
The	O	O
findings	O	O
demonstrate	O	O
differences	O	O
between	O	O
various	O	O
leaving	O	O
groups	O	O
in	O	O
the	O	O
2	O	O
position	O	O
for	O	O
the	O	O
expression	O	O
of	O	O
differential	O	O
cytotoxicity	O	O
.	O	O
Bicyclization	O	O
of	O	O
this	O	O
analogue	O	O
yielded	O	O
[	O	O
dPen1	O	O
,	O	O
cyclo	O	O
(	O	O
Glu4	O	O
,	O	O
Lys8	O	O
)	O	O
]	O	O
oxytocin	O	O
,	O	O
a	O	O
potent	O	O
antagonist	O	O
of	O	O
oxytocin	O	O
in	O	O
the	O	O
uterotonic	O	O
assay	O	O
(	O	O
pA2	O	O
8.74	O	O
)	O	O
with	O	O
a	O	O
potency	O	O
3	O	O
times	O	O
greater	O	O
than	O	O
that	O	O
of	O	O
[	O	O
Mpa1	O	O
,	O	O
cyclo	O	O
(	O	O
Glu4	O	O
,	O	O
Lys8	O	O
)	O	O
]	O	O
oxytocin	O	O
.	O	O
With	O	O
the	O	O
exception	O	O
of	O	O
[	O	O
Sar1	O	O
,	O	O
Thr	O	O
(	O	O
ObetaMe	O	O
)	O	O
8	O	O
]	O	O
angiotensin	O	O
II	O	O
,	O	O
which	O	O
gave	O	O
lower	O	O
antagonistic	O	O
properties	O	O
,	O	O
all	O	O
other	O	O
analogs	O	O
had	O	O
either	O	O
similar	O	O
antagonistic	O	O
properties	O	O
or	O	O
were	O	O
better	O	O
antagonists	O	O
in	O	O
adrenal	O	O
medulla	O	O
than	O	O
in	O	O
smooth	O	O
muscle	O	O
.	O	O
In	O	O
order	O	O
to	O	O
improve	O	O
the	O	O
oral	O	O
bioavailability	O	O
(	O	O
BA	O	O
)	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimid	I-IUPAC	I-IUPAC
azole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3	O	O
:	O	O
CV	O	O
-	O	O
11194	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4	O	O
:	O	O
CV	O	O
-	O	O
11974	O	O
)	O	O
,	O	O
novel	O	O
angiotensin	O	O
II	O	O
(	O	O
AII	O	O
)	O	O
receptor	O	O
antagonists	O	O
,	O	O
chemical	O	O
modification	O	O
to	O	O
yield	O	O
prodrugs	O	O
has	O	O
been	O	O
examined	O	O
.	O	O
Specifically	O	O
,	O	O
compound	O	O
4	O	O
,	O	O
in	O	O
which	O	O
the	O	O
aminosulfonyl	O	O
NH	O	O
group	O	O
is	O	O
more	O	O
acidic	O	O
than	O	O
that	O	O
in	O	O
1	O	O
,	O	O
showed	O	O
greatly	O	O
reduced	O	O
selectivity	O	O
on	O	O
account	O	O
of	O	O
increased	O	O
alpha	O	O
2	O	O
-	O	O
adrenoceptor	O	O
affinity	O	O
as	O	O
compared	O	O
to	O	O
1	O	O
(	O	O
PNMT	O	O
Ki	O	O
=	O	O
2.6	O	O
microM	O	O
,	O	O
alpha	O	O
2	O	O
Ki	O	O
=	O	O
6.3	O	O
microM	O	O
,	O	O
selectivity	O	O
=	O	O
2.4	O	O
)	O	O
.	O	O
Antiparasite	O	O
activity	O	O
was	O	O
not	O	O
solely	O	O
determined	O	O
by	O	O
inhibition	O	O
strength	O	O
against	O	O
trypanothione	O	O
reductase	O	O
,	O	O
there	O	O
being	O	O
a	O	O
strong	O	O
contribution	O	O
from	O	O
hydrophobicity	O	O
(	O	O
for	O	O
example	O	O
,	O	O
benzhydryl	B-IUPAC	B-IUPAC
-	O	O
quaternized	B-MODIFIER	O
chlorpromazime	B-IUPAC	O
had	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
&	O	O
lt	O	O
;	O	O
1	O	O
microM	O	O
)	O	O
.	O	O
A	O	O
series	O	O
of	O	O
imidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isothiazole	I-IUPAC	I-IUPAC
nucleosides	B-MODIFIER	B-MODIFIER
related	O	O
to	O	O
the	O	O
antibiotic	O	O
nebularine	O	O
and	O	O
the	O	O
highly	O	O
cytotoxic	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosylpurine	I-IUPAC	I-IUPAC
have	O	O
been	O	O
synthesized	O	O
from	O	O
the	O	O
corresponding	O	O
heterocycles	O	O
.	O	O
The	O	O
compounds	O	O
are	O	O
bioisosteres	O	O
of	O	O
beta	O	O
-	O	O
carbolines	O	O
and	O	O
1,2,3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbolines	I-IUPAC	I-IUPAC
where	O	O
the	O	O
indole	O	O
nitrogen	O	O
is	O	O
replaced	O	O
by	O	O
sulfur	O	O
.	O	O
These	O	O
results	O	O
open	O	O
the	O	O
way	O	O
toward	O	O
a	O	O
new	O	O
class	O	O
of	O	O
selective	O	O
NO	O	O
donors	O	O
after	O	O
in	O	O
situ	O	O
oxidation	O	O
by	O	O
each	O	O
NOS	O	O
family	O	O
.	O	O
Various	O	O
6	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
aryl	I-PARTIUPAC	I-PARTIUPAC
and	O	O
aralkyl	B-PARTIUPAC	B-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
amino	I-PARTIUPAC	I-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
methyl	I-PARTIUPAC	I-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
2,4	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
pteridinediamines	I-PARTIUPAC	I-PARTIUPAC
and	O	O
their	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxides	I-IUPAC	I-IUPAC
have	O	O
been	O	O
synthesized	O	O
for	O	O
antimalarial	O	O
evaluation	O	O
.	O	O
Thus	O	O
,	O	O
40	O	O
,	O	O
45	O	O
,	O	O
and	O	O
54	O	O
are	O	O
potent	O	O
,	O	O
orally	O	O
active	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
agonists	O	O
with	O	O
marked	O	O
antidepressant	O	O
potential	O	O
.	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1	O	O
were	O	O
synthesized	O	O
from	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminocyclohexanol	I-IUPAC	I-IUPAC
[	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
3	O	O
]	O	O
.	O	O
The	O	O
complexes	O	O
3e	O	O
-	O	O
g	O	O
were	O	O
almost	O	O
equally	O	O
cytotoxic	O	O
to	O	O
cisplatin	O	O
toward	O	O
human	O	O
stomach	O	O
cancer	O	O
cell	O	O
lines	O	O
,	O	O
KATO	O	O
-	O	O
III	O	O
and	O	O
MKN	O	O
-	O	O
45	O	O
,	O	O
and	O	O
a	O	O
human	O	O
non	O	O
-	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
cell	O	O
line	O	O
,	O	O
PC14	O	O
.	O	O
These	O	O
compounds	O	O
have	O	O
been	O	O
evaluated	O	O
in	O	O
vitro	O	O
for	O	O
activity	O	O
against	O	O
Trypanosoma	O	O
b	O	O
.	O	O
Additional	O	O
substituted	O	B-MODIFIER
phenyl	O	B-IUPAC
side	O	B-MODIFIER
chains	O	I-MODIFIER
which	O	O
include	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
,	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
,	O	O
3,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trichloro	I-IUPAC	I-IUPAC
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
,	O	O
and	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
13-17	O	O
were	O	O
also	O	O
synthesized	O	O
.	O	O
Likewise	O	O
,	O	O
for	O	O
the	O	O
enones	O	O
,	O	O
the	O	O
order	O	O
is	O	O
delta	O	O
(	O	O
22	O	O
)	O	O
-	O	O
24	O	O
-	O	O
one	O	O
&	O	O
gt	O	O
;	O	O
delta	O	O
(	O	O
20	O	O
(	O	O
22	O	O
)	O	O
)	O	O
-	O	O
23	O	O
-	O	O
one	O	O
&	O	O
gt	O	O
;	O	O
delta	O	O
(	O	O
22	O	O
)	O	O
-	O	O
20	O	O
-	O	O
one	O	O
&	O	O
gt	O	O
;	O	O
delta	O	O
(	O	O
23	O	O
)	O	O
-	O	O
22	O	O
-	O	O
one	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
biological	O	O
evaluation	O	O
of	O	O
new	O	O
histamine	O	O
H3	O	O
receptor	O	O
antagonists	O	O
with	O	O
an	O	O
iodinated	O	O
aryl	O	O
partial	O	O
structure	O	O
are	O	O
described	O	O
as	O	O
part	O	O
of	O	O
an	O	O
extensive	O	O
research	O	O
program	O	O
to	O	O
find	O	O
model	O	O
compounds	O	O
for	O	O
the	O	O
development	O	O
of	O	O
a	O	O
new	O	O
radioligand	O	O
with	O	O
high	O	O
H3	O	O
receptor	O	O
affinity	O	O
and	O	O
specific	O	O
activity	O	O
.	O	O
These	O	O
results	O	O
demonstrate	O	O
that	O	O
topographical	O	O
modification	O	O
alone	O	O
in	O	O
a	O	O
conformationally	O	O
restricted	O	O
peptide	O	O
ligand	O	O
can	O	O
significantly	O	O
modulate	O	O
both	O	O
potency	O	O
and	O	O
receptor	O	O
selectivity	O	O
of	O	O
peptide	O	O
ligands	O	O
that	O	O
have	O	O
multiple	O	O
sites	O	O
of	O	O
biological	O	O
activity	O	O
and	O	O
suggest	O	O
that	O	O
this	O	O
approach	O	O
may	O	O
have	O	O
general	O	O
application	O	O
to	O	O
peptide	O	O
ligand	O	O
design	O	O
.	O	O
Furthermore	O	O
,	O	O
the	O	O
sigma	O	O
1	O	O
subtype	O	O
is	O	O
highly	O	O
enantioselective	O	O
for	O	O
the	O	O
levorotatory	O	O
isomers	O	O
,	O	O
(	O	B-IUPAC
-	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
-	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
7	O	I-IUPAC
(	O	O
41-1034	O	O
-	O	O
fold	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
sigma	O	O
2	O	O
subtype	O	O
is	O	O
only	O	O
somewhat	O	O
enantioselective	O	O
for	O	O
the	O	O
dextrorotatory	O	O
isomers	O	O
,	O	O
(	O	O
+	O	O
)	O	O
-	O	O
2	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
7	O	O
(	O	O
2.6-9.3	O	O
-	O	O
fold	O	O
)	O	O
.	O	O
Tentative	O	O
stereochemical	O	O
assignments	O	O
are	O	O
based	O	O
on	O	O
chemical	O	O
arguments	O	O
and	O	O
are	O	O
supported	O	O
by	O	O
13C	O	O
NMR	O	O
chemical	O	O
shift	O	O
data	O	O
.	O	O
All	O	O
analogues	O	O
exhibit	O	O
potent	O	O
oxytocic	O	O
antagonism	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O
The	O	O
steady	O	O
-	O	O
state	O	O
rate	O	O
constant	O	O
,	O	O
Ki	O	O
,	O	O
was	O	O
determined	O	O
to	O	O
be	O	O
396	O	O
nM	O	O
.	O	O
The	O	O
importance	O	O
of	O	O
this	O	O
ratio	O	O
remains	O	O
unclear	O	O
in	O	O
terms	O	O
of	O	O
identification	O	O
of	O	O
potential	O	O
cocaine	O	O
antagonists	O	O
.	O	O
Novel	O	O
arylpiperazines	O	O
were	O	O
identified	O	O
as	O	O
alpha	O	O
1	O	O
-	O	O
adrenoceptor	O	O
(	O	O
AR	O	O
)	O	O
subtype	O	O
-	O	O
selective	O	O
antagonists	O	O
by	O	O
functional	O	O
in	O	O
vitro	O	O
screening	O	O
.	O	O
Both	O	O
cyclopropyl	B-PARTIUPAC	O
compounds	B-MODIFIER	O
reduced	O	O
putrescine	O	O
and	O	O
spermidine	O	O
pools	O	O
,	O	O
but	O	O
less	O	O
effectively	O	O
than	O	O
did	O	O
DENSPM	O	O
and	O	O
its	O	O
derivatives	O	O
.	O	O
2	O	B-IUPAC
-	O	I-IUPAC
[	O	I-IUPAC
5	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
Amidinophenyl	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
furan	O	I-IUPAC
-	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
yl	O	I-IUPAC
]	O	I-IUPAC
-	O	I-IUPAC
5,6,7,8	O	I-IUPAC
-	O	I-IUPAC
tetrahydro	O	I-IUPAC
-	O	I-IUPAC
imidazo	O	I-IUPAC
[	O	I-IUPAC
1,2	O	I-IUPAC
-	O	I-IUPAC
a	O	I-IUPAC
]	O	I-IUPAC
pyridine	O	I-IUPAC
-	O	I-IUPAC
6	O	I-IUPAC
-	O	I-IUPAC
carboxamidine	O	I-IUPAC
acetate	O	I-IUPAC
salt	O	I-IUPAC
(	O	O
7	O	O
)	O	O
was	O	O
synthesized	O	O
from	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonitrile	I-IUPAC	I-IUPAC
(	O	O
4a	O	O
)	O	O
,	O	O
through	O	O
the	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyamidoxime	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
hydrogenation	O	O
in	O	O
glacial	O	O
acetic	O	O
acid	O	O
.	O	O
21	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,19	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
epithioprogesterone	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxide	I-IUPAC	I-IUPAC
had	O	O
improved	O	O
activity	O	O
in	O	O
both	O	O
parameters	O	O
,	O	O
while	O	O
21	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,19	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
epithioprogesterone	I-IUPAC	I-IUPAC
had	O	O
improved	O	O
activity	O	O
only	O	O
in	O	O
blocking	O	O
dexamethasone	O	O
-	O	O
induced	O	O
programmed	O	O
cell	O	O
death	O	O
.	O	O
Activity	O	O
among	O	O
the	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pteridinediamines	I-IUPAC	I-IUPAC
IX	O	O
was	O	O
generally	O	O
poor	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
the	O	O
3,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxyphenyl	I-IUPAC	I-IUPAC
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthalenyl	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
which	O	O
showed	O	O
strong	O	O
suppressive	O	O
activity	O	O
at	O	O
doses	O	O
ranging	O	O
from	O	O
80	O	O
to	O	O
640	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
Tomaymycin	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
pyrrolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzodiazepine	I-IUPAC	I-IUPAC
antitumor	O	O
-	O	O
antibiotic	O	O
group	O	O
that	O	O
binds	O	O
covalently	O	O
to	O	O
the	O	O
exocyclic	B-MODIFIER	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
guanine	O	O
in	O	O
DNA	O	O
.	O	O
[	O	O
18F	O	O
]	O	O
4d	O	O
has	O	O
similar	O	O
pharmacokinetic	O	O
properties	O	O
and	O	O
comparable	O	O
specific	O	O
binding	O	O
ratios	O	O
to	O	O
[	O	O
carbonyl	O	O
-	O	O
11C	O	O
]	O	O
4a	O	O
.	O	O
Potency	O	O
showed	O	O
a	O	O
marked	O	O
sensitivity	O	O
to	O	O
the	O	O
introduction	O	O
of	O	O
substituents	O	O
to	O	O
these	O	O
aromatic	O	O
rings	O	O
and	O	O
only	O	O
the	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
9j	O	O
,	O	O
IC50	O	O
=	O	O
0.34	O	O
microM	O	O
,	O	O
demonstrated	O	O
enhanced	O	O
potency	O	O
compared	O	O
to	O	O
the	O	O
parent	O	O
structure	O	O
3	O	O
,	O	O
IC50	O	O
=	O	O
1.2	O	O
microM	O	O
.	O	O
The	O	O
formation	O	O
of	O	O
nitric	O	O
oxide	O	O
(	O	O
NO	O	O
)	O	O
was	O	O
followed	O	O
during	O	O
the	O	O
oxidation	O	O
of	O	O
37	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidines	I-IUPAC	I-IUPAC
or	O	O
related	O	O
derivatives	O	O
,	O	O
including	O	O
18	O	O
new	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidines	I-IUPAC	I-IUPAC
,	O	O
by	O	O
recombinant	O	O
inducible	O	O
nitric	O	O
oxide	O	O
synthase	O	O
(	O	O
NOS	O	O
II	O	O
)	O	O
.	O	O
carinii	O	O
DHFR	O	O
and	O	O
M	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Methoxybenzeneethanamine	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrophenylacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
were	O	O
employed	O	O
as	O	O
starting	O	O
materials	O	O
for	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
indolones	I-IUPAC	I-IUPAC
.	O	O
The	O	O
findings	O	O
showed	O	O
that	O	O
modifications	O	O
at	O	O
the	O	O
position	O	O
of	O	O
the	O	O
amino	O	O
acid	O	O
moiety	O	O
of	O	O
1	O	O
significantly	O	O
influenced	O	O
the	O	O
activity	O	O
and	O	O
that	O	O
the	O	O
1H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
skeleton	B-MODIFIER	O
was	O	O
also	O	O
required	O	O
for	O	O
activity	O	O
to	O	O
occur	O	O
.	O	O
The	O	O
sequence	O	O
of	O	O
enamine	O	O
formation	O	O
with	O	O
pyrrolidine	O	O
,	O	O
catalytic	O	O
reduction	O	O
,	O	O
N	O	O
-	O	O
deprotection	O	O
,	O	O
and	O	O
optical	O	O
resolution	O	O
afforded	O	O
(	B-IUPAC	B-IUPAC
1R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcyclohexylamine	I-IUPAC	I-IUPAC
[	O	O
(	O	O
-	O	O
)	O	O
-	O	O
10	O	O
]	O	O
and	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcyclohexylamine	I-IUPAC	I-IUPAC
[	O	O
(	O	O
+	O	O
)	O	O
-	O	O
10	O	O
]	O	O
.	O	O
Whereas	O	O
AMAA	O	O
(	O	O
6	O	O
)	O	O
and	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propinoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
,	O	O
7	O	O
)	O	O
are	O	O
potent	O	O
and	O	O
highly	O	O
selective	O	O
agonists	O	O
at	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aspartic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
NMDA	O	O
)	O	O
and	O	O
AMPA	O	O
receptors	O	O
,	O	O
respectively	O	O
,	O	O
the	O	O
higher	O	O
homologue	O	O
of	O	O
AMPA	O	O
(	O	O
7	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyric	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
homo	O	O
-	O	O
AMPA	O	O
,	O	O
8	O	O
)	O	O
,	O	O
is	O	O
inactive	O	O
at	O	O
ionotropic	O	O
excitatory	O	O
amino	O	O
acid	O	O
receptors	O	O
.	O	O
In	O	O
the	O	O
latter	O	O
assay	O	O
,	O	O
both	O	O
enantiomers	O	O
of	O	O
6	O	O
had	O	O
identical	O	O
potencies	O	O
,	O	O
but	O	O
their	O	O
dose	O	O
-	O	O
response	O	O
curves	O	O
were	O	O
not	O	O
parallel	O	O
.	O	O
These	O	O
prodrugs	O	O
of	O	O
ara	O	O
-	O	O
C	O	O
include	O	O
ara	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
CDP	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
rac	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexadecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
palmitoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thioglycerol	I-IUPAC	I-IUPAC
(	O	O
8a	O	O
)	O	O
,	O	O
ara	B-IUPAC	O
-	I-IUPAC	O
CDP	I-IUPAC	O
-	I-IUPAC	O
rac	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
octadecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
palmitoylthioglycerol	I-IUPAC	I-IUPAC
(	O	O
8b	O	O
)	O	O
,	O	O
and	O	O
ara	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
CDP	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
rac	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
octadecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
(	O	O
or	O	O
-	B-PARTIUPAC	B-PARTIUPAC
ethyl	I-PARTIUPAC	I-PARTIUPAC
,	O	O
-	B-PARTIUPAC	O
hexadecyl	I-PARTIUPAC	O
)	O	O
thioglycerols	B-PARTIUPAC	O
(	O	O
8c	O	O
-	O	O
e	O	O
)	O	O
.	O	O
The	O	O
k	O	O
(	O	O
cat	O	O
)	O	O
value	O	O
for	O	O
NOS	O	O
II	O	O
-	O	O
catalyzed	O	O
oxidation	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
para	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidine	I-IUPAC	I-IUPAC
was	O	O
80%	O	O
of	O	O
that	O	O
found	O	O
for	O	O
NOHA	O	O
,	O	O
and	O	O
its	O	O
k	O	O
(	O	O
cat	O	O
)	O	O
/	O	O
K	O	O
(	O	O
m	O	O
)	O	O
value	O	O
was	O	O
only	O	O
9	O	O
-	O	O
fold	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
NOHA	O	O
.	O	O
beta	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
1	O	I-IUPAC
-	O	I-IUPAC
Chloro	O	I-IUPAC
-	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
naphthyl	O	I-IUPAC
)	O	I-IUPAC
alanine	O	I-IUPAC
and	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
by	O	O
ammonolysis	O	O
of	O	O
the	O	O
corresponding	O	O
alpha	B-IUPAC	O
,	I-IUPAC	O
1	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihalo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthalenepropanoic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
derived	O	O
from	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthylamine	I-IUPAC	I-IUPAC
by	O	O
diazotization	O	O
and	O	O
condensation	O	O
with	O	O
acrylic	O	O
acid	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
cuprous	O	O
halides	O	O
.	O	O
Compounds	O	O
possessing	O	O
a	O	O
3	B-MODIFIER	O
-	I-MODIFIER	O
or	O	O
6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
,	O	O
in	O	O
conjuction	O	O
with	O	O
an	O	O
i	O	O
-	O	O
Pr	O	O
ester	O	O
substituent	O	O
,	O	O
are	O	O
novel	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyridine	I-IUPAC	I-IUPAC
calcium	O	O
channel	O	O
modulators	O	O
that	O	O
offer	O	O
a	O	O
new	O	O
drug	O	O
design	O	O
approach	O	O
directed	O	O
to	O	O
the	O	O
treatment	O	O
of	O	O
congestive	O	O
heart	O	O
failure	O	O
and	O	O
may	O	O
also	O	O
be	O	O
useful	O	O
as	O	O
probes	O	O
to	O	O
study	O	O
the	O	O
structure	O	O
-	O	O
function	O	O
relationships	O	O
of	O	O
calcium	O	O
channels	O	O
.	O	O
Noteworthy	O	O
are	O	O
the	O	O
tissue	O	O
-	O	O
selective	O	O
bronchodilator	O	O
activity	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
PGE2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
and	O	O
the	O	O
selectivity	O	O
for	O	O
uterine	O	O
tissue	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methanesulfonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
PGE2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
decarboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
16,16	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
PGE2	I-IUPAC	I-IUPAC
,	O	I-IUPAC
N	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
16,16	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
PGE2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
,	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methanesulfonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
16,16	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
PGE2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
.	O	O
Here	O	O
,	O	O
we	O	O
report	O	O
the	O	O
synthesis	O	O
and	O	O
biological	O	O
evaluation	O	O
of	O	O
additional	O	O
PAT	O	O
analogues	O	O
in	O	O
order	O	O
to	O	O
identify	O	O
differences	O	O
in	O	O
binding	O	O
at	O	O
these	O	O
two	O	O
sites	O	O
.	O	O
This	O	O
antiviral	O	O
activity	O	O
did	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
related	O	O
to	O	O
the	O	O
decomposition	O	O
to	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
formyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
,	O	O
which	O	O
was	O	O
itself	O	O
devoid	O	O
of	O	O
anti	O	O
-	O	O
orthopoxvirus	O	O
activity	O	O
in	O	O
these	O	O
assays	O	O
.	O	O
A	O	O
number	O	O
of	O	O
compounds	O	O
were	O	O
orally	O	O
effective	O	O
at	O	O
doses	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
in	O	O
blocking	O	O
LTD4	O	O
-	O	O
induced	O	O
"	O	O
dyspnea	O	O
"	O	O
in	O	O
guinea	O	O
pigs	O	O
.	O	O
The	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
are	O	O
demonstrated	O	O
to	O	O
be	O	O
orally	O	O
active	O	O
under	O	O
the	O	O
in	O	O
vivo	O	O
conditions	O	O
adopted	O	O
.	O	O
01	O	O
)	O	O
.	O	O
We	O	O
found	O	O
that	O	O
the	O	O
antimicrobial	O	O
and	O	O
cytotoxic	O	O
activity	O	O
of	O	O
indolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinolines	I-IUPAC	I-IUPAC
was	O	O
strongly	O	O
influenced	O	O
by	O	O
the	O	O
position	O	O
,	O	O
and	O	O
the	O	O
number	O	O
of	O	O
methyl	B-IUPAC	O
substituents	B-MODIFIER	O
and	O	O
the	O	O
presence	O	O
of	O	O
methyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
at	O	O
pyridine	O	O
nitrogen	O	O
was	O	O
essential	O	O
for	O	O
the	O	O
cytotoxicity	O	O
of	O	O
these	O	O
compounds	O	O
.	O	O
For	O	O
instance	O	O
,	O	O
compound	O	O
34	O	O
was	O	O
orally	O	O
active	O	O
in	O	O
the	O	O
rat	O	O
catalepsy	O	O
model	O	O
at	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
Thus	O	O
,	O	O
the	O	O
compound	O	O
series	O	O
reported	O	O
herein	O	O
comprise	O	O
an	O	O
important	O	O
new	O	O
series	O	O
of	O	O
selective	O	O
A	O	O
(	O	O
3	O	O
)	O	O
AR	O	O
antagonists	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
present	O	O
the	O	O
synthesis	O	O
and	O	O
biological	O	O
evaluations	O	O
of	O	O
six	O	O
of	O	O
the	O	O
possible	O	O
eight	O	O
isomers	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylenedioxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
nortropane	I-IUPAC	I-IUPAC
+	O	O
+	O	O
+	O	O
(	O	O
4	O	O
)	O	O
.	O	O
The	O	O
aromatic	O	O
substituents	O	O
included	O	O
OH	O	O
,	O	O
OCH3	O	O
,	O	O
OCOCH3	O	O
,	O	O
CH2CH3	O	O
,	O	O
and	O	O
Cl	O	O
.	O	O
6beta	B-IUPAC	O
-	I-IUPAC	O
Acetoxynortropane	I-IUPAC	O
had	O	O
K	O	O
(	O	O
i	O	O
)	O	O
values	O	O
versus	O	O
oxotremorine	O	O
-	O	O
M	O	O
binding	O	O
at	O	O
m	O	O
(	O	O
1	O	O
)	O	O
-	O	O
,	O	O
m	O	O
(	O	O
2	O	O
)	O	O
-	O	O
,	O	O
and	O	O
m	O	O
(	O	O
4	O	O
)	O	O
-	O	O
receptors	O	O
ranging	O	O
from	O	O
4	O	O
to	O	O
7	O	O
nM	O	O
.	O	O
2	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
Chloro	O	I-IUPAC
-	O	I-IUPAC
3	O	I-IUPAC
-	O	I-IUPAC
hydroxyphenyl	O	I-IUPAC
)	O	I-IUPAC
ethylamine	O	I-IUPAC
(	O	O
4	O	O
)	O	O
and	O	O
some	O	O
derivatives	O	O
were	O	O
synthesized	O	O
as	O	O
dopamine	O	O
(	O	O
DA	O	O
)	O	O
receptor	O	O
ligands	O	O
.	O	O
Radiolabeled	O	O
m	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodobenzylguanidine	I-IUPAC	I-IUPAC
(	O	O
MIBG	O	O
)	O	O
is	O	O
a	O	O
tumor	O	O
-	O	O
seeking	O	O
radioactive	O	O
drug	O	O
used	O	O
in	O	O
the	O	O
diagnosis	O	O
and	O	O
treatment	O	O
of	O	O
pheochromocytomas	O	O
and	O	O
neuroblastomas	O	O
.	O	O
Friedel	O	O
-	O	O
Crafts	O	O
reaction	O	O
of	O	O
5	O	O
led	O	O
to	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetylbenzylamine	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
which	O	O
on	O	O
treatment	O	O
with	O	O
KCN	O	O
,	O	O
hydrolysis	O	O
of	O	O
the	O	O
resultant	O	O
nitrile	O	O
,	O	O
and	O	O
subsequent	O	O
esterification	O	O
afforded	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbethoxymethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
compound	O	O
was	O	O
(	B-IUPAC	B-IUPAC
2S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxolane	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
,	O	O
where	O	O
a	O	O
chlorine	O	O
moiety	O	O
was	O	O
placed	O	O
in	O	O
the	O	O
ortho	O	O
position	O	O
in	O	O
the	O	O
aromatic	O	O
ring	O	O
of	O	O
etoxadrol	O	O
.	O	O
Addition	O	O
of	O	O
2	O	O
to	O	O
an	O	O
equimolar	O	O
amount	O	O
of	O	O
the	O	O
reaction	O	O
product	O	O
of	O	O
HOPO	O	O
-	O	O
C	O	O
and	O	O
CDI	O	O
in	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylacetamide	I-IUPAC	I-IUPAC
(	O	O
DMAA	O	O
)	O	O
,	O	O
purification	O	O
of	O	O
the	O	O
hexadentate	O	O
intermediate	O	O
,	O	O
subsequent	O	O
treatment	O	O
with	O	O
an	O	O
equimolar	O	O
amount	O	O
of	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzoyl	I-IUPAC	I-IUPAC
chloride	I-IUPAC	I-IUPAC
(	O	O
DMB	O	O
)	O	O
,	O	O
and	O	O
deprotection	O	O
with	O	O
BBr3	O	O
gave	O	O
1,5,14	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tris	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxybenzoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridon	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5,10,14	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetraazatetradecane	I-IUPAC	I-IUPAC
[	O	O
4	O	O
,	O	O
3,4,3	O	O
-	O	O
LI	O	O
(	O	O
triCAM	O	O
-	O	O
HOPO	O	O
)	O	O
]	O	O
in	O	O
5%	O	O
yield	O	O
.	O	O
Reaction	O	O
of	O	O
8	O	O
with	O	O
dimethyl	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminobenzoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
gave	O	O
the	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acetylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
11	O	O
,	O	O
which	O	O
was	O	O
hydrolyzed	O	O
with	O	O
1	O	O
N	O	O
sodium	O	O
hydroxide	O	O
to	O	O
give	O	O
1	O	O
;	O	O
the	O	O
glycine	O	O
analogue	O	O
16	O	O
was	O	O
prepared	O	O
in	O	O
a	O	O
similar	O	O
manner	O	O
.	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexylamine	I-IUPAC	I-IUPAC
platinum	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
exhibited	O	O
higher	O	O
activity	O	O
than	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexanediamine	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
in	O	O
this	O	O
tumor	O	O
system	O	O
.	O	O
The	O	O
NMR	O	O
structure	O	O
of	O	O
cyclo	O	O
[	O	O
21,29	O	O
]	O	O
[	O	O
D	O	O
-	O	O
Cys	O	O
(	O	O
21	O	O
)	O	O
Cys	O	O
(	O	O
29	O	O
)	O	O
]	O	O
-	O	O
uPA	O	O
(	O	O
21	O	O
)	O	O
(	O	O
-	O	O
)	O	O
(	O	O
30	O	O
)	O	O
is	O	O
very	O	O
similar	O	O
to	O	O
the	O	O
previously	O	O
reported	O	O
structure	O	O
of	O	O
the	O	O
amino	O	O
terminal	O	O
fragment	O	O
of	O	O
uPA	O	O
.	O	O
Treatment	O	O
of	O	O
6a	O	O
-	O	O
d	O	O
and	O	O
7a	O	O
-	O	O
d	O	O
with	O	O
thiourea	O	O
furnished	O	O
the	O	O
corresponding	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
9a	O	O
-	O	O
d	O	O
and	O	O
8a	O	O
-	O	O
d	O	O
)	O	O
.	O	O
Reaction	O	O
of	O	O
Z	O	O
-	O	O
Lys	O	O
(	O	O
Z	O	O
)	O	O
-	O	O
Trp	O	O
-	O	O
OMe	O	O
(	O	O
3	O	O
)	O	O
with	O	O
PS	O	O
-	O	O
,	O	O
CmPS	O	O
-	O	O
,	O	O
pNPS	O	O
-	O	O
,	O	O
DNPS	O	O
-	O	O
,	O	O
and	O	O
AacCmES	O	O
-	O	O
Cl	O	O
afforded	O	O
the	O	O
corresponding	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
sulfenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tryptophan	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
which	O	O
on	O	O
treatment	O	O
with	O	O
boron	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tris	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoroacetate	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
/	O	I-IUPAC
trifluoroacetic	O	I-IUPAC
acid	O	I-IUPAC
or	O	O
trimethylsilyl	O	O
iodide	O	O
in	O	O
acetonitrile	O	O
(	O	O
Me3SiI	O	O
/	O	O
CH3CN	O	O
)	O	O
provided	O	O
9-13	O	O
,	O	O
respectively	O	O
.	O	O
Oxidation	O	O
was	O	O
effected	O	O
with	O	O
hydrogen	O	O
peroxide	O	O
or	O	O
the	O	O
bromine	O	O
complex	O	O
of	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diazabicyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2.2.2	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
octane	I-IUPAC	I-IUPAC
.	O	O
While	O	O
[	O	O
131I	O	O
]	O	O
NGA	O	O
indicated	O	O
high	O	O
radioactivity	O	O
levels	O	O
in	O	O
the	O	O
murine	O	O
neck	O	O
,	O	O
stomach	O	O
,	O	O
and	O	O
blood	O	O
,	O	O
such	O	O
increases	O	O
in	O	O
the	O	O
radioactivity	O	O
count	O	O
were	O	O
not	O	O
detectable	O	O
by	O	O
the	O	O
administration	O	O
of	O	O
either	O	O
[	O	O
131I	O	O
]	O	O
MIH	O	O
-	O	O
NGA	O	O
or	O	O
[	O	O
131I	O	O
]	O	O
ATE	O	O
-	O	O
NGA	O	O
.	O	O
All	O	O
analogues	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
the	O	O
Pro4	O	O
-	O	O
containing	O	O
analogue	O	O
,	O	O
are	O	O
antidiuretic	O	O
antagonists	O	O
.	O	O
More	O	O
bulky	O	O
substituents	O	O
at	O	O
position	O	O
9	O	O
led	O	O
to	O	O
less	O	O
active	O	O
compounds	O	O
,	O	O
although	O	O
some	O	O
of	O	O
them	O	O
[	O	B-IUPAC
9	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
(	O	O
rac	O	O
-	O	O
22	O	O
)	O	O
,	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
allyl	I-IUPAC	I-IUPAC
(	O	O
rac	O	O
-	O	O
23	O	O
)	O	O
,	O	O
and	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
(	O	O
rac	O	O
-	O	O
26	O	O
)	O	O
]	O	O
show	O	O
activities	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
THA	O	O
.	O	O
The	O	O
acute	O	O
toxicity	O	O
usually	O	O
exhibited	O	O
by	O	O
the	O	O
parent	O	O
amidine	O	O
1	O	O
at	O	O
a	O	O
dosage	O	O
level	O	O
of	O	O
22	O	O
micromol	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
on	O	O
intravenous	O	O
administration	O	O
has	O	O
been	O	O
significantly	O	O
reduced	O	O
by	O	O
the	O	O
prodrug	O	O
modifications	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
compound	O	O
10	O	O
which	O	O
exhibited	O	O
some	O	O
toxicity	O	O
.	O	O
The	O	O
mechanism	O	O
of	O	O
action	O	O
of	O	O
these	O	O
agents	O	O
has	O	O
been	O	O
attributed	O	O
to	O	O
the	O	O
accumulation	O	O
of	O	O
cells	O	O
at	O	O
mitosis	O	O
.	O	O
The	O	O
novel	O	O
benzylidene	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
10H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
anthracenones	I-IUPAC	I-IUPAC
described	O	O
in	O	O
the	O	O
present	O	O
study	O	O
constitute	O	O
an	O	O
interesting	O	O
group	O	O
of	O	O
highly	O	O
active	O	O
and	O	O
easily	O	O
accessible	O	O
antimitotic	O	O
agents	O	O
that	O	O
inhibit	O	O
tubulin	O	O
polymerization	O	O
.	O	O
Several	O	O
of	O	O
the	O	O
compounds	O	O
have	O	O
CCK	O	O
-	O	O
B	O	O
binding	O	O
affinities	O	O
similar	O	O
to	O	O
the	O	O
parent	O	O
carboxylic	O	O
acid	O	O
1	O	O
(	O	O
CCK	O	O
-	O	O
B	O	O
,	O	O
IC50	O	O
=	O	O
1.7	O	O
nM	O	O
;	O	O
pK	O	O
(	O	O
a	O	O
)	O	O
=	O	O
5.6	O	O
)	O	O
and	O	O
span	O	O
a	O	O
pK	O	O
(	O	O
a	O	O
)	O	O
range	O	O
of	O	O
less	O	O
than	O	O
1	O	O
(	O	O
sulfonic	O	O
acid	O	O
27	O	O
)	O	O
to	O	O
greater	O	O
than	O	O
9.5	O	O
(	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazole	I-IUPAC	I-IUPAC
24	O	O
)	O	O
.	O	O
2	B-IUPAC	O
-	I-IUPAC	O
Methoxytetrahydrofuran	I-IUPAC	O
can	O	O
be	O	O
used	O	O
instead	O	O
of	O	O
Thf	O	O
-	O	O
OAc	O	O
for	O	O
preparation	O	O
of	O	O
Thf	O	O
-	O	O
FU	O	O
under	O	O
similar	O	O
conditions	O	O
.	O	O
The	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolol	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	B-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
,	O	O
2	O	O
)	O	O
and	O	O
the	O	O
isomeric	O	O
compound	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	I-IUPAC
4	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylhomoibotenic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
4a	O	O
)	O	O
are	O	O
potent	O	O
agonists	O	O
at	O	O
the	O	O
AMPA	O	O
subtype	O	O
of	O	O
central	O	O
excitatory	O	O
amino	O	O
acid	O	O
receptors	O	O
.	O	O
The	O	O
analogue	O	O
proved	O	O
to	O	O
retard	O	O
the	O	O
rate	O	O
of	O	O
formation	O	O
of	O	O
formylglycinamide	O	O
ribonucleotide	O	O
apparently	O	O
by	O	O
inhibiting	O	O
the	O	O
rate	O	O
of	O	O
synthesis	O	O
of	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
formyltetrahydrofolate	I-IUPAC	I-IUPAC
,	O	O
the	O	O
actual	O	O
cofactor	O	O
for	O	O
the	O	O
transformylase	O	O
enzyme	O	O
,	O	O
from	O	O
5,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methenyltetrahydrofolate	I-IUPAC	I-IUPAC
.	O	O
Using	O	O
4a	O	O
as	O	O
a	O	O
lead	O	O
structure	O	O
,	O	O
the	O	O
amino	O	O
acids	O	O
4c	O	O
-	O	O
e	O	O
,	O	O
in	O	O
which	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
4a	O	O
is	O	O
replaced	O	O
by	O	O
substituents	O	O
of	O	O
different	O	O
size	O	O
and	O	O
polarity	O	O
,	O	O
were	O	O
synthesized	O	O
.	O	O
;	O	O
Thurston	O	O
,	O	O
D	O	O
.	O	O
These	O	O
precursors	O	O
were	O	O
subjected	O	O
to	O	O
a	O	O
five	O	O
-	O	O
step	O	O
route	O	O
to	O	O
obtain	O	O
thieno2	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
\C5	I-IUPAC	I-IUPAC
\8F	I-IUPAC	I-IUPAC
xazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
bearing	O	O
various	O	O
substituents	O	O
at	O	O
positions	O	O
5	O	O
and	O	O
6	O	O
.	O	O
N4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Alkylaminopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
were	O	O
generally	O	O
prepared	O	O
by	O	O
displacement	O	O
of	O	O
the	O	O
chlorine	O	O
from	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloropyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
with	O	O
various	O	O
amines	O	O
.	O	O
A	O	O
series	O	O
of	O	O
6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
anilinopyrimido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
has	O	O
been	O	O
prepared	O	O
and	O	O
shown	O	O
to	O	O
be	O	O
potent	O	O
inhibitors	O	O
of	O	O
the	O	O
tyrosine	O	O
kinase	O	O
activity	O	O
of	O	O
the	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
(	O	O
EGFR	O	O
)	O	O
.	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
mitochondrial	O	O
peripheral	O	O
benzodiazepine	O	O
receptor	O	O
(	O	O
PBR	O	O
)	O	O
is	O	O
not	O	O
the	O	O
cellular	O	O
binding	O	O
site	O	O
for	O	O
this	O	O
class	O	O
of	O	O
compounds	O	O
.	O	O
Clinical	O	O
studies	O	O
concerning	O	O
the	O	O
role	O	O
of	O	O
poly	O	O
(	O	O
ADP	O	O
-	O	O
ribose	O	O
)	O	O
polymerase	O	O
(	O	O
PARP	O	O
)	O	O
in	O	O
the	O	O
repair	O	O
of	O	O
drug	O	O
-	O	O
and	O	O
radiation	O	O
-	O	O
induced	O	O
DNA	O	O
damage	O	O
have	O	O
been	O	O
impeded	O	O
by	O	O
the	O	O
poor	O	O
solubility	O	O
,	O	O
lack	O	O
of	O	O
potency	O	O
,	O	O
and	O	O
limited	O	O
specificity	O	O
of	O	O
currently	O	O
available	O	O
inhibitors	O	O
.	O	O
The	O	O
dicyclic	O	O
analogue	O	O
dicyclo	O	O
(	O	O
1-3/4-10	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DAsp	O	O
(	O	O
1	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DLys	O	O
(	O	O
3	O	O
)	O	O
,	O	O
Asp	O	O
(	O	O
4	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Dpr	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
26	O	O
)	O	O
was	O	O
fully	O	O
active	O	O
at	O	O
500	O	O
microgram	O	O
,	O	O
with	O	O
a	O	O
K	O	O
(	O	O
i	O	O
)	O	O
value	O	O
of	O	O
1	O	O
nM	O	O
.	O	O
Aromatic	O	O
L	O	O
-	O	O
amino	O	O
acid	O	O
decarboxylase	O	O
(	O	O
AADC	O	O
)	O	O
is	O	O
the	O	O
enzyme	O	O
responsible	O	O
for	O	O
the	O	O
final	O	O
step	O	O
in	O	O
the	O	O
biosynthesis	O	O
of	O	O
both	O	O
dopamine	O	O
and	O	O
serotonin	O	O
via	O	O
decarboxylation	O	O
of	O	O
L	B-IUPAC	O
-	I-IUPAC	O
dopa	I-IUPAC	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tryptophan	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
.	O	O
Novel	O	O
A	O	O
(	O	O
1	O	O
)	O	O
agonists	O	O
with	O	O
potent	O	O
central	O	O
nervous	O	O
system	O	O
effects	O	O
and	O	O
diminished	O	O
influence	O	O
on	O	O
the	O	O
cardiovascular	O	O
system	O	O
are	O	O
reported	O	O
and	O	O
compared	O	O
to	O	O
selected	O	O
reference	O	O
adenosine	O	O
agonists	O	O
.	O	O
In	O	O
the	O	O
presence	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
mercaptoehtanesulfonic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
an	O	O
acrolein	O	O
scavenger	O	O
,	O	O
1c	O	O
was	O	O
equally	O	O
effective	O	O
against	O	O
a	O	O
P	O	O
-	O	O
388	O	O
mutant	O	O
cell	O	O
line	O	O
that	O	O
was	O	O
resistant	O	O
to	O	O
FU	O	O
.	O	O
In	O	O
the	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzothieno	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
,	O	O
the	O	O
aminoethyl	B-IUPAC	B-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
12a	O	O
)	O	O
group	B-MODIFIER	O
at	O	O
C	O	O
-	O	O
3	O	O
also	O	O
conferred	O	O
activity	O	O
,	O	O
but	O	O
other	O	O
amides	O	O
studied	O	O
were	O	O
not	O	O
active	O	O
.	O	O
In	O	O
vivo	O	O
,	O	O
they	O	O
are	O	O
comparable	O	O
to	O	O
the	O	O
6,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
difluoro	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
and	O	O
show	O	O
up	O	O
to	O	O
10	O	O
-	O	O
fold	O	O
improvement	O	O
in	O	O
efficacy	O	O
when	O	O
compared	O	O
to	O	O
their	O	O
ciprofloxacin	O	O
counterparts	O	O
vs	O	O
Streptococcus	O	O
pyogenes	O	O
and	O	O
Streptococcus	O	O
pneumonia	O	O
.	O	O
Both	O	O
analogs	O	O
in	O	O
which	O	O
the	O	O
alpha	O	O
carbon	O	O
of	O	O
the	O	O
Phe3	O	O
replacement	O	O
has	O	O
L	O	O
-	O	O
stereochemistry	O	O
display	O	O
high	O	O
affinity	O	O
for	O	O
delta	O	O
receptors	O	O
with	O	O
the	O	O
(	O	O
2S	O	O
,	O	O
3S	O	O
)	O	O
-	O	O
MePhe3	O	O
analog	O	O
exhibiting	O	O
approximately	O	O
8	O	O
-	O	O
fold	O	O
higher	O	O
affinity	O	O
than	O	O
the	O	O
(	O	O
2S	O	O
,	O	O
3R	O	O
)	O	O
-	O	O
MePhe3	O	O
diastereomer	O	O
.	O	O
Compound	O	O
11	O	O
was	O	O
found	O	O
to	O	O
have	O	O
the	O	O
most	O	O
significant	O	O
and	O	O
selective	O	O
antiviral	O	O
activity	O	O
against	O	O
herpes	O	O
simplex	O	O
virus	O	O
.	O	O
A	O	O
series	O	O
of	O	O
28	O	O
4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
and	O	O
4,5	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridylimidazoles	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
and	O	O
evaluated	O	O
in	O	O
vitro	O	O
for	O	O
inhibition	O	O
of	O	O
xanthine	O	O
oxidase	O	O
.	O	O
It	O	O
appears	O	O
that	O	O
2A	O	O
displayed	O	O
a	O	O
higher	O	O
lipophilicity	O	O
than	O	O
2B	O	O
(	O	O
PC	O	O
=	O	O
305	O	O
and	O	O
229	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
and	O	O
a	O	O
similar	O	O
trend	O	O
was	O	O
observed	O	O
for	O	O
the	O	O
initial	O	O
brain	O	O
uptake	O	O
at	O	O
2	O	O
min	O	O
postinjection	O	O
(	O	O
0.50%	O	O
and	O	O
0.28%	O	O
dose	O	O
/	O	O
organ	O	O
for	O	O
2A	O	O
,	O	O
B	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
One	O	O
assay	O	O
measured	O	O
the	O	O
ability	O	O
of	O	O
a	O	O
retinoid	O	O
to	O	O
inhibit	O	O
the	O	O
phorbol	O	O
ester	O	O
induced	O	O
increase	O	O
of	O	O
mouse	O	O
epidermal	O	O
ornithine	O	O
decarboxylase	O	O
(	O	O
ODC	O	O
)	O	O
activity	O	O
.	O	O
Several	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
display	O	O
antitetrabenazine	O	O
activity	O	O
comparable	O	O
to	O	O
imipramine	O	O
or	O	O
amitriptyline	O	O
but	O	O
are	O	O
two	O	O
-	O	O
to	O	O
fourfold	O	O
less	O	O
active	O	O
than	O	O
analogous	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
arylspiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
.	O	O
The	O	O
dibenzothiophene	O	O
32	O	O
{	O	O
38	O	O
}	O	O
sensitized	O	O
HeLa	O	O
cells	O	O
to	O	O
ionizing	O	O
radiation	O	O
in	O	O
vitro	O	O
,	O	O
with	O	O
dose	O	O
modification	O	O
factors	O	O
of	O	O
2.5	O	O
at	O	O
10%	O	O
survival	O	O
being	O	O
observed	O	O
at	O	O
0.5	O	O
microM	O	O
.	O	O
A	O	O
corresponding	O	O
series	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
halo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
galactose	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
,	O	O
which	O	O
are	O	O
enantiomers	O	O
of	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
halomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fucose	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
,	O	O
has	O	O
also	O	O
been	O	O
synthesized	O	O
.	O	O
Molecular	O	O
mechanics	O	O
computations	O	O
revealed	O	O
,	O	O
however	O	O
,	O	O
that	O	O
the	O	O
conformational	O	O
constraints	O	O
imposed	O	O
by	O	O
the	O	O
beta	O	O
-	O	O
methyl	O	O
group	O	O
in	O	O
the	O	O
(	O	O
2S	O	O
,	O	O
3S	O	O
)	O	O
-	O	O
MePhe3	O	O
and	O	O
(	O	O
2S	O	O
,	O	O
3R	O	O
)	O	O
-	O	O
MePhe3	O	O
analogs	O	O
were	O	O
too	O	O
modest	O	O
to	O	O
allow	O	O
unequivocal	O	O
determination	O	O
of	O	O
delta	O	O
receptor	O	O
-	O	O
bound	O	O
residue	O	O
3	O	O
side	O	O
chain	O	O
conformation	O	O
.	O	O
Against	O	O
the	O	O
colon	O	O
38	O	O
adenocarcinoma	O	O
,	O	O
the	O	O
three	O	O
compounds	O	O
17	O	O
,	O	O
21	O	O
,	O	O
and	O	O
22	O	O
were	O	O
highly	O	O
efficient	O	O
.	O	O
Cyclization	O	O
of	O	O
4	O	O
with	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbethoxybutane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
(	O	O
5e	O	O
)	O	O
gave	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylpyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thione	I-IUPAC	I-IUPAC
(	O	O
6e	O	O
)	O	O
,	O	O
whereas	O	O
reaction	O	O
of	O	O
4	O	O
with	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpropane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
(	O	O
5f	O	O
)	O	O
yielded	O	O
two	O	O
products	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thione	I-IUPAC	I-IUPAC
(	O	O
6f	O	O
)	O	O
and	O	O
the	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
isomer	B-MODIFIER	B-MODIFIER
6g	O	O
.	O	O
Synadenol	O	O
(	O	O
14	O	O
)	O	O
was	O	O
also	O	O
deaminated	O	O
by	O	O
AMP	O	O
deaminase	O	O
from	O	O
aspergillus	O	O
sp	O	O
.	O	O
We	O	O
have	O	O
previously	O	O
reported	O	O
that	O	O
a	O	O
series	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	B-MODIFIER
-	I-IUPAC	I-MODIFIER
substituted	I-IUPAC	I-MODIFIER
(	I-IUPAC	B-IUPAC
thio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperazinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxyquinazoline	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
potent	O	O
and	O	O
selective	O	O
inhibitors	O	O
of	O	O
platelet	O	O
-	O	O
derived	O	O
growth	O	O
factor	O	O
receptor	O	O
(	O	O
PDGFR	O	O
)	O	O
phosphorylation	O	O
and	O	O
demonstrated	O	O
several	O	O
biological	O	O
effects	O	O
such	O	O
as	O	O
suppression	O	O
of	O	O
neointima	O	O
formation	O	O
following	O	O
balloon	O	O
injury	O	O
in	O	O
rat	O	O
carotid	O	O
artery	O	O
by	O	O
oral	O	O
administration	O	O
.	O	O
A	O	O
functionalized	O	O
congener	O	O
bearing	O	O
an	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
aminoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
was	O	O
also	O	O
prepared	O	O
as	O	O
an	O	O
intermediate	O	O
in	O	O
the	O	O
synthesis	O	O
of	O	O
biologically	O	O
active	O	O
conjugates	O	O
.	O	O
gondii	O	O
enzyme	O	O
was	O	O
always	O	O
more	O	O
sensitive	O	O
than	O	O
the	O	O
P	O	O
.	O	O
Condesations	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpteroic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
mAPA	O	O
)	O	O
with	O	O
dimethyl	B-IUPAC	B-IUPAC
DL	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyleneglutamate	I-IUPAC	I-IUPAC
in	O	O
the	O	O
presence	O	O
of	O	O
diethyl	O	O
phosphorocyanidate	O	O
(	O	O
DEPC	O	O
)	O	O
followed	O	O
by	O	O
alkaline	O	O
hydrolysis	O	O
yielded	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpteroyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
DL	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyleneglutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
gamma	O	O
-	O	O
methyleneMTX	O	O
)	O	O
.	O	O
They	O	O
behaved	O	O
as	O	O
antagonists	O	O
,	O	O
but	O	O
they	O	O
proved	O	O
to	O	O
be	O	O
less	O	O
effective	O	O
than	O	O
1	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcarbamoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
met	I-IUPAC	I-IUPAC
hylenedioxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzodiazepine	I-IUPAC	I-IUPAC
(	O	O
2	O	O
,	O	O
GYKI	O	O
53655	O	O
)	O	O
to	O	O
reduce	O	O
the	O	O
KA	O	O
-	O	O
evoked	O	O
currents	O	O
.	O	O
Substitution	O	O
of	O	O
1	O	O
at	O	O
the	O	O
6	O	O
-	O	O
position	O	O
resulted	O	O
in	O	O
compounds	O	O
having	O	O
selective	O	O
non	O	O
-	O	O
NMDA	O	O
antagonism	O	O
and	O	O
8	O	O
-	O	O
substituted	O	O
compounds	O	O
were	O	O
inactive	O	O
at	O	O
all	O	O
receptors	O	O
.	O	O
Compound	O	O
20	O	O
exhibited	O	O
the	O	O
most	O	O
significant	O	O
broad	O	O
-	O	O
spectrum	O	O
in	O	O
vitro	O	O
antiviral	O	O
and	O	O
antitumor	O	O
activity	O	O
.	O	O
A	O	O
series	O	O
of	O	O
7	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2,3	B-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
disubstituted	I-MODIFIER	I-IUPAC
-	O	I-IUPAC
1	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azetidinyl	I-IUPAC	I-IUPAC
)	B-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
1,4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dihydro	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
fluoro	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
oxoquinoline	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
and	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
1,8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
naphthyridine	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
carboxylic	I-PARTIUPAC	I-IUPAC
acids	I-PARTIUPAC	I-IUPAC
,	O	O
with	O	O
varied	O	O
substituents	O	O
at	O	O
the	O	O
1	O	O
-	O	O
,	O	O
5	O	O
-	O	O
,	O	O
and	O	O
8	O	O
-	O	O
positions	O	O
,	O	O
was	O	O
prepared	O	O
to	O	O
study	O	O
the	O	O
effects	O	O
on	O	O
potency	O	O
and	O	O
physicochemical	O	O
properties	O	O
of	O	O
the	O	O
substituent	O	O
at	O	O
position	O	O
2	O	O
of	O	O
the	O	O
azetidine	O	O
moiety	O	O
.	O	O
Furthermore	O	O
,	O	O
the	O	O
greater	O	O
activity	O	O
of	O	O
12	O	O
,	O	O
relative	O	O
to	O	O
8	O	O
,	O	O
is	O	O
consistent	O	O
with	O	O
an	O	O
active	O	O
site	O	O
binding	O	O
preference	O	O
for	O	O
molecules	O	O
in	O	O
which	O	O
a	O	O
more	O	O
coplanar	O	O
relationship	O	O
exists	O	O
between	O	O
the	O	O
aromatic	O	O
ring	O	O
and	O	O
the	O	O
amine	O	O
nitrogen	O	O
.	O	O
N	O	O
-	O	O
Methylation	O	O
of	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylquinazolinone	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
with	O	O
MeI	O	O
,	O	O
followed	O	O
by	O	O
O	O	O
-	O	O
demethylation	O	O
by	O	O
BBr3	O	O
,	O	O
afforded	O	O
the	O	O
control	O	O
N3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylquinazolinones	I-IUPAC	I-IUPAC
42	O	O
and	O	O
43	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
highly	O	O
active	O	O
compound	O	O
9h	O	O
and	O	O
the	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxybenzylidene	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
9l	O	O
were	O	O
tested	O	O
against	O	O
five	O	O
tumor	O	O
cell	O	O
lines	O	O
using	O	O
the	O	O
XTT	O	O
assay	O	O
,	O	O
including	O	O
multidrug	O	O
resistant	O	O
phenotypes	O	O
.	O	O
In	O	O
biodistribution	O	O
studies	O	O
using	O	O
[	O	O
131I	O	O
]	O	O
-	O	O
MIH	O	O
-	O	O
OST7	O	O
and	O	O
[	O	O
131I	O	O
]	O	O
ATE	O	O
-	O	O
OST7	O	O
,	O	O
while	O	O
both	O	O
131I	O	O
-	O	O
labeled	O	O
OST7s	O	O
registered	O	O
almost	O	O
identical	O	O
radioactivity	O	O
levels	O	O
in	O	O
the	O	O
blood	O	O
up	O	O
to	O	O
6	O	O
h	O	O
postinjection	O	O
,	O	O
the	O	O
former	O	O
demonstrated	O	O
a	O	O
lower	O	O
radioactivity	O	O
level	O	O
than	O	O
[	O	O
131I	O	O
]	O	O
ATE	O	O
-	O	O
OST7	O	O
in	O	O
nontarget	O	O
tissues	O	O
throughout	O	O
the	O	O
experiment	O	O
.	O	O
These	O	O
high	O	O
-	O	O
potency	O	O
antagonists	O	O
are	O	O
&	O	O
gt	O	O
;	O	O
1000	O	O
times	O	O
more	O	O
potent	O	O
at	O	O
the	O	O
NR1A	O	O
/	O	O
2B	O	O
subtype	O	O
than	O	O
at	O	O
either	O	O
the	O	O
NR1A	O	O
/	O	O
2A	O	O
or	O	O
NR1A	O	O
/	O	O
2C	O	O
subtypes	O	O
.	O	O
Their	O	O
pharmacological	O	O
activity	O	O
was	O	O
evaluated	O	O
in	O	O
a	O	O
water	O	O
lick	O	O
conflict	O	O
test	O	O
in	O	O
rats	O	O
and	O	O
a	O	O
passive	O	O
avoidance	O	O
test	O	O
in	O	O
mice	O	O
.	O	O
We	O	O
have	O	O
designed	O	O
and	O	O
synthesized	O	O
16	O	O
new	O	O
olean	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
urs	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
en	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
triterpenoids	I-IUPAC	I-IUPAC
with	O	O
various	O	O
modified	O	O
rings	O	O
C	O	O
as	O	O
potential	O	O
antiinflammatory	O	O
and	O	O
cancer	O	O
chemopreventive	O	O
agents	O	O
and	O	O
evaluated	O	O
their	O	O
inhibitory	O	O
activities	O	O
against	O	O
production	O	O
of	O	O
nitric	O	O
oxide	O	O
induced	O	O
by	O	O
interferon	O	O
-	O	O
gamma	O	O
in	O	O
mouse	O	O
macrophages	O	O
.	O	O
Those	O	O
molecules	O	O
that	O	O
showed	O	O
an	O	O
excellent	O	O
in	O	O
vitro	O	O
activity	O	O
as	O	O
well	O	O
as	O	O
high	O	O
selectivity	O	O
for	O	O
the	O	O
parasite	O	O
[	O	O
e.g.	O	O
1c	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
49	O	O
nM	O	O
;	O	O
SI	O	O
&	O	O
gt	O	O
;	O	O
5294	O	O
)	O	O
,	O	O
28b	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
69	O	O
nM	O	O
;	O	O
SI	O	O
=	O	O
3072	O	O
)	O	O
,	O	O
32b	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
22	O	O
nM	O	O
;	O	O
SI	O	O
=	O	O
29.5	O	O
)	O	O
,	O	O
41b	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
118	O	O
nM	O	O
;	O	O
SI	O	O
=	O	O
881	O	O
)	O	O
]	O	O
represent	O	O
new	O	O
antitrypanosomal	O	O
lead	O	O
compounds	O	O
.	O	O
The	O	O
lipophilic	O	O
side	O	O
chain	O	O
of	O	O
the	O	O
naphthyl	B-IUPAC	O
series	B-MODIFIER	O
was	O	O
found	O	O
to	O	O
tolerate	O	O
minor	O	O
variations	O	O
,	O	O
ranging	O	O
from	O	O
a	O	O
phenylmethoxy	B-IUPAC	O
group	B-MODIFIER	O
to	O	O
phenyl	B-IUPAC	O
and	O	O
alkyloxy	B-IUPAC	O
groups	B-MODIFIER	O
.	O	O
Their	O	O
anti	O	O
-	O	O
V1	O	O
pA2	O	O
values	O	O
range	O	O
from	O	O
7.92	O	O
to	O	O
8.45	O	O
.	O	O
Acetylation	O	O
of	O	O
5beta	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
6alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
19	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
30	O	O
and	O	O
its	O	O
5alpha	B-IUPAC	O
,	I-IUPAC	O
6beta	I-IUPAC	O
-	I-IUPAC	O
analogue	I-IUPAC	O
31	O	O
followed	O	O
by	O	O
dehydration	O	O
with	O	O
SOCl	O	O
(	O	O
2	O	O
)	O	O
and	O	O
alkaline	O	O
hydroxysis	O	O
gave	O	O
6alpha	O	O
,	O	O
19	O	B-IUPAC
-	O	I-IUPAC
diol	O	I-IUPAC
36	O	O
and	O	O
its	O	O
6beta	O	O
-	O	O
isomer	O	O
37	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
3	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
alkylamino	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
7	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
trifluoromethyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	O
(	O	O
20a	O	O
-	O	O
c	O	O
)	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzothiadiazine	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxides	I-IUPAC	I-IUPAC
(	O	O
11a	O	O
,	O	O
b	O	O
)	O	O
expressed	O	O
a	O	O
marked	O	O
myorelaxant	O	O
activity	O	O
on	O	O
rat	O	O
aorta	O	O
ring	O	O
.	O	O
The	O	O
excitatory	O	O
activity	O	O
in	O	O
rat	O	O
cortical	O	O
wedge	O	O
also	O	O
showed	O	O
that	O	O
ACPA	O	O
was	O	O
more	O	O
potent	O	O
than	O	O
AMPA	O	O
(	O	O
EC50	O	O
=	O	O
1.0	O	O
microM	O	O
compared	O	O
to	O	O
EC50	O	O
=	O	O
3.5	O	O
microM	O	O
for	O	O
AMPA	O	O
)	O	O
.	O	O
Certain	O	O
intermediates	O	O
,	O	O
e.g.	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
iodoalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
,	O	O
were	O	O
converted	O	O
to	O	O
a	O	O
variety	O	O
of	O	O
(	O	O
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
alkyl	B-IUPAC	O
)	O	O
-	O	O
EMAUs	O	O
by	O	O
displacement	O	O
.	O	O
Each	O	O
of	O	O
the	O	O
respective	O	O
Wittig	O	O
products	O	O
8a	O	O
and	O	O
8b	O	O
was	O	O
obtained	O	O
in	O	O
75-80%	O	O
yield	O	O
.	O	O
The	O	O
reaction	O	O
of	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dinitroimidazole	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
oxiranes	O	O
upon	O	O
heating	O	O
in	O	O
absolute	O	O
ethanol	O	O
yielded	O	O
the	O	O
expected	O	O
1	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dinitroimidazoles	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
and	O	O
also	O	O
resulted	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
a	O	O
novel	O	O
class	O	O
of	O	O
isomeric	B-MODIFIER	O
nitroimidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxazoles	I-IUPAC	I-IUPAC
3	O	O
and	O	O
4	O	O
)	O	O
by	O	O
intramolecular	O	O
cyclization	O	O
.	O	O
From	O	O
this	O	O
series	O	O
,	O	O
compound	O	O
45	O	O
was	O	O
selected	O	O
for	O	O
further	O	O
evaluation	O	O
where	O	O
it	O	O
was	O	O
also	O	O
found	O	O
to	O	O
be	O	O
active	O	O
against	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
bicuculline	O	O
,	O	O
and	O	O
quinolinic	O	O
acid	O	O
induced	O	O
seizures	O	O
in	O	O
mice	O	O
.	O	O
The	O	O
corresponding	O	O
bridged	O	O
analogues	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deazapteroyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ornithine	I-IUPAC	I-IUPAC
and	O	O
(	B-IUPAC	B-IUPAC
6R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6,7	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropteroyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ornithine	I-IUPAC	I-IUPAC
were	O	O
also	O	O
synthesized	O	O
as	O	O
potential	O	O
inhibitors	O	O
.	O	O
Five	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabinofuranosylcytosine	I-IUPAC	I-IUPAC
conjugates	B-MODIFIER	B-MODIFIER
and	O	O
two	O	O
cytidine	O	O
conjugates	O	O
of	O	O
thioether	O	O
lipids	O	O
(	O	O
1	B-IUPAC	O
-	I-IUPAC	O
S	I-IUPAC	O
-	I-IUPAC	O
alkylthioglycerols	I-IUPAC	O
)	O	O
linked	O	O
by	O	O
a	O	O
pyrophosphate	O	O
diester	O	O
bond	O	O
have	O	O
been	O	O
prepared	O	O
and	O	O
their	O	O
antitumor	O	O
activity	O	O
against	O	O
an	O	O
ara	O	O
-	O	O
C2	O	O
sensitive	O	O
(	O	O
L1210/0	O	O
)	O	O
and	O	O
two	O	O
ara	O	O
-	O	O
C	O	O
resistant	O	O
L1210	O	O
lymphoid	O	O
leukemia	O	O
sublines	O	O
in	O	O
mice	O	O
were	O	O
evaluated	O	O
.	O	O
Adenosine	O	O
monophosphate	O	O
analogues	O	O
were	O	O
full	O	O
agonists	O	O
,	O	O
although	O	O
generally	O	O
4	O	O
orders	O	O
of	O	O
magnitude	O	O
less	O	O
potent	O	O
.	O	O
The	O	O
DA	O	O
autoreceptor	O	O
selectivity	O	O
of	O	O
these	O	O
heterocyclic	O	O
analogues	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenol	I-IUPAC	I-IUPAC
(	O	O
3	O	O
-	O	O
PPP	O	O
)	O	O
was	O	O
also	O	O
evaluated	O	O
.	O	O
Syntheses	O	O
of	O	O
the	O	O
enantiomers	O	O
of	O	O
myo	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
1,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trisphosphate	I-IUPAC	I-IUPAC
are	O	O
described	O	O
.	O	O
Collectively	O	O
,	O	O
these	O	O
data	O	O
suggest	O	O
that	O	O
1c	O	O
acts	O	O
as	O	O
a	O	O
membrane	O	O
-	O	O
permeable	O	O
prodrug	O	O
of	O	O
FdUMP	O	O
.	O	O
We	O	O
now	O	O
report	O	O
the	O	O
synthesis	O	O
of	O	O
2	O	O
-	O	O
Py	O	O
-	O	O
AMPA	O	O
(	O	O
7a	O	O
)	O	O
and	O	O
the	O	O
isomeric	O	O
compounds	O	O
3	O	O
-	O	O
Py	O	O
-	O	O
AMPA	O	O
(	O	O
7b	O	O
)	O	O
and	O	O
4	O	O
-	O	O
Py	O	O
-	O	O
AMPA	O	O
(	O	O
7c	O	O
)	O	O
as	O	O
well	O	O
as	O	O
the	O	O
7a	O	O
analogues	O	O
,	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
ropion	I-IUPAC	I-IUPAC
ic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
7d	O	O
)	O	O
and	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinolinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
7e	O	O
)	O	O
.	O	O
N	O	O
-	O	O
Methylation	O	O
,	O	O
followed	O	O
by	O	O
treatment	O	O
with	O	O
aliphatic	O	O
diamines	O	O
,	O	O
aromatic	O	O
amines	O	O
,	O	O
or	O	O
their	O	O
derived	O	O
lithium	O	O
anions	O	O
,	O	O
gave	O	O
the	O	O
desired	O	O
compounds	O	O
.	O	O
IV	O	O
,	O	O
[	O	O
des	O	O
-	O	O
Asp1	O	O
]	O	O
angiotensin	O	O
II	O	O
(	O	O
III	O	O
)	O	O
,	O	O
[	O	O
des	O	O
-	O	O
(	O	O
Asp1	O	O
,	O	O
Arg2	O	O
)	O	O
]	O	O
angiotensin	O	O
II	O	O
(	O	O
V	O	O
)	O	O
,	O	O
[	O	O
des	O	O
-	O	O
(	O	O
Asp1	O	O
,	O	O
Arg2	O	O
,	O	O
Val3	O	O
)	O	O
]	O	O
angiotensin	O	O
II	O	O
(	O	O
VI	O	O
)	O	O
,	O	O
[	O	O
Sar1	O	O
,	O	O
Ile8	O	O
]	O	O
angiotensin	O	O
II	O	O
(	O	O
VII	O	O
)	O	O
,	O	O
and	O	O
[	O	O
des	O	O
-	O	O
Asp1	O	O
,	O	O
Ile8	O	O
]	O	O
angiotensin	O	O
II	O	O
(	O	O
VIII	O	O
)	O	O
possessed	O	O
0.5	O	O
,	O	O
20	O	O
,	O	O
2	O	O
,	O	O
0	O	O
less	O	O
than	O	O
0.1	O	O
,	O	O
and	O	O
less	O	O
than	O	O
0.01%	O	O
of	O	O
the	O	O
inotropic	O	O
activity	O	O
(	O	O
rabbit	O	O
atria	O	O
)	O	O
,	O	O
1	O	O
,	O	O
15	O	O
,	O	O
5	O	O
,	O	O
0	O	O
,	O	O
3	O	O
,	O	O
and	O	O
0%	O	O
secretory	O	O
activity	O	O
of	O	O
the	O	O
cat	O	O
adrenal	O	O
medulla	O	O
,	O	O
and	O	O
0.0	O	O
,	O	O
150	O	O
,	O	O
0.5	O	O
,	O	O
3	O	O
,	O	O
and	O	O
10%	O	O
of	O	O
the	O	O
adrenal	O	O
steroidogenic	O	O
activity	O	O
of	O	O
angiotensin	O	O
II	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
variation	O	O
of	O	O
the	O	O
heterocycle	O	O
moiety	O	O
revealed	O	O
a	O	O
much	O	O
less	O	O
stringent	O	O
SAR	O	O
and	O	O
many	O	O
5	O	O
-	O	O
and	O	O
6	O	O
-	O	O
membered	O	O
heterocycles	O	O
were	O	O
found	O	O
to	O	O
effectively	O	O
substitute	O	O
for	O	O
the	O	O
oxazole	O	O
ring	O	O
of	O	O
2	O	O
and	O	O
3	O	O
.	O	O
A	O	O
series	O	O
of	O	O
N	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
imidazolines	O	B-IUPAC
and	O	O
ethylenediamines	O	O
were	O	O
synthesized	O	O
and	O	O
examined	O	O
for	O	O
their	O	O
activity	O	O
in	O	O
alpha	O	O
-	O	O
and	O	O
beta	O	O
-	O	O
adrenergic	O	O
systems	O	O
.	O	O
Optimization	O	O
of	O	O
6	O	O
resulted	O	O
in	O	O
the	O	O
preparation	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
thien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pro	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enol	I-IUPAC	I-IUPAC
33	O	O
with	O	O
an	O	O
IC50	O	O
of	O	O
300	O	O
nM	O	O
on	O	O
the	O	O
ETA	O	O
receptor	O	O
.	O	O
Results	O	O
presented	O	O
in	O	O
this	O	O
paper	O	O
confirm	O	O
the	O	O
first	O	O
assignment	O	O
and	O	O
establish	O	O
that	O	O
,	O	O
although	O	O
the	O	O
proposed	O	O
6	O	B-IUPAC
-	O	I-IUPAC
cyano	O	I-IUPAC
adduct	O	I-IUPAC
is	O	O
initially	O	O
formed	O	O
,	O	O
the	O	O
product	O	O
that	O	O
was	O	O
isolated	O	O
from	O	O
the	O	O
mitochondrial	O	O
incubation	O	O
mixtures	O	O
of	O	O
MPTP	O	O
and	O	O
sodium	O	O
cyanide	O	O
actually	O	O
is	O	O
the	O	O
isomeric	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyridine	I-IUPAC	I-IUPAC
.	O	O
Reinforcement	O	O
of	O	O
the	O	O
characteristics	O	O
of	O	O
amphiphilicity	O	O
,	O	O
helicity	O	O
,	O	O
and	O	O
peptide	O	O
dipolar	O	O
effects	O	O
,	O	O
using	O	O
recognized	O	O
medicinal	O	O
chemistry	O	O
approaches	O	O
including	O	O
introduction	O	O
of	O	O
conformational	O	O
constraints	O	O
,	O	O
has	O	O
resulted	O	O
in	O	O
several	O	O
potent	O	O
GHRH	O	O
analogues	O	O
.	O	O
However	O	O
,	O	O
4	O	O
-	O	O
AHCP	O	O
was	O	O
found	O	O
to	O	O
be	O	O
much	O	O
weaker	O	O
than	O	O
AMPA	O	O
as	O	O
an	O	O
inhibitor	O	O
of	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
AMPA	O	O
binding	O	O
and	O	O
to	O	O
have	O	O
limited	O	O
effect	O	O
in	O	O
a	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
kainic	O	O
acid	O	O
binding	O	O
assay	O	O
using	O	O
rat	O	O
cortical	O	O
membranes	O	O
.	O	O
The	O	O
deamination	O	O
of	O	O
14	O	O
effectively	O	O
stopped	O	O
at	O	O
50%	O	O
conversion	O	O
.	O	O
Many	O	O
of	O	O
these	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
potent	O	O
antihypertensive	O	O
agents	O	O
in	O	O
the	O	O
spontaneously	O	O
hypertensive	O	O
rat	O	O
(	O	O
SHR	O	O
)	O	O
.	O	O
Aromatic	O	O
carboxylic	O	O
esters	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinol	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
and	O	O
evaluated	O	O
for	O	O
analgesic	O	O
activity	O	O
.	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
Bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihyroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxynoraporphine	I-IUPAC	I-IUPAC
(	O	O
1b	O	O
)	O	O
and	O	O
its	O	O
mono	O	O
-	O	O
and	O	O
diacetyl	O	O
ester	O	O
derivatives	O	O
(	O	O
1c	O	O
-	O	O
d	O	O
)	O	O
were	O	O
prepared	O	O
from	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloroacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diacetoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxynoraporphine	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
.	O	O
Free	O	O
energy	O	O
of	O	O
binding	O	O
,	O	O
derived	O	O
from	O	O
radioligand	O	O
displacement	O	O
KA	O	O
values	O	O
,	O	O
indicated	O	O
that	O	O
addition	O	O
of	O	O
the	O	O
bromine	O	O
in	O	O
either	O	O
series	O	O
contributes	O	O
2.4-3.2	O	O
kcal	O	O
/	O	O
mol	O	O
of	O	O
binding	O	O
energy	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
displace	O	O
bound	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
WIN	O	O
35,428	O	O
(	O	O
5	O	O
)	O	O
from	O	O
rat	O	O
caudate	O	O
putamen	O	O
tissue	O	O
and	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
inhibit	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
dopamine	O	O
uptake	O	O
.	O	O
IR	O	O
,	O	O
1H	O	O
NMR	O	O
and	O	O
13C	O	O
NMR	O	O
data	O	O
have	O	O
been	O	O
recorded	O	O
for	O	O
each	O	O
compound	O	O
and	O	O
support	O	O
the	O	O
structural	O	O
assignments	O	O
.	O	O
A	O	O
number	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyazole	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
as	O	O
bioisosteres	O	O
of	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
Glu	O	O
)	O	O
and	O	O
as	O	O
analogues	O	O
of	O	O
the	O	O
AMPA	O	O
receptor	O	O
agonist	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
,	O	O
3b	O	O
)	O	O
.	O	O
The	O	O
protected	O	O
intermediate	O	O
above	O	O
was	O	O
synthesized	O	O
from	O	O
Z	O	O
-	O	O
Cys	O	O
(	O	O
Bzl	O	O
)	O	O
-	O	O
Pro	O	O
-	O	O
Leu	O	O
-	O	O
Gly	O	O
-	O	O
NH2	O	O
by	O	O
the	O	O
stepwose	O	O
p	O	B-IUPAC
-	O	I-IUPAC
nitrophenyl	O	I-IUPAC
ester	O	I-IUPAC
method	O	O
using	O	O
Nalpha	O	O
-	O	O
Boc	O	O
protection	O	O
at	O	O
the	O	O
penta	O	O
-	O	O
,	O	O
hexa	O	O
-	O	O
,	O	O
and	O	O
octapeptide	O	O
stages	O	O
.	O	O
The	O	O
1H	O	O
NMR	O	O
spectra	O	O
of	O	O
the	O	O
Z	O	O
-	O	O
analogues	O	O
14	O	O
and	O	O
15	O	O
are	O	O
consistent	O	O
with	O	O
an	O	O
anti	O	O
-	O	O
like	O	O
conformation	O	O
of	O	O
the	O	O
nucleobases	O	O
.	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenethylphenylacetamide	I-IUPAC	I-IUPAC
has	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
a	O	O
key	O	O
binding	O	O
domain	O	O
to	O	O
LTB4	O	O
receptors	O	O
.	O	O
Fluoride	O	O
was	O	O
also	O	O
found	O	O
after	O	O
injection	O	O
of	O	O
[	O	O
18F	O	O
]	O	O
4d	O	O
.	O	O
5	O	B-PARTIUPAC
-	O	I-PARTIUPAC
Alkyl	O	I-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
arylalkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenedihydrofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
13a	O	O
-	O	O
e	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylidenedihydrofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
18a	O	O
-	O	O
c	O	O
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylenepyrrolidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
16a	O	O
-	O	O
e	O	O
were	O	O
synthesized	O	O
utilizing	O	O
ethyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diethoxyphosphoryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitroalkanoates	I-IUPAC	I-IUPAC
9a	O	O
-	O	O
e	O	O
as	O	O
common	O	O
intermediates	O	O
.	O	O
These	O	O
new	O	O
nucleosides	O	O
were	O	O
screened	O	O
for	O	O
their	O	O
activity	O	O
against	O	O
HIV	O	O
and	O	O
feline	O	O
TLV	O	O
in	O	O
vitro	O	O
.	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
(	O	O
59-61	O	O
)	O	O
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
prepared	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
alkylation	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
(	O	O
58	O	O
)	O	O
.	O	O
In	O	O
this	O	O
case	O	O
,	O	O
cleavage	O	O
of	O	O
the	O	O
P	O	O
-	O	O
N	O	O
bond	O	O
of	O	O
the	O	O
type	O	O
2	O	O
phosphoramidic	O	O
acid	O	O
monoesters	O	O
leads	O	O
directly	O	O
to	O	O
the	O	O
type	O	O
4	O	O
phosphoric	O	O
acid	O	O
monoesters	O	O
.	O	O
Further	O	O
,	O	O
selected	O	O
analogues	O	O
were	O	O
potent	O	O
inhibitors	O	O
of	O	O
the	O	O
growth	O	O
of	O	O
tumor	O	O
cells	O	O
in	O	O
culture	O	O
in	O	O
the	O	O
in	O	O
vitro	O	O
screening	O	O
program	O	O
of	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
with	O	O
GI50s	O	O
in	O	O
the	O	O
nanomolar	O	O
and	O	O
subnanomolar	O	O
range	O	O
.	O	O
N	B-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
2	I-IUPAC	O
-	I-IUPAC	O
Naphthyl	I-IUPAC	O
)	I-IUPAC	O
alanine	I-IUPAC	O
hydrazide	I-IUPAC	O
(	O	O
3	O	O
)	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
glycine	I-IUPAC	I-IUPAC
hydrazide	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
glycine	I-IUPAC	I-IUPAC
hydrazide	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyric	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
hydrazide	I-IUPAC	I-IUPAC
(	O	O
23	O	O
)	O	O
showed	O	O
potent	O	O
inhibitory	O	O
action	O	O
against	O	O
Mycobacterium	O	O
tuberculosis	O	O
H37Rv	O	O
in	O	O
Youman	O	O
's	O	O
medium	O	O
at	O	O
concentrations	O	O
ranging	O	O
from	O	O
0.5	O	O
to	O	O
10.0	O	O
micrograms	O	O
/	O	O
mL	O	O
.	O	O
All	O	O
obtained	O	O
compounds	O	O
were	O	O
tested	O	O
against	O	O
L	O	O
-	O	O
1210	O	O
,	O	O
HL	O	O
-	O	O
60	O	O
,	O	O
and	O	O
NALM	O	O
-	O	O
6	O	O
leukemia	O	O
cells	O	O
.	O	O
Treatment	O	O
of	O	O
4,5,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiadiazine	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxide	I-IUPAC	I-IUPAC
with	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thionylaniline	I-IUPAC	I-IUPAC
gave	O	O
a	O	O
derivative	O	O
of	O	O
another	O	O
new	O	O
ring	O	O
system	O	O
,	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,5	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiadiazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,6	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiadiazine	I-IUPAC	I-IUPAC
5,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxide	I-IUPAC	I-IUPAC
.	O	O
Using	O	O
the	O	O
patch	O	O
-	O	O
clamp	O	O
technique	O	O
,	O	O
the	O	O
capability	O	O
of	O	O
derivatives	O	O
16	O	O
and	O	O
21	O	O
to	O	O
antagonize	O	O
KA	O	O
-	O	O
evoked	O	O
currents	O	O
in	O	O
primary	O	O
cultures	O	O
of	O	O
granule	O	O
neurons	O	O
was	O	O
tested	O	O
.	O	O
(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O
A	O	O
series	O	O
of	O	O
6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
decahydroisoquinoline	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
as	O	O
excitatory	O	O
amino	O	O
acid	O	O
(	O	O
EAA	O	O
)	O	O
receptor	O	O
antagonists	O	O
.	O	O
Preliminary	O	O
evidence	O	O
suggests	O	O
that	O	O
2b	O	O
is	O	O
a	O	O
storage	O	O
analogue	O	O
of	O	O
norepinephrine	O	O
.	O	O
The	O	O
results	O	O
allow	O	O
the	O	O
establishment	O	O
of	O	O
a	O	O
three	O	O
-	O	O
dimensional	O	O
pharmacophore	O	O
of	O	O
the	O	O
glycine	O	O
receptor	O	O
antagonist	O	O
site	O	O
,	O	O
incorporating	O	O
a	O	O
newly	O	O
defined	O	O
bulk	O	O
tolerance	O	O
/	O	O
hydrophobic	O	O
region	O	O
.	O	O
The	O	O
binding	O	O
affinity	O	O
for	O	O
3	O	O
was	O	O
2	O	O
-	O	O
fold	O	O
greater	O	O
than	O	O
those	O	O
observed	O	O
for	O	O
cocaine	O	O
(	O	O
1	O	O
)	O	O
and	O	O
2	O	O
,	O	O
while	O	O
the	O	O
binding	O	O
affinity	O	O
for	O	O
4	O	O
was	O	O
found	O	O
to	O	O
be	O	O
100	O	O
-	O	O
fold	O	O
less	O	O
than	O	O
those	O	O
of	O	O
1	O	O
and	O	O
2	O	O
.	O	O
However	O	O
,	O	O
as	O	O
with	O	O
these	O	O
standard	O	O
agents	O	O
,	O	O
10	O	O
showed	O	O
no	O	O
appreciable	O	O
selectivity	O	O
for	O	O
either	O	O
the	O	O
P	O	O
.	O	O
The	O	O
absolute	O	O
bioavailability	O	O
of	O	O
5q	O	O
has	O	O
been	O	O
found	O	O
to	O	O
be	O	O
28%	O	O
in	O	O
the	O	O
rat	O	O
,	O	O
as	O	O
compared	O	O
to	O	O
68%	O	O
for	O	O
ICI	O	O
204,219	O	O
,	O	O
with	O	O
significant	O	O
levels	O	O
of	O	O
5q	O	O
observed	O	O
in	O	O
the	O	O
blood	O	O
of	O	O
rats	O	O
up	O	O
to	O	O
24	O	O
h	O	O
postdose	O	O
.	O	O
Thus	O	O
,	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
{	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
}	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methanone	I-IUPAC	I-IUPAC
40	O	O
behaved	O	O
as	O	O
a	O	O
more	O	O
potent	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
agonist	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
than	O	O
its	O	O
5	O	O
-	O	O
unsubstituted	O	O
analogue	O	O
38	O	O
.	O	O
The	O	O
RAR	O	O
gamma	O	O
selective	O	O
ligands	O	O
induce	O	O
differentiation	O	O
in	O	O
F9	O	O
cells	O	O
(	O	O
7	O	O
,	O	O
AC50	O	O
=	O	O
33	O	O
nM	O	O
;	O	O
19	O	O
,	O	O
AC50	O	O
=	O	O
66	O	O
nM	O	O
)	O	O
.	O	O
d	O	O
.	O	O
B	O	O
.	O	O
In	O	O
accordance	O	O
with	O	O
this	O	O
disparity	O	O
,	O	O
compound	O	O
8a	O	O
was	O	O
found	O	O
to	O	O
inhibit	O	O
synaptosomal	O	O
[	O	O
3H	O	O
]	O	O
D	O	O
-	O	O
aspartic	O	O
acid	O	O
uptake	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
93	O	O
+	O	O
/	O	O
-	O	O
25	O	O
microM	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
excitatory	O	O
amino	O	O
acid	O	O
transporters	O	O
(	O	O
EAATs	O	O
)	O	O
EAAT1	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
100	O	O
+	O	O
/	O	O
-	O	O
30	O	O
microM	O	O
)	O	O
and	O	O
EAAT2	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
300	O	O
+	O	O
/	O	O
-	O	O
80	O	O
microM	O	O
)	O	O
.	O	O
The	O	O
relative	O	O
amounts	O	O
of	O	O
these	O	O
materials	O	O
excreted	O	O
during	O	O
the	O	O
24	O	O
-	O	O
h	O	O
period	O	O
following	O	O
administration	O	O
of	O	O
tolazamide	O	O
were	O	O
10	O	O
,	O	O
5	O	O
,	O	O
5	O	O
,	O	O
and	O	O
80%	O	O
for	O	O
1-4	O	O
,	O	O
respectively	O	O
.	O	O
Evaluation	O	O
of	O	O
the	O	O
compounds	O	O
was	O	O
carried	O	O
out	O	O
in	O	O
vitro	O	O
on	O	O
human	O	O
blood	O	O
platelets	O	O
.	O	O
Water	O	O
gave	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoquinone	I-IUPAC	I-IUPAC
.	O	O
This	O	O
study	O	O
shows	O	O
that	O	O
the	O	O
pyrrolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
scaffold	B-MODIFIER	B-MODIFIER
is	O	O
conducive	O	O
to	O	O
dual	O	O
DHFR	O	O
-	O	O
TS	O	O
and	O	O
tumor	O	O
inhibitory	O	O
activity	O	O
,	O	O
and	O	O
the	O	O
potency	O	O
is	O	O
determined	O	O
by	O	O
the	O	O
4	O	O
-	O	O
position	O	O
substituent	O	O
.	O	O
Treatment	O	O
of	O	O
9	O	O
with	O	O
triethyloxonium	O	O
fluoborate	O	O
followed	O	O
by	O	O
dehydrogenation	O	O
of	O	O
the	O	O
product	O	O
gave	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoquinoline	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
.	O	O
Overall	O	O
the	O	O
R	O	O
-	O	O
enantiomer	O	O
was	O	O
usually	O	O
the	O	O
more	O	O
potent	O	O
enantiomer	O	O
at	O	O
both	O	O
PNMT	O	O
and	O	O
the	O	O
alpha	O	O
(	O	O
2	O	O
)	O	O
-	O	O
adrenoceptor	O	O
for	O	O
these	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
fluoromethyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
THIQs	I-IUPAC	I-IUPAC
.	O	O
The	O	O
(	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
estrogens	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
from	O	O
the	O	O
hydroxyalkyl	O	O
derivatives	O	O
with	O	O
phthalimide	O	O
under	O	O
Mitsunobu	O	O
conditions	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationship	O	O
studies	O	O
showed	O	O
that	O	O
two	O	O
structural	O	O
factors	O	O
are	O	O
crucial	O	O
for	O	O
NO	O	O
formation	O	O
from	O	O
compounds	O	O
containing	O	O
a	O	O
C	O	O
(	O	O
triple	O	O
bond	O	O
)	O	O
NOH	O	O
function	O	O
.	O	O
These	O	O
analogues	O	O
displayed	O	O
potent	O	O
T	O	O
.	O	O
There	O	O
is	O	O
also	O	O
a	O	O
correlation	O	O
between	O	O
the	O	O
substitution	O	O
on	O	O
the	O	O
7	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pyridinyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
and	O	O
the	O	O
Gram	O	O
positive	O	O
activity	O	O
,	O	O
particularly	O	O
for	O	O
S	O	O
.	O	O
1c	O	O
might	O	O
also	O	O
penetrate	O	O
cells	O	O
directly	O	O
and	O	O
undergo	O	O
the	O	O
same	O	O
degradation	O	O
sequence	O	O
after	O	O
hydrolysis	O	O
by	O	O
cellular	O	O
esterases	O	O
.	O	O
Analogues	O	O
with	O	O
ring	O	O
sizes	O	O
of	O	O
18	O	O
\C2	O	O
\BF	O	O
cyclo	O	O
(	O	O
1	O	O
,	O	O
1'	O	O
-	O	O
3	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DGlu	O	O
(	O	O
1	O	O
)	O	O
(	O	O
Gly	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DLys	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
DA	O	O
la	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
24	O	O
)	O	O
\C2	O	O
\BF	O	O
and	O	O
19	O	O
\C2	O	O
\BF	O	O
cyclo	O	O
(	O	O
1,1	O	O
'	O	O
-	O	O
3	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DGlu	O	O
(	O	O
1	O	O
)	O	O
(	O	O
betaAla	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DLys	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
DAla	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
25	O	O
)	O	O
\C2	O	O
\BF	O	O
atoms	O	O
were	O	O
also	O	O
less	O	O
potent	O	O
than	O	O
21	O	O
with	O	O
slightly	O	O
higher	O	O
K	O	O
(	O	O
i	O	O
)	O	O
values	O	O
(	O	O
1.5	O	O
and	O	O
2.2	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
All	O	O
target	O	O
compounds	O	O
were	O	O
evaluated	O	O
for	O	O
antiarrhythmic	O	O
efficacy	O	O
against	O	O
chloroform	O	O
-	O	O
induced	O	O
ventricular	O	O
tachycardia	O	O
,	O	O
as	O	O
well	O	O
as	O	O
for	O	O
acute	O	O
CNS	O	O
toxicity	O	O
in	O	O
mice	O	O
.	O	O
carinii	O	O
and	O	O
M	O	O
.	O	O
H	O	O
-	O	O
Dmt	O	O
-	O	O
Tic	O	O
-	O	O
NH	O	O
-	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
-	O	B-PARTIUPAC
1H	O	I-PARTIUPAC
-	O	I-PARTIUPAC
benzimidazole	O	I-PARTIUPAC
-	O	I-PARTIUPAC
2	O	I-PARTIUPAC
-	O	I-PARTIUPAC
yl	O	I-PARTIUPAC
(	O	O
Bid	O	O
)	O	O
(	O	O
2	O	O
)	O	O
became	O	O
a	O	O
highly	O	O
potent	O	O
delta	O	O
-	O	O
agonist	O	O
(	O	O
pEC	O	O
(	O	O
50	O	O
)	O	O
,	O	O
9.90	O	O
)	O	O
,	O	O
slightly	O	O
greater	O	O
than	O	O
deltorphin	O	O
C	O	O
(	O	O
pEC	O	O
(	O	O
50	O	O
)	O	O
,	O	O
9.56	O	O
)	O	O
,	O	O
with	O	O
mu	O	O
-	O	O
agonism	O	O
(	O	O
pE	O	O
(	O	O
50	O	O
)	O	O
,	O	O
7.57	O	O
)	O	O
,	O	O
while	O	O
H	O	O
-	O	O
Dmt	O	O
-	O	O
Tic	O	O
-	O	O
Gly	O	O
-	O	O
NH	O	O
-	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
-	O	O
Bid	O	O
(	O	O
4	O	O
)	O	O
retained	O	O
potent	O	O
delta	O	O
-	O	O
antagonism	O	O
(	O	O
pA	O	O
(	O	O
2	O	O
)	O	O
,	O	O
9.0	O	O
)	O	O
but	O	O
with	O	O
an	O	O
order	O	O
of	O	O
magnitude	O	O
less	O	O
mu	O	O
-	O	O
agonism	O	O
.	O	O
The	O	O
complete	O	O
abolishment	O	O
or	O	O
the	O	O
significant	O	O
reduction	O	O
in	O	O
PKC	O	O
-	O	O
ligand	O	O
binding	O	O
observed	O	O
for	O	O
these	O	O
mutants	O	O
thus	O	O
reflects	O	O
the	O	O
loss	O	O
of	O	O
certain	O	O
direct	O	O
contacts	O	O
between	O	O
the	O	O
side	O	O
chain	O	O
of	O	O
the	O	O
mutated	O	O
residue	O	O
in	O	O
PKC	O	O
and	O	O
ligands	O	O
as	O	O
well	O	O
as	O	O
the	O	O
large	O	O
conformational	O	O
alteration	O	O
to	O	O
the	O	O
binding	O	O
site	O	O
caused	O	O
by	O	O
the	O	O
mutation	O	O
.	O	O
If	O	O
the	O	O
antiproliferative	O	O
effect	O	O
of	O	O
these	O	O
amantidine	O	O
analogues	O	O
proves	O	O
to	O	O
be	O	O
an	O	O
effect	O	O
of	O	O
binding	O	O
and	O	O
activating	O	O
CD81	O	O
,	O	O
then	O	O
these	O	O
compounds	O	O
may	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
prevent	O	O
or	O	O
treat	O	O
HCV	O	O
infections	O	O
.	O	O
034	O	O
nM	O	O
and	O	O
with	O	O
a	O	O
2000	O	O
-	O	O
fold	O	O
selectivity	O	O
for	O	O
the	O	O
ETA	O	O
receptor	O	O
versus	O	O
the	O	O
ETB	O	O
receptor	O	O
.	O	O
Study	O	O
of	O	O
P2	O	O
-	O	O
purinoceptor	O	O
subtypes	O	O
has	O	O
been	O	O
difficult	O	O
due	O	O
to	O	O
the	O	O
lack	O	O
of	O	O
potent	O	O
and	O	O
selective	O	O
ligands	O	O
.	O	O
Any	O	O
substitution	O	O
on	O	O
the	O	O
piperazine	O	O
ring	O	O
of	O	O
type	O	O
7	O	O
compounds	O	O
led	O	O
to	O	O
a	O	O
decline	O	O
in	O	O
activity	O	O
,	O	O
the	O	O
most	O	O
active	O	O
analog	B-MODIFIER	O
being	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
decylnipecotoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperazine	I-IUPAC	I-IUPAC
(	O	O
7a	O	O
)	O	O
.	O	O
Modifications	O	O
of	O	O
the	O	O
4	O	B-IUPAC
-	O	I-IUPAC
amide	O	I-IUPAC
show	O	O
that	O	O
bulky	O	O
substituents	O	O
are	O	O
tolerated	O	O
and	O	O
reveal	O	O
the	O	O
critical	O	O
importance	O	O
for	O	O
activity	O	O
of	O	O
correct	O	O
positioning	O	O
of	O	O
the	O	O
carbonyl	O	B-IUPAC
group	O	B-MODIFIER
.	O	O
Stannic	O	O
chloride	O	O
catalyzed	O	O
condensation	O	O
of	O	O
the	O	O
pertrimethylsilyl	O	B-IUPAC
derivatives	O	B-MODIFIER
of	O	O
4b	O	O
and	O	O
4c	O	O
with	O	O
a	O	O
protected	O	O
glycosyl	O	O
halide	O	O
afforded	O	O
anomeric	O	O
mixtures	O	O
of	O	O
ketonucleosides	O	O
3	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
deoxy	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3,5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
di	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
O	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
p	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
toluoyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
beta	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
and	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
alpha	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
D	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
erythro	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pentofuranosyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
6,7	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dihydro	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methylimidazo	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
4,5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
d	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
1,3	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
diazepin	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
3H	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
one	I-PARTIUPAC	I-IUPAC
(	O	O
5b	O	O
and	O	O
6b	O	O
)	O	O
and	O	O
3	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
deoxy	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3,5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
di	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
O	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
p	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
toluoyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
beta	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
and	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
alpha	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
D	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
erythro	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pentofuranosyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
ethyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
6,7	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dihydroimidazo	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
4,5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
d	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
1,3	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
diazepin	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
3H	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
one	I-PARTIUPAC	I-IUPAC
(	O	O
5c	O	O
and	O	O
6c	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
All	O	O
were	O	O
thus	O	O
less	O	O
inhibitory	O	O
than	O	O
1a	O	O
.	O	O
Alkylation	O	O
of	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminopurine	I-IUPAC	I-IUPAC
with	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyne	I-IUPAC	I-IUPAC
led	O	O
to	O	O
chloro	B-IUPAC	O
derivative	B-MODIFIER	O
6a	O	O
,	O	O
which	O	O
was	O	O
hydrolyzed	O	O
to	O	O
alcohol	O	O
6b	O	O
.	O	O
Only	O	O
CPMENSPM	O	O
,	O	O
and	O	O
not	O	O
(	O	O
2R	O	O
,	O	O
10S	O	O
)	O	O
-	O	O
(	O	O
HO	O	O
)	O	O
(	O	O
2	O	O
)	O	O
CPMENSPM	O	O
,	O	O
lowered	O	O
spermine	O	O
pools	O	O
.	O	O
In	O	O
both	O	O
these	O	O
assays	O	O
DL	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylglycine	I-IUPAC	I-IUPAC
proved	O	O
to	O	O
be	O	O
more	O	O
potent	O	O
and	O	O
efficacious	O	O
than	O	O
NMDA	O	O
and	O	O
cis	O	O
-	O	O
methanoglutamate	O	O
.	O	O
The	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
is	O	O
capable	O	O
of	O	O
reacting	O	O
with	O	O
nucleophilic	O	O
groups	O	O
as	O	O
evidenced	O	O
by	O	O
the	O	O
colorimetric	O	O
reaction	O	O
with	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
.	O	O
Substituted	B-MODIFIER	B-IUPAC
-	I-MODIFIER	I-IUPAC
benzyl	I-MODIFIER	I-IUPAC
[	B-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
10a	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenothiazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
dimethylammonium	I-IUPAC	I-IUPAC
salts	I-IUPAC	I-IUPAC
,	O	O
synthesized	O	O
by	O	O
Menschutkin	O	O
quaternization	O	O
of	O	O
the	O	O
tertiary	O	O
alkylamine	O	O
omega	O	O
-	O	O
nitrogen	O	O
atom	O	O
of	O	O
chlorpromazine	O	O
,	O	O
were	O	O
linear	O	O
,	O	O
competitive	O	O
inhibitors	O	O
of	O	O
recombinant	O	O
trypanothione	O	O
reductase	O	O
from	O	O
T	O	O
.	O	O
These	O	O
compounds	O	O
exhibit	O	O
time	O	O
-	O	O
dependent	O	O
inhibition	O	O
consistent	O	O
with	O	O
mechanism	O	O
-	O	O
based	O	O
inhibition	O	O
.	O	O
Protection	O	O
studies	O	O
with	O	O
3	O	O
in	O	O
the	O	O
FaDu	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
cell	O	O
line	O	O
indicated	O	O
that	O	O
inhibition	O	O
was	O	O
completely	O	O
reversed	O	O
by	O	O
leucovorin	O	O
[	O	O
(	O	O
6R	B-IUPAC	O
,	I-IUPAC	O
S	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formyltetrahydrofolate	I-IUPAC	I-IUPAC
]	O	O
or	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
thymidine	O	O
and	O	O
hypoxanthine	O	O
,	O	O
suggesting	O	O
an	O	O
antifolate	O	O
effect	O	O
directed	O	O
at	O	O
DHFR	O	O
.	O	O
The	O	O
relative	O	O
amounts	O	O
of	O	O
these	O	O
materials	O	O
excreted	O	O
in	O	O
0-24	O	O
-	O	O
h	O	O
urine	O	O
collections	O	O
from	O	O
eight	O	O
subjects	O	O
averaged	O	O
7	O	O
,	O	O
17	O	O
,	O	O
26	O	O
,	O	O
10	O	O
,	O	O
25	O	O
,	O	O
and	O	O
15%	O	O
for	O	O
1-6	O	O
,	O	O
respectively	O	O
.	O	O
Methyl	O	O
and	O	O
ethyl	O	B-IUPAC
substituents	O	B-MODIFIER
are	O	O
most	O	O
preferred	O	O
in	O	O
the	O	O
tri	O	O
-	O	O
and	O	O
tetrasubstituted	O	O
diarylguanidines	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
of	O	O
a	O	O
series	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxobut	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enoic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
and	O	O
esters	B-PARTIUPAC	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxobut	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enoic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
and	O	O
esters	B-PARTIUPAC	O
as	O	O
potent	O	O
inhibitors	O	O
of	O	O
kynurenine	O	B-IUPAC
-	O	I-IUPAC
3	O	I-IUPAC
-	O	I-IUPAC
hydroxylase	O	I-IUPAC
are	O	O
described	O	O
.	O	O
Analogues	O	O
with	O	O
low	O	O
nitrogen	O	O
pKa	O	O
's	O	O
such	O	O
that	O	O
the	O	O
nitrogens	O	O
are	O	O
poorly	O	O
protonated	O	O
at	O	O
physiological	O	O
pH	O	O
do	O	O
not	O	O
compete	O	O
well	O	O
with	O	O
spermidine	O	O
for	O	O
uptake	O	O
and	O	O
,	O	O
as	O	O
expected	O	O
,	O	O
have	O	O
high	O	O
96	O	O
h	O	O
IC50	O	O
values	O	O
and	O	O
have	O	O
little	O	O
effect	O	O
on	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
adenosylmethionine	I-IUPAC	I-IUPAC
decarboxylase	O	I-IUPAC
,	O	O
ornithine	O	O
decarboxylase	O	O
,	O	O
and	O	O
spermidine	O	O
/	O	O
spermine	O	O
N1	O	O
-	O	O
acetyltransferase	O	O
activities	O	O
and	O	O
on	O	O
intracellular	O	O
polyamine	O	O
pools	O	O
.	O	O
A	O	O
series	O	O
of	O	O
1	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dinitroimidazole	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
have	O	O
been	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
their	O	O
radiosensitizing	O	O
ability	O	O
for	O	O
selectively	O	O
sensitizing	O	O
hypoxic	O	O
mammalian	O	O
cells	O	O
to	O	O
the	O	O
lethal	O	O
effect	O	O
of	O	O
radiation	O	O
.	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Dimethylacetaminophen	I-IUPAC	I-IUPAC
,	O	O
like	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylacetaminophen	I-IUPAC	I-IUPAC
,	O	O
showed	O	O
very	O	O
little	O	O
tissue	O	O
damage	O	O
.	O	O
Such	O	O
compounds	O	O
were	O	O
analyzed	O	O
as	O	O
true	O	O
alternate	O	O
substrate	O	O
inhibitors	O	O
.	O	O
Attempts	O	O
at	O	O
reducing	O	O
the	O	O
size	O	O
of	O	O
the	O	O
ring	O	O
with	O	O
maintenance	O	O
of	O	O
selectivity	O	O
failed	O	O
in	O	O
that	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,4,5,13	O	O
)	O	O
-	O	O
[	O	O
Tyr	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
33	O	O
)	O	O
and	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,4,5,6,12,13	O	O
)	O	O
-	O	O
[	O	O
Tyr	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
34	O	O
)	O	O
progressively	O	O
lost	O	O
affinity	O	O
for	O	O
all	O	O
receptors	O	O
.	O	O
Synthesis	O	O
of	O	O
various	O	O
substituted	B-MODIFIER	B-MODIFIER
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
and	O	O
their	O	O
derivatives	O	O
is	O	O
described	O	O
by	O	O
three	O	O
methods	O	O
,	O	O
i.e.	O	O
,	O	O
displacement	O	O
of	O	O
nitrite	O	O
from	O	O
methyl	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylate	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
by	O	O
a	O	O
thiol	O	O
anion	O	O
,	O	O
alkylation	O	O
of	O	O
methyl	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylate	I-IUPAC	I-IUPAC
derived	O	O
from	O	O
reaction	O	O
of	O	O
the	O	O
diazotized	B-MODIFIER	O
methyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylate	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
with	O	O
thiocyanate	O	O
followed	O	O
by	O	O
borohydride	O	O
reduction	O	O
of	O	O
the	O	O
product	O	O
,	O	O
and	O	O
alkylation	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarbonitrile	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
hydrolysis	O	O
.	O	O
Condensation	O	O
of	O	O
1	O	O
with	O	O
dibenzoylmethane	B-IUPAC	O
gave	O	O
15	O	O
.	O	O
Consequently	O	O
,	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
boraadamantaneamine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
present	O	O
a	O	O
promising	O	O
lead	O	O
in	O	O
the	O	O
development	O	O
of	O	O
small	O	O
molecules	O	O
with	O	O
potential	O	O
to	O	O
bind	O	O
to	O	O
CD81	O	O
and	O	O
treat	O	O
HCV	O	O
infections	O	O
.	O	O
The	O	O
optimal	O	O
ratios	O	O
of	O	O
Me3Si	O	O
-	O	O
FU	O	O
,	O	O
Thf	O	O
-	O	O
OAc	O	O
,	O	O
and	O	O
SnCl4	O	O
or	O	O
NaI	O	O
for	O	O
preparation	O	O
of	O	O
Thf	O	O
-	O	O
FU	O	O
and	O	O
Thf2	O	O
-	O	O
FU	O	O
were	O	O
determined	O	O
.	O	O
The	O	O
N	B-PARTIUPAC	B-IUPAC
(	I-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
naphthalenylmethyl	I-PARTIUPAC	I-IUPAC
,	O	O
N	B-PARTIUPAC	B-IUPAC
(	I-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
anthracenylmethyl	I-PARTIUPAC	I-IUPAC
,	O	O
and	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrenylmethyl	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triamines	I-IUPAC	I-IUPAC
had	O	O
similar	O	O
toxicity	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
s	O	O
:	O	O
approximately	O	O
0.5	O	O
microM	O	O
)	O	O
in	O	O
CHO	O	O
cells	O	O
,	O	O
which	O	O
have	O	O
an	O	O
active	O	O
polyamine	O	O
transporter	O	O
(	O	O
PAT	O	O
)	O	O
.	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Arylhydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropyluracil	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
15-18	O	O
were	O	O
prepared	O	O
from	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiouracil	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
13	O	O
and	O	O
14	O	O
by	O	O
the	O	O
above	O	O
procedure	O	O
following	O	O
oxidative	O	O
hydrolysis	O	O
of	O	O
the	O	O
thione	O	O
.	O	O
The	O	O
relative	O	O
efficacy	O	O
of	O	O
11	O	O
,	O	O
which	O	O
has	O	O
a	O	O
higher	O	O
receptor	O	O
affinity	O	O
(	O	O
IC50	O	O
=	O	O
1.3	O	O
+	O	O
/	O	O
-	O	O
0.3	O	O
microM	O	O
)	O	O
than	O	O
10	O	O
(	O	O
IC50	O	O
=	O	O
9.3	O	O
+	O	O
/	O	O
-	O	O
2.6	O	O
microM	O	O
)	O	O
,	O	O
was	O	O
comparable	O	O
with	O	O
that	O	O
of	O	O
10	O	O
(	O	O
30-35%	O	O
)	O	O
.	O	O
Their	O	O
potency	O	O
is	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
dexamethasone	O	O
although	O	O
they	O	O
do	O	O
not	O	O
act	O	O
through	O	O
the	O	O
glucocorticoid	O	O
receptor	O	O
.	O	O
The	O	O
eight	O	O
analogues	O	O
of	O	O
DPDPE	O	O
showed	O	O
highly	O	O
variable	O	O
binding	O	O
and	O	O
bioassay	O	O
activities	O	O
particularly	O	O
at	O	O
the	O	O
delta	O	O
opioid	O	O
receptor	O	O
(	O	O
4	O	O
orders	O	O
of	O	O
magnitude	O	O
)	O	O
,	O	O
but	O	O
also	O	O
at	O	O
the	O	O
mu	O	O
opioid	O	O
receptor	O	O
,	O	O
which	O	O
led	O	O
to	O	O
large	O	O
differences	O	O
(	O	O
3	O	O
orders	O	O
of	O	O
magnitude	O	O
)	O	O
in	O	O
receptor	O	O
selectivity	O	O
.	O	O
However	O	O
,	O	O
the	O	O
rigid	O	O
A	O	O
-	O	O
tract	O	O
ODN	O	O
caused	O	O
loss	O	O
of	O	O
RNase	O	O
H	O	O
recruitment	O	O
.	O	O
Deblocking	O	O
of	O	O
6a	O	O
-	O	O
c	O	O
gave	O	O
the	O	O
corresponding	O	O
amino	B-IUPAC	O
acids	I-IUPAC	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromoacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
hydrobromide	I-IUPAC	I-IUPAC
(	O	O
7a	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloroacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
7b	O	O
)	O	O
,	O	O
and	O	O
ethyl	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxyethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
fumarate	I-IUPAC	I-IUPAC
(	O	O
7c	O	O
)	O	O
.	O	O
The	O	O
most	O	O
active	O	O
compound	O	O
(	O	O
ED50	O	O
=	O	O
8.3	O	O
x	O	O
10	O	O
(	O	O
-	O	O
9	O	O
)	O	O
M	O	O
)	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyrazinylcarboxamidobenzoates	I-IUPAC	I-IUPAC
is	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5,6,7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,5,8	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetramethylquinoxalyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carboxamido	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
9u	O	O
)	O	O
,	O	O
while	O	O
the	O	O
most	O	O
active	O	O
analogue	O	O
of	O	O
the	O	O
beta	O	O
-	O	O
ionylideneacetamidobenzoates	O	O
is	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentadienamido	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
10a	O	O
,	O	O
ED50	O	O
=	O	O
3.2	O	O
x	O	O
10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
M	O	O
)	O	O
.	O	O
The	O	O
sulfones	O	O
could	O	O
be	O	O
synthesized	O	O
by	O	O
a	O	O
novel	O	O
,	O	O
selective	O	O
C	O	O
-	O	O
5	O	O
sulfonylation	O	O
of	O	O
dilithio	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolidinedione	I-IUPAC	I-IUPAC
with	O	O
appropriate	O	O
sulfonyl	O	O
chlorides	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
X	O	O
-	O	O
ray	O	O
crystallographic	O	O
analyses	O	O
,	O	O
the	O	O
configuration	O	O
of	O	O
oxime	O	O
22a	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
E	O	O
and	O	O
the	O	O
absolute	O	O
configurations	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
8	O	O
x	O	O
HCl	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
9	O	O
x	O	O
HBr	O	O
were	O	O
established	O	O
to	O	O
be	O	O
R	O	O
.	O	O
By	O	O
contrast	O	O
,	O	O
inhibitors	O	O
based	O	O
on	O	O
the	O	O
benzochromen	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
coumarin	O	O
)	O	O
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzochromen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	I-IUPAC
flavone	O	I-IUPAC
)	O	I-IUPAC
scaffolds	B-MODIFIER	B-MODIFIER
were	O	O
less	O	O
potent	O	O
.	O	O
Compounds	O	O
3	O	O
and	O	O
4	O	O
were	O	O
obtained	O	O
from	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
7	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
12	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
a	O	O
concise	O	O
three	O	O
-	O	O
step	O	O
sequence	O	O
.	O	O
These	O	O
results	O	O
were	O	O
particularly	O	O
unexpected	O	O
in	O	O
view	O	O
of	O	O
the	O	O
critical	O	O
role	O	O
(	O	O
s	O	O
)	O	O
originally	O	O
ascribed	O	O
to	O	O
the	O	O
side	O	O
chains	O	O
of	O	O
residues	O	O
1	O	O
and	O	O
3	O	O
.	O	O
Compound	O	O
6a	O	O
produced	O	O
cures	O	O
at	O	O
an	O	O
oral	O	O
dosage	O	O
of	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
The	O	O
effect	O	O
of	O	O
N	O	B-MODIFIER
-	O	I-MODIFIER
and	O	O
5	O	O
-	O	O
substitution	O	O
on	O	O
affinity	O	O
for	O	O
the	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
was	O	O
evaluated	O	O
in	O	O
competition	O	O
experiments	O	O
using	O	O
rat	O	O
hippocampal	O	O
membranes	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
8	O	O
-	O	O
OH	O	O
-	O	O
DPAT	O	O
as	O	O
radioligand	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
there	O	O
were	O	O
certain	O	O
relationships	O	O
among	O	O
the	O	O
in	O	O
vitro	O	O
tracheal	O	O
relaxant	O	O
activities	O	O
of	O	O
these	O	O
compounds	O	O
,	O	O
their	O	O
affinities	O	O
for	O	O
adenosine	O	O
(	O	O
A1	O	O
)	O	O
receptors	O	O
in	O	O
the	O	O
brain	O	O
membrane	O	O
,	O	O
and	O	O
their	O	O
inhibition	O	O
of	O	O
cyclic	O	O
AMP	O	O
-	O	O
phosphodiesterase	O	O
(	O	O
PDE	O	O
)	O	O
in	O	O
the	O	O
tracheal	O	O
muscle	O	O
.	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
allyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
was	O	O
regioselectively	O	O
p	O	O
-	O	O
methoxybenzylated	O	O
at	O	O
the	O	O
3	O	O
-	O	O
position	O	O
to	O	O
give	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
allyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
benzylation	O	O
of	O	O
the	O	O
remaining	O	O
free	O	O
hydroxyl	B-IUPAC	O
groups	B-MODIFIER	O
to	O	O
give	O	O
the	O	O
key	O	O
intermediate	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
allyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
.	O	O
A	O	O
similar	O	O
reaction	O	O
with	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropropionyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
folic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
gave	O	O
10	O	O
-	O	O
(	O	O
ClCH2CH2CO	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
14	O	O
)	O	O
rather	O	O
than	O	O
5,10	O	O
-	O	O
(	O	O
CH2CH2CO	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
13	O	O
)	O	O
.	O	O
In	O	O
the	O	O
thalamus	O	O
,	O	O
a	O	O
nAChR	O	O
-	O	O
rich	O	O
area	O	O
,	O	O
uptake	O	O
of	O	O
radioactivity	O	O
reached	O	O
a	O	O
maximum	O	O
at	O	O
60	O	O
min	O	O
(	O	O
4%	O	O
I	O	O
.	O	O
The	O	O
inhibitions	O	O
of	O	O
cytochrome	O	O
P	O	O
-	O	O
450	O	O
dependent	O	O
monooxygenase	O	O
activity	O	O
in	O	O
microsomes	O	O
from	O	O
rat	O	O
liver	O	O
by	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpyrrole	I-IUPAC	I-IUPAC
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrrole	I-IUPAC	I-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylimidazole	I-IUPAC	I-IUPAC
,	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazole	I-IUPAC	I-IUPAC
have	O	O
been	O	O
compared	O	O
.	O	O
Substituents	O	O
on	O	O
position	O	O
4	O	O
included	O	O
CH3	O	O
,	O	O
CO2H	O	O
,	O	O
CH2CO2H	O	O
,	O	O
CH	O	O
=	O	O
CHCO2H	O	O
,	O	O
and	O	O
CH2CH2CO2H	O	O
.	O	O
In	O	O
each	O	O
assay	O	O
(	O	O
all	O	O
-	O	O
E	O	O
)	O	O
-	O	O
1	O	O
was	O	O
the	O	O
most	O	O
active	O	O
isomer	O	O
,	O	O
and	O	O
this	O	O
activity	O	O
was	O	O
comparable	O	O
to	O	O
or	O	O
better	O	O
than	O	O
that	O	O
for	O	O
(	B-IUPAC	B-IUPAC
all	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
retinoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
provide	O	O
an	O	O
explanation	O	O
at	O	O
the	O	O
molecular	O	O
level	O	O
for	O	O
observed	O	O
activity	O	O
differences	O	O
between	O	O
cannabinoids	O	O
that	O	O
exhibit	O	O
shape	O	O
differences	O	O
associated	O	O
with	O	O
their	O	O
carbocyclic	O	O
rings	O	O
.	O	O
The	O	O
structure	O	O
of	O	O
compound	O	O
69	O	O
is	O	O
of	O	O
interest	O	O
because	O	O
it	O	O
provides	O	O
only	O	O
a	O	O
single	O	O
aromatic	O	O
unit	O	O
linked	O	O
through	O	O
a	O	O
chain	O	O
to	O	O
a	O	O
basic	O	O
nitrogen	O	O
,	O	O
while	O	O
most	O	O
H1	O	O
-	O	O
antihistaminic	O	O
agents	O	O
have	O	O
structures	O	O
that	O	O
comprise	O	O
a	O	O
double	O	O
-	O	O
aromatic	O	O
unit	O	O
linked	O	O
through	O	O
a	O	O
chain	O	O
to	O	O
a	O	O
basic	O	O
tertiary	O	O
amino	O	O
group	O	O
.	O	O
A	O	O
compound	O	O
was	O	O
prepared	O	O
in	O	O
which	O	O
both	O	O
the	O	O
Cys	O	O
-	O	O
Val	O	O
methyleneamine	O	O
isostere	O	O
and	O	O
the	O	O
Tic	O	O
replacement	O	O
were	O	O
incorporated	O	O
.	O	O
The	O	O
biphasic	O	O
dose	O	O
-	O	O
response	O	O
relationship	O	O
characteristically	O	O
shown	O	O
by	O	O
the	O	O
benzothiazole	O	O
series	O	O
against	O	O
sensitive	O	O
cell	O	O
lines	O	O
was	O	O
exhibited	O	O
by	O	O
the	O	O
4	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzothiazoles	I-IUPAC	I-IUPAC
(	O	O
10b	O	O
,	O	O
d	O	O
)	O	O
but	O	O
not	O	O
by	O	O
the	O	O
5	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzothiazoles	I-IUPAC	I-IUPAC
(	O	O
10h	O	O
,	O	O
i	O	O
)	O	O
.	O	O
When	O	O
the	O	O
MTX	O	O
-	O	O
equivalent	O	O
dose	O	O
of	O	O
MTX	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropiperonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
was	O	O
increased	O	O
to	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
a	O	O
+	O	O
167%	O	O
ILS	O	O
was	O	O
observed	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
a	O	O
+	O	O
100%	O	O
ILS	O	O
with	O	O
60	O	O
mg	O	O
/	O	O
kg	O	O
of	O	O
the	O	O
parent	O	O
drug	O	O
.	O	O
Spiro	O	B-IUPAC
[	O	I-IUPAC
isobenzofuran	O	I-IUPAC
-	O	I-IUPAC
1	O	I-IUPAC
(	O	I-IUPAC
3H	O	I-IUPAC
)	O	I-IUPAC
,	O	I-IUPAC
4'	O	I-IUPAC
-	O	I-IUPAC
piperidines	O	I-IUPAC
]	O	I-IUPAC
and	O	O
the	O	O
corresponding	O	O
benzofuran	O	O
and	O	O
benzopyran	O	O
derivatives	O	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
as	O	O
sigma	O	O
ligands	O	O
.	O	O
The	O	O
stereoselectivity	O	O
of	O	O
the	O	O
Grignard	O	O
reagent	O	O
's	O	O
attachment	O	O
to	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxyfuranose	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ulosides	I-IUPAC	I-IUPAC
has	O	O
been	O	O
ruled	O	O
by	O	O
the	O	O
substitute	O	O
configuration	O	O
at	O	O
Cl	O	O
.	O	O
This	O	O
compound	O	O
binds	O	O
to	O	O
the	O	O
ETA	O	O
receptor	O	O
with	O	O
an	O	O
affinity	O	O
(	O	O
Ki	O	O
)	O	O
of	O	O
0	O	O
.	O	O
Compounds	O	O
were	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
on	O	O
selectivity	O	O
of	O	O
the	O	O
acidity	O	O
of	O	O
the	O	O
NH	O	O
group	O	O
[	O	O
the	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
(	O	O
compound	O	O
5	O	O
)	O	O
and	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	O	O
compound	O	O
4	O	O
)	O	O
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
1	O	O
]	O	O
,	O	O
the	O	O
relative	O	O
spatial	O	O
position	O	O
of	O	O
the	O	O
acidic	O	O
hydrogen	B-IUPAC	O
[	I-IUPAC	O
7	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylsulfonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinoline	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
and	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylsulfonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinoline	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
]	O	O
,	O	O
or	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
substitution	O	O
of	O	O
an	O	O
acidic	O	O
phenolic	O	O
group	O	O
for	O	O
the	O	O
aminosulfonyl	B-IUPAC	B-IUPAC
moiety	B-MODIFIER	B-MODIFIER
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxynaphthalene	I-IUPAC	I-IUPAC
(	O	O
23	O	O
)	O	O
and	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrobenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
h	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoquinoline	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
]	O	O
.	O	O
Piperidine	O	O
and	O	O
cyclohexyl	O	O
ring	O	O
homologues	O	O
of	O	O
the	O	O
high	O	O
-	O	O
affinity	O	O
dopamine	O	O
(	O	O
DA	O	O
)	O	O
uptake	O	O
inhibitor	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
(	O	O
BTCP	O	O
,	O	O
3	O	O
)	O	O
were	O	O
each	O	O
prepared	O	O
in	O	O
four	O	O
steps	O	O
from	O	O
the	O	O
appropriate	O	O
cycloalkanones	O	O
.	O	O
Binding	O	O
studies	O	O
with	O	O
rat	O	O
hippocampal	O	O
membrane	O	O
homogenates	O	O
showed	O	O
that	O	O
8	O	O
exhibited	O	O
a	O	O
Ki	O	O
value	O	O
of	O	O
0.92	O	O
nM	O	O
against	O	O
(	O	O
R	O	O
,	O	O
S	O	O
)	O	O
-	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
8	O	O
-	O	O
OH	O	O
-	O	O
DPAT	O	O
.	O	O
Cyclization	O	O
of	O	O
VI	O	O
and	O	O
VII	O	O
with	O	O
guanidine	O	O
then	O	O
produced	O	O
the	O	O
desired	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pteridinediamine	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxides	I-IUPAC	I-IUPAC
VIII	O	O
and	O	O
teridinediamines	O	O
IX	O	O
,	O	O
respectively	O	O
.	O	O
Eleven	O	O
new	O	O
12	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7,10,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methanocycloocta	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinoline	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
[	O	O
tacrine	O	O
(	O	O
THA	O	O
)	O	O
-	O	O
huperzine	O	O
A	O	O
hybrids	O	O
,	O	O
rac	O	O
-	O	O
21-31	O	O
]	O	O
have	O	O
been	O	O
synthesized	O	O
as	O	O
racemic	O	O
mixtures	O	O
and	O	O
tested	O	O
as	O	O
acetylcholinesterase	O	O
(	O	O
AChE	O	O
)	O	O
inhibitors	O	O
.	O	O
Several	O	O
4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
N	I-MODIFIER	I-MODIFIER
-	I-MODIFIER	I-MODIFIER
unsubstituted	I-MODIFIER	I-MODIFIER
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyridothiadiazines	I-IUPAC	I-IUPAC
and	O	O
some	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorobenzothiadiazines	I-IUPAC	I-IUPAC
were	O	O
found	O	O
to	O	O
be	O	O
more	O	O
potent	O	O
than	O	O
diazoxide	O	O
for	O	O
the	O	O
inhibition	O	O
of	O	O
the	O	O
insulin	O	O
-	O	O
releasing	O	O
process	O	O
.	O	O
Among	O	O
the	O	O
phenyl	O	B-IUPAC
ring	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
analogs	O	B-IUPAC
,	O	O
those	O	O
containing	O	O
the	O	O
smaller	O	O
and	O	O
electron	O	O
-	O	O
withdrawing	O	O
halogens	O	O
were	O	O
favored	O	O
over	O	O
those	O	O
with	O	O
larger	O	O
,	O	O
electron	O	O
-	O	O
releasing	O	O
methyl	O	O
groups	O	O
,	O	O
although	O	O
delta	O	O
opioid	O	O
binding	O	O
affinity	O	O
was	O	O
reduced	O	O
in	O	O
all	O	O
cases	O	O
.	O	O
Strikingly	O	O
,	O	O
the	O	O
most	O	O
potent	O	O
compounds	O	O
for	O	O
inhibition	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
WIN	O	O
-	O	O
35,428	O	O
binding	O	O
were	O	O
not	O	O
the	O	O
(	O	O
1R	O	O
)	O	O
-	O	O
2	O	O
beta	O	O
,	O	O
3	O	O
beta	O	O
-	O	O
isomers	O	O
but	O	O
rather	O	O
(	O	O
1R	O	O
)	O	O
-	O	O
2	O	O
beta	O	O
,	O	O
3	O	O
alpha	O	O
-	O	O
4c	O	O
and	O	O
(	O	O
1S	O	O
)	O	O
-	O	O
2	O	O
beta	O	O
,	O	O
3	O	O
alpha	O	O
-	O	O
4f	O	O
.	O	O
In	O	O
all	O	O
cases	O	O
,	O	O
2-2.5	O	O
equiv	O	O
of	O	O
Thf	O	O
-	O	O
OAc	O	O
with	O	O
respect	O	O
to	O	O
Me3Si	O	O
-	O	O
FU	O	O
gave	O	O
the	O	O
best	O	O
results	O	O
.	O	O
Treatment	O	O
of	O	O
5	O	O
and	O	O
7	O	O
with	O	O
methanolic	O	O
ammonia	O	O
gave	O	O
the	O	O
deprotected	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
nucleosides	B-MODIFIER	B-MODIFIER
9	O	O
.	O	O
Lu	O	O
28-179	O	O
)	O	O
,	O	O
with	O	O
the	O	O
binding	O	O
affinities	O	O
:	O	O
IC50	O	O
(	O	O
sigma	O	O
1	O	O
)	O	O
=	O	O
17	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
sigma	O	O
2	O	O
)	O	O
=	O	O
0.12	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
5	O	O
-	O	O
HT1A	O	O
)	O	O
=	O	O
21,000	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
5	O	O
-	O	O
HT2A	O	O
)	O	O
=	O	O
2000	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
D2	O	O
)	O	O
=	O	O
800	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
alpha	O	O
1	O	O
)	O	O
=	O	O
330	O	O
nM	O	O
.	O	O
Thus	O	O
replacement	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazolidinon	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
side	B-MODIFIER	B-MODIFIER
chain	I-MODIFIER	I-MODIFIER
with	O	O
a	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ureido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
or	O	O
methyl	B-IUPAC	B-IUPAC
substituent	B-MODIFIER	B-MODIFIER
resulted	O	O
in	O	O
unchanged	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
5	O	O
-	O	O
HT2	O	O
receptors	O	O
.	O	O
The	O	O
enantiomers	O	O
of	O	O
8	O	O
were	O	O
obtained	O	O
in	O	O
high	O	O
enantiomeric	O	O
purities	O	O
(	O	O
ee	O	O
&	O	O
gt	O	O
;	O	O
/	O	O
=	O	O
99.1%	O	O
)	O	O
via	O	O
the	O	O
diastereomeric	O	O
amides	O	O
32	O	O
and	O	O
33	O	O
,	O	O
synthesized	O	O
from	O	O
the	O	O
primary	O	O
amine	O	O
23b	O	O
and	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenylacetyl	I-IUPAC	I-IUPAC
chloride	I-IUPAC	I-IUPAC
and	O	O
subsequent	O	O
separation	O	O
by	O	O
preparative	O	O
HPLC	O	O
.	O	O
The	O	O
inhibition	O	O
of	O	O
ASase	O	O
by	O	O
7a	O	O
-	O	O
c	O	O
at	O	O
1	O	O
mM	O	O
was	O	O
93	O	O
,	O	O
19	O	O
,	O	O
and	O	O
37%	O	O
,	O	O
respectively	O	O
,	O	O
while	O	O
7d	O	O
was	O	O
without	O	O
inhibition	O	O
at	O	O
2	O	O
mM	O	O
.	O	O
To	O	O
provide	O	O
potential	O	O
new	O	O
leads	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
orthopoxvirus	O	O
infections	O	O
,	O	O
the	O	O
5	O	O
-	O	O
position	O	O
of	O	O
the	O	O
pyrimidine	O	O
nucleosides	O	O
have	O	O
been	O	O
modified	O	O
with	O	O
a	O	O
gem	O	O
diether	O	O
moiety	O	O
to	O	O
yield	O	O
the	O	O
following	O	O
new	O	O
nucleosides	O	O
:	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
2b	O	O
)	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diethoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
3b	O	O
)	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
formyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
ethylene	I-IUPAC	I-IUPAC
acetal	I-IUPAC	I-IUPAC
(	O	O
4b	O	O
)	O	O
,	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
formyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
propylene	I-IUPAC	I-IUPAC
acetal	I-IUPAC	I-IUPAC
(	O	O
5b	O	O
)	O	O
.	O	O
i	O	O
.	O	O
The	O	O
effects	O	O
of	O	O
some	O	O
compounds	O	O
on	O	O
hexobarbital	O	O
sleeping	O	O
times	O	O
and	O	O
zoxazolamine	O	O
paralysis	O	O
times	O	O
in	O	O
mice	O	O
were	O	O
also	O	O
examined	O	O
.	O	O
The	O	O
radioiodinated	O	O
agents	O	O
are	O	O
of	O	O
interest	O	O
because	O	O
of	O	O
the	O	O
high	O	O
expected	O	O
uptake	O	O
and	O	O
prolonged	O	O
brain	O	O
retention	O	O
that	O	O
may	O	O
result	O	O
from	O	O
binding	O	O
to	O	O
high	O	O
-	O	O
capacity	O	O
,	O	O
relatively	O	O
nonspecific	O	O
amine	O	O
binding	O	O
sites	O	O
.	O	O
Compounds	O	O
9a	O	O
-	O	O
f	O	O
were	O	O
devoid	O	O
of	O	O
activity	O	O
against	O	O
intraperitoneally	O	O
implanted	O	O
L1210	O	O
leukemia	O	O
in	O	O
mice	O	O
.	O	O
A	O	O
selective	O	O
reduction	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
allylpyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbon	I-IUPAC	I-IUPAC
ril	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
(	O	O
3k	O	O
)	O	O
in	O	O
zinc	O	O
and	O	O
acetic	O	O
acid	O	O
furnished	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
allylpyrrolo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonitrile	I-IUPAC	I-IUPAC
(	O	O
4k	O	O
)	O	O
.	O	O
[	O	O
(	O	O
18	O	O
)	O	O
F	O	O
]	O	O
(	O	O
R	O	O
)	O	O
-	O	O
FIPCT	O	O
uptake	O	O
in	O	O
the	O	O
caudate	O	O
/	O	O
putamen	O	O
achieved	O	O
transient	O	O
equilibrium	O	O
at	O	O
75	O	O
min	O	O
.	O	O
The	O	O
activity	O	O
of	O	O
some	O	O
THA	O	O
-	O	O
huperzine	O	O
A	O	O
hybrids	O	O
(	O	O
rac	O	O
-	O	O
19	O	O
,	O	O
rac	O	O
-	O	O
20	O	O
,	O	O
rac	O	O
-	O	O
28	O	O
,	O	O
and	O	O
rac	O	O
-	O	O
30	O	O
)	O	O
,	O	O
which	O	O
were	O	O
separated	O	O
into	O	O
their	O	O
enantiomers	O	O
by	O	O
chiral	O	O
medium	O	O
-	O	O
pressure	O	O
liquid	O	O
chromatography	O	O
(	O	O
chiral	O	O
MPLC	O	O
)	O	O
,	O	O
using	O	O
microcrystalline	O	O
cellulose	O	O
triacetate	O	O
as	O	O
the	O	O
chiral	O	O
stationary	O	O
phase	O	O
,	O	O
showed	O	O
the	O	O
eutomer	O	O
to	O	O
be	O	O
always	O	O
the	O	O
levorotatory	O	O
enantiomer	O	O
,	O	O
their	O	O
activity	O	O
being	O	O
roughly	O	O
double	O	O
that	O	O
of	O	O
the	O	O
corresponding	O	O
racemic	O	O
mixture	O	O
,	O	O
the	O	O
distomer	O	O
being	O	O
much	O	O
less	O	O
active	O	O
.	O	O
Against	O	O
HL60	O	O
cells	O	O
,	O	O
4	O	O
was	O	O
about	O	O
7	O	O
-	O	O
fold	O	O
more	O	O
cytotoxic	O	O
than	O	O
PDDF	O	O
(	O	O
IC50	O	O
values	O	O
0.72	O	O
and	O	O
5.29	O	O
microM	O	O
)	O	O
.	O	O
Overall	O	O
,	O	O
the	O	O
combination	O	O
of	O	O
modified	O	O
rings	O	O
A	O	O
and	O	O
C	O	O
increases	O	O
the	O	O
potency	O	O
by	O	O
about	O	O
10	O	O
000	O	O
times	O	O
compared	O	O
with	O	O
the	O	O
lead	O	O
compound	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxooleana	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
28	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1	O	O
microM	O	O
level	O	O
)	O	O
.	O	O
All	O	O
compounds	O	O
were	O	O
markedly	O	O
active	O	O
against	O	O
P388	O	O
at	O	O
doses	O	O
4-16	O	O
-	O	O
fold	O	O
lower	O	O
than	O	O
acronycine	O	O
itself	O	O
.	O	O
The	O	O
wide	O	O
differences	O	O
in	O	O
the	O	O
relative	O	O
abilities	O	O
of	O	O
these	O	O
compounds	O	O
to	O	O
displace	O	O
[	O	O
3H	O	O
]	O	O
BTCP	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
cocaine	O	O
suggests	O	O
that	O	O
these	O	O
two	O	O
radioligands	O	O
are	O	O
labeling	O	O
different	O	O
sites	O	O
on	O	O
the	O	O
transporter	O	O
.	O	O
Corresponding	O	O
data	O	O
were	O	O
included	O	O
for	O	O
analogous	O	O
,	O	O
resolved	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
and	O	O
a	O	O
few	O	O
other	O	O
substituted	O	O
,	O	O
racemic	B-MODIFIER	B-MODIFIER
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperidines	I-IUPAC	I-IUPAC
.	O	O
In	O	O
the	O	O
second	O	O
stage	O	O
of	O	O
hydrolysis	O	O
,	O	O
the	O	O
remaining	O	O
P	O	O
-	O	O
N	O	O
bond	O	O
is	O	O
cleaved	O	O
together	O	O
with	O	O
an	O	O
intramolecular	O	O
attack	O	O
at	O	O
the	O	O
phosphorus	O	O
atom	O	O
by	O	O
the	O	O
non	O	O
-	O	O
P	O	O
-	O	O
linked	O	O
nitrogen	O	O
of	O	O
the	O	O
compounds	O	O
2a	O	O
-	O	O
d	O	O
.	O	O
At	O	O
C	O	O
-	O	O
7	O	O
the	O	O
introduction	O	O
of	O	O
some	O	O
novel	O	O
piperazines	O	O
was	O	O
made	O	O
.	O	O
In	O	O
particular	O	O
,	O	O
we	O	O
have	O	O
obtained	O	O
the	O	O
RAR	O	O
gamma	O	O
selective	O	O
derivatives	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
adamantyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
[	O	O
Ki	O	O
(	O	O
RAR	O	O
alpha	O	O
)	O	O
=	O	O
6500	O	O
nM	O	O
,	O	O
Ki	O	O
(	O	O
RAR	O	O
beta	O	O
)	O	O
=	O	O
2480	O	O
nM	O	O
,	O	O
Ki	O	O
(	O	O
RAR	O	O
gamma	O	O
)	O	O
=	O	O
77	O	O
nM	O	O
]	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
adamantyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
19	O	O
)	O	O
[	O	O
Ki	O	O
(	O	O
RAR	O	O
alpha	O	O
)	O	O
=	O	O
1,144	O	O
nM	O	O
,	O	O
Ki	O	O
(	O	O
RAR	O	O
beta	O	O
)	O	O
=	O	O
1245	O	O
nM	O	O
,	O	O
Ki	O	O
(	O	O
RAR	O	O
gamma	O	O
)	O	O
=	O	O
53	O	O
nM	O	O
]	O	O
.	O	O
The	O	O
steady	O	O
-	O	O
state	O	O
inhibition	O	O
constants	O	O
,	O	O
Ki	O	O
,	O	O
for	O	O
7d	O	O
and	O	O
7n	O	O
were	O	O
calculated	O	O
to	O	O
be	O	O
60	O	O
and	O	O
52	O	O
nM	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
high	O	O
affinity	O	O
of	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoimidazolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroquinoline	I-IUPAC	I-IUPAC
(	O	O
55	O	O
;	O	O
IC50	O	O
=	O	O
6	O	O
nM	O	O
)	O	O
suggests	O	O
that	O	O
the	O	O
Z	O	O
,	O	O
Z	O	O
conformer	O	O
of	O	O
the	O	O
phenyl	O	O
urea	O	O
moiety	O	O
in	O	O
35	O	O
is	O	O
recognized	O	O
by	O	O
the	O	O
receptor	O	O
.	O	O
Results	O	O
obtained	O	O
are	O	O
discussed	O	O
in	O	O
terms	O	O
of	O	O
conformational	O	O
,	O	O
steric	O	O
,	O	O
and	O	O
electronic	O	O
requirements	O	O
for	O	O
5	O	O
-	O	O
HT	O	O
-	O	O
receptor	O	O
activation	O	O
.	O	O
A	O	O
series	O	O
of	O	O
1,1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triarylcyclopropanes	I-IUPAC	I-IUPAC
(	O	O
DTACs	O	O
)	O	O
was	O	O
synthesized	O	O
and	O	O
evaluated	O	O
as	O	O
pure	O	O
antiestrogens	O	O
.	O	O
Pharmacological	O	O
profiles	O	O
of	O	O
these	O	O
conformationally	O	O
restricted	O	O
analogues	O	O
were	O	O
shown	O	O
to	O	O
be	O	O
different	O	O
depending	O	O
on	O	O
the	O	O
cyclopropane	O	O
backbones	O	O
.	O	O
Affinity	O	O
was	O	O
determined	O	O
at	O	O
cloned	O	O
human	O	O
A3	O	O
receptors	O	O
using	O	O
[	O	O
125I	O	O
]	O	O
AB	O	O
-	O	O
MECA	O	O
(	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
)	O	O
.	O	O
Thiation	O	O
of	O	O
5b	O	O
,	O	O
followed	O	O
by	O	O
deblocking	O	O
,	O	O
gave	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyanothiopurinol	I-IUPAC	I-IUPAC
ribonucleoside	B-MODIFIER	I-IUPAC
(	O	O
20	O	O
)	O	O
.	O	O
In	O	O
the	O	O
first	O	O
instance	O	O
,	O	O
further	O	O
work	O	O
led	O	O
from	O	O
the	O	O
F2Pmp	O	O
-	O	O
containing	O	O
peptide	O	O
to	O	O
monomeric	O	O
inhibitor	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonodifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
22	O	O
microM	O	O
)	O	O
,	O	O
and	O	O
to	O	O
the	O	O
pseudo	O	O
-	O	O
dipeptide	O	O
mimetic	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonodifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
12	O	O
microM	O	O
)	O	O
.	O	O
A	O	O
series	O	O
of	O	O
O'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
epoxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tyrosines	I-IUPAC	I-IUPAC
and	O	O
a	O	O
carboxy	O	O
terminal	O	O
(	B-IUPAC	B-IUPAC
epoxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tyrosine	I-IUPAC	I-IUPAC
and	O	O
-	B-PARTIUPAC	O
phenylalanine	I-PARTIUPAC	O
were	O	O
synthesized	O	O
as	O	O
potential	O	O
serine	O	O
protease	O	O
inhibitors	O	O
.	O	O
One	O	O
compound	O	O
(	O	O
5l	O	O
)	O	O
was	O	O
tested	O	O
for	O	O
antiproliferative	O	O
activity	O	O
against	O	O
P	O	O
.	O	O
Four	O	O
isomers	O	O
of	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
trimethylammonium	I-IUPAC	I-IUPAC
iodide	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
muscarines	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
in	O	O
enantiomerically	O	O
and	O	O
diastereomerically	O	O
pure	O	O
form	O	O
from	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
sulfoxide	I-IUPAC	I-IUPAC
,	O	O
ethyl	O	B-IUPAC
fluoroacetate	O	I-IUPAC
,	O	O
and	O	O
allyl	O	O
bromide	O	O
.	O	O
The	O	O
three	O	O
synthesized	O	O
proAELs	O	O
were	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexadecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
palmitoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sn	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glycero	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphocholine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
-	O	O
O	O	O
-	O	O
DPPC	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexadecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
palmitoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sn	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glycero	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphoethanolamine	I-IUPAC	I-IUPAC
poly	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethylene	I-IUPAC	I-IUPAC
glycol	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	O	O
350	O	O
)	O	O
(	O	O
1	O	O
-	O	O
O	O	O
-	O	O
DPPE	O	O
-	O	O
PEG	O	O
(	O	O
350	O	O
)	O	O
)	O	O
,	O	O
and	O	O
1	O	O
-	O	O
O	O	O
-	O	O
DPPE	O	O
-	O	O
PEG	O	O
(	O	O
2000	O	O
)	O	O
of	O	O
which	O	O
1	O	O
-	O	O
O	O	O
-	O	O
DPPC	O	O
was	O	O
the	O	O
main	O	O
liposome	O	O
component	O	O
.	O	O
Their	O	O
effects	O	O
were	O	O
compared	O	O
to	O	O
those	O	O
induced	O	O
by	O	O
milrinone	O	O
in	O	O
both	O	O
atria	O	O
preparations	O	O
.	O	O
These	O	O
data	O	O
were	O	O
compared	O	O
with	O	O
the	O	O
earlier	O	O
reported	O	O
effects	O	O
of	O	O
the	O	O
compounds	O	O
on	O	O
single	O	O
neurons	O	O
in	O	O
the	O	O
feline	O	O
spinal	O	O
cord	O	O
obtained	O	O
by	O	O
microelectrophoretic	O	O
techniques	O	O
.	O	O
The	O	O
binding	O	O
data	O	O
suggests	O	O
that	O	O
this	O	O
conformation	O	O
in	O	O
1	O	O
favors	O	O
strong	O	O
binding	O	O
interaction	O	O
at	O	O
sigma	O	O
-	O	O
receptors	O	O
.	O	O
The	O	O
relative	O	O
influx	O	O
of	O	O
12a	O	O
was	O	O
enhanced	O	O
about	O	O
3.2	O	O
-	O	O
fold	O	O
over	O	O
MTX	O	O
,	O	O
but	O	O
as	O	O
an	O	O
inhibitor	O	O
of	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
from	O	O
L1210	O	O
cells	O	O
and	O	O
in	O	O
the	O	O
inhibition	O	O
of	O	O
L1210	O	O
cell	O	O
growth	O	O
in	O	O
vitro	O	O
,	O	O
this	O	O
compound	O	O
was	O	O
approximately	O	O
20	O	O
-	O	O
fold	O	O
less	O	O
effective	O	O
than	O	O
MTX	O	O
(	O	O
DHFR	O	O
inhibition	O	O
,	O	O
Ki	O	O
=	O	O
4.82	O	O
+	O	O
/	O	O
-	O	O
0.60	O	O
pM	O	O
for	O	O
MTX	O	O
,	O	O
100	O	O
pM	O	O
for	O	O
12a	O	O
;	O	O
cell	O	O
growth	O	O
,	O	O
IC50	O	O
=	O	O
3.4	O	O
+	O	O
/	O	O
-	O	O
1.0	O	O
nM	O	O
for	O	O
MTX	O	O
,	O	O
65	O	O
+	O	O
/	O	O
-	O	O
18	O	O
nM	O	O
for	O	O
12a	O	O
)	O	O
.	O	O
In	O	O
particular	O	O
,	O	O
the	O	O
combination	O	O
of	O	O
a	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentenyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
and	O	O
a	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzodioxol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
provided	O	O
hydrophobic	O	O
compound	O	O
10b	O	O
with	O	O
subnanomolar	O	O
affinity	O	O
for	O	O
human	O	O
ETA	O	O
receptor	O	O
subtype	O	O
and	O	O
with	O	O
an	O	O
ETB	O	O
/	O	O
ETA	O	O
activity	O	O
ratio	O	O
of	O	O
over	O	O
130000	O	O
.	O	O
The	O	O
increased	O	O
rigidity	O	O
of	O	O
these	O	O
spiro	O	O
-	O	O
fused	O	O
compounds	O	O
,	O	O
relative	O	O
to	O	O
the	O	O
corresponding	O	O
simple	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperidine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
vesamicol	O	O
,	O	O
is	O	O
expected	O	O
to	O	O
confer	O	O
greater	O	O
selectivity	O	O
for	O	O
the	O	O
vesamicol	O	O
receptor	O	O
.	O	O
The	O	O
antiviral	O	O
activity	O	O
was	O	O
lower	O	O
if	O	O
the	O	O
oxygen	O	O
at	O	O
the	O	O
position	O	O
6	O	O
was	O	O
replaced	O	O
by	O	O
a	O	O
sulfur	O	O
atom	O	O
,	O	O
as	O	O
in	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonomethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethylsulfanyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
.	O	O
gondii	O	O
DHFR	O	O
inhibition	O	O
as	O	O
well	O	O
as	O	O
inhibition	O	O
of	O	O
the	O	O
growth	O	O
of	O	O
T	O	O
.	O	O
in	O	O
electrophysiological	O	O
experiments	O	O
using	O	O
rat	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
beta	O	O
(	O	O
2	O	O
)	O	O
gamma	O	O
(	O	O
2L	O	O
)	O	O
GABA	O	O
(	O	O
A	O	O
)	O	O
receptors	O	O
expressed	O	O
in	O	O
Xenopus	O	O
laevis	O	O
oocytes	O	O
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
.	O	O
A	O	O
few	O	O
selected	O	O
examples	O	O
from	O	O
each	O	O
type	O	O
of	O	O
the	O	O
active	O	O
new	O	O
compounds	O	O
showed	O	O
strong	O	O
activity	O	O
against	O	O
ouabain	O	O
-	O	O
induced	O	O
arrhythmia	O	O
;	O	O
for	O	O
comparison	O	O
known	O	O
drugs	O	O
such	O	O
as	O	O
lidocaine	O	O
,	O	O
mexiletine	O	O
,	O	O
and	O	O
tocainide	O	O
were	O	O
selected	O	O
.	O	O
This	O	O
report	O	O
describes	O	O
the	O	O
synthesis	O	O
and	O	O
initial	O	O
biochemical	O	O
evaluation	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
estrogens	I-IUPAC	I-IUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminoalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
estradiols	I-IUPAC	I-IUPAC
.	O	O
Comparison	O	O
of	O	O
the	O	O
binding	O	O
data	O	O
of	O	O
7-9	O	O
with	O	O
that	O	O
of	O	O
the	O	O
previously	O	O
described	O	O
methylcyclohexyl	O	O
-	O	O
PCP	O	O
derivatives	O	O
allowed	O	O
its	O	O
rationalization	O	O
in	O	O
terms	O	O
of	O	O
this	O	O
model	O	O
.	O	O
A	O	O
novel	O	O
class	O	O
of	O	O
tricyclic	O	O
tropane	O	O
analogues	O	O
has	O	O
been	O	O
synthesized	O	O
by	O	O
making	O	O
use	O	O
of	O	O
radical	O	O
cyclization	O	O
technology	O	O
in	O	O
combination	O	O
with	O	O
the	O	O
Stille	O	O
coupling	O	O
reaction	O	O
.	O	O
Thus	O	O
,	O	O
a	O	O
variety	O	O
of	O	O
compounds	O	O
with	O	O
different	O	O
pharmacological	O	O
profiles	O	O
have	O	O
been	O	O
developed	O	O
.	O	O
The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
indicate	O	O
that	O	O
the	O	O
ring	O	O
-	O	O
expanded	O	O
analogues	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propananilido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
retain	O	O
a	O	O
relatively	O	O
high	O	O
degree	O	O
of	O	O
analgesic	O	O
potency	O	O
,	O	O
except	O	O
in	O	O
the	O	O
case	O	O
of	O	O
the	O	O
1	B-IUPAC	O
-	I-IUPAC	O
phenylethylated	I-IUPAC	O
analogue	B-MODIFIER	O
which	O	O
is	O	O
approximately	O	O
150	O	O
-	O	O
fold	O	O
less	O	O
potent	O	O
than	O	O
the	O	O
correspondingly	O	O
1	O	O
-	O	O
substituted	O	O
piperidine	O	O
analgesic	O	O
.	O	O
The	O	O
AdoHcy	O	O
derivatives	O	O
as	O	O
well	O	O
as	O	O
the	O	O
nucleoside	O	O
precursors	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
antiviral	O	O
activity	O	O
.	O	O
Dose	O	O
ratios	O	O
(	O	O
ratio	O	O
of	O	O
ED20	O	O
of	O	O
angiotensin	O	O
II	O	O
during	O	O
infusion	O	O
of	O	O
the	O	O
antagonist	O	O
and	O	O
before	O	O
infusion	O	O
of	O	O
the	O	O
antagonist	O	O
)	O	O
in	O	O
vagotomized	O	O
,	O	O
ganglion	O	O
-	O	O
blocked	O	O
rats	O	O
,	O	O
infused	O	O
at	O	O
250	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
,	O	O
were	O	O
33.43	O	O
,	O	O
2.14	O	O
,	O	O
3.26	O	O
,	O	O
2.99	O	O
,	O	O
0.62	O	O
,	O	O
62.52	O	O
,	O	O
incalculable	O	O
,	O	O
and	O	O
11.15	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
benzothiazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
were	O	O
the	O	O
most	O	O
potent	O	O
antagonists	O	O
,	O	O
being	O	O
nearly	O	O
as	O	O
potent	O	O
as	O	O
theophylline	O	O
at	O	O
A1	O	O
-	O	O
adenosine	O	O
receptors	O	O
and	O	O
somewhat	O	O
more	O	O
potent	O	O
than	O	O
theophylline	O	O
at	O	O
A2	O	O
-	O	O
adenosine	O	O
receptors	O	O
.	O	O
The	O	O
homologous	O	O
series	O	O
of	O	O
acidic	O	O
amino	O	O
acids	O	O
,	O	O
ranging	O	O
from	O	O
aspartic	O	O
acid	O	O
(	O	O
1	O	O
)	O	O
to	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminosuberic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
,	O	O
and	O	O
the	O	O
corresponding	O	O
series	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolol	I-IUPAC	I-IUPAC
bioisosteres	B-MODIFIER	B-MODIFIER
of	O	O
these	O	O
amino	O	O
acids	O	O
,	O	O
ranging	O	O
from	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMAA	O	O
,	O	O
6	O	O
)	O	O
to	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
hexanoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
,	O	O
were	O	O
tested	O	O
as	O	O
ligands	O	O
for	O	O
metabotropic	O	O
excitatory	O	O
amino	O	O
acid	O	O
receptors	O	O
(	O	O
mGlu1	O	O
alpha	O	O
,	O	O
mGlu2	O	O
,	O	O
mGlu4a	O	O
,	O	O
and	O	O
mGlu6	O	O
)	O	O
.	O	O
Substitution	O	O
on	O	O
the	O	O
aromatic	O	O
ring	O	O
of	O	O
4b	O	O
with	O	O
halogen	O	O
or	O	O
increasing	O	O
the	O	O
size	O	O
of	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
of	O	O
4b	O	O
gave	O	O
alpha	O	O
2	O	O
-	O	O
adrenergic	O	O
antagonists	O	O
without	O	O
agonist	O	O
activity	O	O
.	O	O
The	O	O
Z	O	O
-	O	O
isomers	O	O
were	O	O
always	O	O
predominant	O	O
in	O	O
these	O	O
mixtures	O	O
(	O	O
Z	O	O
/	O	O
E	O	O
approximately	O	O
2/1	O	O
)	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
radioligand	O	O
-	O	O
binding	O	O
parameters	O	O
in	O	O
rat	O	O
brain	O	O
homogenate	O	O
with	O	O
the	O	O
5	O	O
-	O	O
HT	O	O
uptake	O	O
inhibitor	O	O
[	O	O
3H	O	O
]	O	O
paroxetine	O	O
were	O	O
unchanged	O	O
after	O	O
subacute	O	O
dosing	O	O
with	O	O
either	O	O
racemic	O	O
6	O	O
or	O	O
11	O	O
.	O	O
The	O	O
preferred	O	O
conformation	O	O
of	O	O
the	O	O
trans	B-MODIFIER	B-IUPAC
-	I-MODIFIER	I-IUPAC
2,4	I-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
disubstituted	I-MODIFIER	I-IUPAC
tetrahydroquinoline	B-IUPAC	I-IUPAC
system	O	B-MODIFIER
,	O	O
as	O	O
shown	O	O
by	O	O
X	O	O
-	O	O
ray	O	O
crystallography	O	O
and	O	O
1H	O	O
NMR	O	O
studies	O	O
,	O	O
places	O	O
the	O	O
2	O	B-IUPAC
-	O	I-IUPAC
carboxyl	O	I-IUPAC
pseudoequatorial	O	I-IUPAC
and	O	O
the	O	O
4	O	O
-	O	O
substituent	O	O
pseudoaxial	O	O
.	O	O
We	O	O
report	O	O
here	O	O
an	O	O
enantiospecific	O	O
synthesis	O	O
of	O	O
alpha	B-IUPAC	O
(	I-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
fluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tryptophan	I-IUPAC	I-IUPAC
[	O	I-IUPAC
(	O	I-IUPAC
S	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
11a	O	I-IUPAC
]	O	I-IUPAC
and	O	O
alpha	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
fluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxytryptophan	I-IUPAC	I-IUPAC
[	O	O
(	O	O
S	O	O
)	O	O
-	O	O
11b	O	O
]	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
(	O	O
R	O	O
)	O	O
-	O	O
enantiomers	O	O
,	O	O
based	O	O
upon	O	O
recent	O	O
methodology	O	O
involving	O	O
the	O	O
face	O	O
-	O	O
selective	O	O
alkylation	O	O
of	O	O
cyclic	O	O
tryptophan	O	O
tautomers	O	O
.	O	O
None	O	O
of	O	O
the	O	O
compounds	O	O
showed	O	O
significant	O	O
activity	O	O
at	O	O
metabotropic	O	O
Glu	O	O
receptors	O	O
.	O	O
The	O	O
5	B-PARTIUPAC	O
-	I-PARTIUPAC	O
Cl	I-PARTIUPAC	O
and	O	O
5	B-IUPAC	O
-	I-IUPAC	O
NO	I-IUPAC	O
(	I-IUPAC	O
2	I-IUPAC	O
)	I-IUPAC	O
(	I-IUPAC	O
R	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
1	I-IUPAC	O
-	I-IUPAC	O
indanylamides	I-IUPAC	O
7b	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
80	O	O
nM	O	O
)	O	O
and	O	O
7c	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
28	O	O
nM	O	O
)	O	O
were	O	O
the	O	O
most	O	O
potent	O	O
among	O	O
the	O	O
indoles	O	O
5-8	O	O
geometrically	O	O
constrained	O	O
about	O	O
the	O	O
side	O	O
chain	O	O
.	O	O
The	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxypropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dinitroimidazole	I-IUPAC	I-IUPAC
(	O	O
2d	O	O
)	O	O
was	O	O
found	O	O
to	O	O
be	O	O
the	O	O
most	O	O
effective	O	O
radiosensitizer	O	O
of	O	O
this	O	O
series	O	O
.	O	O
A	O	O
series	O	O
of	O	O
novel	O	O
(	B-IUPAC	O
1,3	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dialkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
arylmethanones	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
.	O	O
These	O	O
results	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
3	O	O
-	O	O
aza	O	O
atom	O	O
in	O	O
the	O	O
pyrido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
8H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
is	O	O
mandatory	O	O
,	O	O
whereas	O	O
the	O	O
1	O	O
-	O	O
aza	O	O
atom	O	O
is	O	O
not	O	O
,	O	O
support	O	O
the	O	O
published	O	O
binding	O	O
model	O	O
for	O	O
these	O	O
compounds	O	O
to	O	O
c	O	O
-	O	O
Src	O	O
(	O	O
J	O	O
.	O	O
The	O	O
structure	O	O
of	O	O
cis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexylamine	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
is	O	O
flexible	O	O
,	O	O
and	O	O
the	O	O
cyclohexane	O	O
ring	O	O
is	O	O
not	O	O
perpendicular	O	O
to	O	O
the	O	O
chelate	O	O
ring	O	O
.	O	O
In	O	O
particular	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylethynyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
Ado	O	O
(	O	O
8b	O	O
)	O	O
showed	O	O
an	O	O
A	O	O
(	O	O
3	O	O
)	O	O
affinity	O	O
in	O	O
the	O	O
low	O	O
nanomolar	O	O
range	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
(	O	O
A	O	O
(	O	O
3	O	O
)	O	O
)	O	O
=	O	O
3.4	O	O
nM	O	O
)	O	O
,	O	O
with	O	O
a	O	O
A	O	O
(	O	O
1	O	O
)	O	O
/	O	O
A	O	O
(	O	O
3	O	O
)	O	O
and	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
/	O	O
A	O	O
(	O	O
3	O	O
)	O	O
selectivity	O	O
of	O	O
about	O	O
500	O	O
and	O	O
2500	O	O
,	O	O
respectively	O	O
.	O	O
Chain	O	O
extension	O	O
of	O	O
14	O	O
followed	O	O
by	O	O
cyclization	O	O
led	O	O
to	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclopenta	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoquinolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
19	O	O
)	O	O
which	O	O
on	O	O
reduction	O	O
and	O	O
subsequent	O	O
dehydration	O	O
yielded	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclopenta	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoquinoline	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
.	O	O
The	O	O
design	O	O
,	O	O
synthesis	O	O
,	O	O
and	O	O
biological	O	O
evaluation	O	O
of	O	O
several	O	O
unsaturated	O	O
acyclonucleosides	O	O
related	O	O
to	O	O
augustmycin	O	O
A	O	O
are	O	O
described	O	O
.	O	O
Negative	O	O
results	O	O
obtained	O	O
with	O	O
other	O	O
17	O	B-IUPAC
alpha	O	I-IUPAC
-	O	I-IUPAC
electrophilic	O	I-IUPAC
estradiol	O	I-IUPAC
derivatives	O	B-MODIFIER
suggested	O	O
that	O	O
affinity	O	O
labeling	O	O
of	O	O
the	O	O
receptor	O	O
by	O	O
such	O	O
derivatives	O	O
required	O	O
a	O	O
minimal	O	O
distance	O	O
,	O	O
including	O	O
at	O	O
least	O	O
four	O	O
C	O	O
-	O	O
C	O	O
or	O	O
C	O	O
-	O	O
N	O	O
bonds	O	O
,	O	O
between	O	O
the	O	O
steroid	O	O
and	O	O
the	O	O
electrophilic	O	O
carbon	O	O
.	O	O
Following	O	O
the	O	O
discovery	O	O
of	O	O
moderately	O	O
potent	O	O
antagonist	O	O
activity	O	O
platelet	O	O
-	O	O
activating	O	O
factor	O	O
(	O	O
PAF	O	O
)	O	O
in	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
(	O	O
IC50	O	O
=	O	O
840	O	O
nM	O	O
)	O	O
,	O	O
19	O	O
derivatives	O	O
(	O	O
3-21	O	O
)	O	O
were	O	O
prepared	O	O
which	O	O
incorporated	O	O
various	O	O
lipophilic	O	O
groups	O	O
attached	O	O
to	O	O
the	O	O
phenyl	O	O
4	O	O
-	O	O
position	O	O
.	O	O
Ep	O	O
.	O	O
The	O	O
affinity	O	O
of	O	O
ZIENT	O	O
and	O	O
EIENT	O	O
for	O	O
DAT	O	O
was	O	O
69	O	O
and	O	O
1.6	O	O
-	O	O
fold	O	O
lower	O	O
,	O	O
respectively	O	O
,	O	O
than	O	O
for	O	O
SERT	O	O
.	O	O
Nearly	O	O
all	O	O
compounds	O	O
substituted	O	O
in	O	O
the	O	O
amino	O	O
group	O	O
either	O	O
decrease	O	O
the	O	O
spontaneous	O	O
motility	O	O
in	O	O
mice	O	O
or	O	O
exert	O	O
no	O	O
effect	O	O
on	O	O
it	O	O
.	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
tetralin	I-IUPAC	I-IUPAC
(	O	O
trans	O	O
-	O	O
8	O	O
-	O	O
OH	O	O
-	O	O
PIPAT	O	O
)	O	O
,	O	O
8	O	O
,	O	O
was	O	O
synthesized	O	O
by	O	O
a	O	O
10	O	O
-	O	O
step	O	O
reaction	O	O
.	O	O
Within	O	O
the	O	O
series	O	O
of	O	O
complexes	O	O
under	O	O
investigation	O	O
,	O	O
potency	O	O
decreases	O	O
depending	O	O
on	O	O
the	O	O
coordinated	O	O
amine	O	O
ligand	O	O
in	O	O
the	O	O
following	O	O
order	O	O
:	O	O
trans	O	O
-	O	O
R	O	O
,	O	O
R	O	O
-	O	O
chxn	O	O
&	O	O
gt	O	O
;	O	O
trans	O	O
-	O	O
S	O	O
,	O	O
S	O	O
-	O	O
chxn	O	O
&	O	O
gt	O	O
;	O	O
NH	O	O
(	O	O
3	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
or	O	O
=	O	O
cis	O	B-IUPAC
-	O	I-IUPAC
R	O	I-IUPAC
,	O	I-IUPAC
S	O	I-IUPAC
-	O	I-IUPAC
chxn	O	I-IUPAC
&	O	O
gt	O	O
;	O	O
en	O	O
.	O	O
We	O	O
have	O	O
developed	O	O
a	O	O
new	O	O
class	O	O
of	O	O
sigma	O	O
subtype	O	O
selective	O	O
receptor	O	O
ligands	O	O
that	O	O
are	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylidene	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
the	O	O
synthetic	O	O
opioid	O	O
(	B-PARTIUPAC	O
+	I-PARTIUPAC	O
/	I-PARTIUPAC	O
-	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
(	B-PARTIUPAC	O
+	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
morphan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
.	O	O
Remaining	O	O
steps	O	O
were	O	O
ester	O	O
hydrolysis	O	O
of	O	O
9a	O	O
,	O	O
b	O	O
to	O	O
give	O	O
carboxylic	O	O
acids	O	O
10a	O	O
,	O	O
b	O	O
followed	O	O
by	O	O
standard	O	O
peptide	O	O
coupling	O	O
with	O	O
diethyl	O	O
L	O	O
-	O	O
glutamate	O	O
to	O	O
produce	O	O
diethyl	O	O
esters	O	O
11a	O	O
,	O	O
b	O	O
,	O	O
which	O	O
on	O	O
hydrolysis	O	O
gave	O	O
12a	O	O
and	O	O
10	O	O
-	O	O
EDAM	O	O
(	O	O
12b	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
Several	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
analogs	B-MODIFIER	B-MODIFIER
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
;	O	O
HEPT	O	O
)	O	O
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
their	O	O
anti	O	O
-	O	O
HIV	O	O
-	O	O
1	O	O
activity	O	O
.	O	O
The	O	O
synthesis	O	O
,	O	O
physical	O	O
properties	O	O
,	O	O
antitumor	O	O
activity	O	O
,	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
,	O	O
and	O	O
nephrotoxicity	O	O
of	O	O
a	O	O
series	O	O
of	O	O
[	O	O
2	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxolane	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
platinum	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
are	O	O
described	O	O
.	O	O
The	O	O
combination	O	O
of	O	O
Tyr	O	O
(	O	O
2	O	O
)	O	O
and	O	O
dTrp	O	O
(	O	O
8	O	O
)	O	O
in	O	O
analogues	O	O
14	O	O
and	O	O
22	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
affinity	O	O
of	O	O
the	O	O
analogues	O	O
for	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.2	O	O
and	O	O
1.1	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
but	O	O
resulted	O	O
in	O	O
loss	O	O
of	O	O
selectivity	O	O
,	O	O
whereas	O	O
the	O	O
combination	O	O
of	O	O
Tyr	O	O
(	O	O
2	O	O
)	O	O
and	O	O
LTrp	O	O
(	O	O
8	O	O
)	O	O
in	O	O
H	O	O
-	O	O
Tyr	O	O
-	O	O
c	O	O
[	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
Aph	O	O
-	O	O
Trp	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
]	O	O
-	O	O
OH	O	O
(	O	O
13	O	O
)	O	O
and	O	O
H	O	O
-	O	O
Tyr	O	O
-	O	O
c	O	O
[	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
Ala	O	O
-	O	O
Trp	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
]	O	O
-	O	O
OH	O	O
(	O	O
19	O	O
)	O	O
retained	O	O
high	O	O
affinity	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.9	O	O
and	O	O
1.98	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
selectivity	O	O
(	O	O
&	O	O
gt	O	O
;	O	O
50	O	O
and	O	O
&	O	O
gt	O	O
;	O	O
250	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
The	O	O
derivatives	O	O
can	O	O
be	O	O
prepared	O	O
by	O	O
reaction	O	O
of	O	O
1	O	O
,	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1	O	O
,	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1	O	O
with	O	O
the	O	O
appropriate	O	O
benzaldehyde	O	O
under	O	O
Claisen	O	O
-	O	O
Schmidt	O	O
conditions	O	O
.	O	O
The	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzylidene	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
9h	O	O
was	O	O
found	O	O
to	O	O
be	O	O
the	O	O
most	O	O
active	O	O
compound	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
K562	O	O
:	O	O
20	O	O
nM	O	O
)	O	O
.	O	O
The	O	O
isolated	O	O
DTPA	O	O
-	O	O
D	O	O
-	O	O
Phe1	O	O
-	O	O
octreotide	O	O
had	O	O
the	O	O
correct	O	O
molecular	O	O
mass	O	O
(	O	O
[	O	O
M+	O	O
H	O	O
]	O	O
+	O	O
=	O	O
1395	O	O
Da	O	O
)	O	O
and	O	O
was	O	O
obtained	O	O
in	O	O
5%	O	O
yield	O	O
at	O	O
&	O	O
gt	O	O
;	O	O
90%	O	O
purity	O	O
.	O	O
Internalization	O	O
of	O	O
the	O	O
compounds	O	O
by	O	O
ABIR	O	O
-	O	O
positive	O	O
tumor	O	O
cells	O	O
(	O	O
A549	O	O
)	O	O
was	O	O
monitored	O	O
by	O	O
NIR	O	O
fluorescence	O	O
microscopy	O	O
.	O	O
Compound	O	O
195	O	O
was	O	O
highly	O	O
potent	O	O
in	O	O
vitro	O	O
(	O	O
IC50	O	O
=	O	O
5.2	O	O
x	O	O
10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
M	O	O
)	O	O
but	O	O
did	O	O
not	O	O
show	O	O
oral	O	O
activity	O	O
when	O	O
tested	O	O
at	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
These	O	O
are	O	O
based	O	O
on	O	O
modifications	O	O
of	O	O
three	O	O
peptides	O	O
:	O	O
A	O	O
,	O	O
B	O	O
,	O	O
and	O	O
C	O	O
.	O	O
A	O	O
still	O	O
unknown	O	O
tricyclic	O	O
heterocyclic	O	O
system	O	O
(	O	O
5	O	O
)	O	O
was	O	O
synthesized	O	O
from	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyridazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
and	O	O
its	O	O
structure	O	O
identified	O	O
as	O	O
2,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
:	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d'	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
dipyridazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
by	O	O
spectroscopic	O	O
investigations	O	O
.	O	O
This	O	O
suggests	O	O
that	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1f	O	O
and	O	O
other	O	O
N	O	O
-	O	O
substituted	O	O
benzomorphan	O	O
analogues	O	O
may	O	O
be	O	O
binding	O	O
to	O	O
single	O	O
sigma	O	O
1	O	O
receptors	O	O
in	O	O
a	O	O
different	O	O
way	O	O
or	O	O
to	O	O
different	O	O
sigma	O	O
1	O	O
receptors	O	O
.	O	O
In	O	O
a	O	O
standardized	O	O
assay	O	O
that	O	O
measures	O	O
Pgp	O	O
function	O	O
by	O	O
the	O	O
Pgp	O	O
-	O	O
mediated	O	O
efflux	O	O
of	O	O
the	O	O
calcein	O	O
-	O	O
AM	O	O
Pgp	O	O
substrate	O	O
and	O	O
uses	O	O
human	O	O
lymphoblastoid	O	O
MDR	O	O
-	O	O
CEM	O	O
(	O	O
VBL	O	O
(	O	O
100	O	O
)	O	O
)	O	O
cells	O	O
as	O	O
highly	O	O
resistant	O	O
Pgp	O	O
-	O	O
expressing	O	O
cells	O	O
and	O	O
the	O	O
cyclic	O	O
undecapeptide	O	O
cyclosporin	O	O
A	O	O
(	O	O
CsA	O	O
)	O	O
as	O	O
a	O	O
reference	O	O
MDR	O	O
-	O	O
reversing	O	O
agent	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
3.4	O	O
microM	O	O
)	O	O
,	O	O
AbA	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
more	O	O
active	O	O
Pgp	O	O
inhibitor	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
2.3	O	O
microM	O	O
)	O	O
.	O	O
Now	O	O
we	O	O
report	O	O
the	O	O
details	O	O
required	O	O
for	O	O
its	O	O
synthesis	O	O
,	O	O
together	O	O
with	O	O
its	O	O
potency	O	O
and	O	O
efficacy	O	O
in	O	O
two	O	O
assays	O	O
of	O	O
functional	O	O
activation	O	O
of	O	O
the	O	O
NMDA	O	O
receptor	O	O
,	O	O
namely	O	O
agonist	O	O
-	O	O
influenced	O	O
[	O	O
3H	O	O
]	O	O
MK801	O	O
binding	O	O
and	O	O
agonist	O	O
-	O	O
induced	O	O
release	O	O
of	O	O
the	O	O
neurotransmitter	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
norepinephrine	O	O
from	O	O
brain	O	O
slices	O	O
.	O	O
The	O	O
novel	O	O
semirigid	O	O
derivatives	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bicyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3.1.0	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
hexyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
[	O	O
(	O	O
+	O	O
)	O	O
-	O	O
8	O	O
]	O	O
,	O	O
its	O	O
enantiomer	O	O
(	B-PARTIUPAC	O
-	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
8	I-PARTIUPAC	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bicyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3.1.0	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
hexyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
[	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
9	O	O
]	O	O
were	O	O
synthesized	O	O
as	O	O
probes	O	O
to	O	O
investigate	O	O
the	O	O
mode	O	O
of	O	O
interaction	O	O
of	O	O
phencyclidine	O	O
(	O	O
PCP	O	O
)	O	O
with	O	O
its	O	O
binding	O	O
site	O	O
on	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aspartate	I-IUPAC	I-IUPAC
receptor	O	O
complex	O	O
.	O	O
An	O	O
(	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methanocarba	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
-	I-IUPAC	O
ADP	I-IUPAC	O
analogue	B-MODIFIER	O
displayed	O	O
an	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
at	O	O
the	O	O
hP2Y	O	O
(	O	O
1	O	O
)	O	O
receptor	O	O
of	O	O
0.40	O	O
nM	O	O
and	O	O
was	O	O
55	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
the	O	O
corresponding	O	O
triphosphate	O	O
and	O	O
16	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
the	O	O
riboside	O	O
5'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diphosphate	I-IUPAC	I-IUPAC
.	O	O
The	O	O
effects	O	O
of	O	O
the	O	O
target	O	O
compounds	O	O
on	O	O
GABA	O	O
uptake	O	O
mechanisms	O	O
in	O	O
vitro	O	O
were	O	O
measured	O	O
using	O	O
a	O	O
rat	O	O
brain	O	O
synaptosomal	O	O
preparation	O	O
and	O	O
primary	O	O
cultures	O	O
of	O	O
mouse	O	O
cortical	O	O
neurons	O	O
and	O	O
glia	O	O
cells	O	O
(	O	O
astrocytes	O	O
)	O	O
.	O	O
In	O	O
in	O	O
vivo	O	O
tests	O	O
against	O	O
L1210	O	O
in	O	O
mice	O	O
,	O	O
4	O	O
failed	O	O
to	O	O
show	O	O
therapeutic	O	O
effect	O	O
.	O	O
The	O	O
lead	O	O
compound	O	O
1a	O	O
was	O	O
inactive	O	O
in	O	O
the	O	O
LE1210	O	O
and	O	O
P388	O	O
systems	O	O
at	O	O
the	O	O
doses	O	O
tested	O	O
.	O	O
The	O	O
5	B-IUPAC	O
-	I-IUPAC	O
bromo	I-IUPAC	O
and	O	O
5	B-IUPAC	O
-	I-IUPAC	O
iodo	I-IUPAC	O
analogues	B-MODIFIER	O
10	O	O
and	O	O
11	O	O
,	O	O
respectively	O	O
,	O	O
were	O	O
obtained	O	O
similarly	O	O
.	O	O
In	O	O
furtherance	O	O
of	O	O
our	O	O
SAR	O	O
study	O	O
on	O	O
the	O	O
chemistry	O	O
and	O	O
antitumor	O	O
activity	O	O
of	O	O
fused	O	O
nitrogen	O	O
heteroaromatic	O	O
compounds	O	O
,	O	O
a	O	O
series	O	O
of	O	O
linear	O	O
,	O	O
methyl	B-IUPAC	B-IUPAC
-	O	O
substituted	B-MODIFIER	B-MODIFIER
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
5H	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
6H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
indolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinolines	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
according	O	O
to	O	O
the	O	O
modified	O	O
Graebe	O	O
-	O	O
Ullmann	O	O
reaction	O	O
.	O	O
These	O	O
synthetic	O	O
steroids	O	O
would	O	O
facilitate	O	O
investigations	O	O
on	O	O
the	O	O
potential	O	O
biological	O	O
role	O	O
of	O	O
catechol	O	O
estrogens	O	O
and	O	O
also	O	O
enable	O	O
further	O	O
examination	O	O
of	O	O
the	O	O
structural	O	O
and	O	O
electronic	O	O
constraints	O	O
on	O	O
the	O	O
A	O	O
ring	O	O
in	O	O
the	O	O
interaction	O	O
of	O	O
estrogens	O	O
with	O	O
the	O	O
estrogen	O	O
receptor	O	O
.	O	O
Further	O	O
conjugation	O	O
of	O	O
[	O	O
131I	O	O
]	O	O
MIH	O	O
with	O	O
a	O	O
mAb	O	O
against	O	O
osteogenic	O	O
sarcoma	O	O
(	O	O
OST7	O	O
)	O	O
after	O	O
reduction	O	O
of	O	O
its	O	O
disulfide	O	O
bonds	O	O
was	O	O
followed	O	O
up	O	O
.	O	O
2	O	B-IUPAC
-	O	I-IUPAC
Amino	O	I-IUPAC
-	O	I-IUPAC
3	O	I-IUPAC
-	O	I-IUPAC
aroylthiophenes	O	I-IUPAC
are	O	O
agonist	O	O
allosteric	O	O
enhancers	O	O
(	O	O
AE	O	O
)	O	O
at	O	O
the	O	O
A	O	O
(	O	O
1	O	O
)	O	O
adenosine	O	O
receptor	O	O
(	O	O
A	O	O
(	O	O
1	O	O
)	O	O
AR	O	O
)	O	O
.	O	O
The	O	O
templates	O	O
reported	O	O
in	O	O
this	O	O
work	O	O
correspond	O	O
to	O	O
2,3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
dideoxy	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
L	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
erythro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
or	O	O
-	B-PARTIUPAC	B-PARTIUPAC
threo	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
hexono	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
1,4	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
lactone	I-PARTIUPAC	I-PARTIUPAC
(	O	O
template	O	O
III	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxyapiolactone	I-IUPAC	I-IUPAC
(	O	O
template	O	O
IV	O	O
)	O	O
.	O	O
Separation	O	O
of	O	O
diastereoisomers	O	O
was	O	O
achieved	O	O
by	O	O
HPLC	O	O
or	O	O
by	O	O
preparative	O	O
TLC	O	O
plates	O	O
.	O	O
Compounds	O	O
3b	O	O
,	O	O
3c	O	O
-	O	O
f	O	O
,	O	O
3h	O	O
,	O	O
7a	O	O
,	O	O
and	O	O
7b	O	O
were	O	O
found	O	O
to	O	O
exert	O	O
cytostatic	O	O
activity	O	O
against	O	O
malignant	O	O
cell	O	O
lines	O	O
:	O	O
pancreatic	O	O
carcinoma	O	O
(	O	O
MiaPaCa2	O	O
)	O	O
,	O	O
breast	O	O
carcinoma	O	O
(	O	O
MCF7	O	O
)	O	O
,	O	O
cervical	O	O
carcinoma	O	O
(	O	O
HeLa	O	O
)	O	O
,	O	O
laryngeal	O	O
carcinoma	O	O
(	O	O
Hep2	O	O
)	O	O
,	O	O
colon	O	O
carcinoma	O	O
(	O	O
CaCo	O	O
-	O	O
2	O	O
)	O	O
,	O	O
melanoma	O	O
(	O	O
HBL	O	O
)	O	O
,	O	O
human	O	O
fibroblast	O	O
cell	O	O
lines	O	O
(	O	O
WI	O	O
-	O	O
38	O	O
)	O	O
.	O	O
Several	O	O
of	O	O
these	O	O
quaternary	O	O
phenothiazines	O	O
completely	O	O
inhibited	O	O
T	O	O
.	O	O
A	O	O
novel	O	O
class	O	O
of	O	O
5	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
acyclic	O	B-IUPAC
pyrimidine	O	I-IUPAC
nucleosides	O	B-MODIFIER
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azidovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
(	O	O
9a	O	O
)	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azidovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
(	O	O
9b	O	O
)	O	O
,	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azidovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
(	O	O
9c	O	O
)	O	O
,	O	O
were	O	O
synthesized	O	O
by	O	O
regiospecific	O	O
addition	O	O
of	O	O
bromine	O	O
azide	O	O
to	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
vinyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
of	O	O
the	O	O
respective	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
vinyluracils	I-IUPAC	I-IUPAC
(	O	O
2a	O	O
-	O	O
c	O	O
)	O	O
followed	O	O
by	O	O
treatment	O	O
of	O	O
the	O	O
obtained	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
(	O	O
3a	O	O
-	O	O
c	O	O
)	O	O
with	O	O
t	O	O
-	O	O
BuOK	O	O
,	O	O
to	O	O
affect	O	O
the	O	O
base	O	O
-	O	O
catalyzed	O	O
elimination	O	O
of	O	O
HBr	O	O
.	O	O
Fifteen	O	O
glucagon	O	O
analogues	O	O
have	O	O
been	O	O
designed	O	O
and	O	O
synthesized	O	O
by	O	O
incorporating	O	O
structural	O	O
changes	O	O
in	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
region	O	O
of	O	O
glucagon	O	O
,	O	O
in	O	O
particular	O	O
histidine	O	O
-	O	O
1	O	O
,	O	O
phenylalanine	O	B-IUPAC
-	O	O
6	O	O
,	O	O
and	O	O
aspartic	O	O
acid	O	O
-	O	O
9	O	O
.	O	O
Following	O	O
deblocking	O	O
with	O	O
Na	O	O
in	O	O
NH3	O	O
and	O	O
oxidizing	O	O
with	O	O
K3	O	O
[	O	O
Fe	O	O
(	O	O
CN	O	O
)	O	O
6	O	O
]	O	O
,	O	O
each	O	O
peptide	O	O
was	O	O
purified	O	O
on	O	O
Sephadex	O	O
G	O	O
-	O	O
15	O	O
in	O	O
a	O	O
two	O	O
-	O	O
step	O	O
procedure	O	O
using	O	O
50%	O	O
HOAc	O	O
and	O	O
0.2	O	O
M	O	O
HOAc	O	O
as	O	O
eluants	O	O
.	O	O
,	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2RS	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3SR	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxybutylladenine	I-IUPAC	I-IUPAC
,	O	O
9	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
RS	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
or	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxybutyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
,	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trihydroxybutyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
adenin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
,	O	O
an	O	O
antiviral	O	O
effect	O	O
was	O	O
noted	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
0.5-1	O	O
mM	O	O
.	O	O
These	O	O
results	O	O
provide	O	O
the	O	O
first	O	O
experimental	O	O
evidence	O	O
that	O	O
peptides	O	O
can	O	O
carry	O	O
pyrimidines	O	O
into	O	O
a	O	O
eukaryote	O	O
.	O	O
Substitution	O	O
with	O	O
a	O	O
cyclopropylmethyl	O	B-IUPAC
or	O	O
benzyl	O	B-IUPAC
group	O	B-MODIFIER
resulted	O	O
in	O	O
reduced	O	O
activity	O	O
.	O	O
Therefore	O	O
,	O	O
this	O	O
paper	O	O
describes	O	O
the	O	O
synthesis	O	O
and	O	O
characterization	O	O
of	O	O
two	O	O
types	O	O
of	O	O
carbonic	O	O
anhydrase	O	O
inhibitors	O	O
;	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
sulfonamides	B-IUPAC	O
are	O	O
reversible	O	O
competitive	O	O
inhibitors	O	O
of	O	O
carbonic	O	O
anhydrase	O	O
,	O	O
while	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
sulfonamides	B-IUPAC	O
are	O	O
irreversible	O	O
inhibitors	O	O
.	O	O
A	O	O
selected	O	O
number	O	O
of	O	O
previously	O	O
known	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminothieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
lacking	O	O
the	O	O
3,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxyphenyl	I-IUPAC	I-IUPAC
and	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxyphenyl	I-IUPAC	I-IUPAC
substitution	B-MODIFIER	B-MODIFIER
pattern	I-MODIFIER	O
of	O	O
TMQ	O	O
and	O	O
PTX	O	O
,	O	O
respectively	O	O
,	O	O
were	O	O
also	O	O
tested	O	O
for	O	O
comparison	O	O
.	O	O
N3	B-IUPAC	O
-	I-IUPAC	O
Methylquinazolinones	I-IUPAC	O
42	O	O
and	O	O
43	O	O
were	O	O
essentially	O	O
devoid	O	O
of	O	O
activity	O	O
(	O	O
IC50	O	O
values	O	O
&	O	O
gt	O	O
;	O	O
100	O	O
microM	O	O
)	O	O
.	O	O
The	O	O
data	O	O
provide	O	O
a	O	O
basis	O	O
for	O	O
identifying	O	O
muscarinic	O	O
receptor	O	O
subtypes	O	O
(	O	O
as	O	O
defined	O	O
through	O	O
cloning	O	O
procedures	O	O
)	O	O
with	O	O
selective	O	O
ligands	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
estradiol	I-IUPAC	I-IUPAC
1	O	O
did	O	O
not	O	O
stimulate	O	O
the	O	O
growth	O	O
of	O	O
MCF	O	O
-	O	O
7	O	O
cells	O	O
at	O	O
concentrations	O	O
up	O	O
to	O	O
1	O	O
microM	O	O
.	O	O
Most	O	O
compounds	O	O
were	O	O
orally	O	O
active	O	O
in	O	O
blocking	O	O
the	O	O
conditioned	O	O
avoidance	O	O
response	O	O
(	O	O
CAR	O	O
)	O	O
but	O	O
did	O	O
not	O	O
antagonize	O	O
apomorphine	O	O
-	O	O
induced	O	O
stereotyped	O	O
behavior	O	O
.	O	O
The	O	O
most	O	O
active	O	O
compound	O	O
in	O	O
the	O	O
functional	O	O
test	O	O
(	O	O
-	O	O
log	O	O
Ki	O	O
=	O	O
8.3	O	O
)	O	O
and	O	O
in	O	O
binding	O	O
studies	O	O
with	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylhistamine	I-IUPAC	I-IUPAC
on	O	O
rat	O	O
cerebral	O	O
cortex	O	O
(	O	O
-	O	O
log	O	O
Ki	O	O
=	O	O
9.0	O	O
)	O	O
in	O	O
vitro	O	O
was	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ether	I-IUPAC	I-IUPAC
(	O	O
iodoproxyfan	O	O
,	O	O
19	O	O
)	O	O
exhibiting	O	O
no	O	O
central	O	O
H3	O	O
receptor	O	O
antagonist	O	O
activity	O	O
in	O	O
vivo	O	O
.	O	O
5	B-IUPAC	O
-	I-IUPAC	O
Deazaaminopterins	I-IUPAC	O
bearing	O	O
an	O	O
alkyl	O	O
substituent	O	O
at	O	O
the	O	O
5	O	O
-	O	O
position	O	O
were	O	O
generally	O	O
quite	O	O
effective	O	O
as	O	O
antiinflammatory	O	O
agents	O	O
.	O	O
Of	O	O
a	O	O
series	O	O
of	O	O
58	O	O
aliphatic	O	O
nucleoside	O	O
analogues	O	O
,	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxypropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
[	O	O
(	O	O
S	O	O
)	O	O
-	O	O
DHPA	O	O
]	O	O
proved	O	O
to	O	O
be	O	O
the	O	O
most	O	O
active	O	O
congener	O	O
,	O	O
when	O	O
assayed	O	O
for	O	O
antiviral	O	O
activity	O	O
in	O	O
primary	O	O
rabbit	O	O
kidney	O	O
cell	O	O
cultures	O	O
challenged	O	O
with	O	O
either	O	O
vaccinia	O	O
or	O	O
vesicular	O	O
stomatitis	O	O
virus	O	O
.	O	O
4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
N	I-MODIFIER	I-MODIFIER
-	I-MODIFIER	I-MODIFIER
Substituted	B-MODIFIER	I-MODIFIER
and	O	O
-	B-MODIFIER	B-PARTIUPAC
unsubstituted	I-MODIFIER	I-PARTIUPAC
3	B-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
alkyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiadiazine	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxides	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
tested	O	O
vs	O	O
diazoxide	O	O
and	O	O
selected	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
alykl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzothiadiazine	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxides	I-IUPAC	I-IUPAC
as	O	O
potassium	O	O
channel	O	O
openers	O	O
on	O	O
pancreatic	O	O
and	O	O
vascular	O	O
tissues	O	O
.	O	O
These	O	O
analogues	O	O
were	O	O
compared	O	O
to	O	O
the	O	O
corresponding	O	O
series	O	O
of	O	O
6,8	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
difluoro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinolones	I-IUPAC	I-IUPAC
(	O	O
ciprofloxacin	O	O
type	O	O
)	O	O
.	O	O
Further	O	O
modification	O	O
of	O	O
this	O	O
series	O	O
produced	O	O
benzoic	O	O
acid	O	O
derivative	O	O
(	B-IUPAC	O
1	I-IUPAC	O
,	I-IUPAC	O
1	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dioxido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzisothiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylmethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
(	O	O
7n	O	O
)	O	O
which	O	O
is	O	O
the	O	O
most	O	O
potent	O	O
inhibitor	O	O
identified	O	O
in	O	O
this	O	O
series	O	O
(	O	O
IC50	O	O
=	O	O
0.064	O	O
microM	O	O
)	O	O
.	O	O
A	O	O
hemolysis	O	O
investigation	O	O
was	O	O
conducted	O	O
on	O	O
human	O	O
red	O	O
blood	O	O
cells	O	O
,	O	O
and	O	O
the	O	O
results	O	O
demonstrate	O	O
that	O	O
proAEL	O	O
liposomes	O	O
display	O	O
a	O	O
very	O	O
low	O	O
hemotoxicity	O	O
,	O	O
which	O	O
has	O	O
been	O	O
a	O	O
major	O	O
obstacle	O	O
for	O	O
using	O	O
AELs	O	O
in	O	O
cancer	O	O
therapy	O	O
.	O	O
Among	O	O
the	O	O
3	O	O
-	O	O
substituted	O	O
allopurinol	O	O
nucleosides	O	O
,	O	O
18b	O	O
and	O	O
18c	O	O
showed	O	O
significant	O	O
activity	O	O
against	O	O
Para	O	O
3	O	O
virus	O	O
and	O	O
were	O	O
found	O	O
to	O	O
be	O	O
potent	O	O
inhibitors	O	O
of	O	O
growth	O	O
of	O	O
L1210	O	O
and	O	O
P388	O	O
leukemia	O	O
.	O	O
Hydrolysis	O	O
of	O	O
the	O	O
lactone	O	O
ring	O	O
of	O	O
the	O	O
1H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
skeleton	B-MODIFIER	O
,	O	O
to	O	O
give	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylhex	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ammoniohexanoate	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
,	O	O
led	O	O
to	O	O
a	O	O
considerable	O	O
decrease	O	O
in	O	O
activity	O	O
.	O	O
Of	O	O
the	O	O
four	O	O
gem	O	O
diether	O	O
nucleosides	O	O
,	O	O
only	O	O
the	O	O
dimethyl	O	O
gem	O	O
diether	O	O
congener	O	O
showed	O	O
significant	O	O
antiviral	O	O
activity	O	O
against	O	O
both	O	O
viruses	O	O
.	O	O
By	O	O
these	O	O
approaches	O	O
eight	O	O
new	O	O
diamidines	O	O
and	O	O
four	O	O
potential	O	O
prodrugs	O	O
were	O	O
prepared	O	O
.	O	O
The	O	O
binding	O	O
of	O	O
selective	O	O
muscarinic	O	O
receptor	O	O
antagonists	O	O
to	O	O
regions	O	O
of	O	O
rat	O	O
brain	O	O
was	O	O
examined	O	O
through	O	O
quantitative	O	O
autoradiographic	O	O
techniques	O	O
.	O	O
Compound	O	O
2	O	O
was	O	O
obtained	O	O
from	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyrimidine	I-IUPAC	I-IUPAC
and	O	O
1	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloroacetone	I-IUPAC	I-IUPAC
.	O	O
Beta	O	O
-	O	O
glucuronidase	O	O
from	O	O
both	O	O
Escherichia	O	O
coli	O	O
and	O	O
bovine	O	O
liver	O	O
cleaved	O	O
the	O	O
prodrugs	O	O
efficiently	O	O
to	O	O
release	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylguanine	I-IUPAC	I-IUPAC
and	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyguanosine	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
.	O	O
However	O	O
,	O	O
the	O	O
intrinsic	O	O
receptor	O	O
-	O	O
alkylating	O	O
activities	O	O
of	O	O
these	O	O
compounds	O	O
were	O	O
probably	O	O
very	O	O
hampered	O	O
by	O	O
their	O	O
poor	O	O
hydrolytic	O	O
stability	O	O
in	O	O
estrogen	O	O
receptor	O	O
-	O	O
containing	O	O
tissue	O	O
extracts	O	O
.	O	O
Compound	O	O
5h	O	O
was	O	O
also	O	O
active	O	O
against	O	O
T	O	O
.	O	O
This	O	O
agrees	O	O
with	O	O
a	O	O
recent	O	O
binding	O	O
model	O	O
that	O	O
suggests	O	O
this	O	O
general	O	O
class	O	O
of	O	O
compounds	O	O
binds	O	O
to	O	O
EGFR	O	O
with	O	O
the	O	O
6	O	O
-	O	O
position	O	O
located	O	O
in	O	O
an	O	O
area	O	O
of	O	O
comparative	O	O
bulk	O	O
tolerance	O	O
at	O	O
the	O	O
entrance	O	O
to	O	O
the	O	O
ATP	O	O
-	O	O
binding	O	O
pocket	O	O
.	O	O
N5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ornithine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
,	O	O
the	O	O
key	O	O
constituent	O	O
of	O	O
several	O	O
microbial	O	O
siderophores	O	O
,	O	O
has	O	O
been	O	O
synthesized	O	O
in	O	O
23%	O	O
yield	O	O
overall	O	O
from	O	O
N	O	B-IUPAC
-	O	I-IUPAC
Cbz	O	I-IUPAC
-	O	I-IUPAC
L	O	I-IUPAC
-	O	I-IUPAC
glutamic	O	I-IUPAC
acid	O	I-IUPAC
1	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
derived	O	O
from	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
For	O	O
example	O	O
,	O	O
[	O	O
(	O	O
2S	O	O
,	O	O
3S	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
MePhe4	O	O
]	O	O
DPDPE	O	O
(	O	O
2	O	O
)	O	O
is	O	O
1800	O	O
-	O	O
fold	O	O
selective	O	O
in	O	O
binding	O	O
to	O	O
the	O	O
delta	O	O
vs	O	O
mu	O	O
receptor	O	O
,	O	O
making	O	O
it	O	O
one	O	O
of	O	O
the	O	O
most	O	O
selective	O	O
delta	O	O
opioid	O	O
receptor	O	O
ligands	O	O
in	O	O
the	O	O
enkephalin	O	O
series	O	O
as	O	O
assessed	O	O
by	O	O
the	O	O
rat	O	O
brain	O	O
binding	O	O
assay	O	O
,	O	O
whereas	O	O
the	O	O
corresponding	O	O
(	O	O
2R	O	O
,	O	O
3R	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
Me	O	O
-	O	O
p	O	O
-	O	O
NO2Phe	O	O
-	O	O
containing	O	O
analogue	O	O
9	O	O
is	O	O
only	O	O
4.5	O	O
-	O	O
fold	O	O
selective	O	O
(	O	O
nonselective	O	O
)	O	O
in	O	O
this	O	O
same	O	O
assay	O	O
.	O	O
Thus	O	O
,	O	O
MTX	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropiperonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
at	O	O
an	O	O
MTX	O	O
-	O	O
equivalent	O	O
dose	O	O
of	O	O
5.5	O	O
mg	O	O
/	O	O
kg	O	O
gave	O	O
a	O	O
+	O	O
88%	O	O
increase	O	O
in	O	O
median	O	O
life	O	O
span	O	O
(	O	O
ILS	O	O
)	O	O
,	O	O
whereas	O	O
for	O	O
MTX	O	O
a	O	O
+	O	O
88%	O	O
ILS	O	O
required	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
Analyses	O	O
of	O	O
urine	O	O
samples	O	O
indicated	O	O
that	O	O
m	O	B-IUPAC
-	O	I-IUPAC
iodohippuric	O	I-IUPAC
acid	O	I-IUPAC
was	O	O
the	O	O
sole	O	O
radiolabeled	O	O
metabolite	O	O
.	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Carbomethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
nortropane	I-IUPAC	I-IUPAC
(	O	O
ZIENT	O	O
)	O	O
(	O	O
6	O	O
)	O	O
and	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
nortropane	I-IUPAC	I-IUPAC
(	O	O
EIENT	O	O
)	O	O
(	O	O
10	O	O
)	O	O
were	O	O
prepared	O	O
and	O	O
evaluated	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
for	O	O
serotonin	O	O
transporter	O	O
(	O	O
SERT	O	O
)	O	O
selectivity	O	O
and	O	O
specificity	O	O
.	O	O
Four	O	O
compounds	O	O
(	O	O
5a	O	O
,	O	O
h	O	O
,	O	O
k	O	O
,	O	O
l	O	O
)	O	O
were	O	O
tested	O	O
against	O	O
T	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
evaluated	O	O
as	O	O
inhibitors	O	O
against	O	O
DHFR	O	O
from	O	O
P	O	O
.	O	O
Where	O	O
substantial	O	O
reduction	O	O
or	O	O
abolition	O	O
of	O	O
affinity	O	O
at	O	O
AMPA	O	O
receptors	O	O
was	O	O
observed	O	O
,	O	O
this	O	O
could	O	O
be	O	O
rationalized	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
ability	O	O
of	O	O
the	O	O
ligand	O	O
to	O	O
fit	O	O
the	O	O
construct	O	O
.	O	O
Several	O	O
of	O	O
the	O	O
compounds	O	O
showed	O	O
much	O	O
lower	O	O
levels	O	O
of	O	O
cross	O	O
-	O	O
resistance	O	O
to	O	O
the	O	O
P388	O	O
/	O	O
AMSA	O	O
line	O	O
than	O	O
classical	O	O
DNA	O	O
-	O	O
intercalating	O	O
agents	O	O
,	O	O
which	O	O
suggests	O	O
that	O	O
their	O	O
primary	O	O
mechanism	O	O
of	O	O
action	O	O
may	O	O
not	O	O
be	O	O
via	O	O
interference	O	O
with	O	O
topoisomerase	O	O
II	O	O
alpha	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Arylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyridine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
at	O	O
best	O	O
,	O	O
exhibit	O	O
modest	O	O
antitetrabenazine	O	O
activity	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyridine	I-IUPAC	I-IUPAC
which	O	O
is	O	O
approximately	O	O
equipotent	O	O
with	O	O
amitriptyline	O	O
.	O	O
Subsequently	O	O
,	O	O
we	O	O
have	O	O
designed	O	O
and	O	O
synthesized	O	O
novel	O	O
olean	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
urs	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
en	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
with	O	O
nitrile	B-IUPAC	O
and	O	O
carboxyl	B-IUPAC	O
groups	B-MODIFIER	O
at	O	O
C	O	O
-	O	O
2	O	O
in	O	O
ring	O	O
A	O	O
and	O	O
with	O	O
9	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
en	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
and	O	O
12	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
en	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
functionalities	B-MODIFIER	O
in	O	O
ring	O	O
C	O	O
.	O	O
Most	O	O
compounds	O	O
showed	O	O
slower	O	O
on	O	O
-	O	O
set	O	O
and	O	O
longer	O	O
duration	O	O
of	O	O
action	O	O
relative	O	O
to	O	O
cocaine	O	O
.	O	O
Radioiodine	O	O
was	O	O
introduced	O	O
into	O	O
the	O	O
5	O	O
-	O	O
position	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodothiophene	I-IUPAC	I-IUPAC
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodothiophene	I-IUPAC	I-IUPAC
by	O	O
radioiodination	O	O
of	O	O
the	O	O
corresponding	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
boronic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
or	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trimethylstannyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
for	O	O
inhibition	O	O
of	O	O
DNA	O	O
-	O	O
dependent	O	O
protein	O	O
kinase	O	O
(	O	O
DNA	O	O
-	O	O
PK	O	O
)	O	O
have	O	O
been	O	O
defined	O	O
for	O	O
substituted	B-MODIFIER	B-MODIFIER
chromen	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
.	O	O
Both	O	O
of	O	O
these	O	O
retinoids	O	O
had	O	O
ID50	O	O
values	O	O
(	O	O
dose	O	O
required	O	O
for	O	O
half	O	O
-	O	O
maximal	O	O
inhibition	O	O
of	O	O
phorbol	O	O
ester	O	O
induced	O	O
ODC	O	O
activity	O	O
)	O	O
of	O	O
about	O	O
0.3	O	O
nmol	O	O
.	O	O
(	O	O
R	O	O
)	O	O
-	O	O
11a	O	O
was	O	O
not	O	O
a	O	O
substrate	O	O
for	O	O
P815	O	O
tryptophan	O	O
hydroxylase	O	O
.	O	O
Bicyclic	O	O
hydantoin	O	O
4	O	O
was	O	O
nevertheless	O	O
a	O	O
good	O	O
anti	O	O
-	O	O
MES	O	O
anticonvulsant	O	O
in	O	O
mice	O	O
(	O	O
ED50	O	O
=	O	O
86	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
although	O	O
this	O	O
activity	O	O
likely	O	O
results	O	O
from	O	O
mechanisms	O	O
other	O	O
than	O	O
interactions	O	O
at	O	O
the	O	O
neuronal	O	O
voltage	O	O
-	O	O
dependent	O	O
sodium	O	O
channel	O	O
.	O	O
This	O	O
compound	O	O
was	O	O
inactive	O	O
against	O	O
Brugia	O	O
pahangi	O	O
at	O	O
a	O	O
dosage	O	O
of	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
x	O	O
5	O	O
days	O	O
.	O	O
6beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Acyloxy	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
nor	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tropanes	I-IUPAC	I-IUPAC
and	O	O
classical	O	O
muscarinic	O	O
agonists	O	O
,	O	O
such	O	O
as	O	O
muscarine	O	O
and	O	O
oxotremorine	O	O
,	O	O
had	O	O
higher	O	O
affinity	O	O
versus	O	O
oxotremorine	O	O
-	O	O
M	O	O
binding	O	O
compared	O	O
to	O	O
quinuclidinyl	O	O
benzilate	O	O
binding	O	O
at	O	O
native	O	O
M	O	O
(	O	O
2	O	O
)	O	O
-	O	O
muscarinic	O	O
receptors	O	O
of	O	O
heart	O	O
,	O	O
but	O	O
not	O	O
at	O	O
transfected	O	O
m	O	O
(	O	O
2	O	O
)	O	O
-	O	O
muscarinic	O	O
receptors	O	O
.	O	O
Protolytic	O	O
properties	O	O
of	O	O
compounds	O	O
7a	O	O
,	O	O
b	O	O
,	O	O
8b	O	O
,	O	O
and	O	O
9b	O	O
were	O	O
determined	O	O
by	O	O
titration	O	O
,	O	O
and	O	O
a	O	O
correlation	O	O
between	O	O
the	O	O
pK	O	O
(	O	O
a	O	O
)	O	O
values	O	O
and	O	O
the	O	O
activity	O	O
at	O	O
AMPA	O	O
receptors	O	O
was	O	O
apparent	O	O
.	O	O
Two	O	O
additional	O	O
7	O	O
-	O	O
oxa	O	O
-	O	O
7,8	O	O
-	O	O
dihydro	O	O
-	O	O
RAs	O	O
exhibited	O	O
modest	O	O
activity	O	O
in	O	O
the	O	O
papilloma	O	O
assay	O	O
.	O	O
The	O	O
key	O	O
intermediate	O	O
,	O	O
hemiaminal	O	O
8	O	O
,	O	O
was	O	O
prepared	O	O
in	O	O
four	O	O
stages	O	O
from	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloropropionaldehyde	I-IUPAC	I-IUPAC
diethyl	I-IUPAC	I-IUPAC
acetal	I-IUPAC	I-IUPAC
.	O	O
Indolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinolines	I-IUPAC	I-IUPAC
with	O	O
the	O	O
highest	O	O
number	O	O
of	O	O
methyl	B-IUPAC	O
groups	B-MODIFIER	O
had	O	O
the	O	O
greatest	O	O
contribution	O	O
to	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
Tm	O	O
of	O	O
calf	O	O
thymus	O	O
DNA	O	O
.	O	O
Convenient	O	O
procedures	O	O
are	O	O
described	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
5	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxycytidines	I-IUPAC	I-IUPAC
5a	O	O
,	O	O
b	O	O
,	O	O
d	O	O
-	O	O
h	O	O
via	O	O
transformation	O	O
of	O	O
the	O	O
respective	O	O
5	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	B-MODIFIER
3'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridines	I-IUPAC	I-IUPAC
1a	O	O
-	O	O
c	O	O
,	O	O
e	O	O
-	O	O
h	O	O
.	O	O
Although	O	O
less	O	O
potent	O	O
than	O	O
PDDF	O	O
,	O	O
marked	O	O
inhibition	O	O
of	O	O
thymidylate	O	O
synthase	O	O
by	O	O
2	O	O
was	O	O
observed	O	O
in	O	O
permeabilized	O	O
L1210	O	O
cells	O	O
.	O	O
The	O	O
results	O	O
also	O	O
indicate	O	O
that	O	O
the	O	O
microsomal	O	O
monooxygenase	O	O
activities	O	O
induced	O	O
in	O	O
rat	O	O
liver	O	O
by	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthoflavone	I-IUPAC	I-IUPAC
,	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthoflavone	I-IUPAC	I-IUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylcholanthrene	I-IUPAC	I-IUPAC
are	O	O
not	O	O
equivalent	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
12	O	O
was	O	O
inactive	O	O
at	O	O
up	O	O
to	O	O
1	O	O
x	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
M	O	O
,	O	O
and	O	O
the	O	O
other	O	O
halogenated	O	O
derivatives	O	O
10	O	O
and	O	O
11	O	O
had	O	O
no	O	O
effect	O	O
even	O	O
at	O	O
1	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
M	O	O
.	O	O
Several	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
(	O	O
1-21	O	O
)	O	O
,	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
(	O	O
37-49	O	O
)	O	O
,	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylpyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
(	O	O
50-55	O	O
)	O	O
and	O	O
the	O	O
corresponding	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylpyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiones	I-IUPAC	I-IUPAC
(	O	O
56-60	O	O
)	O	O
were	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
antischistosomal	O	O
activity	O	O
against	O	O
Schistosoma	O	O
mansoni	O	O
.	O	O
Thus	O	O
both	O	O
1	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
hydroxyalkyl	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carboxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyridinones	I-IUPAC	I-IUPAC
are	O	O
able	O	O
to	O	O
remove	O	O
iron	O	O
from	O	O
the	O	O
liver	O	O
.	O	O
Fifty	O	O
nanomoles	O	O
of	O	O
4a	O	O
blocked	O	O
only	O	O
30%	O	O
of	O	O
the	O	O
specific	O	O
binding	O	O
of	O	O
[	O	O
18F	O	O
]	O	O
4d	O	O
,	O	O
while	O	O
complete	O	O
blockade	O	O
was	O	O
obtained	O	O
from	O	O
co	O	O
-	O	O
injection	O	O
of	O	O
200	O	O
nmol	O	O
of	O	O
4a	O	O
(	O	O
H	O	O
/	O	O
Cb	O	O
-	O	O
1	O	O
from	O	O
17.2	O	O
to	O	O
0.6	O	O
)	O	O
.	O	O
Optimization	O	O
of	O	O
the	O	O
spatial	O	O
alignment	O	O
of	O	O
the	O	O
RGD	O	O
moieties	O	O
through	O	O
careful	O	O
molecular	O	O
design	O	O
and	O	O
library	O	O
construction	O	O
could	O	O
induce	O	O
multivalent	O	O
ligand	O	O
-	O	O
receptor	O	O
interactions	O	O
useful	O	O
for	O	O
in	O	O
vivo	O	O
tumor	O	O
imaging	O	O
and	O	O
tumor	O	O
-	O	O
targeted	O	O
therapy	O	O
.	O	O
To	O	O
elucidate	O	O
the	O	O
structural	O	O
requirements	O	O
for	O	O
selective	O	O
activation	O	O
of	O	O
the	O	O
site	O	O
/	O	O
conformation	O	O
of	O	O
AMPA	O	O
receptors	O	O
recognized	O	O
by	O	O
2	O	O
,	O	O
a	O	O
number	O	O
of	O	O
isosteric	O	O
analogues	O	O
of	O	O
2	O	O
have	O	O
now	O	O
been	O	O
synthesized	O	O
and	O	O
pharmacologically	O	O
characterized	O	O
.	O	O
Subacute	O	O
toxicity	O	O
evaluation	O	O
in	O	O
dogs	O	O
and	O	O
guinea	O	O
pigs	O	O
showed	O	O
it	O	O
to	O	O
have	O	O
an	O	O
unfavorable	O	O
therapeutic	O	O
ratio	O	O
.	O	O
Inhibition	O	O
of	O	O
macromolecular	O	O
synthesis	O	O
with	O	O
compounds	O	O
4c	O	O
,	O	O
4d	O	O
,	O	O
6e	O	O
,	O	O
9c	O	O
,	O	O
and	O	O
9d	O	O
follows	O	O
the	O	O
order	O	O
:	O	O
DNA	O	O
greater	O	O
than	O	O
RNA	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
protein	O	O
.	O	O
The	O	O
activity	O	O
of	O	O
ring	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
(	O	O
F	O	O
,	O	O
Cl	O	O
,	O	O
CH3	O	O
,	O	O
and	O	O
OCH3	O	O
)	O	O
2	B-IUPAC	O
-	I-IUPAC	O
phenethoxyadenosines	I-IUPAC	O
increases	O	O
ortho	O	O
less	O	O
than	O	O
meta	O	O
less	O	O
than	O	O
para	O	O
.	O	O
The	O	O
inhibition	O	O
constants	O	O
,	O	O
alpha	O	O
(	O	O
the	O	O
ratio	O	O
of	O	O
the	O	O
molar	O	O
I50	O	O
of	O	O
theophylline	O	O
to	O	O
the	O	O
molar	O	O
I50	O	O
of	O	O
the	O	O
test	O	O
compounds	O	O
)	O	O
,	O	O
were	O	O
subjected	O	O
to	O	O
a	O	O
Hansch	O	O
correlation	O	O
analysis	O	O
.	O	O
Two	O	O
control	O	O
compounds	O	O
were	O	O
also	O	O
evaluated	O	O
:	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
anthracen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butylamine	I-IUPAC	I-IUPAC
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
anthracen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butanediamine	I-IUPAC	I-IUPAC
.	O	O
The	O	O
Pgp	O	O
-	O	O
inhibitory	O	O
activity	O	O
was	O	O
increased	O	O
about	O	O
2	O	O
-	O	O
fold	O	O
by	O	O
some	O	O
minor	O	O
modifications	O	O
such	O	O
as	O	O
those	O	O
found	O	O
in	O	O
the	O	O
naturally	O	O
occurring	O	O
aureobasidins	O	O
AbB	O	O
(	O	O
[	O	O
D	O	O
-	O	O
Hiv	O	O
(	O	O
1	O	O
)	O	O
]	O	O
-	O	O
AbA	O	O
)	O	O
,	O	O
AbC	O	O
(	O	O
[	O	O
Val	O	O
(	O	O
6	O	O
)	O	O
]	O	O
-	O	O
AbA	O	O
)	O	O
,	O	O
and	O	O
AbD	O	O
[	O	O
gammaHOMeVal	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
AbA	O	O
)	O	O
.	O	O
The	O	O
potency	O	O
pattern	O	O
due	O	O
to	O	O
substituents	O	O
of	O	O
the	O	O
phenyl	B-IUPAC	O
ring	B-MODIFIER	O
was	O	O
found	O	O
to	O	O
parallel	O	O
that	O	O
found	O	O
in	O	O
a	O	O
previously	O	O
reported	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dialkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylxanthine	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
.	O	O
The	O	O
enantiomerically	O	O
pure	O	O
key	O	O
intermediate	O	O
8	O	O
has	O	O
been	O	O
synthesized	O	O
in	O	O
six	O	O
steps	O	O
from	O	O
1,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
anhydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
gulose	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
compound	O	O
8	O	O
was	O	O
condensed	O	O
with	O	O
5	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	B-MODIFIER
pyrimidines	B-IUPAC	B-IUPAC
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
2,6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
purine	B-IUPAC	B-IUPAC
to	O	O
obtain	O	O
various	O	O
dioxolanylpyrimidine	B-IUPAC	O
and	O	O
-	B-PARTIUPAC	B-PARTIUPAC
purine	I-PARTIUPAC	I-PARTIUPAC
nucleosides	I-PARTIUPAC	I-PARTIUPAC
,	O	O
respectively	O	O
.	O	O
A	O	O
conformationally	O	O
defined	O	O
retinoic	O	O
acid	O	O
analog	O	O
(	O	O
1	O	O
)	O	O
which	O	O
contains	O	O
a	O	O
dimethylene	O	O
bridge	O	O
to	O	O
maintain	O	O
the	O	O
6	O	O
-	O	O
s	O	O
-	O	O
trans	O	O
orientation	O	O
for	O	O
two	O	O
terminal	O	O
double	O	O
bonds	O	O
in	O	O
the	O	O
polyene	O	O
chain	O	O
was	O	O
synthesized	O	O
.	O	O
The	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylfuranone	I-IUPAC	I-IUPAC
(	O	O
1	O	O
and	O	O
2	O	O
)	O	O
and	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpyranone	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
proved	O	O
to	O	O
be	O	O
only	O	O
reversible	O	O
,	O	O
competitive	O	O
inhibitors	O	O
.	O	O
We	O	O
also	O	O
obtained	O	O
the	O	O
following	O	O
order	O	O
for	O	O
thrombin	O	O
binding	O	O
:	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzamidine	I-IUPAC	I-IUPAC
&	O	O
gt	O	O
;	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethylbenzamidine	I-IUPAC	I-IUPAC
&	O	O
gt	O	O
;	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzamidine	I-IUPAC	I-IUPAC
&	O	O
gt	O	O
;	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylbenzamidine	I-IUPAC	I-IUPAC
&	O	O
gt	O	O
;	O	O
benzamidine	B-IUPAC	B-IUPAC
&	O	O
gt	O	O
;	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amidinophenylpyruvate	I-IUPAC	I-IUPAC
.	O	O
Syntheses	O	O
of	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyapomorphine	I-IUPAC	I-IUPAC
(	O	O
R	O	O
-	O	O
8	O	O
)	O	O
,	O	O
its	O	O
antipode	O	O
S	O	O
-	O	O
8	O	O
,	O	O
and	O	O
its	O	O
(	B-PARTIUPAC	B-IUPAC
R	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
n	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
propyl	I-PARTIUPAC	I-IUPAC
R	O	I-IUPAC
-	O	I-IUPAC
9	O	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
are	O	O
described	O	O
.	O	O
Evidence	O	O
incicating	O	O
that	O	O
effective	O	O
in	O	O
vivo	O	O
inhibition	O	O
of	O	O
hypoxanthine	O	B-IUPAC
-	O	I-IUPAC
guanine	O	I-IUPAC
phosphoribosyltransferase	O	I-IUPAC
(	O	O
HGPRT	O	O
,	O	O
EC	O	O
2.4.2.8	O	O
)	O	O
should	O	O
produce	O	O
antiprotozoal	O	O
activity	O	O
without	O	O
significant	O	O
toxic	O	O
effects	O	O
on	O	O
mammalian	O	O
hosts	O	O
prompted	O	O
syntheses	O	O
of	O	O
1	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
hypoxanthines	O	B-IUPAC
bearing	O	O
functionalized	O	O
side	O	O
chains	O	O
whose	O	O
groupings	O	O
might	O	O
interact	O	O
with	O	O
appropriate	O	O
groupings	O	O
of	O	O
HGPRT	O	O
to	O	O
form	O	O
covalent	O	O
bonds	O	O
or	O	O
strong	O	O
hydrophobic	O	O
bonds	O	O
.	O	O
These	O	O
findings	O	O
indicate	O	O
that	O	O
[	O	O
99mTc	O	O
]	O	O
CpTT	O	O
-	O	O
PA	O	O
was	O	O
recognized	O	O
,	O	O
transported	O	O
,	O	O
and	O	O
metabolized	O	O
as	O	O
a	O	O
long	O	O
chain	O	O
fatty	O	O
acid	O	O
analogue	O	O
for	O	O
energy	O	O
production	O	O
in	O	O
the	O	O
myocardium	O	O
.	O	O
However	O	O
,	O	O
evaluation	O	O
in	O	O
sheep	O	O
indicated	O	O
that	O	O
its	O	O
anthelmintic	O	O
spectrum	O	O
was	O	O
inferior	O	O
to	O	O
methyl	B-IUPAC	B-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylsulfinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
.	O	O
Direct	O	O
alkylation	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidone	I-IUPAC	I-IUPAC
produced	O	O
the	O	O
N3	O	O
-	O	O
substituted	O	O
derivatives	O	O
,	O	O
which	O	O
were	O	O
separated	O	O
from	O	O
the	O	O
byproduct	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkoxy	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
.	O	O
Finally	O	O
these	O	O
two	O	O
compounds	O	O
have	O	O
been	O	O
evaluated	O	O
against	O	O
Brugia	O	O
malayi	O	O
.	O	O
The	O	O
heterocyclic	O	O
systems	O	O
studied	O	O
were	O	O
based	O	O
on	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylfuran	I-IUPAC	I-IUPAC
(	O	O
2-4	O	O
)	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpyrazole	I-IUPAC	I-IUPAC
(	O	O
5-7	O	O
)	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyrazole	I-IUPAC	I-IUPAC
(	O	O
9-11	O	O
)	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylthiophene	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazole	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylisoxazole	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylisothiazole	I-IUPAC	I-IUPAC
(	O	O
16	O	O
)	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylthiazole	I-IUPAC	I-IUPAC
(	O	O
17	O	O
)	O	O
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyloxazole	I-IUPAC	I-IUPAC
(	O	O
18	O	O
)	O	O
.	O	O
We	O	O
were	O	O
able	O	O
to	O	O
confirm	O	O
the	O	O
substantial	O	O
cardioselectivity	O	O
of	O	O
1	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
3,4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dimethoxyphenethyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
4	B-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
substituted	I-MODIFIER	I-IUPAC
aryl	B-IUPAC	I-IUPAC
)	B-PARTIUPAC	I-IUPAC
oxy	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
propan	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
ols	I-PARTIUPAC	I-IUPAC
when	O	O
compared	O	O
to	O	O
those	O	O
with	O	O
a	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
.	O	O
Biodistribution	O	O
of	O	O
the	O	O
purified	O	O
diastereomers	O	O
2A	O	O
,	O	O
B	O	O
was	O	O
evaluated	O	O
in	O	O
rats	O	O
.	O	O
The	O	O
optical	O	O
purity	O	O
(	O	O
greater	O	O
than	O	O
99.5%	O	O
)	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
10	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
10	O	O
was	O	O
determined	O	O
by	O	O
HPLC	O	O
analysis	O	O
of	O	O
the	O	O
diastereomeric	O	O
ureas	O	O
formed	O	O
by	O	O
reaction	O	O
with	O	O
optically	O	O
pure	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenzyl	I-IUPAC	I-IUPAC
isocyanate	I-IUPAC	I-IUPAC
.	O	O
The	O	O
first	O	O
one	O	O
is	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
monosubstituted	B-MODIFIER	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidine	I-IUPAC	I-IUPAC
function	O	B-MODIFIER
,	O	O
since	O	O
disubstituted	B-MODIFIER	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidines	I-IUPAC	I-IUPAC
,	O	O
amidoximes	O	O
,	O	O
ketoximes	O	O
,	O	O
and	O	O
aldoximes	O	O
failed	O	O
to	O	O
produce	O	O
NO	O	O
.	O	O
Deprotection	O	O
with	O	O
sodium	O	O
in	O	O
liquid	O	O
ammonia	O	O
was	O	O
followed	O	O
by	O	O
sulfhydryl	O	O
oxidation	O	O
with	O	O
I2	O	O
to	O	O
give	O	O
the	O	O
hormone	O	O
analogue	O	O
.	O	O
2	O	O
cells	O	O
in	O	O
culture	O	O
except	O	O
the	O	O
parent	O	O
base	O	O
,	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
and	O	O
the	O	O
8	O	O
-	O	O
isomers	O	O
(	O	O
3,12	O	O
,	O	O
and	O	O
13	O	O
)	O	O
.	O	O
Nine	O	O
of	O	O
these	O	O
heterocycles	O	O
contained	O	O
a	O	O
thiochroman	O	B-IUPAC
group	O	B-MODIFIER
,	O	O
two	O	O
had	O	O
a	O	O
chroman	O	B-IUPAC
group	O	B-MODIFIER
,	O	O
and	O	O
two	O	O
others	O	O
had	O	O
a	O	O
benzothienyl	O	O
system	O	O
.	O	O
Both	O	O
of	O	O
these	O	O
series	O	O
display	O	O
much	O	O
higher	O	O
no	O	O
effect	O	O
doses	O	O
(	O	O
greater	O	O
tolerance	O	O
)	O	O
than	O	O
the	O	O
corresponding	O	O
6,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
difluoroquinolones	I-IUPAC	I-IUPAC
.	O	O
Compounds	O	O
11	O	O
(	O	O
n	O	O
equals	O	O
3	O	O
)	O	O
,	O	O
20	O	O
,	O	O
26	O	O
,	O	O
and	O	O
49	O	O
were	O	O
highly	O	O
protective	O	O
when	O	O
administered	O	O
intraperitoneally	O	O
but	O	O
were	O	O
generally	O	O
ineffective	O	O
when	O	O
given	O	O
perorally	O	O
,	O	O
as	O	O
were	O	O
the	O	O
other	O	O
hydroxylated	O	O
phosphorothioates	O	O
prepared	O	O
.	O	O
Meanwhile	O	O
,	O	O
synthetic	O	O
efforts	O	O
en	O	O
route	O	O
to	O	O
olefinic	O	O
compounds	O	O
led	O	O
to	O	O
the	O	O
discovery	O	O
that	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridylethyl	I-IUPAC	I-IUPAC
(	O	O
9o	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
(	O	O
9u	O	O
)	O	O
replacement	B-MODIFIER	O
of	O	O
the	O	O
p	O	O
-	O	O
anisyl	O	O
group	O	O
of	O	O
1yielded	O	O
very	O	O
hydrophilic	O	O
ETA	O	O
antagonists	O	O
with	O	O
potency	O	O
and	O	O
selectivity	O	O
equal	O	O
to	O	O
those	O	O
of	O	O
10b	O	O
.	O	O
All	O	O
of	O	O
the	O	O
analogues	O	O
are	O	O
weak	O	O
agonists	O	O
at	O	O
the	O	O
A1	O	O
receptor	O	O
,	O	O
requiring	O	O
concentrations	O	O
greater	O	O
than	O	O
9	O	O
microM	O	O
to	O	O
cause	O	O
second	O	O
degree	O	O
heart	O	O
block	O	O
.	O	O
Biochemical	O	O
evaluation	O	O
of	O	O
the	O	O
enantiomers	O	O
of	O	O
these	O	O
compounds	O	O
at	O	O
both	O	O
PNMT	O	O
and	O	O
the	O	O
alpha	O	O
(	O	O
2	O	O
)	O	O
-	O	O
adrenoceptor	O	O
indicates	O	O
that	O	O
both	O	O
sites	O	O
display	O	O
similar	O	O
stereoselectivity	O	O
.	O	O
These	O	O
materials	O	O
were	O	O
obtained	O	O
by	O	O
reacting	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
picoline	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
,	O	O
either	O	O
directly	O	O
or	O	O
after	O	O
conversion	O	O
to	O	O
the	O	O
corresponding	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
,	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
secondary	O	O
amines	O	O
.	O	O
A	O	O
combination	O	O
of	O	O
a	O	O
cyclopropyl	O	B-IUPAC
or	O	O
a	O	O
substituted	O	B-MODIFIER
phenyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
at	O	O
N	O	O
-	O	O
1	O	O
and	O	O
a	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azetidinyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
at	O	O
C	O	O
-	O	O
7	O	O
conferred	O	O
the	O	O
best	O	O
overall	O	O
antibacterial	O	O
,	O	O
pharmacokinetic	O	O
,	O	O
and	O	O
physicochemical	O	O
properties	O	O
to	O	O
the	O	O
azetidinylquinolones	O	O
studied	O	O
.	O	O
8	B-PARTIUPAC	O
-	I-PARTIUPAC	O
Methoxy	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylquinazolinones	I-IUPAC	I-IUPAC
(	O	O
14-34	O	O
)	O	O
were	O	O
readily	O	O
prepared	O	O
by	O	O
acylation	O	O
of	O	O
3	O	O
-	O	O
substituted	O	O
anthranilamides	O	O
with	O	O
the	O	O
appropriate	O	O
acid	O	O
chloride	O	O
,	O	O
followed	O	O
by	O	O
base	O	O
-	O	O
catalyzed	O	O
cyclization	O	O
.	O	O
An	O	O
examination	O	O
of	O	O
nitrogen	O	O
substitution	O	O
(	O	O
R2	O	O
in	O	O
3	O	O
)	O	O
revealed	O	O
that	O	O
analogs	O	O
with	O	O
either	O	O
an	O	O
allyl	O	O
or	O	O
an	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
displayed	O	O
equipotent	O	O
activities	O	O
.	O	O
In	O	O
the	O	O
linear	O	O
series	O	O
(	O	O
analogues	O	O
of	O	O
metoclopramide	O	O
)	O	O
,	O	O
introduction	O	O
of	O	O
a	O	O
benzyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
terminal	O	O
nitrogen	O	O
,	O	O
rather	O	O
than	O	O
an	O	O
ethyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
,	O	O
and	O	O
a	O	O
methyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
metoclopramide	O	O
both	O	O
enhanced	O	O
the	O	O
activity	O	O
.	O	O
This	O	O
research	O	O
has	O	O
identified	O	O
the	O	O
4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
adamantyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
as	O	O
a	O	O
new	O	O
pharmacophore	O	O
which	O	O
can	O	O
replace	O	O
the	O	O
beta	B-IUPAC	O
-	I-IUPAC	O
cyclogeranylidene	I-IUPAC	O
ring	B-MODIFIER	O
of	O	O
the	O	O
naturally	O	O
occurring	O	O
all	B-IUPAC	O
-	I-IUPAC	O
trans	I-IUPAC	O
-	I-IUPAC	O
retinoic	I-IUPAC	O
acid	I-IUPAC	O
.	O	O
8a	O	O
,	O	O
8b	O	O
,	O	O
and	O	O
14b	O	O
exhibited	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
less	O	O
than	O	O
10	O	O
nM	O	O
.	O	O
When	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
27	O	O
and	O	O
31	O	O
was	O	O
replaced	O	O
by	O	O
an	O	O
ethyl	B-IUPAC	O
or	O	O
an	O	O
isopropyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
,	O	O
the	O	O
anti	O	O
-	O	O
HIV	O	O
-	O	O
1	O	O
activity	O	O
was	O	O
improved	O	O
remarkably	O	O
[	O	O
EC50	O	O
:	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
(	O	O
46	O	O
)	O	O
,	O	O
0.019	O	O
microM	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
(	O	O
52	O	O
)	O	O
,	O	O
0.0059	O	O
microM	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
(	O	O
55	O	O
)	O	O
,	O	O
0.012	O	O
microM	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
(	O	O
56	O	O
)	O	O
,	O	O
0.0027	O	O
microM	O	O
]	O	O
.	O	O
The	O	O
Gewald	O	O
thiophene	O	O
synthesis	O	O
was	O	O
utilized	O	O
to	O	O
obtain	O	O
several	O	O
ethyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminothiophene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylates	I-IUPAC	I-IUPAC
.	O	O
The	O	O
pA2	O	O
values	O	O
(	O	O
rabbit	O	O
aortic	O	O
strips	O	O
)	O	O
obtained	O	O
were	O	O
7.68	O	O
,	O	O
7.53	O	O
,	O	O
7.23	O	O
,	O	O
7.53	O	O
,	O	O
and	O	O
9.66	O	O
,	O	O
and	O	O
the	O	O
dose	O	O
ratios	O	O
(	O	O
in	O	O
vagotomized	O	O
ganglion	O	O
-	O	O
blocked	O	O
rats	O	O
infused	O	O
at	O	O
250	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
obtained	O	O
were	O	O
2.37	O	O
,	O	O
4.49	O	O
,	O	O
1.02	O	O
,	O	O
1.47	O	O
,	O	O
and	O	O
24.04	O	O
,	O	O
respectively	O	O
.	O	O
Structurally	O	O
,	O	O
this	O	O
series	O	O
of	O	O
analogues	O	O
has	O	O
novel	O	O
substitutions	O	O
at	O	O
positions	O	O
3	O	O
,	O	O
7	O	O
,	O	O
and	O	O
8	O	O
and	O	O
N	O	O
(	O	O
alpha	O	O
)	O	O
-	O	O
methylation	O	O
at	O	O
positions	O	O
6	O	O
,	O	O
7	O	O
,	O	O
and	O	O
8	O	O
in	O	O
the	O	O
structure	O	O
of	O	O
degarelix	O	O
.	O	O
The	O	O
insulin	O	O
constituent	O	O
of	O	O
the	O	O
(	O	O
FMS	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
insulin	O	O
conjugate	O	O
undergoes	O	O
a	O	O
slow	O	O
,	O	O
spontaneous	O	O
activation	O	O
in	O	O
the	O	O
circulatory	O	O
system	O	O
,	O	O
manifesting	O	O
a	O	O
prolonged	O	O
glucose	O	O
-	O	O
lowering	O	O
action	O	O
in	O	O
vivo	O	O
.	O	O
The	O	O
lead	O	O
structure	O	O
19	O	O
has	O	O
been	O	O
selected	O	O
for	O	O
in	O	O
-	O	O
depth	O	O
pharmacological	O	O
evaluation	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
replacement	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
with	O	O
other	O	O
substituents	O	O
destroyed	O	O
activity	O	O
.	O	O
Small	O	O
libraries	O	O
of	O	O
6	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
7	B-IUPAC	B-MODIFIER
-	I-IUPAC	I-MODIFIER
alkoxy	I-IUPAC	I-MODIFIER
-	O	I-MODIFIER
substituted	B-MODIFIER	I-MODIFIER
chromen	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
showed	O	O
that	O	O
a	O	O
number	O	O
of	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkoxy	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
chromenones	B-IUPAC	O
displayed	O	O
improved	O	O
activity	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
conjugates	O	O
8c	O	O
-	O	O
e	O	O
were	O	O
less	O	O
effective	O	O
(	O	O
ILS	O	O
19-75%	O	O
)	O	O
and	O	O
cytidine	O	O
conjugates	O	O
(	O	O
9a	O	O
and	O	O
9b	O	O
)	O	O
were	O	O
ineffective	O	O
.	O	O
Tumorigenicity	O	O
assays	O	O
indicate	O	O
that	O	O
the	O	O
9,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydrodiol	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
cholanthrene	O	O
and	O	O
its	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
are	O	O
all	O	O
potent	O	O
tumor	O	O
initiators	O	O
on	O	O
mouse	O	O
skin	O	O
.	O	O
SPECT	O	O
brain	O	O
imaging	O	O
studies	O	O
in	O	O
monkeys	O	O
demonstrated	O	O
high	O	O
[	O	O
(	O	O
123	O	O
)	O	O
I	O	O
]	O	O
ZIENT	O	O
uptake	O	O
in	O	O
the	O	O
diencephalon	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
diencephalon	O	O
-	O	O
to	O	O
-	O	O
cerebellum	O	O
ratios	O	O
of	O	O
2.12	O	O
at	O	O
190	O	O
min	O	O
.	O	O
Chlorination	O	O
with	O	O
phosphorus	O	O
oxychloride	O	O
and	O	O
condensation	O	O
with	O	O
a	O	O
requisite	O	O
arylamine	O	O
provided	O	O
the	O	O
N2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dialkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinazolinediamines	I-IUPAC	I-IUPAC
(	O	O
X	O	O
)	O	O
.	O	O
Interestingly	O	O
,	O	O
the	O	O
related	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
1n	O	O
)	O	O
analogue	O	O
proved	O	O
to	O	O
be	O	O
markedly	O	O
inhibitory	O	O
to	O	O
DHBV	O	O
replication	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
2.6-6.6	O	O
microM	O	O
)	O	O
.	O	O
aureus	O	O
(	O	O
Smith	O	O
)	O	O
when	O	O
given	O	O
by	O	O
the	O	O
ip	O	O
route	O	O
.	O	O
From	O	O
incubations	O	O
of	O	O
the	O	O
enantiomers	O	O
of	O	O
1	O	O
and	O	O
pseudoracemic	O	O
propranolol	O	O
[	O	O
equimolar	O	O
(	B-IUPAC	O
2R	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
propranolol	I-IUPAC	O
-	I-IUPAC	O
3,3	I-IUPAC	O
-	I-IUPAC	O
d2	I-IUPAC	O
and	O	O
(	B-IUPAC	O
2S	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
propranolol	I-IUPAC	O
-	I-IUPAC	O
d0	I-IUPAC	O
]	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
rat	O	O
liver	O	O
microsomal	O	O
fraction	O	O
,	O	O
we	O	O
established	O	O
that	O	O
the	O	O
diastereomeric	O	O
products	O	O
were	O	O
formed	O	O
in	O	O
the	O	O
order	O	O
(	O	O
2S	O	O
,	O	O
2	O	O
"	O	O
S	O	O
)	O	O
-	O	O
2	O	O
approximately	O	O
equal	O	O
to	O	O
(	O	O
2S	O	O
,	O	O
2	O	O
"	O	O
R	O	O
)	O	O
-	O	O
2	O	O
greater	O	O
than	O	O
(	O	O
2R	O	O
,	O	O
2	O	O
"	O	O
R	O	O
)	O	O
-	O	O
2	O	O
greater	O	O
than	O	O
(	O	O
2R	O	O
,	O	O
2	O	O
"	O	O
S	O	O
)	O	O
-	O	O
2	O	O
.	O	O
These	O	O
agents	O	O
were	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
sensitize	O	O
hypoxic	O	O
Escherichia	O	O
coli	O	O
cells	O	O
to	O	O
killing	O	O
by	O	O
ionizing	O	O
radiation	O	O
.	O	O
Compound	O	O
4	O	O
was	O	O
synthesized	O	O
by	O	O
the	O	O
nucleophilic	O	O
displacement	O	O
of	O	O
5	O	O
with	O	O
diethyl	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
and	O	O
saponification	O	O
.	O	O
Similarly	O	O
,	O	O
replacement	O	O
of	O	O
the	O	O
carboxyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
3b	O	O
by	O	O
isosteric	O	O
tetrazolyl	B-IUPAC	O
or	O	O
1,2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triazolyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
to	O	O
give	O	O
5	O	O
and	O	O
6	O	O
,	O	O
respectively	O	O
,	O	O
or	O	O
conversion	O	O
of	O	O
3b	O	O
into	O	O
analogue	O	O
7	O	O
,	O	O
in	O	O
which	O	O
the	O	O
diaminosquaric	O	O
acid	O	O
group	O	O
has	O	O
been	O	O
bioisosterically	O	O
substituted	O	O
for	O	O
the	O	O
alpha	B-IUPAC	O
-	I-IUPAC	O
aminocarboxylic	I-IUPAC	O
acid	I-IUPAC	O
unit	O	O
,	O	O
provided	O	O
compounds	O	O
completely	O	O
devoid	O	O
of	O	O
effect	O	O
at	O	O
AMPA	O	O
receptors	O	O
.	O	O
However	O	O
,	O	O
the	O	O
new	O	O
compounds	O	O
we	O	O
describe	O	O
exhibit	O	O
diminished	O	O
cardiovascular	O	O
effects	O	O
in	O	O
both	O	O
anesthetized	O	O
and	O	O
awake	O	O
rats	O	O
when	O	O
compared	O	O
to	O	O
reference	O	O
A	O	O
(	O	O
1	O	O
)	O	O
agonists	O	O
such	O	O
as	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylisopropyladenosine	I-IUPAC	I-IUPAC
(	O	O
R	O	O
-	O	O
PIA	O	O
,	O	O
5	O	O
)	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclopentyladenosine	I-IUPAC	I-IUPAC
(	O	O
CPA	O	O
,	O	O
2	O	O
)	O	O
,	O	O
4	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxycyclopentyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
(	O	O
GR	O	O
79236	O	O
,	O	O
26	O	O
)	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyladenosine	I-IUPAC	I-IUPAC
(	O	O
SDZ	O	O
WAG	O	O
994	O	O
,	O	O
27	O	O
)	O	O
,	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
(	O	O
Metrifudil	O	O
,	O	O
28	O	O
)	O	O
.	O	O
Most	O	O
of	O	O
the	O	O
new	O	O
compounds	O	O
were	O	O
active	O	O
in	O	O
a	O	O
PAF	O	O
-	O	O
binding	O	O
assay	O	O
employing	O	O
whole	O	O
,	O	O
washed	O	O
dog	O	O
platelets	O	O
as	O	O
the	O	O
receptor	O	O
source	O	O
and	O	O
inhibited	O	O
PAF	O	O
-	O	O
induced	O	O
bronchoconstriction	O	O
in	O	O
guinea	O	O
pigs	O	O
after	O	O
intravenous	O	O
administration	O	O
.	O	O
These	O	O
same	O	O
five	O	O
compounds	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
lead	O	O
compound	O	O
Analog	O	O
II	O	O
,	O	O
were	O	O
active	O	O
in	O	O
vitro	O	O
against	O	O
the	O	O
estrogen	O	O
-	O	O
dependent	O	O
MCF	O	O
-	O	O
7	O	O
human	O	O
breast	O	O
tumor	O	O
cell	O	O
line	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
fashion	O	O
.	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
latent	O	O
alkyl	B-IUPAC	O
isocyanates	I-IUPAC	O
are	O	O
inhibitors	O	O
of	O	O
AlDH	O	O
,	O	O
giving	O	O
further	O	O
support	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
inhibition	O	O
of	O	O
AlDH	O	O
in	O	O
vivo	O	O
by	O	O
the	O	O
hypoglycemic	O	O
agent	O	O
chlorpropamide	O	O
may	O	O
be	O	O
due	O	O
to	O	O
the	O	O
release	O	O
of	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
isocyanate	I-IUPAC	I-IUPAC
following	O	O
metabolic	O	O
bioactivation	O	O
.	O	O
The	O	O
most	O	O
active	O	O
cytotoxic	O	O
agent	O	O
(	O	O
16	O	O
)	O	O
,	O	O
possessing	O	O
a	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diiodoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
(	O	O
ED50	O	O
=	O	O
0.77	O	O
micrograms	O	O
/	O	O
mL	O	O
)	O	O
,	O	O
exhibited	O	O
an	O	O
activity	O	O
approaching	O	O
that	O	O
of	O	O
melphalan	O	O
(	O	O
ED50	O	O
=	O	O
0.15	O	O
micrograms	O	O
/	O	O
mL	O	O
)	O	O
.	O	O
Most	O	O
importantly	O	O
,	O	O
three	O	O
compounds	O	O
from	O	O
this	O	O
series	O	O
demonstrated	O	O
statistically	O	O
significant	O	O
protective	O	O
effects	O	O
in	O	O
rat	O	O
models	O	O
of	O	O
stroke	O	O
and	O	O
heart	O	O
ischemia	O	O
.	O	O
The	O	O
ring	O	O
-	O	O
opened	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acylamino	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
46	O	O
and	O	O
47	O	O
were	O	O
prepared	O	O
via	O	O
nitration	O	O
of	O	O
the	O	O
phenethylamine	O	O
43	O	O
derived	O	O
from	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenylacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
Unit	O	O
cell	O	O
dimensions	O	O
(	O	O
at	O	O
15	O	O
degrees	O	O
C	O	O
)	O	O
are	O	O
as	O	O
follows	O	O
:	O	O
for	O	O
1b	O	O
,	O	O
a	O	O
=	O	O
20.568	O	O
(	O	O
6	O	O
)	O	O
A	O	O
,	O	O
b	O	O
=	O	O
14.760	O	O
(	O	O
3	O	O
)	O	O
A	O	O
,	O	O
c	O	O
=	O	O
7.679	O	O
(	O	O
2	O	O
)	O	O
A	O	O
,	O	O
alpha	O	O
=	O	O
113.33	O	O
(	O	O
2	O	O
)	O	O
degrees	O	O
,	O	O
beta	O	O
=	O	O
79.45	O	O
(	O	O
2	O	O
)	O	O
degrees	O	O
,	O	O
gamma	O	O
=	O	O
79.98	O	O
(	O	O
2	O	O
)	O	O
degrees	O	O
,	O	O
Z	O	O
=	O	O
4	O	O
;	O	O
for	O	O
18	O	O
,	O	O
a	O	O
=	O	O
9.292	O	O
(	O	O
5	O	O
)	O	O
A	O	O
,	O	O
b	O	O
=	O	O
9.291	O	O
(	O	O
5	O	O
)	O	O
A	O	O
,	O	O
c	O	O
=	O	O
7.951	O	O
(	O	O
3	O	O
)	O	O
A	O	O
,	O	O
alpha	O	O
=	O	O
102.16	O	O
(	O	O
3	O	O
)	O	O
degrees	O	O
,	O	O
beta	O	O
=	O	O
77.49	O	O
(	O	O
3	O	O
)	O	O
degrees	O	O
,	O	O
gamma	O	O
=	O	O
79.60	O	O
(	O	O
4	O	O
)	O	O
degrees	O	O
,	O	O
Z	O	O
=	O	O
2	O	O
.	O	O
We	O	O
have	O	O
found	O	O
that	O	O
alpha	B-IUPAC	O
-	I-IUPAC	O
aryl	I-IUPAC	O
-	O	O
substituted	B-MODIFIER	B-MODIFIER
halo	B-IUPAC	B-IUPAC
enol	I-IUPAC	I-IUPAC
lactones	I-IUPAC	I-IUPAC
(	O	O
I	O	O
and	O	O
II	O	O
)	O	O
are	O	O
effective	O	O
mechanism	O	O
-	O	O
based	O	O
inactivators	O	O
for	O	O
chymotrypsin	O	O
.	O	O
The	O	O
original	O	O
synthetic	O	O
procedure	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
21	O	O
of	O	O
these	O	O
compounds	O	O
is	O	O
also	O	O
reported	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
pharmacological	O	O
properties	O	O
of	O	O
several	O	O
racemic	B-MODIFIER	O
6,7,8,9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzazepine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diones	I-IUPAC	I-IUPAC
(	O	O
THHBADs	O	O
)	O	O
are	O	O
described	O	O
.	O	O
A	O	O
series	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thieno1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
\C5	I-IUPAC	I-IUPAC
\8F	I-IUPAC	I-IUPAC
xazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
and	O	O
evaluated	O	O
in	O	O
vitro	O	O
for	O	O
inhibitory	O	O
activity	O	O
toward	O	O
human	O	O
leukocyte	O	O
elastase	O	O
(	O	O
HLE	O	O
)	O	O
.	O	O
In	O	O
this	O	O
article	O	O
,	O	O
we	O	O
report	O	O
synthesis	O	O
and	O	O
cytotoxicity	O	O
of	O	O
a	O	O
series	O	O
of	O	O
new	O	O
pyrido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
nucleosides	B-MODIFIER	B-MODIFIER
.	O	O
All	O	O
the	O	O
furoxan	O	O
and	O	O
furazan	O	O
derivatives	O	O
showed	O	O
activity	O	O
as	O	O
inhibitors	O	O
of	O	O
platelet	O	O
aggregation	O	O
.	O	O
The	O	O
potencies	O	O
of	O	O
the	O	O
complexes	O	O
3	O	O
and	O	O
4	O	O
correlated	O	O
well	O	O
with	O	O
the	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
of	O	O
other	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aryltropane	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
.	O	O
The	O	O
insertion	O	O
of	O	O
substituents	O	O
on	O	O
the	O	O
furan	O	O
ring	O	O
of	O	O
3	O	O
,	O	O
as	O	O
in	O	O
compounds	O	O
4	O	O
and	O	O
5	O	O
,	O	O
did	O	O
not	O	O
improve	O	O
the	O	O
selectivity	O	O
profile	O	O
.	O	O
gondii	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O
This	O	O
rather	O	O
surprising	O	O
and	O	O
unexpected	O	O
finding	O	O
may	O	O
be	O	O
explained	O	O
by	O	O
considering	O	O
neutral	O	O
and	O	O
negative	O	O
antagonism	O	O
.	O	O
Prolonging	O	O
such	O	O
treatment	O	O
was	O	O
found	O	O
to	O	O
result	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloroethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
norapocodeine	I-IUPAC	I-IUPAC
(	O	O
1f	O	O
)	O	O
at	O	O
the	O	O
expense	O	O
of	O	O
1e	O	O
.	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
label	O	O
the	O	O
potent	O	O
PBR	O	O
agonist	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenoxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
isopropoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetamide	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
and	O	O
its	O	O
ethyl	B-IUPAC	O
(	O	O
7	O	O
)	O	O
and	O	O
methyl	B-IUPAC	O
(	O	O
8	O	O
)	O	O
homologues	B-MODIFIER	O
with	O	O
(	O	O
11	O	O
)	O	O
C	O	O
and	O	O
to	O	O
evaluate	O	O
them	O	O
as	O	O
PET	O	O
ligands	O	O
for	O	O
PBR	O	O
with	O	O
mice	O	O
,	O	O
rats	O	O
,	O	O
and	O	O
monkeys	O	O
.	O	O
The	O	O
pyridopyrimidine	O	O
with	O	O
the	O	O
best	O	O
combination	O	O
of	O	O
potency	O	O
and	O	O
selectivity	O	O
was	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
,	O	O
with	O	O
an	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
value	O	O
of	O	O
0.65	O	O
nM	O	O
against	O	O
P	O	O
.	O	O
albicans	O	O
in	O	O
the	O	O
intact	O	O
form	O	O
.	O	O
4	O	B-PARTIUPAC
-	O	I-PARTIUPAC
(	O	I-PARTIUPAC
Dimethylamino	O	I-PARTIUPAC
)	O	I-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arylspiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
cyclohexane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
prepared	O	O
as	O	O
analogues	O	O
of	O	O
previously	O	O
reported	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
arylspiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
.	O	O
Although	O	O
active	O	O
against	O	O
Leishmania	O	O
donovani	O	O
,	O	O
none	O	O
of	O	O
the	O	O
analogues	O	O
showed	O	O
major	O	O
improvement	O	O
in	O	O
this	O	O
activity	O	O
relative	O	O
to	O	O
chlorpromazine	O	O
or	O	O
other	O	O
nonquaternized	O	O
phenothiazines	O	O
.	O	O
Most	O	O
notably	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrrolidine	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
exhibited	O	O
a	O	O
3.4	O	O
-	O	O
fold	O	O
greater	O	O
affinity	O	O
for	O	O
these	O	O
sites	O	O
compared	O	O
with	O	O
BTCP	O	O
and	O	O
a	O	O
9	O	O
-	O	O
fold	O	O
greater	O	O
affinity	O	O
at	O	O
these	O	O
sites	O	O
than	O	O
cocaine	O	O
.	O	O
The	O	O
binding	O	O
compatibility	O	O
of	O	O
the	O	O
most	O	O
active	O	O
compounds	O	O
with	O	O
a	O	O
model	O	O
of	O	O
ACE	O	O
active	O	O
site	O	O
was	O	O
evaluated	O	O
by	O	O
molecular	O	O
modeling	O	O
techniques	O	O
.	O	O
The	O	O
pA2	O	O
values	O	O
for	O	O
VII	O	O
and	O	O
VIII	O	O
were	O	O
8.31	O	O
and	O	O
10.0	O	O
in	O	O
the	O	O
adrenal	O	O
cortex	O	O
and	O	O
9.31	O	O
and	O	O
9.16	O	O
in	O	O
the	O	O
adrenal	O	O
medulla	O	O
,	O	O
respectively	O	O
.	O	O
Cold	O	O
monoiodination	O	O
of	O	O
19	O	O
yielded	O	O
21	O	O
,	O	O
with	O	O
retention	O	O
of	O	O
high	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
selectivity	O	O
and	O	O
affinity	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
3.5	O	O
nM	O	O
)	O	O
.	O	O
These	O	O
compounds	O	O
are	O	O
not	O	O
inhibitors	O	O
of	O	O
thrombin	O	O
,	O	O
plasmin	O	O
t	O	O
-	O	O
PA	O	O
,	O	O
urokinase	O	O
,	O	O
and	O	O
factor	O	O
Xa	O	O
(	O	O
IC50	O	O
&	O	O
gt	O	O
;	O	O
33	O	O
microM	O	O
)	O	O
.	O	O
The	O	O
conformationally	O	O
restricted	O	O
,	O	O
cyclic	O	O
disulfide	O	O
-	O	O
containing	O	O
delta	O	O
opioid	O	O
receptor	O	O
selective	O	O
enkephalin	O	O
analogue	O	O
[	O	O
D	O	O
-	O	O
Pen2	O	O
,	O	O
D	O	O
-	O	O
Pen5	O	O
]	O	O
enkephalin	O	O
(	O	O
1	O	O
,	O	O
DPDPE	O	O
)	O	O
was	O	O
systematically	O	O
modified	O	O
topographically	O	O
by	O	O
addition	O	O
of	O	O
a	O	O
methyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
at	O	O
either	O	O
the	O	O
pro	O	O
-	O	O
S	O	O
or	O	O
pro	O	O
-	O	O
R	O	O
position	O	O
of	O	O
the	O	O
beta	O	O
carbon	O	O
of	O	O
an	O	O
L	O	O
-	O	O
Phe4	O	O
or	O	O
D	O	O
-	O	O
Phe4	O	O
residue	O	O
to	O	O
give	O	O
[	O	O
(	O	O
2S	O	O
,	O	O
3S	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
MePhe4	O	O
]	O	O
DPDPE	O	O
(	O	O
2	O	O
)	O	O
,	O	O
[	O	O
(	O	O
2R	O	O
,	O	O
3R	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
MePhe4	O	O
]	O	O
DPDPE	O	O
(	O	O
3	O	O
)	O	O
,	O	O
[	O	O
(	O	O
2S	O	O
,	O	O
3R	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
MePhe4	O	O
]	O	O
DPDPE	O	O
(	O	O
4	O	O
)	O	O
,	O	O
and	O	O
[	O	O
(	O	O
2R	O	O
,	O	O
3S	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
MePhe4	O	O
]	O	O
DPDPE	O	O
(	O	O
5	O	O
)	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
the	O	O
chiral	O	O
cis	O	O
compounds	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1	O	O
showed	O	O
high	O	O
affinity	O	O
for	O	O
sigma	O	O
receptors	O	O
and	O	O
negligible	O	O
affinity	O	O
for	O	O
kappa	O	O
opioid	O	O
receptors	O	O
in	O	O
the	O	O
[	O	O
3H	O	O
]	O	O
BREM	O	O
assay	O	O
.	O	O
The	O	O
structural	O	O
basis	O	O
of	O	O
protein	O	O
kinase	O	O
C	O	O
(	O	O
PKC	O	O
)	O	O
binding	O	O
to	O	O
several	O	O
classes	O	O
of	O	O
high	O	O
-	O	O
affinity	O	O
ligands	O	O
has	O	O
been	O	O
investigated	O	O
through	O	O
complementary	O	O
computational	O	O
and	O	O
experimental	O	O
methods	O	O
.	O	O
In	O	O
the	O	O
female	O	O
rat	O	O
,	O	O
79%	O	O
of	O	O
an	O	O
orally	O	O
administered	O	O
dose	O	O
of	O	O
tritiated	O	O
tolazamide	O	O
was	O	O
excreted	O	O
in	O	O
urine	O	O
during	O	O
a	O	O
5	O	O
-	O	O
day	O	O
period	O	O
as	O	O
1-4	O	O
.	O	O
Compound	O	O
4	O	O
was	O	O
prepared	O	O
from	O	O
3i	O	O
by	O	O
alkylation	O	O
with	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylaminopropyl	I-IUPAC	I-IUPAC
chloride	I-IUPAC	I-IUPAC
in	O	O
the	O	O
presence	O	O
of	O	O
NaH	O	O
.	O	O
Intracerebroventricular	O	O
administration	O	O
of	O	O
10	O	O
elicited	O	O
a	O	O
naloxone	O	O
-	O	O
reversible	O	O
antinociceptive	O	O
effect	O	O
in	O	O
mice	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
H	O	O
-	O	O
Lys	O	O
-	O	O
Trp	O	O
(	O	O
NPS	O	O
)	O	O
-	O	O
OMe	O	O
.	O	O
Contribution	O	O
of	O	O
both	O	O
an	O	O
N	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
n	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
propyl	I-PARTIUPAC	I-IUPAC
and	O	O
a	O	O
2	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
hydroxy	I-PARTIUPAC	I-IUPAC
in	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylnorapomorphine	I-IUPAC	I-IUPAC
(	O	O
R	O	O
(	O	O
-	O	O
)	O	O
-	O	O
2	O	O
-	O	O
OH	O	O
-	O	O
NPA	O	O
,	O	O
R	O	O
-	O	O
7	O	O
)	O	O
or	O	O
a	O	O
methoxy	O	O
group	O	O
in	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylnorapomorphine	I-IUPAC	I-IUPAC
(	O	O
R	O	O
(	O	O
-	O	O
)	O	O
-	O	O
2	O	O
-	O	O
OCH3	O	O
-	O	O
NPA	O	O
,	O	O
R	O	O
-	O	O
9	O	O
)	O	O
produced	O	O
the	O	O
highest	O	O
D2	O	O
affinity	O	O
(	O	O
0.053	O	O
and	O	O
0.17	O	O
nM	O	O
)	O	O
and	O	O
D2	O	O
over	O	O
D1	O	O
selectivity	O	O
(	O	O
17,300	O	O
and	O	O
10,500	O	O
times	O	O
)	O	O
of	O	O
the	O	O
compounds	O	O
evaluated	O	O
.	O	O
Serial	O	O
measurements	O	O
of	O	O
tumor	O	O
size	O	O
,	O	O
and	O	O
evaluation	O	O
of	O	O
increased	O	O
life	O	O
span	O	O
,	O	O
in	O	O
response	O	O
to	O	O
drug	O	O
treatment	O	O
also	O	O
revealed	O	O
potentially	O	O
1,4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
bis	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
alkylating	O	I-IUPAC
)	O	I-IUPAC
(	B-PARTIUPAC	I-IUPAC
bromomethyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
1,4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
quinone	I-PARTIUPAC	I-IUPAC
7	O	O
and	O	O
1,3	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
bis	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
alkylating	O	I-IUPAC
)	O	I-IUPAC
(	B-PARTIUPAC	I-IUPAC
hydroxymethyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
1,4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
quinone	I-PARTIUPAC	I-IUPAC
10	O	O
to	O	O
have	O	O
variable	O	O
activity	O	O
,	O	O
but	O	O
none	O	O
of	O	O
the	O	O
potentially	O	O
bis	O	O
(	O	O
alkylating	O	O
)	O	O
bis	O	O
(	O	O
quinones	O	O
)	O	O
showed	O	O
antitumor	O	O
properties	O	O
in	O	O
this	O	O
model	O	O
.	O	O
Compounds	O	O
1	O	O
[	O	O
especially	O	O
1s	O	O
[	O	O
R1	O	O
=	O	O
(	B-PARTIUPAC	B-PARTIUPAC
CH2	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
2N	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
benzyl	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
naphthylmethyl	I-PARTIUPAC	I-PARTIUPAC
)	O	O
,	O	O
R2	O	O
=	O	O
i	O	O
-	O	O
Pr	O	O
,	O	O
X	O	O
=	O	O
0	O	O
-	O	O
NO2	O	O
]	O	O
and	O	O
1t	O	O
[	O	O
R1	O	O
=	O	O
(	B-PARTIUPAC	B-PARTIUPAC
CH2	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
2N	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
benzyl	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
3,4	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
dichlorobenzyl	I-PARTIUPAC	I-PARTIUPAC
)	O	O
,	O	O
R2	O	O
=	O	O
i	O	O
-	O	O
Pr	O	O
,	O	O
X	O	O
=	O	O
0	O	O
-	O	O
NO2	O	O
]	O	O
]	O	O
exhibited	O	O
not	O	O
only	O	O
more	O	O
potent	O	O
and	O	O
longer	O	O
lasting	O	O
vasodilative	O	O
action	O	O
but	O	O
also	O	O
a	O	O
hypotensive	O	O
activity	O	O
with	O	O
slow	O	O
onset	O	O
as	O	O
compared	O	O
with	O	O
dihydropyridines	O	O
.	O	O
Some	O	O
functional	O	O
groups	O	O
were	O	O
introduced	O	O
that	O	O
were	O	O
hypothesized	O	O
to	O	O
influence	O	O
the	O	O
phamacokinetic	O	O
properties	O	O
of	O	O
the	O	O
analogues	O	O
such	O	O
as	O	O
bioavailability	O	O
,	O	O
solubility	O	O
,	O	O
intra	O	O
-	O	O
or	O	O
intermolecular	O	O
hydrogen	O	O
bond	O	O
forming	O	O
capacity	O	O
,	O	O
and	O	O
ability	O	O
to	O	O
bind	O	O
carrier	O	O
proteins	O	O
.	O	O
Aqueous	O	O
base	O	O
transformed	O	O
4	O	O
into	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
in	O	O
good	O	O
yield	O	O
.	O	O
The	O	O
simultaneous	O	O
replacement	O	O
of	O	O
both	O	O
piperazine	O	O
and	O	O
furan	O	O
rings	O	O
of	O	O
1	O	O
gave	O	O
8	O	O
which	O	O
resulted	O	O
in	O	O
a	O	O
potent	O	O
,	O	O
selective	O	O
alpha1B	O	O
-	O	O
adrenoreceptor	O	O
antagonist	O	O
(	O	O
85	O	O
-	O	O
and	O	O
15	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
at	O	O
alpha1A	O	O
-	O	O
and	O	O
alpha1D	O	O
-	O	O
subtypes	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
However	O	O
,	O	O
no	O	O
correlation	O	O
between	O	O
the	O	O
binding	O	O
constant	O	O
values	O	O
and	O	O
photosensitizing	O	O
efficacy	O	O
was	O	O
observed	O	O
.	O	O
The	O	O
transformation	O	O
of	O	O
milrinone	O	O
to	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
13a	O	O
)	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
51	O	O
)	O	O
,	O	O
and	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
22	O	O
)	O	O
resulted	O	O
in	O	O
very	O	O
potent	O	O
cAMP	O	O
PDE	O	O
III	O	O
inhibitors	O	O
with	O	O
in	O	O
vitro	O	O
activity	O	O
in	O	O
the	O	O
nanomolar	O	O
range	O	O
.	O	O
A	O	O
competitive	O	O
intracellular	O	O
localization	O	O
study	O	O
of	O	O
these	O	O
novel	O	O
structures	O	O
with	O	O
Rhodamine	O	O
-	O	O
123	O	O
(	O	O
a	O	O
mitochondrial	O	O
probe	O	O
)	O	O
indicated	O	O
their	O	O
preferential	O	O
localization	O	O
in	O	O
mitochondria	O	O
,	O	O
without	O	O
producing	O	O
any	O	O
specific	O	O
displacement	O	O
of	O	O
(	O	O
3	O	O
)	O	O
H	O	O
-	O	O
PK11195	O	O
(	O	O
PBR	O	O
probe	O	O
,	O	O
(	B-MODIFIER	O
3	I-MODIFIER	O
)	I-MODIFIER	O
H	I-MODIFIER	O
-	I-MODIFIER	O
labeled	I-MODIFIER	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoquinoline	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
)	O	O
.	O	O
A	O	O
number	O	O
of	O	O
nucleoside	O	O
and	O	O
nucleotide	O	O
derivatives	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosylpyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
pyrazofurin	O	O
,	O	O
1	O	O
)	O	O
were	O	O
prepared	O	O
and	O	O
tested	O	O
for	O	O
their	O	O
antiviral	O	O
and	O	O
cytostatic	O	O
activity	O	O
in	O	O
cell	O	O
culture	O	O
.	O	O
Five	O	O
of	O	O
these	O	O
analogues	O	O
(	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
6	O	O
,	O	O
and	O	O
7	O	O
)	O	O
exhibit	O	O
enhanced	O	O
antiantidiuretic	O	O
/	O	O
antivasopressor	O	O
selectivity	O	O
.	O	O
Condensation	O	O
of	O	O
the	O	O
appropriate	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloroquinazoline	I-IUPAC	I-IUPAC
(	O	O
IV	O	O
)	O	O
with	O	O
the	O	O
requisite	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dialkylalkylenediamine	I-IUPAC	I-IUPAC
afforded	O	O
a	O	O
series	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dialkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinazolinamines	I-IUPAC	I-IUPAC
(	O	O
V	O	O
)	O	O
which	O	O
were	O	O
condensed	O	O
with	O	O
the	O	O
appropriate	O	O
arylamine	O	O
to	O	O
provide	O	O
the	O	O
corresponding	O	O
N2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dialkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinazolinediamines	I-IUPAC	I-IUPAC
(	O	O
VI	O	O
)	O	O
.	O	O
The	O	O
antitumor	O	O
activity	O	O
of	O	O
3	O	O
-	O	O
Thf	O	O
-	O	O
FU	O	O
is	O	O
also	O	O
reported	O	O
.	O	O
In	O	O
the	O	O
first	O	O
approach	O	O
,	O	O
17	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
18,19,20	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trinorprostaglandin	I-IUPAC	I-IUPAC
F2	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
,	O	I-IUPAC
16	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17,18,19,20	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetranorprostaglandin	I-IUPAC	I-IUPAC
F2	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
,	O	O
and	O	O
16	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17,18,19,20	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetranorprostaglandin	I-IUPAC	I-IUPAC
F2	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
by	O	O
using	O	O
the	O	O
Corey	O	O
synthesis	O	O
,	O	O
but	O	O
were	O	O
biologically	O	O
inactive	O	O
presumably	O	O
as	O	O
a	O	O
result	O	O
of	O	O
the	O	O
hydrophilic	O	O
phenolic	O	O
hydroxyl	O	O
group	O	O
.	O	O
N	O	O
-	O	O
Methylation	O	O
(	O	O
9y	O	O
)	O	O
results	O	O
in	O	O
loss	O	O
of	O	O
activity	O	O
.	O	O
Although	O	O
it	O	O
had	O	O
2.5	O	O
-	O	O
fold	O	O
lower	O	O
potency	O	O
than	O	O
28	O	O
against	O	O
Ma	O	O
DHFR	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
3.7	O	O
nM	O	O
)	O	O
and	O	O
was	O	O
substantially	O	O
weaker	O	O
against	O	O
Pc	O	O
and	O	O
Tg	O	O
DHFR	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethynylbenzyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
29	O	O
)	O	O
,	O	O
with	O	O
the	O	O
carboxy	B-IUPAC	O
group	B-MODIFIER	O
at	O	O
the	O	O
para	O	O
rather	O	O
than	O	O
the	O	O
meta	O	O
position	O	O
,	O	O
displayed	O	O
2200	O	O
-	O	O
fold	O	O
selectivity	O	O
against	O	O
the	O	O
Ma	O	O
enzyme	O	O
and	O	O
was	O	O
the	O	O
most	O	O
selective	O	O
2,4	B-IUPAC	B-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
diamino	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
5	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
(	O	I-PARTIUPAC
5'	B-MODIFIER	B-MODIFIER
-	O	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
benzyl	B-PARTIUPAC	B-IUPAC
)	O	O
pyrimidine	B-PARTIUPAC	O
inhibitor	O	O
of	O	O
this	O	O
enzyme	O	O
we	O	O
have	O	O
encountered	O	O
to	O	O
date	O	O
.	O	O
Analogues	O	O
of	O	O
the	O	O
2'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tyrosine	I-IUPAC	I-IUPAC
(	I-IUPAC	O
Dmt	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
1,2,3,4	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
Tic	O	O
)	O	O
pharmacophore	O	O
were	O	O
prepared	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O	O
that	O	O
a	O	O
"	O	O
spacer	O	O
"	O	O
and	O	O
a	O	O
third	O	O
aromatic	O	O
center	O	O
in	O	O
opioid	O	O
peptides	O	O
are	O	O
required	O	O
to	O	O
convert	O	O
a	O	O
delta	O	O
-	O	O
antagonist	O	O
into	O	O
ligands	O	O
with	O	O
delta	O	O
-	O	O
agonist	O	O
or	O	O
with	O	O
mixed	O	O
delta	O	O
-	O	O
antagonist	O	O
/	O	O
mu	O	O
-	O	O
agonist	O	O
properties	O	O
.	O	O
Compounds	O	O
constructed	O	O
with	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxyapiolactone	I-IUPAC	I-IUPAC
template	O	O
were	O	O
synthesized	O	O
stereoselectively	O	O
from	O	O
di	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropylidene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
apiose	I-IUPAC	I-IUPAC
.	O	O
Treatment	O	O
of	O	O
the	O	O
latter	O	O
in	O	O
dilute	O	O
hydrochloric	O	O
acid	O	O
with	O	O
sodium	O	O
iodide	O	O
-	O	O
125	O	O
and	O	O
chloramine	O	O
-	O	O
T	O	O
gave	O	O
[	O	O
125I	O	O
]	O	O
(	O	O
S	O	O
)	O	O
-	O	O
6b	O	O
in	O	O
56%	O	O
radiochemical	O	O
yield	O	O
and	O	O
at	O	O
least	O	O
97%	O	O
radiochemical	O	O
purity	O	O
.	O	O
Subnanomolar	O	O
IC50	O	O
values	O	O
at	O	O
the	O	O
AT1	O	O
receptor	O	O
subtype	O	O
were	O	O
observed	O	O
for	O	O
a	O	O
variety	O	O
of	O	O
acylsulfonamides	O	O
,	O	O
including	O	O
aroyl	O	O
,	O	O
heteroaroyl	O	O
,	O	O
and	O	O
cycloalkylcarbonyl	B-IUPAC	B-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
.	O	O
The	O	O
selected	O	O
oleanane	O	O
triterpenoid	O	O
,	O	O
CDDO	O	O
(	O	O
26	O	O
)	O	O
,	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
potent	O	O
,	O	O
multifunctional	O	O
agent	O	O
in	O	O
various	O	O
in	O	O
vitro	O	O
assays	O	O
and	O	O
to	O	O
show	O	O
antiinflammatory	O	O
activity	O	O
against	O	O
thioglycollate	O	O
-	O	O
interferon	O	O
-	O	O
gamma	O	O
-	O	O
induced	O	O
mouse	O	O
peritonitis	O	O
.	O	O
(	O	O
We	O	O
considered	O	O
the	O	O
possibility	O	O
that	O	O
some	O	O
decarboxylation	O	O
of	O	O
DL	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylglycine	I-IUPAC	I-IUPAC
may	O	O
have	O	O
occurred	O	O
during	O	O
testing	O	O
.	O	O
In	O	O
pursuit	O	O
of	O	O
radiolabeled	O	O
monoclonal	O	O
antibodies	O	O
(	O	O
mAbs	O	O
)	O	O
with	O	O
rapid	O	O
urinary	O	O
excretion	O	O
of	O	O
radioactivity	O	O
from	O	O
nontarget	O	O
tissues	O	O
,	O	O
radioiodinated	O	O
mAbs	O	O
releasing	O	O
a	O	O
m	B-IUPAC	O
-	I-IUPAC	O
iodohippuric	I-IUPAC	O
acid	I-IUPAC	O
from	O	O
the	O	O
mAbs	O	O
in	O	O
nontarget	O	O
tissues	O	O
were	O	O
designed	O	O
.	O	O
The	O	O
intermediate	O	O
adducts	O	O
on	O	O
1,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diazabicyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5.4.0	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
undec	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ene	I-IUPAC	I-IUPAC
(	O	O
DBU	O	O
)	O	O
treatment	O	O
rearranged	O	O
to	O	O
the	O	O
corresponding	O	O
stable	O	O
benzobacteriochlorins	O	O
,	O	O
exhibiting	O	O
the	O	O
longest	O	O
wavelength	O	O
absorption	O	O
in	O	O
the	O	O
range	O	O
of	O	O
737	O	O
to	O	O
805	O	O
nm	O	O
.	O	O
All	O	O
the	O	O
double	O	O
-	O	O
armed	O	O
aporphine	O	O
amide	O	O
nitrogen	O	O
mustards	O	O
(	O	O
ab	O	O
-	O	O
d	O	O
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
antitumor	O	O
activity	O	O
.	O	O
Indeed	O	O
,	O	O
when	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
itself	O	O
was	O	O
examined	O	O
at	O	O
neutral	O	O
pH	O	O
for	O	O
inhibitory	O	O
potency	O	O
,	O	O
it	O	O
was	O	O
found	O	O
to	O	O
have	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
31	O	O
+	O	O
/	O	O
-	O	O
7	O	O
microM	O	O
,	O	O
which	O	O
is	O	O
lower	O	O
than	O	O
parent	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxymethyloxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
In	O	O
contrast	O	O
,	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylidene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyluridine	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triphosphate	I-IUPAC	I-IUPAC
was	O	O
found	O	O
to	O	O
be	O	O
incorporated	O	O
at	O	O
the	O	O
3'	O	O
-	O	O
end	O	O
of	O	O
the	O	O
DNA	O	O
chain	O	O
by	O	O
HIV	O	O
-	O	O
1	O	O
reverse	O	O
transcriptase	O	O
,	O	O
albeit	O	O
with	O	O
very	O	O
low	O	O
efficiency	O	O
.	O	O
Next	O	O
,	O	O
cyclo	O	O
[	O	O
21,29	O	O
]	O	O
[	O	O
D	O	O
-	O	O
Cys	O	O
(	O	O
21	O	O
)	O	O
Cys	O	O
(	O	O
29	O	O
)	O	O
]	O	O
-	O	O
uPA	O	O
(	O	O
21	O	O
)	O	O
(	O	O
-	O	O
)	O	O
(	O	O
30	O	O
)	O	O
was	O	O
yielded	O	O
by	O	O
changing	O	O
the	O	O
chirality	O	O
of	O	O
Cys	O	O
(	O	O
21	O	O
)	O	O
to	O	O
D	O	O
-	O	O
Cys	O	O
(	O	O
21	O	O
)	O	O
.	O	O
The	O	O
pKa	O	O
values	O	O
of	O	O
respective	O	O
ligands	O	O
and	O	O
the	O	O
stability	O	O
constants	O	O
of	O	O
their	O	O
iron	O	O
(	O	O
III	O	O
)	O	O
complexes	O	O
are	O	O
presented	O	O
.	O	O
The	O	O
AII	O	O
-	O	O
induced	O	O
contraction	O	O
of	O	O
rabbit	O	O
aortic	O	O
strips	O	O
was	O	O
antagonized	O	O
by	O	O
CV	O	O
-	O	O
11974	O	O
(	O	O
IC50	O	O
value	O	O
,	O	O
3.0	O	O
x	O	O
10	O	O
(	O	O
-	O	O
10	O	O
)	O	O
M	O	O
)	O	O
.	O	O
This	O	O
has	O	O
led	O	O
to	O	O
syntheses	O	O
and	O	O
macrofilaricidal	O	O
evaluations	O	O
of	O	O
a	O	O
number	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
3-7	O	O
)	O	O
.	O	O
Certain	O	O
other	O	O
acidic	O	O
sulfonamides	O	O
,	O	O
such	O	O
as	O	O
sulfonylcarbamates	O	O
and	O	O
disulfimides	O	O
also	O	O
displayed	O	O
high	O	O
affinity	O	O
for	O	O
the	O	O
AT1	O	O
receptor	O	O
.	O	O
Analogues	O	O
4b	O	O
,	O	O
4c	O	O
,	O	O
and	O	O
9b	O	O
at	O	O
1	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
M	O	O
specifically	O	O
inhibited	O	O
the	O	O
incorporation	O	O
of	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
fucose	I-IUPAC	I-IUPAC
into	O	O
macromolecular	O	O
components	O	O
of	O	O
SW613	O	O
human	O	O
mammary	O	O
tumor	O	O
cells	O	O
.	O	O
Most	O	O
of	O	O
these	O	O
analogues	O	O
demonstrated	O	O
high	O	O
affinity	O	O
binding	O	O
to	O	O
the	O	O
dopamine	O	O
transporter	O	O
(	O	O
DAT	O	O
;	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
1.8-40	O	O
nM	O	O
)	O	O
,	O	O
and	O	O
selectivity	O	O
over	O	O
the	O	O
other	O	O
monoamine	O	O
transporters	O	O
and	O	O
muscarinic	O	O
M	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
.	O	O
Thus	O	O
,	O	O
IV	O	O
is	O	O
a	O	O
good	O	O
substrate	O	O
for	O	O
converting	O	O
enzymes	O	O
from	O	O
lung	O	O
and	O	O
plasma	O	O
while	O	O
all	O	O
other	O	O
compounds	O	O
were	O	O
inhibitors	O	O
of	O	O
these	O	O
enzymes	O	O
.	O	O
A	O	O
series	O	O
of	O	O
synthetic	O	O
estrogens	O	O
containing	O	O
hydroxyalkyl	O	O
side	O	O
chains	O	O
at	O	O
the	O	O
C	O	O
-	O	O
4	O	O
position	O	O
of	O	O
the	O	O
A	O	O
ring	O	O
were	O	O
designed	O	O
as	O	O
metabolically	O	O
stable	O	O
analogs	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyestradiol	I-IUPAC	I-IUPAC
,	O	O
a	O	O
catechol	O	O
estrogen	O	O
.	O	O
carinii	O	O
pneumonia	O	O
in	O	O
AIDS	O	O
patients	O	O
.	O	O
The	O	O
acyclic	B-MODIFIER	O
analog	I-MODIFIER	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
24	O	O
)	O	O
was	O	O
prepared	O	O
via	O	O
the	O	O
sodium	O	O
salt	O	O
glycosylation	O	O
of	O	O
5	O	O
with	O	O
(	B-IUPAC	B-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
bromide	I-IUPAC	I-IUPAC
(	O	O
22	O	O
)	O	O
followed	O	O
by	O	O
a	O	O
ring	O	O
annulation	O	O
with	O	O
hydrazine	O	O
.	O	O

